paclitaxel has been researched along with Disease Exacerbation in 653 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 51 (7.81) | 18.2507 |
| 2000's | 322 (49.31) | 29.6817 |
| 2010's | 245 (37.52) | 24.3611 |
| 2020's | 35 (5.36) | 2.80 |
| Authors | Studies |
|---|---|
| Bai, L; Curran, DP; Day, BW; Eiseman, JL; Jung, WH; Moura-Letts, G | 1 |
| Bao, S; Cai, J; Peng, S | 1 |
| Adenis, A; Al-Rajabi, R; Amonkar, M; Bhagia, P; de la Fouchardiere, C; Girotto, GC; Kulkarni, AS; Mansoor, W; Metges, JP; Norquist, J; Senellart, H; Suryawanshi, S; van Laarhoven, HWM | 1 |
| Kirita, T; Kurita, H; Matsumura, T; Naruse, T; Okura, M; Ota, Y; Otsuru, M; Sasaki, M; Shintani, Y; Umeda, M; Yamada, SI; Yamakawa, N; Yanamoto, S | 1 |
| Abdeddaim, C; Clatot, F; Even, C; Guiard, E; Johnson, A; Perréard, M; Rambeau, A; Vauléon, E | 1 |
| Bales, CL; Cantor, EL; Cunningham, GM; Fehrenbacher, JC; Gardner, L; Jiang, G; Liu, Y; Philips, S; Schneider, BP; Shen, F; Tan, Z; Wan, J; Wu, X | 1 |
| Birrer, MJ; Bonebrake, A; Brady, WE; Farley, JH; Fujiwara, K; Gershenson, DM; Nam, JH; O'Malley, D; Secord, AA; Stephan, JM; Walker, JL; Yonemori, K | 1 |
| Bhosale, P; Chisholm, GB; Flores-Legarreta, A; Frumovitz, M; Gonzales, NR; Hillman, RT; Jhingran, A; Ramalingam, P; Salvo, G | 1 |
| Ballinger, M; Bruno, R; Friberg, LE; Hoang, T; Jin, JY; Karlsson, MO; Krishnan, SM; Mercier, F; Wu, B; Zhang, R | 1 |
| Chen, X; He, Q; Li, M; Liu, Y; Sheng, Q; Shi, K; Wang, Y; Yu, Q; Zhang, Z | 1 |
| Gao, SP; Huang, W; Li, KS; Luo, JH; Wang, F; Wu, J; Wu, Y; Zhang, PF; Zhang, PN; Zhang, XM | 1 |
| Arnouk, S; Berus, D; Bolli, E; Clappaert, EJ; D'Huyvetter, M; Devoogdt, N; Gonçalves, A; Krasniqi, A; Lahoutte, T; Movahedi, K; Murgaski, A; Pombo Antunes, AR; Raes, G; Stangé, G; Van Ginderachter, JA; Vuylsteke, M | 1 |
| Bahar, I; Chi, JJ; Cristofanilli, M; Izquierdo-Ferrer, J; Li, H; Lu, X; Schiltz, GE; Wan, Y; Wavelet, CM; Xue, Y; Zhang, B; Zhou, Z | 1 |
| Chou, JF; Lu, Y | 1 |
| Fremd, C; Jäger, D; Mavratzas, A; Schneeweiss, A; Seitz, J; Smetanay, K | 1 |
| Hwang, I; Lee, JL; Park, I; Yoon, SK | 1 |
| Li, L; Li, M; Li, X; Ren, H; Wang, X; Xiao, T; Yang, B; Zhang, L; Zhang, W; Zhou, H | 1 |
| Adenis, A; Barbier, E; Borg, C; Breysacher, G; Dahan, L; Desrame, J; Di Fiore, F; Faroux, R; Gaba, L; Laurent-Puig, P; Lièvre, A; Lopez, A; Louafi, S; Louvet, C; Manfredi, S; Metges, JP; Mineur, L; Randrian, V; Roquin, G; Tougeron, D | 1 |
| Berg, T; Nøttrup, TJ; Peen, UBS; Roed, H | 1 |
| Gundu, N; Jain, D; Kancharla, H; Khurana, S; Kumar, S; Malik, PS; Mohan, A; Pathak, N; Pathy, S; Pushpam, D; Vandidassane, I | 1 |
| Chu, NQ; Colby, A; Colson, YL; de Forcrand, C; Grinstaff, MW; Liu, R; Padera, RF | 1 |
| Marnitz, S; Waltar, T | 1 |
| Abbasnezhad, A; Abd El-Ghafar, OA; Abhilash, L; Abouzid, KAM; Achberger, AM; Ackerman, S; Akhatayeva, Z; Akin, D; Al-Kaysi, RO; Alakhdar, AA; Alame, M; Aleksic Sabo, V; Alinezhadbalalami, N; Allen, JD; Alonso, JM; Alqatani, S; Alsayed, B; Álvarez Larraondo, M; Alvarez, M; Amini, SB; An, Z; Anasir, MI; Anderson, GH; Andremont, A; Andrés, S; Angel, S; Anigboro, AA; Anini, Y; Antonides, CFJ; Arafa, K; Arafa, RK; Aryal, UK; Asbaghi, O; Assefa, MK; Atyah, M; Avwioroko, OJ; Ayora-Talavera, G; Azpilikueta, A; Azyazov, VN; Ba, YF; Bachmann, KF; Badoual, J; Bae, SJ; Baek, SH; Bahrami, B; Bai, J; Baid-Agrawal, S; Bailey, MR; Baillie, JK; Balani, N; Balcar, VJ; Banica, T; Banks, L; Barb, J; Bardeen, CJ; Barrett, HE; Bartnikowski, N; Bashir, R; Battaglia, M; Bautista-Hernández, V; Becker, B; Beekman, FJ; Benidir, M; Benjelloun, M; Bentley, RF; Bergé, J; Berger, D; Bernsen, MR; Berraondo, P; Bhattacharya, R; Bhayani, SB; Bi, W; Bi, X; Bi, YL; Bi, Z; Bian, K; Biesecker, LG; Billadeau, DD; Blaszczyk, R; Blum, JL; Boachie, R; Boelte, K; Bogers, AJJC; Boileau, I; Bonduelle, C; Bonny, O; Bonsu, JM; Boos, LA; Borges-Argáez, R; Bouchard, PA; Boudot, C; Bourgeade-Delmas, S; Boutet-Robinet, E; Boyle, AJ; Branigan, D; Briones, S; Broniowska, KA; Brossas, JY; Brown, WA; Brzezinska, J; Buitron, G; Burnier, M; Bursulaya, B; Burton, PR; Bush, AA; Busuttil, RW; Cabello-Aguilar, S; Cáceres-Farfán, M; Cacheux, V; Caffrey, PJ; Cai, B; Cai, Q; Cai, S; Cai, Y; Calders, P; Cammarota, G; Campbell, DA; Cancelli, C; Cao, Q; Cao, WH; Cao, X; Capet, M; Capoluongo, E; Carey, ME; Carnero, M; Carrasco, LI; Carreno, J; Carrillo-Reyes, J; Casini, I; Cassar, M; Catalan, G; Cattamanchi, A; Cazares-Granillo, M; Celie, B; Cen, YK; Cena, H; Cerbo, RM; Ceron, E; Cetina-Montejo, L; Chaâbane-Banaoues, R; Chabanet, C; Chace-Donahue, F; Chalfun-Júnior, A; Chan-Balan, R; Chang, CS; Chen, CS; Chen, D; Chen, J; Chen, L; Chen, PN; Chen, Q; Chen, S; Chen, W; Chen, WP; Chen, X; Chen, Z; Cheng, H; Cheng, J; Cheng, Q; Cheng, T; Chi, T; Chianelli, D; Chieppa, M; Child, CJ; Cho, JH; Cho, JY; Chogtu, B; Choi, GH; Choi, J; Choi, M; Choi, NG; Cholu, CO; Chow, ES; Chowdhury, AH; Chu, PC; Chu, Q; Chu, S; Chua, H; Chung, T; Chunyan, L; Church, JS; Civardi, E; Cobiella, J; Colinge, J; Collado, CJ; Collins, TJ; Cong, LM; Conkrite, KL; Cope, SJ; Corbett, JA; Cornet, M; Cornillot, E; Corvaisier, S; Costes-Martineau, V; Courtioux, B; Coussens, M; Covino, M; Criado, A; Cui, J; Cui, Y; Cunitz, BW; Curry, AE; Cussó, L; D'Urzo, AD; D'Urzo, KA; Dabbous, S; Dahlgren, RA; Dai, H; Dai, T; Dai, W; Dalinghaus, M; Dang, S; Davalos, RV; Davidson, H; de Andrea, CE; De Angelis, M; de Blois, E; de Carvalho, PA; De Clercq, E; De Giuseppe, R; de Jong, M; De Langhe, S; De Oliveira, L; de Souza Pinto Lemgruber, R; de Souza, LB; de Swart, J; De Wandele, I; de Woestijne, PCV; Delaney, S; Delorme, M; Delvenne, P; Deng, L; Deng, Z; Denkinger, CM; der Meulen, MHV; Deraeve, C; Desco, M; DeSilva, S; Destere, A; Dhali, A; Di Ciano, P; Dias-Santagata, D; Diskin, SJ; Djè, MK; Doddipatla, S; Doerr, AJ; Dokla, EME; Domiciano, D; Domingo, N; Dong, C; Dong, J; Dong, Q; Dong, S; Dong, X; Dong, Z; Douair, I; Douglas, TA; Doyle, SM; Drain, PK; Du, K; Du, L; Du, Q; Du, S; Duan, C; Duan, H; Duan, J; Duan, S; Duan, W; Dueluzeau, R; Dukic, L; Dunmire, BL; Duvauchelle, T; Dymek, B; Dzwonek, K; Earnest, A; Eckardt, KU; El Ghadraoui, L; El Massoudi, S; Elloumi, F; Elnour, IE; Embarak, S; Ende, M; England, K; Enikeev, D; Enyedy, I; Epple, R; Erickson, GE; Eriksson, J; Erndt-Marino, J; Errachidi, F; Etxeberria, I; Evan, AP; Fairlamb, AH; Falahi, E; Fan, CC; Fan, H; Fan, M; Fan, MZ; Fan, S; Fan, Y; Fang, CS; Fang, J; Fang, X; Fang, Z; Farmany, A; Farooqi, A; Farouk, HO; Fazelipour, S; Feng, D; Feng, J; Feng, JX; Feng, YL; Ferraz, SL; Ferreira, CR; Figenshau, RS; Finn, AV; Fiseha, T; Fleischer, AS; Fogleman, AD; Fontaine, O; Ford, CR; Fouladvand, F; Four, M; Fousteri, G; Francis, JR; Fraser, JF; Frazier, RP; Fu, H; Fu, P; Fu, YJ; Fujishima, A; Fuster, V; Gabilan, JC; Gagliani, N; Gai, QY; Galán-Arriola, C; Gale, P; Galimova, GR; Galkin, A; Gallo, A; Gallo, AA; Gang, DD; Ganschow, S; Gao, C; Gao, F; Gao, GP; Gao, H; Gao, K; Gao, M; Gao, MY; Gao, P; Gao, R; Gao, S; Gao, WJ; Gao, Y; Garbacz, P; García Ruiz, L; Garcia, EM; Garofoli, F; Gasbarrini, A; Gattinoni, L; Gaudig, M; Gbureck, U; Ge, X; Genko, N; Gentile, GL; George, MW; Gerety, GF; Gestwicki, JE; Geusens, PP; Ghassemi, M; Giardina, JD; Giebultowicz, JM; Gifford, CA; Gijsen, FJH; Gilfillan, R; Gilson, E; Gingl, K; Giuliano, C; Glybochko, P; Goessler, W; Gofflot, S; Golab, J; Goldstein, A; Golebiowski, A; Gómez, L; Gómez-Carballo, J; Gonçalves, PEO; Gonzales, R; Gonzalez-Cotto, M; González-Fernández, D; Gonzalez-Lopez de Turiso, F; Goodman, JM; Govinda Raju, S; Grimm, J; Gross, AJ; Gruenheid, S; Gu, C; Gu, FF; Gu, S; Gu, Z; Guest, RL; Gui, C; Gui, J; Guillem, A; Guo, G; Guo, L; Guo, Q; Guo, S; Guo, SW; Guo, W; Guo, Y; Guo, YG; Guo, Z; Guretzky, JA; Haenggi, M; Hahn, MS; Hakkola, J; Halim, AA; Hampel, D; Han, B; Han, BH; Han, D; Han, G; Han, J; Han, LZ; Han, R; Han, S; Han, X; Han, Z; Handley, MA; Hanke, I; Hannongbua, S; Hao, P; Happ, JT; Hara, M; Haraux, F; Hare, JL; Harper, JD; Hartley, AM; Harvey, E; Hashimoto, K; Hassan, HM; Hautajärvi, H; Hayton, TW; He, C; He, H; He, HJ; He, WP; He, Y; He, Z; Hedrick, V; Heffernan, JK; Hegrová, J; Heidarimoghadam, R; Helms, K; Hengphasatporn, K; Henry, D; Herrmann, TRW; Hesson, T; Himmelbauer, MK; Hindle, A; Hoffmann, R; Hogg, N; Hong, KB; Hong, SK; Honjol, Y; Hood, C; Hsi, RS; Hsu, JL; Hu, B; Hu, BC; Hu, D; Hu, H; Hu, J; Hu, K; Hu, M; Hu, MK; Hu, T; Hu, W; Hu, Y; Hu, Z; Hua, S; Huang, H; Huang, J; Huang, L; Huang, M; Huang, P; Huang, X; Huang, Y; Huang, Z; Hukkanen, J; Hung, MC; Huo, X; Hyötyläinen, T; Ianiro, G; Ibanez, B; Imran, M; Ireland, S; Irwin, MS; Ishiguro, H; Jackowski, K; Jackson, C; Jacob, SI; Jahromy, MH; Jakob, SM; Jang, J; Javvaji, PK; Jefferson, KK; Jena, P; Ji, H; Jiang, F; Jiang, GH; Jiang, H; Jiang, J; Jiang, X; Jiang, Z; Jiao, J; Jiménez, A; Jin, X; Jincai, W; Jintao, X; Jo, K; Jofra, T; Johari, Y; Johnson, ACM; Jones, JH; Josephine Fauci, A; Juhl, AK; Jun, S; Kaiser, RI; Kajioka, J; Kajiyama, H; Kalliyil, A; Kalthur, SG; Kamalanathan, M; Kamaldinov, T; Kanaani, L; Kang, D; Kang, J; Kang, S; Känsäkoski, P; Kaplan, DL; Karwan, M; Kasibhatla, S; Kaur, A; Kawazoe, Y; Ke, C; Keyser, J; Khalique, A; Khan, IT; Kharshoum, RM; Kher, R; Kherani, J; Ki, KK; Kikkawa, F; Kikkawa, R; Kim, BT; Kim, EH; Kim, GA; Kim, GD; Kim, HB; Kim, HG; Kim, JS; Kim, MJ; Kim, SI; Kim, SJ; Kim, Y; King, K; Kinyamu-Akunda, J; Kirkkala, T; Kjaer-Sorensen, K; Kleppinger, EL; Kloner, RA; Klopfenstein, TJ; Knappe, D; Knezevic, P; Kobos, LM; Kohli, M; Kolano, L; Kolodgie, FD; Kolte, AP; Koneru, B; Kong, D; Kong, F; Kong, X; Konggidinata, MI; Köpke, M; Koski, KG; Kotsis, F; Köttgen, A; Kouakou-Kouamé, CA; Kraemer, US; Krane, V; Krehbiel, CR; Krenning, BJ; Kretzschmar, D; Ku, KB; Kubota, Y; Kulich, P; Kumar, NG; Kupiec-Weglinski, JW; Lalani, SS; Lan, X; Landfeldt, E; Langenberg, E; Lapauw, B; Larkin, J; Lassoued, MA; Laukhtina, E; Laura Martinez, J; Laveillé, A; Lavela, P; Law, AD; Lazraq, A; Le Foll, B; Lee, BK; Lee, C; Lee, CS; Lee, EJ; Lee, EY; Lee, G; Lee, HY; Lee, JH; Lee, JJ; Lee, JO; Lee, JS; Lee, R; Lei, H; Lei, P; Lellouche, F; Lennerz, JK; Leong, W; Leslie, I; Lessem, E; Levin, M; Levinger, I; Li, C; Li, CW; Li, CX; Li, CY; Li, D; Li, H; Li, HM; Li, J; Li, L; Li, LM; Li, N; Li, S; Li, W; Li, X; Li, XX; Li, Y; Li, Z; Li, ZL; Li, ZX; Lian, Q; Liang, C; Liang, GH; Liang, H; Liang, J; Liang, X; Liao, CX; Liao, R; Ličbinský, R; Lim, YS; Lima, HK; Lin, JG; Lin, L; Lin, S; Lin, WP; Lin, Z; Liso, M; Liu, BX; Liu, C; Liu, H; Liu, J; Liu, M; Liu, Q; Liu, S; Liu, SF; Liu, SL; Liu, T; Liu, W; Liu, X; Liu, XB; Liu, Y; Liu, YY; Liu, Z; Liu, ZQ; Lobo, M; Loitzenbauer, M; López, F; Lopez, G; López, GJ; Lou, Z; Lu, IC; Lu, J; Lu, M; Lu, W; Lu, X; Lu, Y; Luhovyy, BL; Luna-Abanto, J; Luo, J; Luo, K; Luo, L; Luo, M; Luo, W; Luo, X; Luo, XM; Lv, Y; Lv, YQ; Lyu, HD; Lyu, J; Ma, C; Ma, G; Ma, L; Ma, Q; Ma, X; Ma, Y; Macha, SJ; MacLean, E; Mahalapbutr, P; Maina, T; Malfait, F; Malfertheiner, MV; Malzert-Fréon, A; Mansouri, E; Mao, C; Marcellin, E; Marchiori, PER; Marcotte, DJ; Maréchal, A; Maric, N; Maris, JM; Maron, L; Marti, CN; Martínez-Milla, J; Mateo, J; Mather, K; Mathison, CJN; Matthay, MA; Maxwell, CL; Mazier, D; Mazumder, D; Mazurkiewicz, M; Mazzucchelli, TG; McAuley, DF; Mccoy, K; McVicar, DW; Mebel, AM; Mech, A; Meester, EJ; Meiselbach, H; Melero, I; Ménard, G; Meng, X; Mengya, Y; Merle, G; Meunier, B; Mfarrej, B; Mi, K; Migueliz, I; Mikuška, P; Miladi, K; Miletich, R; Millar, JE; Mills, MR; Milne, R; Minute, L; Misiak, M; Mo, F; Modi, A; Mok, F; Molina, C; Mollen, CJ; Molteni, V; Montalto, M; Montet, D; Monti, MC; Moor, MB; Moravec, P; Morsiani, C; Murillo, E; Murugan, P; Muslem, R; Myers, RK; N'guessan, FK; Nabil, H; Nadal, J; Nadeem, M; Nafady, MM; Nafie, MS; Nair, HP; Nakano, R; Nance, J; Naren, N; Neil, CJ; Nelson, J; Nery, FC; Netsch, C; Nguyen, TH; Ni, L; Ni, YX; Nie, W; Nielsen, LK; Nigam, K; Nikolayev, AA; Nishiyama, M; Niu, LL; Niu, PP; Nock, BA; Noer, PR; Noll, G; Noll, S; Norenberg, JP; Nowicka, J; Nutho, B; O'Connor, M; Obonyo, NG; Ochiai, T; Ochoa, MC; Oh, BL; Oh, S; Olczak, J; Olivares, X; Ommurugan, B; Oosthuizen, MC; Operario, D; Orešič, M; Oshima, K; Otano, I; Ou, Y; Owen, TW; Oxvig, C; Pacey, V; Pai, M; Paik, H; Paiva, R; Palmieri, EM; Palpant, N; Pan, L; Pan, Q; Panahi, S; Pang, B; Pang, ZC; Pannecouque, C; Paris, L; Park, D; Park, DJ; Park, E; Park, EC; Park, IH; Park, JH; Park, JI; Park, S; Passmore, MR; Pattaranggoon, NC; Paun, M; Pedersen, S; Pedron, J; Peng, M; Peng, X; Penzhorn, BL; Pérez-Camargo, D; Perez-Maldonado, R; Pérez-Vicente, C; Pham, TD; Pickering, L; Pickersgill, NA; Pinault, E; Pinotsis, N; Plan, M; Pocino, K; Poh, CL; Pons, EDC; Popoff, MR; Porri, D; Pourmand, A; Pratviel, G; Prudente, DO; Qi, H; Qi, N; Qian, LY; Qiao, L; Qiao, Q; Qin, QP; Qiu, N; Qiu, SW; Qu, F; Quan, M; Quigg, A; Raee, E; Raibaud, P; Ramanitrahasimbola, D; Rapoport, L; Rasby, RJ; Rasoanirina, BNV; Raspini, B; Ratner, JR; Razafindrakoto, Z; Redd, MA; Ren, H; Ren, N; Rey, J; Reynolds, CP; Rich, PR; Richards, CJ; Rigol, M; Rimoldi, S; Robert, P; Rodrigues, AE; Roe, JH; Rohde, S; Rokita, JL; Roland, J; Rombaut, L; Ronkainen, J; Rothenberg, SM; Roy, SC; Ruan, Z; Rucker, PV; Rueda, D; Ruhwald, M; Rungrotmongkol, T; Rupert, AS; Rusjan, P; Ryabov, AD; Rysä, J; Saad, NES; Sabioni, P; Sadow, PM; Sahai, N; Salem, HF; Salinas, B; Salonurmi, T; Samé Guerra, D; Sánchez, J; Sanchez-González, J; Sanmamed, MF; Sansores-Peraza, P; Santoro, JC; Santschi, PH; Saritas, T; Sarkisova, Y; Savolainen, MJ; Scherberich, JE; Schlom, DG; Schmelz, EM; Schmid, MC; Schneider, MP; Schumacher, S; Schwartz, JC; Schwartzer, JJ; Schwehr, K; Schweitzer, DH; Scott, ME; Sedky, NK; See Hoe, L; Sejian, V; Selvaraju, S; Sen, SK; Seo, G; Šerý, O; Settles, JA; Sfar, S; Shaffer, J; Shan, GL; Shang, Q; Shannahan, JH; Shao, B; Shao, H; Shao, J; Shao, ZH; Shasha, Y; Shaw, K; Sheeba, V; Shekar, K; Shen, G; Shen, H; Shen, XD; Shen, Y; Sherrell, PC; Shete, PB; Shi, AX; Shi, J; Shi, JH; Shi, S; Shi, X; Shigeta, Y; Shimbo, A; Shin, E; Sikka, N; Silhavy, TJ; Simanon, N; Simard, S; Simon, J; Simon, M; Simpson, SD; Simundic, AM; Since, M; Singh, B; Singhroy, DN; Sinisterra, OT; Smith, EH; Sobreira, TJP; Solanes, N; Somasundar, Y; Sommerer, C; Sonei, A; Song, B; Song, E; Song, J; Song, M; Song, Y; Soo Lee, M; Sorensen, MD; Sournia-Saquet, A; Spaepen, E; Spirk, D; Srivastava, S; Stancill, JS; Stanczak, PS; Starenki, D; Starr, F; Step, DL; Steubl, D; Stigliani, JL; Stráská, J; Sträter, N; Su, ZZ; Sudano, I; Suen, JY; Suh, HJ; Sui, ZY; Suico, JG; Suleiman, K; Sumon, K; Sun, HB; Sun, J; Sun, L; Sun, LL; Sun, M; Sun, Q; Sun, W; Sun, X; Sun, XF; Sun, Y; Sun, YB; Sun, YH; Sun, YN; Sun, Z; Sunada, K; Suzuki, S; Sylvan, JB; Takala, J; Talla, D; Tamir, Z; Tan, SJ; Tanda, S; Tang, H; Tang, J; Tang, LF; Tang, SJ; Tang, Y; Tao, FB; Tappel, R; Taratkin, M; Teijeira, Á; Tellew, JE; Thomas, AM; Thomas, SG; Thomson, SR; Tian, J; Tie, Y; Tirado, JL; Tolonen, A; Tosato, G; Tronnet, A; Tsai, S; Turtoi, A; Turtoi, E; Tvrdoňová, M; Tyagi, A; Tzou, DT; Uddin Ahmad, Z; Urias, E; Usawachintachit, M; Ustriyana, P; Utsumi, F; Vacca, M; Vaculovič, T; Vaidya, SS; Valentin, A; Valgepea, K; van den Berg, P; van den Bergh, JP; van der Heiden, K; van Gaalen, K; Van Gemert, W; van Haard, PMM; van Hest, JCM; Vecchiarelli, E; Večeřa, Z; Venkatesh, R; Verhaeghe, P; Verhagen, HJ; Vetter, JM; Vieira, D; Vilchez-Tschischke, JP; Villena-Gutierrez, R; Villoslada Terrones, V; Vital-Jacome, M; Voelkl, J; Vogel, K; Vogrin, S; Volke, D; von Bahr, V; Vysloužil, J; Wade, TL; Wagner-Gillespie, M; Walsh, SW; Wan, LJ; Wan, SP; Wang, AL; Wang, B; Wang, BY; Wang, C; Wang, D; Wang, F; Wang, H; Wang, HR; Wang, HY; Wang, J; Wang, JY; Wang, K; Wang, L; Wang, LF; Wang, P; Wang, Q; Wang, R; Wang, SF; Wang, SP; Wang, SR; Wang, T; Wang, W; Wang, WP; Wang, X; Wang, XJ; Wang, Y; Wang, YL; Wang, YN; Wáng, YXJ; Wang, Z; Wang, ZF; Wang, ZY; Waning, B; Warner, JM; Washington, SL; Watson, AK; Wei, B; Wei, C; Wei, F; Wei, X; Wei, Y; Wemhoff, AP; Wen, Z; Weng, TT; Wesdemiotis, C; Wheeler, DA; Wildner, M; Wilson, BK; Wirth, LJ; Wissler, M; Wu, F; Wu, G; Wu, J; Wu, KH; Wu, MC; Wu, P; Wu, PK; Wu, S; Wu, W; Wu, X; Wu, XP; Wu, Y; Wyatt, E; Wyllie, S; Xia, Y; Xiao, BH; Xiao, SZ; Xiao, W; Xiao, X; Xiao, Z; Xie, D; Xie, K; Xie, X; Xie, Y; Xie, YF; Xin, S; Xin, Z; Xing, Q; Xing, WQ; Xiong, D; Xiong, X; Xu, C; Xu, D; Xu, F; Xu, G; Xu, H; Xu, J; Xu, JY; Xu, L; Xu, N; Xu, W; Xu, X; Xu, Y; Xu, YM; Xue, H; Xue, J; Xue, Z; Yan, R; Yan, SQ; Yan, W; Yan, X; Yan, Z; Yang, C; Yang, D; Yang, F; Yang, FC; Yang, G; Yang, J; Yang, M; Yang, P; Yang, Q; Yang, R; Yang, S; Yang, SJ; Yang, TWW; Yang, X; Yang, Y; Yang, Z; Yao, C; Yao, L; Yao, LP; Yao, M; Yao, T; Yao, W; Yao, Y; Yaseen, T; Yazdani, V; Ye, J; Ye, S; Yerys, BE; Yi, HWL; Yi, JL; Yin, F; Yin, J; Yin, Y; Yin, Z; Yong, ZP; Yongli, S; Yoo, JS; Yoshikawa, N; You, Q; Yu, B; Yu, CQ; Yu, H; Yu, HG; Yu, J; Yu, L; Yu, Q; Yu, X; Yu, Y; Yu, YK; Yu, Z; Yuan, Q; Yuan, R; Yuan, W; Yuan, X; Yuan, Y; Zager, RA; Zagozdzon, A; Zaller, N; Zang, YP; Zappi, ME; Zelikoff, JT; Zeman, T; Zhai, X; Zhan, P; Zhang, B; Zhang, C; Zhang, G; Zhang, H; Zhang, HB; Zhang, J; Zhang, JS; Zhang, L; Zhang, M; Zhang, Q; Zhang, RX; Zhang, S; Zhang, T; Zhang, W; Zhang, WH; Zhang, X; Zhang, XX; Zhang, Y; Zhang, YQ; Zhang, YW; Zhang, Z; Zhang, ZH; Zhao, D; Zhao, FL; Zhao, K; Zhao, L; Zhao, M; Zhao, R; Zhao, S; Zhao, W; Zhao, WG; Zhao, X; Zhao, Y; Zheng, G; Zheng, J; Zheng, S; Zheng, W; Zheng, Y; Zheng, YG; Zhong, Z; Zhou, C; Zhou, D; Zhou, H; Zhou, HY; Zhou, L; Zhou, Q; Zhou, X; Zhou, Y; Zhou, YL; Zhou, Z; Zhu, J; Zhu, L; Zhu, N; Zhu, X; Zhu, XF; Zhu, Y; Zhu, Z | 1 |
| Al-Batran, SE; Dechow, T; Egger, M; Goetze, TO; Hebart, H; Hegewisch-Becker, S; Homann, N; Knorrenschild, JR; Kopp, HG; Kullmann, F; Lorenzen, S; Luley, KB; Pauligk, C; Pink, D; Probst, S; Seraphin, J; Siveke, J; Stahl, M; Thuss-Patience, P; Vogel, A | 1 |
| Arrowsmith, CH; Ba-Alawi, W; Cescon, DW; De Carvalho, DD; Deblois, G; Ettayebi, I; Fedor, AN; Fortier, AM; Grillo, G; Guilhamon, P; Haibe-Kains, B; Kao, YI; Kuasne, H; Lima-Fernandes, E; Liu, X; Locasale, JW; Lupien, M; Martinez, C; Murison, A; Park, M; Savage, P; Tai, F; Tonekaboni, SAM | 1 |
| Pei, J; Wang, B; Wang, Z; Yang, X; Zhang, J; Zhao, L | 1 |
| Bachet, JB; Bouhier Leporrier, K; Coriat, R; Gouttebel, MC; Gratet, A; Khemissa Akouz, F; Laharie, H; Le Malicot, K; Lepage, C; Louafi, S; Malka, D; Miglianico, L; Pointet, AL; Rinaldi, Y; Taieb, J; Terrebonne, E; Texereau, P; Thirot Bidault, A; Wahiba, B | 1 |
| Bolomini, G; Ceni, V; Conte, C; Ditto, A; Fagotti, A; Ferrandina, G; Giudice, E; Lorusso, D; Marchetti, C; Raspagliesi, F; Scambia, G; Vertechy, L | 1 |
| Fukuda, S; Fukumitsu, K; Ito, Y; Kagawa, Y; Kanemitsu, Y; Maeno, K; Niimi, A; Oguri, T; Ohkubo, H; Sone, K; Tajiri, T; Takakuwa, O; Takemura, M; Takeuchi, A; Uemura, T | 1 |
| Zhu, H | 1 |
| Camara, JC; Franco, F; Gutiérrez-Abad, D; Juez, I; León, A; López-Alfonso, A; Marrupe, D; Martín-Valadés, JI; Martínez-Amores, B; Pérez, M; Royuela, A; Ruiz-Casado, A | 1 |
| Cui, J; Qu, S; Wang, L; Zhang, X | 1 |
| Abe, Y; Ashida, R; Fukutake, N; Ikezawa, K; Imai, T; Katayama, K; Kato, K; Kiyota, R; Kukita, Y; Nawa, T; Ohkawa, K; Takada, R; Yamai, T | 1 |
| Ahlström, H; Botling, J; Dahlstrand, H; Koliadi, A; Öberg, K; Tholander, B; Ullenhag, GJ; Von Heideman, A | 1 |
| Aoki, D; Enomoto, T; Fujiwara, K; Kimura, E; Kondo, E; Kotera, Y; Okamoto, A; Sugiyama, T; Sumi, T; Suzuki, N; Tabata, T; Terauchi, F; Tokuyama, O; Yaegashi, N; Yahata, H | 1 |
| du Bois, A; Mirza, MR; Pignata, S; Ray-Coquard, I; Romero, I; Walther, A | 1 |
| Han, C; Li, L; Li, M; Liu, Y; Mao, Y; Song, S; Wang, Z; Xu, B; Yu, G; Zhou, L | 1 |
| Fukutomi, A; Furuse, J; Hashimoto, Y; Honda, G; Ioka, T; Miyamoto, A; Mizuno, N; Morinaga, S; Nakamori, S; Okusaka, T; Saiura, A; Sasahira, N; Seyama, Y; Shimizu, S; Shimizu, Y; Sugiyama, M; Takadate, T; Takahashi, H; Ueno, H; Ueno, M; Umemoto, K; Unno, M | 1 |
| Guan, W; Li, X; Men, T; Wang, F; Xu, G; Xu, X; Zhang, J | 1 |
| Chen, C; Chen, KN; Dai, L; Du, M; Fang, Y; Gong, L; Hou, Y; Jiang, H; Jiao, J; Li, H; Li, K; Li, W; Li, Z; Lian, C; Liao, Y; Liu, J; Shen, Y; Tan, L; Tang, H; Wang, H; Wu, H; Xie, D; Yin, J; Zeng, Z; Zhao, Q; Zheng, B; Zhu, J | 1 |
| Bois, MC; Chakrabarti, S; Chandrasekharan, C; Dong, H; Foster, NR; Graham, RP; Kankeu Fonkoua, LA; Kasi, PM; Liu, AJ; Markovic, SN; Maus, RL; Nevala, WK; Pitot, HC; Ross, HJ; Sonbol, MB; Starr, JS; Villasboas, JC; Weiss, M; Wu, TT; Yoon, HH | 1 |
| Jia, H; Jiang, S; Li, R; Lin, P; Liu, C; Wang, N; Wang, W; Xie, H; Yu, X | 1 |
| Alfonsi, M; Chevalier, T; Daste, A; Dupuis, C; Fakhry, N; Fayette, J; Huguet, F; Lambert, T; Le Tourneau, C; Loundou, A; Peyrade, F; Peyraud, F; Reure, J; Saada-Bouzid, E; Salas, S; Toullec, C | 1 |
| Goto, Y; Hasegawa, Y; Hosomi, Y; Hotta, K; Inoue, A; Kishi, K; Kunitoh, H; Mori, K; Naito, Y; Nishio, M; Ohashi, Y; Tanai, C; Tomizawa, Y; Yamada, K; Yoh, K | 1 |
| Bianchi, G; Capri, G; de Braud, F; Ferrari, B; Maggi, C; Mariani, G; Mennitto, A; Mennitto, R; Milano, M; Re, B; Rinaldi, L; Stefanetti, C; Vernieri, C | 1 |
| Curiel, T; Garcia, L; Kost, E; Li, R; Liu, J; Nair, BC; Rao Tekmal, R; Rao, MK; Sareddy, GR; Vadlamudi, RK; Viswanadhapalli, S; Zhou, M | 1 |
| Maloney, A; Relias, V; Saif, MW; Smith, MH | 1 |
| Alberts, DS; Angioli, R; Baldelli, E; Dong, T; Gambara, G; Guillen-Rodriguez, JM; Hodge, KA; Liotta, LA; Memo, M; Odicino, F; Pecorelli, SL; Petricoin, EF; Pierobon, M; Ravaggi, A; Sereni, MI | 1 |
| Hirata, H; Hosoda, H; Kangawa, K; Kijima, T; Komuta, K; Kuroyama, M; Minami, S; Nakanishi, K; Nojiri, T; Otsuka, T; Yamamoto, S | 1 |
| Ando, M; Atagi, S; Horinouchi, H; Ichihara, E; Ichikado, K; Kato, T; Kenmotsu, H; Kishimoto, J; Kondoh, Y; Kusumoto, M; Minegishi, Y; Nakanishi, Y; Okamoto, I; Otsubo, K; Shiraki, A; Yamamoto, N | 1 |
| Wang, L; Wang, Y | 1 |
| Fernandes Junior, HJ; Graziani, SR; Kalil Filho, R; Maranhão, RC; Morikawa, AT; Van Eyll, BM; Vital, CG | 1 |
| Arenare, L; Bergamini, A; Bologna, A; Breda, E; Bryce, J; Cecere, SC; Cinieri, S; Cormio, G; Daniele, G; Di Napoli, M; Ferrandina, G; Gallo, C; Lorusso, D; Mangili, G; Murgia, V; Natale, D; Perrone, F; Piccirillo, MC; Pignata, S; Pisano, C; Raspagliesi, F; Sacco, C; Salutari, V; Scambia, G; Signoriello, S; Sorio, R; Vergote, IB; Wagner, U | 1 |
| Dadi, N; O'Neil, BH; Sehdev, A; Shahda, S; Stanley, M | 1 |
| Chen, H; Huang, J; Kong, C; Liu, C; Liu, Z; Qian, F; Yang, K; Zhang, L | 1 |
| Bang, YJ; Boku, N; Chin, K; Hodgson, D; Im, SA; Lee, KW; Liu, YZ; Locker, G; Park, SH; Qin, S; Rha, SY; Rowe, P; Shen, L; Shi, X; Xu, N; Xu, RH | 1 |
| Li, SY; Lin, XQ; Liu, YQ; Ouyang, M; Qin, YY; Xie, ZH; Zhang, DH; Zhang, JX; Zhou, CZ | 1 |
| Azuma, M; Bando, H; Fujitani, K; Hironaka, S; Komatsu, Y; Nakayama, N; Nishina, T; Oki, E; Shimodaira, H; Shitara, K; Takahashi, T; Takashima, A; Yamaguchi, K | 1 |
| Kellett, C; Kim, CA; Lambert, P; Zhang, H | 1 |
| Aleksa, N; Benedetti Panici, P; D'Oria, O; De Felice, F; Di Pinto, A; Marchetti, C; Musella, A; Muzii, L; Palaia, I; Tombolini, V | 1 |
| Chakrabarti, S; Dong, H; Paripati, HR; Ross, HJ; Yoon, HH | 1 |
| Brugaletta, S; Filipiak, KJ; Jąkała, J; Kochman, J; Kołtowski, Ł; Malinowski, K; Ochijewicz, D; Opolski, G; Pietrasik, A; Proniewska, K; Rdzanek, A; Tomaniak, M | 1 |
| Alessandro Peccatori, F; Bani, MR; Bizzaro, F; Colombo, N; D'Agostini, E; Decio, A; Erba, E; Falcetta, F; Giavazzi, R; Minoli, L; Scanziani, E; Ubezio, P; Zucchetti, M | 1 |
| Hamada, N; Nakanishi, Y; Okamoto, I; Otsubo, K | 1 |
| Du, X; Li, M; Lin, H; Wang, PC; Zou, SH | 1 |
| Abraham, I; Alberts, DS; Alsaid, N; Bootman, JL; Erstad, B; Gharaibeh, M; McBride, A; Slack, M | 1 |
| Hazama, Y; Ishida, T; Kurebayashi, J; Matsumoto, K; Matsumoto, R; Moriya, T; Murata, S; Murata, T; Nakai, Y; Nakamura, T; Nomura, T; Shimoya, K; Sugawara, S; Sugihara, M | 1 |
| Bongiorno, C; Dahm, P; Gartlehner, G; Hwang, EC; Jung, JH; Kahlmeyer, A; Kunath, F; Narayan, V; Patel, N; Risk, MC; Skoetz, N | 1 |
| de Bruin-Visser, J; de Langen, AJ; Hashemi, SMS; Jebbink, M; Kuiper, JL; Monkhorst, K; Smit, EF; Thunnissen, E | 1 |
| Alspach, E; Burnette, B; Faget, DV; Flanagan, KC; Fu, Y; Gruosso, T; Johnson, RM; Leahy, K; Luo, X; Mbalaviele, G; Monahan, JB; Murali, B; Park, M; Ren, Q; Ross, MH; Stewart, SA; Su, X; Wang, C; Weilbaecher, KN | 1 |
| Bodurka, DC; Bookman, MA; Friedlander, M; Geller, M; Glaser, G; Herzog, TJ; Java, JJ; Krivak, TC; Lee, RB; Mutch, DG; O'Malley, DM; Olawaiye, AB; Wenham, RM | 1 |
| Diao, K; Dong, Y; Liu, Y; Mi, X; Su, L; Zhao, L | 1 |
| Benson, AB; Catalano, PJ; Lubner, SJ; Menge, MR; Munshi, HG; Nimeiri, HS; O'Dwyer, PJ; Sahai, V; Zalupski, MM | 1 |
| Boughey, JC; Buzdar, AU; Ellis, MJ; Hunt, KK; Leitch, AM; Meric-Bernstam, F; Royce, ME; Suman, VJ; Unzeitig, GW | 1 |
| Goto, M; Konishi, E; Nakatsukasa, K; Ouchi, Y; Sakaguchi, K; Taguchi, T | 1 |
| Behbakht, K; Buscema, J; Coleman, RL; Duska, LR; Fabbro, M; Falchook, G; Fu, S; Ghamande, S; Goff, B; Gray, HJ; Kurzrock, R; Leonard, EJ; Lesoin, A; Lin, HM; Lortholary, A; Martin, LP; Matulonis, U; Ray-Coquard, I; Roszak, A; Sawrycki, P; Schilder, RJ; Schwartz, PE; Sheldon-Waniga, E; Tew, W; Venkatakrishnan, K; Zhou, X | 1 |
| Adams, S; Chang, CW; Diamond, JR; Foster, PG; Funke, R; Hamilton, E; Iizuka, K; Molinero, L; Pohlmann, PR; Powderly, J; Tolaney, SM; Zhang, W | 1 |
| Bian, ZJ; Song, YK; Wang, Y; Wen, YY; Zhao, P | 1 |
| Akiyama, H; Endo, I; Fujii, Y; Kimura, J; Kosaka, T; Kunisaki, C; Miyamoto, H; Saigusa, Y; Sato, K; Sato, S; Taguri, M; Takagawa, R; Takahashi, M; Tanaka, Y; Yamanaka, T; Yukawa, N | 1 |
| Antonuzzo, L; Aprile, G; Avallone, A; Bordonaro, R; Cinieri, S; Di Donato, S; Fanotto, V; Fornaro, L; Gerratana, L; Giampieri, R; Leone, F; Melisi, D; Nichetti, F; Pellegrino, A; Rimassa, L; Rosati, G; Santini, D; Scartozzi, M; Silvestris, N; Stragliotto, S; Tomasello, G; Vasile, E | 1 |
| Nazha, B; Owonikoko, TK | 1 |
| Algül, H; Atzpodien, J; Berger, AW; Daum, S; Dickhut, A; Ettrich, TJ; Gallmeier, E; Geissler, M; König, A; Kornmann, M; Muche, R; Perkhofer, L; Prasnikar, N; Reinacher-Schick, A; Seufferlein, T; Tannapfel, A; Uhl, W; Wille, K; Wittel, U | 1 |
| Bai, R; Huang, X; Jiang, X; Li, M; Li, X; Lin, D; Liu, Z; Mai, D; Pan, L; Su, J; Tan, L; Tan, W; Yang, J; Ye, Y; Zhang, B; Zhang, J; Zhao, Q; Zheng, J; Zheng, Y; Zuo, Z | 1 |
| Collins, N; Elisofon, SA; Fawaz, R; Lee, CK; Ocwieja, KE; Sharma, TS; Shulman, DS; Vakili, K; Vargas, SO | 1 |
| Aoki, D; Arai, M; Matoda, M; Michimae, H; Mizuno, M; Nakai, H; Nakanishi, T; Nomura, H; Saito, M; Saito, T; Sasagawa, M; Sugiyama, T; Takahashi, F; Tokunaga, H; Ushijima, K; Watanabe, Y; Yaegashi, N | 1 |
| Amor, M; Belle, L; Boughalem, K; Cayla, G; Faurie, B; Godin, M; Huret, B; Karsenty, B; Leclercq, F; Piot, C; Roncalli, J; Shayne, J | 1 |
| Cybulski, M; Guz, M; Jeleniewicz, W; Kotarski, J; Marzec-Kotarska, B; Nowakowski, A; Stenzel-Bembenek, A; Stepulak, A | 1 |
| Bennink, RJ; Bijlsma, MF; Creemers, A; Ebbing, EA; Hulshof, MCCM; Jibodh, RA; Krishnadath, KK; Medema, JP; Meijer, SL; Punt, CJA; Steins, A; van Delden, OM; van der Zalm, AP; van Laarhoven, HWM; Waasdorp, C | 1 |
| Asakuma, M; Gonen, M; Haeno, H; Hur, C; Inoue, Y; Kartoun, U; Kong, CY; Liu, LL; Michor, F; Nakamura, A; Shimizu, T; Stein, S; Tramontano, AC; Uchiyama, K; Yamamoto, KN | 1 |
| Adamchuk, H; Baselga, J; Boyle, F; Ciruelos, E; Dasappa, L; de Azambuja, E; de la Pena, L; Di Cosimo, S; Fumagalli, D; Gelber, RD; Hackman, J; Hickish, T; Holmes, E; Huober, J; Jackisch, C; Jouannaud, C; Lang, I; Lecocq, C; Piccart-Gebhart, M; Sarp, S; Smith, I; Toral Pena, JC; Untch, M; Wildiers, H; Xu, B | 1 |
| Bingjing, Z; Hu, L; Liang, G; Rufu, X; Xiangdong, Z; Yuliang, W | 1 |
| Chu, DT; Fukuoka, M; Mok, TS; Rukazenkov, Y; Saijo, N; Thongprasert, S; Wu, YL; Yang, JC; Yang, JJ | 1 |
| Angelini, C; Arosio, P; Bertuzzi, A; Colombo, P; Cucchiari, D; De Sanctis, R; Faucher, E; Fusco, N; Pellegrinelli, A | 1 |
| Backes, FJ; Cohn, DE; Copeland, LJ; Eisenhauer, EL; Fowler, JM; McCann, GA; O'Malley, DM; Richardson, DL; Salani, R; Smith, B | 1 |
| Guntinas-Lichius, O; Hartmann, M; Himmel, M | 1 |
| Feeney, A; Fernando, I; Hackshaw, A; Hall-Craggs, MA; Hammond, M; James, L; Kadalayil, L; Ledermann, JA; McCormack, M; Simonds, H; Symonds, RP; Warwick, V | 1 |
| Ala-Luhtala, T; Asola, R; Elomaa, L; Heikkinen, M; Huusko, M; Järvenpää, R; Kaleva-Kerola, J; Kellokumpu-Lehtinen, P; Kokko, R; Lehtinen, I; Maiche, A; Möykkynen, K; Tuunanen, T | 1 |
| Li, D; Yao, X; Zhang, P | 1 |
| Bean, Y; Beckmann, MW; Beesley, J; Berchuck, A; Brown, R; Camey, ME; Chen, X; Chenevix-Trench, G; Cramer, DW; Cunningham, JM; deFazio, A; Despierre, E; du Bois, A; Ekici, AB; Emmanuel, C; Fasching, PA; Fereday, S; Fridley, BL; Gao, B; Goode, EL; Goodman, MT; Haber, M; Harter, P; Hedditch, EL; Heitz, F; Henderson, MJ; Hogdall, C; Hogdall, E; Jensen, A; Johnatty, SE; Karlan, BY; Kjaer, SK; Lambrechts, S; Law, MH; Lester, J; Levine, DA; Lu, Y; Lurie, G; MacGregor, S; Norris, MD; Paul, J; Pejovic, T; Russell, AJ; Schwaab, I; Shildkraut, J; Terry, KL; Thompson, PJ; Vergote, I; Vierkant, RA; Webb, PM | 1 |
| Asami, K; Atagi, S; Hirashima, T; Kawaguchi, T; Kawase, I; Morishita, N; Nakao, K; Okamoto, N; Okishio, K; Otsuka, T; Shiroyama, T; Suzuki, H; Tamiya, A; Tamiya, M; Yamadori, T; Yasue, T | 1 |
| Aoki, D; Banno, K; Katakura, S; Kisu, I; Nogami, Y; Tominaga, E; Tsuji, K; Umene, K | 1 |
| Bergh, J; Carlsson, L; Einbeigi, Z; Hatschek, T; Lidbrink, E; Linderholm, BK; Norberg, B; Olsson, ME; Svensson, H; Tallroth, E; von Wachenfeldt, A; Wilking, N | 1 |
| Arrowsmith, ER; Hainsworth, JD; Hauke, RJ; Infante, JR; Rubin, MS; Shih, KC | 1 |
| Bian, X; Cheng, K; Guo, W; He, X; Huang, S; Jiang, X; Xu, J; Zhang, L | 1 |
| La Flamme, AC; Miller, JH; Northcote, PT; O'Sullivan, D | 1 |
| Abraham, J; Adamson, LM; Buyse, M; Jacobs, SA; Jankowitz, RC; Limentani, SA; Tan, AR; Tierno, MB; Wolmark, N | 1 |
| André, F; Campone, M; Dalenc, F; El-Hashimy, M; Gligorov, J; Hurvitz, SA; Jhangiani, H; Lincy, J; Llombart, A; Miao, S; Mirshahidi, HR; O'Regan, RM; Sahmoud, T; Soria, JC; Tan-Chiu, E; Taran, T; Tjan-Heijnen, VC | 1 |
| Chen, J; Fan, PS; He, YF; Hu, B; Hu, CL; Ji, CS; Jiang, FS; Wang, W; Yao, YW; Zhu, L | 1 |
| Brambilla, D; Caron, J; Couvreur, P; Desmaele, D; Gueutin, C; Lepape, A; Lerondel, S; Maksimenko, A; Mougin, J; Mura, S; Sliwinski, E; Zouhiri, F | 1 |
| Feng, J; Gao, J; Han, Y; Huang, H; Qu, L; Shen, L; Shou, C; Zhu, L | 1 |
| Day, JM; Foster, PA; Kasprzyk, PG; Meyer-Losic, F; Newman, SP; Purohit, A; Reed, MJ | 1 |
| Arnold, AM; Boyer, MJ; Bradbury, PA; Chen, EX; Clingan, P; Ding, K; Ellis, PM; Fenton, D; Goss, GD; Hirsh, V; Laberge, F; Laurie, SA; Lee, CW; Montenegro, A; Seymour, L; Shepherd, FA; Solomon, BJ; Stockler, MR; Zukin, M | 1 |
| He, D; Li, M; Qian, Z; Wang, J; Wang, R; Xiao, Q; Xiao, X | 1 |
| Hakamada, K; Kawasaki, H; Kimura, A; Nakai, M; Nakayama, Y; Wajima, N; Yonaiyama, S | 1 |
| Bai, C; Bai, Y; Cheng, Y; Fan, Q; Gong, J; Hu, B; Hu, G; Jiao, S; Liang, J; Liu, Y; Shen, L; Shi, Y; Wang, J; Xu, N; Xu, R; Zhang, F; Zhang, J; Zhang, X; Zheng, L | 1 |
| Hulshoff, JB; Plukker, JT; Smit, JK; van der Jagt, EJ | 1 |
| Bologna, A; Breda, E; Cavazzini, MG; Cinieri, S; Cormio, G; De Placido, S; Di Maio, M; Ferrandina, G; Gallo, C; Greggi, S; Katsaros, D; Lauria, R; Lorusso, D; Marchetti, C; Murgia, V; Panici, PB; Perrone, F; Piccirillo, MC; Pignata, S; Pisano, C; Pujade-Lauraine, E; Raspagliesi, F; Ricci, C; Sacco, C; Salutari, V; Scambia, G; Selvaggi, L; Signoriello, S; Sorio, R; Weber, B | 1 |
| Chen, X; Dai, H; Qian, Z; Wang, Y; Xu, X; Zhao, Y | 1 |
| Egami, Y; Hamasaki, T; Hara, M; Kato, H; Lee, Y; Makino, N; Nakamura, D; Nishino, M; Sakata, Y; Shutta, R; Taniike, M; Tanouchi, J; Yamada, Y; Yoshimura, T | 1 |
| Choi, M; Kim, R; Saif, MW | 1 |
| Altan, B; Araki, K; Hosouchi, Y; Kashiwabara, K; Kubo, N; Kuwano, H; Suzuki, H; Suzuki, S; Tsukagoshi, M; Wada, S; Watanabe, A; Yokobori, T | 1 |
| Cao, Y; Gong, J; Li, J; Li, Y; Lu, M; Lu, Z; Shen, L; Wang, X; Wu, Y; Zhang, X; Zhou, J | 1 |
| Le, V; Lin, S; Liu, J; Que, Z; Tian, J; Zhang, A; Zhang, L; Zheng, Y | 1 |
| Arrieta, O; Dorantes-Gallareta, Y; Flores-Estrada, D; Macedo-Pérez, EO; Mendoza-García, VO; Morales-Oyarvide, V | 1 |
| Costa, VM; Diniz, C; Fresco, P; Soares, AS | 1 |
| Dedicoat, M; Freeman, EE; Gbabe, OF; Okwundu, CI | 1 |
| Carrasco, M; Cowden Dahl, KD; Dahl, R; Joseph, S; Li, J; Roy, L; Samyesudhas, SJ | 1 |
| Bos, MM; Boven, E; Braun, JJ; de Groot, SM; Honkoop, AH; Jager, A; Kroep, JR; Lam, SW; Linn, SC; ten Tije, AJ; van den Bosch, J; van Tinteren, H | 1 |
| Koizumi, W; Morita, S; Sakata, Y | 1 |
| Chang, CH; Chen, CC; Chiu, WT; Chou, CY; Hsu, KF; Huang, SC; Huang, YF; Tsai, HY | 1 |
| Fujita, S; Hata, A; Hattori, Y; Imamura, F; Kaji, R; Kumagai, T; Mori, M; Morita, S; Negoro, S; Nishimura, T; Satouchi, M; Shimada, T; Sunadome, H; Tachihara, M; Urata, Y; Yoneda, T | 1 |
| Blanchard, Z; Craft, B; ElShamy, WM; Paul, BT | 1 |
| Fujii, K; Kan, S; Kawashima, M; Kiso, M; Takeyama, O; Tanaka, M | 1 |
| Brener, SJ; Brodie, BR; Ertelt, K; Genereux, P; Guagliumi, G; Mehran, R; Stone, GW; Witzenbichler, B; Xu, K | 1 |
| Chang-Halpenny, C; Hwang-Graziano, J; Lu, SM | 1 |
| Ayala, AG; Choi, EK; Divatia, M; Miles, BJ; Okoye, E; Ro, JY | 1 |
| Banna, GL; D'Agate, G; Gieri, S; Lipari, H; Scandurra, G; Scibilia, G; Scollo, P | 1 |
| Chen, Q; Liu, Q; Shen, S; Shi, C; Wu, R; Xu, Q; Yang, B | 1 |
| Ding, W; Li, J; Li, Y; Wang, X | 1 |
| Gemma, A; Hagiwara, K; Inoue, A; Isobe, H; Kobayashi, K; Maemondo, M; Miyauchi, E; Nukiwa, T; Oizumi, S; Saijo, Y; Sugawara, S; Yoshizawa, H | 1 |
| Bernardo, A; Ferzi, A; Gambaro, A; Palumbo, R; Piazza, E; Pozzi, E; Sottotetti, F; Spinapolice, EG; Tagliaferri, B; Teragni, C; Trifirò, G | 1 |
| Funato, Y; Ito, K; Ito, Y; Iwata, H; Nakamura, S | 1 |
| Allen, PK; Blumenschein, GR; Hong, WK; Komaki, R; Lee, JJ; Liu, DD; Tang, X; Wei, X; Welsh, JW; Wistuba, II | 1 |
| Chang, JY; Chang, YW; Chen, HA; Chen, LT; Chen, PS; Hong, CC; Huang, MT; Jiang, SS; Su, CM; Su, JL; Su, YH; Sung, SY; Wang, MY; Wu, CH | 1 |
| Bai, C; Gao, Z; Han, B; Li, H; Li, Q; Li, X; Liu, W; Lu, D; Ma, K; Qian, J; Wang, H; Wang, J; Wang, S; Wang, X; Wu, J; Wu, W; Zhao, X | 1 |
| Chen, J; Lin, X; Liu, P; Liu, X; Song, C; Tang, H; Wang, N; Xie, X; Yang, L | 1 |
| Baumgartner, S; Jüni, P; Meier, B; Räber, L; Stefanini, GG; Taniwaki, M; Wenaweser, P; Windecker, S; Zanchin, T; Zaugg, S | 1 |
| Leunen, K; Moerman, P; Neven, P; Salihi, R; Van Limbergen, E; Vergote, I | 1 |
| Chan, MM; Donoghue, E; Ghersi, D; Simes, J; Wilcken, N; Willson, ML | 1 |
| Beale, P; Carey, MS; Cervantes, A; Cook, AD; Embleton, A; Farrelly, L; Jayson, GC; Joly, F; Kaplan, R; Kristensen, G; Ledermann, JA; Mirza, MR; Oza, AM; Park-Simon, TW; Parmar, MK; Perren, TJ; Pfisterer, J; Plante, M; Poveda, A; Pujade-Lauraine, E; Quinn, M; Rustin, G; Stark, D; Swart, AM | 1 |
| Basu, R; Brunt, KR; Das, SK; Fisher, PB; Konar, S; Kumar, BNP; Mandal, M; Mazumdar, A; Pathak, A; Puvvada, N; Rajput, S; Rao, RR; Sarkar, S | 1 |
| Bartoń, S; Biernacka, B; Krawczyk, P; Małecka-Massalska, T; Milanowski, J; Mlak, R; Powrózek, T | 1 |
| Chen, S; Deng, Q; Jing, S; Li, J; Li, X; Ma, S; Tang, R; Wu, K; Wu, Z; Zheng, Z | 1 |
| Beijnen, JH; Harms, E; Marchetti, S; Mergui-Roelvink, MW; Rehorst, H; Schellens, JH; Sonke, GS; Steeghs, N; van der Noll, R | 1 |
| Dobelbower, M; Donavanik, V; Gomella, L; Grignon, D; Hamstra, DA; Hartford, AC; Hunt, D; Jones, CU; Kerlin, KJ; Kim, H; Kuban, DA; Michalski, J; Moughan, J; Pienta, KJ; Rajan, R; Rosenthal, SA; Rotman, M; Sandler, H; Sartor, AO; Seider, M; Shipley, WU; Zeitzer, K | 1 |
| Albers, P; Bellmunt, J; Buonerba, C; Choueiri, TK; Di Lorenzo, G; Kitamura, H; Kume, H; Lee, JL; Matsumoto, K; Mullane, S; Necchi, A; Niegisch, G; Pond, GR; Rozzi, A; Sonpavde, G | 1 |
| Bafna, UD; Devi, UK; Kundargi, R; Pallavi, VR; Rathod, PS; Vijay, CR | 1 |
| Patel, SA | 1 |
| Kang, X; Li, T; Sun, J | 1 |
| Aggarwal, C; Bauml, J; Brady, AK; Cohen, RB; Evans, TL; Judy, B; Langer, C; McNeill, JD; Vachani, A | 1 |
| Adachi, K; Amano, S; Enomoto, K; Hara, Y; Makishima, M; Nagashima, S; Sakurai, K; Suzuki, S | 1 |
| Arsenic, R; Braicu, EI; Dietel, M; Keilholz, U; Letsch, A; Ochsenreither, S; Sehouli, J | 1 |
| Lariño Noia, J | 1 |
| Brossart, P; Cathomas, R; Klingbiel, D; Mark, M; Mey, U; Volk, V; von Moos, R | 1 |
| Bhonagiri, S; Engblom, C; Farokhzad, OC; Gadde, S; Kamaly, N; Kohler, RH; Laughney, AM; Miller, MA; Pfirschke, C; Pittet, MJ; Sprachman, MM; Weissleder, R; Wojtkiewicz, G; Yang, KS | 1 |
| Bidziński, M; Bjørge, L; Colombo, N; de Gregorio, N; Del Campo, JM; Denison, U; du Bois, A; Harter, P; Heubner, M; Hilpert, F; Kristensen, G; Lortholary, A; Malander, S; Meier, W; Merger, M; Minarik, T; Mirza, MR; Nicoletto, MO; Ottevanger, P; Pfisterer, J; Pignata, S; Ray-Coquard, I; Reuss, A; Sailer, MO; Scambia, G; Sevin, E; Vergote, I | 1 |
| Hara, F; Hozumi, Y; Imoto, S; Matsubara, N; Mukai, H; Nishimura, R; Ohashi, Y; Park, Y; Sagara, Y; Saito, T; Shimozuma, K; Takano, T; Takashima, T; Toyama, T; Tsurutani, J; Watanabe, T | 1 |
| Bennouna, J; Chand, VK; Chen, YM; Chouaid, C; De Marinis, F; Feng, JF; Grossi, F; Kim, DW; Kim, JH; Liu, X; Lu, S; Park, K; Planchard, D; Schuler, M; Strausz, J; Vinnyk, Y; Wang, B; Wiewrodt, R; Yang, JC; Zhou, C | 1 |
| Barton, D; Beck, RM; Brufsky, A; Coleman, RE; Conte, PF; Cortes, J; Glück, S; Harbeck, N; Ko, A; Nabholtz, JM; O'Shaughnessy, J; Renschler, MF; Yardley, DA | 1 |
| Cella, CA; Fazio, N; Frezza, AM; Galdy, S; Murgioni, S; Ravenda, SP; Spada, F; Zampino, MG | 1 |
| Arpino, G; Cortés, J; Leonard, R; Llombart-Cussac, A; Marmé, F; Ricevuto, E | 1 |
| Kovács, G; Meyer, JE; Ritter, M; Schröder, U; Teudt, IU; Wollenberg, B | 1 |
| Costantini, M; Di Leone, A; Ferrucci, M; Franceschini, G; Masetti, R; Mulè, A; Sanchez, AM; Scaldaferri, A | 1 |
| Ansel, GM; Dake, MD; Jaff, MR; Machan, LS; O'Leary, EE; Ohki, T; Ragheb, AO; Saxon, RR; Smouse, HB; Snyder, SA; Zeller, T | 1 |
| Ba, Y; Jiang, RC; Kong, Q; Li, K; Wang, XY | 1 |
| Abrams, KR; Amonkar, MM; Bell, H; Casey, M; Latimer, NR | 1 |
| Pugliano, L; Ryan, C; Tsoi, D; White, M; Woodward, N | 1 |
| Bu, ZD; Ji, JF; Li, ZY; Ren, H; Tang, L; Wu, AW; Yuan, P | 1 |
| Han, SJ; Kim, JH; Kim, JI; Park, KM | 1 |
| Kan, X; Li, Q; Li, Y; Liu, Y; Luo, Y; Ma, Z; Na, D; Su, B; Wang, C; Wang, L; Wang, P; Zhang, G; Zhang, Y; Zhu, X | 1 |
| de Santis, V; Duggett, NA; Flatters, SJ; Griffiths, LA; McKenna, OE; Mokori, EB; Yongsanguanchai, N | 1 |
| Gyawali, B; Prasad, V | 1 |
| Beyer, J; Lorch, A | 1 |
| Choi, KU; Do, KH; Kim, J; Kim, KH; Moon, Y; Park, SH | 1 |
| Li, JS; McGovern, D; Romano, A; Römmler-Zehrer, J; Stahl, M; Vogel, A | 1 |
| Brown, J; Burzawa, JK; Byers, LA; Coleman, RL; Frumovitz, M; Munsell, MF; Ramalingam, P | 1 |
| Jin, SL; Liu, YY; Luo, SX; Tang, H; Wang, HY; Yang, SJ; Yao, SN; Yao, ZH; Zhao, Y; Zhou, WP | 1 |
| Abesamis-Tiambeng, ML; Akewanlop, C; Baczkowski, M; Baramidze, K; Barve, A; Bondarenko, I; Hernandez-Bronchud, M; Herson, J; Kothekar, M; Loganathan, S; Mamillapalli, G; Manikhas, A; Mukhametshina, G; Nemsadze, G; Parra, JD; Pennella, E; Ray, S; Rugo, HS; Sharma, R; Sriuranpong, V; Vynnychenko, I; Waller, CF; Yanez Ruiz, EP; Yuan, J | 1 |
| Fukabori, M; Itoh, Y; Morita, A; Nakayama, M; Saito, H; Suematsu, Y; Takahashi, M; Wakabayashi, K; Yamagishi, S | 1 |
| de Boer, M; Dercksen, MW; Joore, MA; Lobbezoo, DJA; Peters, FPJ; Peters, NAJB; Ramaekers, BLT; Smilde, TJ; Tjan-Heijnen, VCG; van de Wouw, AJ; van den Berkmortel, F; van Kampen, RJW; van Riel, JMG | 1 |
| Goense, L; Haj Mohammad, N; Meijer, GJ; Mook, S; Ruurda, JP; van der Horst, S; van der Sluis, PC; van Hillegersberg, R; van Rossum, PSN; van Vulpen, M | 1 |
| Azuma, M; Goto, H; Hanibuchi, M; Kakiuchi, S; Kawano, H; Nishioka, Y; Ogushi, F; Otsuka, K; Saijo, A; Sakaguchi, S; Tezuka, T; Toyoda, Y | 1 |
| Almendros, P; Blasco, A; Bremnes, RM; Camps, C; Gavilá, J; Iranzo, V; Sirera, R | 1 |
| Cameron, DA; Stein, S | 1 |
| Baselga, J; Prat, A | 1 |
| Ishikawa, H; Kikuchi, N; Ohara, G; Satoh, H; Sekizawa, K | 1 |
| Furuiye, M; Inase, N; Ishiwata, N; Jin, Y; Miyake, S; Miyashita, Y; Takano, S; Yoshizawa, M; Yoshizawa, Y | 1 |
| Ambrosone, CB; Armstrong, D; Baysal, BE; Darcy, KM; DeLoia, JA; Gallion, H; Krivak, TC; Tian, C | 1 |
| Hakenberg, OW; Klebingat, HJ; Protzel, C | 1 |
| Bartelheim, K; Christopeit, M; Forstpointner, R; Kühnbach, R; Lenz, G; Naujoks, K; Schalhorn, A | 1 |
| An, N; Gao, M; Gao, YN; Jiang, GQ; Yan, X | 1 |
| Ettinger, S; Fazli, L; Gleave, ME; Hayashi, N; Kim, Y; Muramaki, M; Narita, S; So, A | 1 |
| Harano, M; Higaki, K; Kagemoto, M; Kin, R; Masumura, K; Matsuura, H; Ohtani, S; Takada, S; Urashima, M | 1 |
| Ahn, JB; Chang, H; Chung, HC; Im, CK; Jeung, HC; Kwon, WS; Rha, SY; Roh, JK; Yoo, NC | 1 |
| Bonomi, PD; Cohen, G; De Braud, F; Eberhardt, WE; Herbst, RS; Heymach, JV; Johnson, BE; Krebs, AD; Paz-Ares, L; Ranade, AA; Sandler, AB; Sebastian, M; Stewart, DJ; Trigo, JM; Vasselli, J | 1 |
| Kamiyama, Y; Kano, Y; Kobayashi, H; Kodama, T; Mori, K | 1 |
| Akimoto, H; Ino, K; Ishida, Y; Isobe, K; Kajiyama, H; Kikkawa, F; Nawa, A; Shibata, K; Takikawa, O; Terauchi, M; Yamamoto, E; Yoshida, N | 1 |
| Allen, CJ; De Souza, R; Grant, J; Moriyama, EH; Piquette-Miller, M; Vassileva, V; Wilson, BC | 1 |
| Bartelsman, JF; Busch, OR; Koning, CC; Koppert, LB; Muller, K; Offerhaus, GJ; Richel, DJ; Steyerberg, EW; Tilanus, HW; van Berge Henegouwen, MI; van Dekken, H; van der Gaast, A; van Heijl, M; van Lanschot, JJ; Wijnhoven, BP | 1 |
| Chae, YS; Chung, HY; Do, YR; Hyun, MS; Jung, JS; Kim, GC; Kim, JG; Kim, MK; Kwon, KY; Lee, KH; Lee, WS; Sohn, CH; Sohn, SK; Song, HS; Yu, W | 1 |
| Chouaid, C; Freitag, L; Gibbs, D; Jameson, MB; Lafitte, JJ; Mainwaring, PN; McKeage, MJ; Quoix, E; Reck, M; Rosenthal, MA; Serke, M; Sullivan, R; Von Pawel, J | 1 |
| Axtell, AE; Bottsford-Miller, J; Drake, RD; Fader, AN; Gehrig, PA; Gibbons, H; Havrilesky, LJ; Huh, WK; Kelley, JL; Moore, KN; Nagel, C; O'Malley, DM; Rose, PG; Secord, AA; Tuller, E; Walsh, CS; Zanotti, KM | 1 |
| Ball, D; Campeau, MP; Drummond, E; Herschtal, A; Hogg, A; Mac Manus, M; Michael, M; Wheeler, G; Wirth, A | 1 |
| Liu, C; Shen, W; Sun, Q; Wang, D; Xu, H; Zhong, B; Zhong, H | 1 |
| Bagley, RG; Crawford, JL; Krumbholz, RD; Kurtzberg, LS; Roth, SD; Rouleau, C; Schmid, SM; Teicher, BA; Yao, M | 1 |
| Bao, QL; Chen, P; Dai, CH; Li, J; Li, XQ | 1 |
| Kunitoh, H; Saijo, N; Takeuchi, M | 1 |
| Manegold, C | 1 |
| Bonomi, P; Langer, C; Lilenbaum, R; O'Brien, M; O'Byrne, K; Oldham, FB; Ross, HJ; Sandilac, L; Singer, JW; Socinski, M; Villaflor, VM | 1 |
| Allocco, DJ; Baim, DS; Dawkins, KD; Leon, MB | 1 |
| Avallone, A; Chiuri, VE; Cioffi, R; Comella, P; Costanzo, R; De Cataldis, G; Filippelli, G; Franco, L; Greco, E; Maiorino, L; Mancarella, S; Palmeri, L; Putzu, C; Vessia, G | 1 |
| Bonomi, P; Girvan, AC; Govindan, R; Guba, SC; Hong, S; Obasaju, C; Patel, JD; Pennella, EJ; Socinski, MA | 1 |
| Akimoto, H; Inaba, T; Ino, K; Kajiyama, H; Kikkawa, F; Nagasaka, T; Nawa, A; Shibata, K; Takikawa, O; Yamamoto, E | 1 |
| Bang, YJ; Heo, DS; Im, SA; Kim, DW; Kim, TY; Kim, YW; Lee, JS; Lee, SH; Oh, DY; Sun, JM | 1 |
| Bockisch, A; Dralle, H; Kegel, T; Mann, K; Matuszczyk, A; Petersenn, S; Schmoll, HJ; Voigt, W | 1 |
| Chen, ZG; Choi, M; El-Naggar, AK; Khuri, FR; Muller, S; Papadimitrakopoulou, VA; Saba, NF; Shin, DM; Shin, HJ; Tighiouart, M | 1 |
| Blaskó, G; Nagy, Z; Turcsik, V | 1 |
| Ozols, RF | 1 |
| Bang, YJ; Han, HS; Im, SA; Jeon, YK; Kim, JH; Kim, JS; Kim, TY; Lee, KW; Oh, DY; Park, IA; Park, JH; Park, SY | 1 |
| Capasso, I; Comella, G; Comella, P; D'Aiuto, G; D'Aiuto, M; Di Bonito, M; Frasci, G; Iodice, G; Lastoria, S; Montella, M; Oliviero, P; Petrillo, A; Ruffolo, P; Santangelo, M; Siani, C; Vizioli, L | 1 |
| Abe, T; Inoue, A; Ishida, T; Kanbe, M; Maemondo, M; Nukiwa, T; Saijo, Y; Sakakibara, T; Sugawara, S; Usui, K; Watanabe, H | 1 |
| Choi, HS; Kang, WD; Kim, SM | 1 |
| Amant, F; Berteloot, P; Leunen, K; Neven, P; Vandenput, I; Vergote, I | 1 |
| Arita, K; Awaya, H; Kajihara, T; Kashiwado, K; Matsuura, K; Mito, A; Nitta, T; Ohashi, N; Yamasaki, M | 1 |
| Blanch, JL; Caballero, M; Grau, JJ; Monzó, M; Verger, E | 1 |
| du Bois, A; Harter, P; Huober, J; Loibl, S; Pfisterer, J; Reichardt, VL; Stopfer, P; Wimberger, P | 1 |
| Allen, AM; Annino, DJ; Busse, PM; Chan, AW; Clark, JR; Goguen, LA; Haddad, RI; Li, Y; Norris, CM; Posner, MR; Tishler, RB; Wirth, LJ | 1 |
| Amant, F; Bauknecht, T; Darstein, C; Kania, M; Michel, AL; Musib, L; Oskay-Oezcelik, G; Sehouli, J; Vergote, I | 1 |
| Baba, K; Hasegawa, Y; Ichikawa, M; Imaizumi, K; Kataoka, K; Kondo, M; Kume, H; Matsumoto, S; Noda, Y; Shindo, Y; Shindoh, J; Suzuki, K; Suzuki, R; Takagi, K; Taniguchi, H; Tanikawa, Y | 1 |
| Aramendía, JM; Arbea, L; Aristu, JJ; Cambeiro, M; Espinós, J; Gaztañaga, M; Jurado, M; Martínez-Monge, R | 1 |
| Hoshina, A; Kato, M; Onishi, T; Yabana, T | 1 |
| Arakawa, S; Fujisawa, M; Matsumoto, O; Shigemura, K; Yasufuku, T | 1 |
| Belani, CP; Chen, R; Edelman, MJ; Monberg, MJ; Obasaju, CK; Socinski, MA; Treat, J | 1 |
| Edina, M; László, L; Tamás, N | 1 |
| Hogberg, T | 1 |
| Antoniou, D; Bastas, A; Dimitroulis, J; Georgatou, N; Lolis, N; Marosis, K; Michalopoulou, P; Pappas, C; Provata, A; Stathopoulos, GP; Stathopoulos, J; Toubis, M; Tsoukalas, G; Veldekis, D; Yiamboudakis, P | 1 |
| Chen, SC; Lu, ZH; Wu, F; Xiong, JP | 1 |
| Khasraw, M; Murphy, CG; Seidman, AD | 1 |
| Bae, SH; Baek, JH; Chae, YS; Do, YR; Kim, JG; Kim, JY; Kim, MK; Lee, KH; Park, KU; Ryoo, HM; Song, HS | 1 |
| Hozumi, Y; Masuda, N; Mitsuyama, S; Mukai, H; Murakami, S; Ohashi, Y; Ohmura, T; Takashima, T; Watanabe, T; Yajima, T | 1 |
| Ito, S; Kawai, H; Matsuo, K; Muro, K; Sawaki, A; Shibata, T; Shitara, K; Tajika, M; Takahari, D; Ura, T; Yokota, T | 1 |
| Alexandre, J; Cottu, P; Falandry, C; Floquet, A; Lebrun, D; Pujade-Lauraine, E; Ray-Coquard, I; Selle, F; Weber, B | 1 |
| Bryan, M; Pavlick, AC; Pliner, L; Pulte, ED; Saunders, T; Toomey, KC; Wieder, R | 1 |
| Alexopoulos, D; Damelou, A; Davlouros, PA; Karantalis, V; Mavronasiou, E; Nikokiris, G; Tsigkas, G; Xanthopoulou, I | 1 |
| Borgato, L; Donach, ME; Furini, L; Lombardi, G; Nicoletto, MO; Palma, MD; Zustovich, F | 1 |
| Socinski, MA; Stinchcombe, TE | 1 |
| Albers, P; Fechner, G; Fimmers, R; Heidenreich, A; Heimbach, D; Lehmann, J; Niegisch, G; Park, SI; Siener, R; Steiner, U | 1 |
| Araki, O; Chida, M; Fukushima, Y; Honma, K; Inoue, T; Tamura, M; Tatewaki, M; Umezu, H | 1 |
| Bondarenko, IN; Jagiello-Gruszfeld, A; Kellum, A; Messam, C; Mostafa Kamel, Y; Patwardhan, R | 1 |
| Aragane, H; Ichikawa, D; Itokawa, Y; Kakihara, N; Koizumi, K; Morii, J; Morita, S; Nishi, H; Okamoto, K; Otsuji, E; Sakamoto, J; Shimotsuma, M; Taniguchi, F; Ueda, Y; Yamagishi, H; Yamashita, T | 1 |
| Agarwala, S; Bedikian, AY; Conry, R; DeConti, RC; Ernstoff, M; Kim, KB; Papadopoulos, N | 1 |
| Casado, MÁ; Cortés, J; Frías, C; Oyagüez, I; Seguí, MÁ | 1 |
| Agustí, C; Campayo, M; Casas, F; Ferrer, F; Jeremic, B; Lomeña, F; Maria Gimferrer, J; Sanchez, M; Viñolas, N | 1 |
| Fujii, M; Hasegawa, Y; Kurono, Y; Minami, H; Nibu, K; Onozawa, Y; Sagae, D; Seriu, T; Tahara, M; Tomita, K; Tsukuda, M; Watanabe, A | 1 |
| Fietkau, R; Iro, H; Klautke, G; Kuwert, T; Lell, M; Linke, R; Semrau, S; Uder, M; Waldfahrer, F | 1 |
| Duman, BB; Ercolak, V; Günaldi, M; Kara, IO | 1 |
| Corona, M; Falbo, T; Lanzetta, G; Nardoni, C; Restuccia, MR; Rozzi, A | 1 |
| Friedlander, ML; Kiernan, MC; Krishnan, AV; Lewis, CR; Lin, CS; Park, SB | 1 |
| Iishi, H; Imamoto, H; Kakutani, C; Morimoto, T; Morita, S; Nakamura, M; Narahara, H; Oba, K; Oriuchi, N; Sakamoto, J; Shiozaki, H; Yumiba, T | 1 |
| Chang, B; Cheng, X; Chiao, P; Du, X; Liu, G; Liu, J; Mercado-Uribe, I; Rosen, DG; Wu, X; Xiao, X; Xue, F; Yang, G | 1 |
| Cordeiro, P; D'Andrea, G; Dang, C; Dickler, MN; Fornier, M; Gilewski, T; Grothusen, J; Hawks, L; Hudis, CA; Lake, D; Laragh, JH; McArthur, HL; Melisko, M; Merali, C; Moasser, M; Modi, S; Morrow, M; Moynahan, ME; Norton, L; Nulsen, B; Park, J; Patil, S; Paulson, M; Robson, M; Rugo, H; Sealey, JE; Seidman, A; Sklarin, N; Steingart, R; Sugarman, S; Theodoulou, M; Traina, T; Zhou, Q | 1 |
| Ducoloné, A; Fraisse, P; Mennecier, B; Quoix, E | 1 |
| Chihade, D; Desai, N; Flister, MJ; Ran, S; Trieu, V; Volk, LD | 1 |
| Bai, H; Han, B; Qian, J; Shen, J | 1 |
| Ambrosone, CB; Bookman, M; Darcy, KM; Deloia, JA; Gallion, H; Krivak, TC; Tian, C | 1 |
| Au, JS; Chang, GC; Cheng, AC; Tsai, CM; Wu, YL; Zhou, C | 1 |
| Dai, H; Liu, JW; Yan, D | 1 |
| Agelaki, S; Ardavanis, A; Chandrinos, V; Christophyllakis, C; Georgoulias, V; Giassas, S; Karachaliou, N; Kotsakis, A; Pallis, AG; Polyzos, A; Samonis, G; Saridaki, Z; Syrigos, K; Vamvakas, L; Vardakis, N; Varthalitis, I | 1 |
| Jenks, S | 1 |
| Brufsky, AM; Copur, MS; Davis, J; Generali, D; Gernhardt, D; Giguere, JK; Gressot, L; Huang, X; Kern, KA; Liau, KF; Minton, SE; Paul, D; Richards, PD; Robert, NJ; Saleh, MN; Smith, JW | 1 |
| Barnett, F; Harris, SJ; Seah, JA; White, SC | 1 |
| Arrieta, O; Bajetta, E; Benner, RJ; Boyer, M; Eberhardt, WE; Fowst, C; Hirsh, V; Meech, SJ; Middleton, G; Paz-Ares, L; Raats, J; Readett, D; Reiterer, P; Rosell, R; Saleh, M; Schiller, JH; Szczesna, A; Webb, RT | 1 |
| Albain, KS; Besse, B; Blais, N; Chao, RC; Gervais, R; Hainsworth, JD; Hamm, JT; Kim, ST; Laskin, J; Lipton, A; Masters, GA; Natale, RB; Page, RD; Selaru, P | 1 |
| Bordeaux, JS; Honda, KS; Robinson, MR | 1 |
| Andelković, T; Banković, J; Pešić, M; Podolski-Renić, A; Ruždijić, S; Tanić, N | 1 |
| Aogi, K; Fujiwara, Y; Ito, Y; Iwata, H; Kamigaki, S; Kashiwaba, M; Masuda, N; Oda, T; Ohno, S; Takashima, S; Ueno, T | 1 |
| Bechstein, WO; Bodoky, G; Cwiertka, K; Fischbach, W; Fölsch, UR; Haas, SL; Jäger, D; Löhr, JM; Lutz, MP; Osinsky, D; Prausova, J; Schmidt, WE | 1 |
| Kang, WK; Lee, J; Lee, S; Lim, HY; Park, JO; Park, S; Park, SH; Park, YS | 1 |
| Colson, YL; Grinstaff, MW; Padera, RF; Schulz, MD; Wade, JE; Xu, X; Zubris, KA | 1 |
| Hamamdzic, D; Huibregtse, BA; Keane, MG; Llano, R; Patel, DB; Seifert, PS; Wang, H; Wilensky, RL; Wilson, GJ; Winsor-Hines, D | 1 |
| Berger, DP; Chen, Y; Krzakowski, MJ; Lizambri, R; Massuti, B; Otterson, GA; Schuette, W; Wei, H | 1 |
| Ahn, H; Ahn, JH; Ahn, S; Hong, JH; Kim, CS; Kwon, JH; Lee, JL; Lim, HY; Park, SH; Song, C | 1 |
| Mäenpää, J | 1 |
| Kondo, C; Mizota, A; Muro, K; Nomura, M; Shitara, K; Takahari, D; Ura, T; Yokota, T | 1 |
| Abbas, A; Fakih, M; Nehme, E | 1 |
| Karlan, BY; Kuchimanchi, M; Lu, JF; Melara, R; Navale, L; Rasmussen, E; Stepan, DE; Sun, YN; Vergote, IB; Weinreich, DM | 1 |
| Bacoyiannis, C; Bafaloukos, D; Boukovinas, I; Dimopoulos, MA; Fountzilas, G; Kalofonos, HP; Kosmidis, PA; Pavlidis, N; Pectasides, D; Skarlos, D; Syrigos, K | 1 |
| Alexandre, J; Brown, C; Chalchal, H; Coeffic, D; Ferrero, A; Fitzharris, B; Mäenpää, J; Pfisterer, J; Pisano, C; Pujade-Lauraine, E; Raban, N; Vergote, I; Volgger, B | 1 |
| Knecht, R; Laban, S; Münscher, A; Schafhausen, P; Tribius, S; Wang, CJ | 1 |
| Bekele, BN; Biernacka, A; Erez, B; Herbst, RS; Hosho, K; Jacoby, JJ; Jürgensmeier, JM; Komaki, R; Korshunova, MV; O'Reilly, MS; Ryan, A; Smith, PD; Takahashi, O; Wistuba, II | 1 |
| Ball, M; Chester, J; Coffey, M; Gore, ME; Hall, GD; Harrington, KJ; Karapanagiotou, EM; Larkin, J; Melcher, AA; Mettinger, K; Newbold, K; Nutting, C; Pandha, HS; Roulstone, V; Syrigos, KN; Tanay, M; Thompson, B; Twigger, K; Vile, RG | 1 |
| Bai, CX; Gu, AQ; Guo, SL; Han, BH; Jiang, LY; Jin, B; Jin, XQ; Liu, WC; Luo, Y; Shen, J; Shi, CL; Wang, HM; Xiu, QY; Zhang, Y; Zhao, YZ; Zhou, JY; Zhuang, ZX | 1 |
| Jin, ZL; Li, K; Li, N; Liu, ZJ; Wang, J | 1 |
| Thigpen, T | 1 |
| Li, Q; Ling, Y; Yu, L | 1 |
| Hindenburg, HJ; Hinke, A; John, M; Mohr, B; Papke, J; Schlosser, J; Stauch, M; Wolf, H | 1 |
| Arbushites, MC; Bernini, P; Bertini, I; Biganzoli, L; Cappadona, S; Claudino, WM; Di Leo, A; Luchinat, C; Nepi, S; Oakman, C; Tenori, L | 1 |
| Bassi, A; Belotti, D; Castiglioni, V; Cesca, M; Decio, A; Giavazzi, R; Oliva, P; Pesenti, E; Scanziani, E | 1 |
| Albino, D; Carbone, GM; Catapano, CV; Chiorino, G; D'Ambrosio, G; Kunderfranco, P; Longoni, N; Mello-Grand, M; Pellini, S; Pinton, S; Sarti, M; Sessa, F | 1 |
| Bu, S; Chen, Y; Guo, W; He, C; Liu, J; Tan, B; Wang, J; Wang, W; Wang, Y; Wu, X | 1 |
| Ding, Y; Liao, Y; Peng, RQ; Zhang, X; Zhang, XS; Zheng, LM | 1 |
| Iida, K; Ishibashi, T; Ishikawa, M; Katagiri, A; Katagiri, H; Miyazaki, K; Nakayama, K; Nakayama, S; Otsuki, Y; Rahman, M; Rahman, MT | 1 |
| Beumer, JH; Cotarla, I; Deeken, J; Egorin, MJ; Elston, B; Firozvi, K; Hartley, ML; He, AR; Hwang, J; Koh, EY; Liu, M; Malik, S; Marshall, JL; Pishvaian, MJ; Slack, R; Strychor, S | 1 |
| Dito, E; Jones, KA; Kantoff, E; Ko, AH; Ong, A; Tempero, MA; Truong, TG | 1 |
| Brahmer, JR; Dowlati, A; Fages, S; Johnson, DH; Leon, L; Lopez-Chavez, A; Sandler, A; Schiller, JH; Young, T | 1 |
| Broaddus, RR; Cittelly, DM; Cochrane, DR; Dimitrova, I; Howe, EN; Jean, A; Lu, X; Post, MD; Richer, JK; Spillman, MA; Spoelstra, NS | 1 |
| Antoine, M; Belmont, L; Cadranel, J; Duruisseaux, M; Giroux Leprieur, E; Gounant, V; Lacave, R; Lavolé, A; Milleron, B; Poulot, V; Rabbe, N; Vieira, T; Wislez, M | 1 |
| Aström, G; Blomqvist, L; Carlsson, L; Einbeigi, Z; Fujii, H; Glimelius, B; Hatschek, T; Jacobsson, H; Linderholm, B; Lindh, B; Loman, N; Malmberg, M; Rotstein, S; Söderberg, M; Sundqvist, M; Suzuki, C; Walz, TM | 1 |
| Jeremić, B; Miličić, B; Milisavljević, S | 1 |
| Baur, M; DeSantis, M; Dittrich, C; Gerber, E; Hudec, M; Kienzer, HR; Pont, J; Schratter-Sehn, AU; Schweiger, J; Wicke, W | 1 |
| Biganzoli, L; Bruning, P; Calvert, AH; Coleman, R; Cufer, T; Duchateau, L; Epelbaum, R; Fargeot, P; Gamucci, T; Lohrisch, C; Piccart, MJ; Twelves, C | 1 |
| Ernst, DS | 1 |
| Chan, AT; Chiu, SK; Ho, WM; Johnson, PJ; Kwan, WH; Lam, KC; Leung, TW; Mo, FK; Mok, TS; Tse, KK; Yeo, W | 1 |
| Adjei, AA; Baron, AT; Geeraerts, L; Hatfield, AK; Ingle, JN; Kugler, JW; Kuross, SA; Lafky, JM; Maihle, N; Michalak, JC; Perez, EA; Suman, VJ | 1 |
| Antonopoulos, MJ; Gregoriou, A; Kosmas, C; Malamos, NA; Rokana, S; Stamataki, M; Tsavaris, NB; Vartholomeou, M | 1 |
| Bakri, K; Hudgens, S; Kies, MS; Lee, JH; Peterman, A; Schell, MJ; Socinski, MA; Unger, P; Yates, S | 1 |
| Antonellini, A; Elfring, GL; Gillenwater, HH; Israel, VK; Locker, PK; Miller, LL; Natale, RB; Sandler, AB; Socinski, MA | 1 |
| Deckert, M; Hans, V; Kristof, RA; Neuloh, G; Schlegel, U; Schramm, J; Simon, M; Urbach, H | 1 |
| Ansari, R; Bhatia, S; Einhorn, L; Hanna, N; Ng, E; Pletcher, W; Sandler, A | 1 |
| Borsellino, N; Cazzato, C; Colucci, G; Durini, E; Galetta, D; Gebbia, V; Giotta, F; Pezzella, G; Romito, S | 1 |
| Campos, B; Carrete, N; Constenla, M; Garcia-Arroyo, R; Lorenzo, I; Palacios, P | 1 |
| Asola, R; Ekholm, E; Hinkka, S; Korpela, J; Mali, P; Pyrhönen, S; Salminen, E; Varjo, P; Varpula, M | 1 |
| Adamo, V; Altavilla, G; Boni, C; Ceribelli, A; Clerici, M; Crinò, L; De Marinis, F; Di Costanzo, F; Failla, G; Frontini, L; Gridelli, C; Marangolo, M; Matano, E; Ricci, S; Rinaldi, M; Scagliotti, GV; Tonato, M | 1 |
| Hahn, PF; Halpern, EF; Jhaveri, KS; Prasad, SR; Saini, S; Sumner, JE | 1 |
| Assadourian, S; Bonneterre, J; Fargeot, P; Guastalla, JP; Monnier, A; Namer, M; Roché, H | 1 |
| Aapro, M; O'Shaughnessy, J; Twelves, C | 1 |
| Bertucci, F; Chabannon, C; Conte, M; Genre, D; Gravis, G; Houvenaeghel, G; Maraninchi, D; Viens, P; Viret, F | 1 |
| Belani, CP; Langer, C | 1 |
| Abratt, RP; Krofta, K; Mattson, KV; ten Velde, G | 1 |
| Gautschi, O; Stahel, RA; Zangemeister-Wittke, U | 1 |
| Biganzoli, L; Bruning, P; Coleman, RE; Cufer, T; Delhaye, F; Duchateau, L; Hamilton, A; Miles, D; Nooij, M; Piccart, M; Rapoport, B; Sulkes, A | 1 |
| Kondrikov, D; Lin, MF; Rothermund, CA; Vishwanatha, JK | 1 |
| Andre, F; Fandi, A; Fossella, F; Herbst, RS; Le Chevalier, T; Lee, JJ; Liu, DD; Massarelli, E; Ochs, J; Wolf, M | 1 |
| Brockstein, BE; Fung, BB; Haraf, DJ; Kies, MS; List, MA; Mittal, BB; Pelzer, H; Portugal, L; Rademaker, AW; Rosen, FR; Stenson, K; Vokes, EE; Weichselbaum, RR; Witt, ME | 1 |
| Bernard-Marty, C; Bissery, MC; Cardoso, F; Di Leo, A; Dumontet, C; Fellous, A; Gancberg, D; Larsimont, D; Paesmans, M; Piccart, MJ; Treilleux, I | 1 |
| Aihara, T; Hiraki, S; Horikoshi, N; Inaji, H; Itoh, K; Katsumata, N; Noguchi, S; Sasaki, Y; Sonoo, H; Tabei, T; Takatsuka, Y; Watanabe, T | 1 |
| Kamura, T; Kawagoe, H; Kumagai, S; Matsuo, G; Nishida, T; Nishio, S; Ota, S; Sugiyama, T; Ushijima, K | 1 |
| Asmar, L; Canfield, VA; Ellis, PG; Ferri, WA; Hynes, HE; Loesch, DM; Parker, GA; Robert, NJ | 1 |
| Bengala, C; Biadi, O; Conte, PF; Danesi, R; Del Tacca, M; Donati, S; Favre, C; Fogli, S; Guarneri, V; Innocenti, F; Mariani, M; Pazzagli, I | 1 |
| Azli, N; Campos, D; Chan, S; Falkson, C; Kennedy, I; Krzakowski, M; Leonard, R; Martin, M; Murawsky, M; Nabholtz, JM; Pienkowski, T; Pinter, T; Pouillart, P; Riva, A; Szanto, J; Vorobiof, D; Zaluski, J | 1 |
| Kruczek, A; Markowska, J; Skasko, E; Steffen, J; Wojciechowska-Lacka, A | 1 |
| Thürlimann, B; von Moos, R | 1 |
| Roth, AD | 1 |
| Cabrera, P; Calderillo, G; de la Garza, J; Dueñas-Gonzalez, A; Gallardo-Rincón, D; Mohar, A; Oñate-Ocaña, LF; Pérez-Landeros, L; Sánchez, B | 1 |
| Almanza, C; Amenedo, M; Gamazo, JL; Gómez-Martín, C; González-Ageitos, A; González-Quintas, A; Losada, G; Ramos, M; Romero, C; Togores, P | 1 |
| Arbuck, SG; Averette, HE; Brady, MF; Delmore, JE; Long, HJ; Look, KY; Omura, GA; Spiegel, G; Wadler, S | 1 |
| Mayer, A; Pete, I; Pulay, T; Szánthó, A; Thurzó, L | 1 |
| Bengtsson, NO; Bergh, J; Blomqvist, C; Hakamies-Blomqvist, L; Luoma, ML; Malmström, P; Mouridsen, H; Ottoson, S; Pluzanska, A; Sjöström, J; Tennvall, L; Valvere, V | 1 |
| Abrams, RA; Regine, WF; Rich, TA; Safran, H; Willett, CG | 1 |
| Airoldi, M; Bumma, C; Cattel, L; Marchionatti, S; Pedani, F; Recalenda, V; Tagini, V | 2 |
| Aravantinos, G; Bafaloukos, D; Christodoulou, C; Dimopoulos, MA; Fountzilas, G; Gogas, H; Kalofonos, HP; Kosmidis, P; Papadimitriou, C; Pavlidis, N | 1 |
| Chay, CH; Dunn, RL; Esper, P; Fardig, J; Olson, K; Pienta, KJ; Smith, DC | 1 |
| Blumenstengel, K; Höffken, K; Issa, MC; Kasper, C; Kath, R; Mügge, LO; Sayer, HG; Schilling, K; Vogt, T | 1 |
| Bonnet, R; Deppermann, KM; Gatzemeier, U; Hessler, S; Kaukel, E; Macha, HN; Reck, M; Ulm, K; von Pawel, J | 1 |
| Donoghue, E; Ghersi, D; Simes, J; Wilcken, N | 2 |
| Bell, J; Blessing, JA; Lentz, SS; Olt, G; Thigpen, JT | 1 |
| Becker, JC; Figl, R; Hauschild, A; Hofmann, U; Keller, I; Schadendorf, D; Trefzer, U; Zimpfer-Rechner, C | 1 |
| van der Burg, ME; Vergote, I | 1 |
| Barbounis, V; Demiri, M; Efremidis, AP; Koumakis, G; Missitzis, J; Vassilomanolakis, M | 1 |
| Anderson, SE; Ilson, DH; Kelsen, DP; O'Reilly, EM | 1 |
| Bower, M; Gazzard, BG; Gotch, F; Hewitt, P; Mandalia, S; Nelson, M; Patterson, S; Portsmouth, S; Powles, T; Stebbing, J; Thirlwell, C; Wildfire, A | 1 |
| Cha, YN; Choi, SC; Chung, HT; Han, WC; Jun, CD; Kim, EC; Kim, TH; Nah, YH; Oh, HM; Park, JS; Yoon, KH; Yun, KJ | 1 |
| Fujii, Y; Hara, Y; Iwase, H; Sugiura, H; Toyama, T; Yamashita, H | 1 |
| Alexander, HR; Bartlett, DL; Beresnev, TH; Feldman, AL; Kleiner, DE; Libutti, SK; Liewehr, DJ; Mavroukakis, SM; Pingpank, JF; Steinberg, SM | 1 |
| Argiris, A; Brockstein, BE; Haraf, DJ; List, MA; Mittal, BB; Pelzer, H; Portugal, L; Rosen, FR; Stenson, K; Vokes, EE; Weichselbaum, RR; Witt, ME | 1 |
| Lane, SR; Ross, GA; ten Bokkel Huinink, W | 1 |
| Basurto, C; Bisacci, C; Cherubini, R; Colozza, M; Crinò, L; De Angelis, V; Franceschi, E; Gori, S; Mosconi, AM; Rulli, A; Sidoni, A; Tonato, M | 1 |
| Garber, K | 1 |
| Bontenbal, M; Kerkhofs, LG; Schothorst, KL; Seynaeve, C; Smorenburg, CH; Sparreboom, A; Stoter, G; ten Tije, AJ; van Reisen, LG; Verweij, J | 1 |
| Markman, M | 2 |
| Alonso, S; Barnadas, A; Carañana, V; Colomer, R; Fernández, Y; García-Conde, J; Guillem, V; Hornedo, J; Llombart-Cussac, A; Lluch, A; Montero, S; Ojeda, B | 1 |
| Agarwal, R; Foster, T; Guppy, AE; Nelstrop, AE; Rustin, GJ; Seckl, MJ | 1 |
| Bowden, C; de Heus, G; de Jonge, MJ; Hartman, CM; Loos, WJ; Planting, AS; Soepenberg, O; Sparreboom, A; Verweij, J | 1 |
| Bedikian, AY; Ellerhorst, J; Eton, O; Papadopoulos, N; Plager, C; Smith, T | 1 |
| Broome, C; Burris, H; Greco, FA; Hainsworth, J; Houston, G; Jones, S; Thompson, D; White, M; Yardley, D | 1 |
| Barduagni, M; Ceribelli, A; Cognetti, F; Cortesi, E; De Marco, S; De Marinis, F; Fabi, A; Facciolo, F; Ferraresi, V; Gabriele, A; Gamucci, T; Pellicciotta, M; Saltarelli, R | 1 |
| Buda, A; Colombo, N; Conte, PF; Floriani, I; Fossati, R; Mangioni, C; Ravaioli, A; Rossi, R; Torri, V | 1 |
| Ahlgren, J; Batista, N; Carabantes, F; Casinello, J; Castellanos, J; Constenla, M; Gonzalez Barón, M; Murias, A; Perez-Manga, G; Regueiro, P; Ruiz, A; Söderberg, M; Villman, K | 1 |
| Hoffman, PC; Kasza, K; Lanzotti, VJ; Mauer, AM; Otterson, GA; Rudin, CM; Szeto, L; Villalona-Calero, MA; Vokes, EE; Winegarden, JD | 1 |
| Amin, B; Chen, YM; Gradishar, WJ; Hill, T; Lower, EE; Marcom, PK; Meza, LA; Samid, D | 1 |
| Jänicke, F; Köhler, G; Löning, T; Lück, HJ; Möbus, V; Müller, V; Pantel, K; Sattler, D; Thomssen, C; von Minckwitz, G; Wilczak, W; Witzel, I | 1 |
| Brown, R; Gifford, G; Kaye, SB; Paul, J; Vasey, PA | 1 |
| Kishida, T; Komiyama, M; Mori, T; Noguchi, M; Noguchi, Y; Ohnishi, M; Sawaguchi, K; Yabushita, H | 1 |
| Argiris, A; Eng, C; Haraf, DJ; Kozloff, MF; Milano, MT; Mittal, BB; Pelzer, H; Stenson, KM; Vokes, EE; Witt, ME | 1 |
| Caprari, P; Catalano, A; Procopio, A; Rippo, MR; Rodilossi, S | 1 |
| Beraldi, E; Fazli, L; Gleave, M; Hurtado-Coll, A; Kojima, S; Rocchi, P; Signaevsky, M; So, A; Yamanaka, K | 1 |
| Au, JL; Song, S; Wei, Y; Wientjes, MG; Yu, B | 1 |
| Argiris, A; Forastiere, A; Li, Y | 1 |
| Dekel, Y; Margalit, R; Melikhov, D; Peer, D | 1 |
| Cole, C; Greystoke, A; Harries, M; Judson, I; Kaye, S; O'Donnell, A; Reade, S; Scurr, M; Twelves, C | 1 |
| Aravantinos, G; Bafaloukos, D; Dimopoulos, AM; Fountzilas, G; Gogas, H; Kalofonos, C; Kosmidis, P; Linardou, H; Papadimitriou, C; Papakostas, P; Skarlos, D | 1 |
| Aghajanian, C; Anderson, S; Brown, JV; Dizon, D; Dupont, J; Eisenfeld, AJ; Jacobs, A; Mehdi, A; Peters, WA; Rivkin, S; Sabbatini, P; Spriggs, D | 1 |
| Cohen, EE; Haraf, DJ; Hellman, S; Mauer, AM; Mehta, N; Vokes, EE; Weichselbaum, RR | 1 |
| Herzog, TJ | 1 |
| Brady, MF; Clarke-Pearson, D; Moore, DH; Nerenstone, S; Olt, G; Rose, PG; Rubin, SC; Small, JM | 1 |
| Besova, NS; Gorbunova, VA | 1 |
| Hausmaninger, H; Heilmann, V; Huebner, G; Nitsch, T; Possinger, K; Schippinger, W; Schmid, P; Schultze, W; Wischnewsky, M | 1 |
| Bighin, C; Catzeddu, T; Del Mastro, L; Fratino, L; Maggi, E; Manzione, L; Marenco, D; Perrone, F; Repetto, L; Rosso, R; Venturini, M; Venturino, A; Zagonel, V | 1 |
| Bak, JY; Bang, YJ; Choi, IS; Heo, DS; Kim, DW; Kim, JH; Kim, NK; Kim, SI; Kim, TY; Kim, YT; Kim, YW; Kwon, JH; Oh, DY; Park, CI; Park, SR; Sung, SW; You, CK | 1 |
| Ando, M; Fujiwara, Y; Katsumata, N; Kouno, T; Matsumoto, K; Shimizu, C; Takeuchi, M; Tokunaga, S; Uno, H; Yamanaka, Y; Yonemori, K | 1 |
| Jaglowski, JR; Leure-duPree, AE; Manning, JD; McLaughlin, PJ; Stack, BC; Verderame, MF; Zagon, IS | 1 |
| Abrial, C; Amat, S; Chollet, P; Delva, R; Fleury, J; Gamelin, E; Leduc, B; Penault-Llorca, F; Sillet-Bach, I; Van Praagh, I | 1 |
| Chansky, K; Crowley, JJ; Dakhil, SR; Franklin, WA; Gandara, DR; Giguere, JK; Kraut, M; Livingston, RB; Rivkin, SE; Vance, RB; West, HL | 1 |
| Ansari, RH; Ellerton, J; Green, MR; Herndon, JE; Kelly, K; Marks, RS; Miller, AA; Niell, HB; Otterson, G; Perry, MC; Sandler, AB; Vokes, EE; Watson, DM | 1 |
| Abrams, RA; Berkey, BA; Byhardt, RW; Curran, WJ; Duncan, PJ; Ettinger, DS; Fontanesi, J; Machtay, M; Movsas, B | 1 |
| Bannowsky, A; Hamann, M; Hautmann, S; Jünemann, KP; Naumann, M; Wefer, B | 1 |
| Besse, B; Le Chevalier, T; Soria, JC | 1 |
| Arquette, M; Azarnia, N; Dicke, K; Herbst, RS; Hong, WK; Kies, MS; Shin, DM; Vokes, EE | 1 |
| Ardizzoni, A; Bosquee, L; de Bruin, HG; Dussenne, S; Eberhardt, W; Giaccone, G; Legrand, C; O'Brien, M; Scagliotti, GV; Smid-Geirnaerdt, M; Smit, E; Zatloukal, P | 1 |
| Fehrenbacher, L; Herbst, RS; Hermann, R; Johnson, BE; Johnson, DH; Klein, P; Kris, MG; Li, X; Miller, VA; Prager, D; Ramies, D; Sandler, A; Tran, HT | 1 |
| Cheng, AL; Hsu, C; Hsu, CH; Kuo, SH; Li, SJ; Lin, JF; Lu, YS; Yeh, KH | 1 |
| Oral, EN | 1 |
| Budd, GT; Erban, J; Hutchins, L; Jones, SE; Laufman, L; Lower, E; Mennel, R; Meyers, ML; Olsen, S; Overmoyer, B; Pritchard, KI; Ravdin, PM; Richards, D; Sundaram, S; Urba, WJ | 1 |
| Ghose, T; Gupta, RK; Kachru, R; Kaul, U; Parida, AK; Samal, MP; Sapra, R; Sharma, S; Singh, B | 1 |
| Bhar, P; Desai, N; Doval, D; Hortobagyi, GN; Ibrahim, NK; Nair, MK; Page, R; Patel, KM; Rao, SC; Samuels, B | 1 |
| Burstein, HJ; Klein, P; Lieberman, G; Slamon, DJ; Winer, EP | 1 |
| Acimović, L; Jeremić, B; Milicić, B; Milisavljević, S | 1 |
| Bokma, HJ; Bontenbal, M; Braun, HJ; Creemers, GJ; de Boer, AC; Goey, SH; Janssen, JT; Kerkhofs, LG; Leys, RB; Ruit, JB; Schmitz, PI; Schothorst, KL; Seynaeve, C; van der Velden, PC; Verweij, J | 1 |
| Gulati, A; Rai, A; Rajeshkumar, NV | 1 |
| Busby, E; Carey, D; Forero, A; Grizzle, WE; Khazaeli, MB; LoBuglio, AF; Meredith, RF; Robert, F; Shen, S | 1 |
| Andersen, N; Brandt, D; Davies, MJ; Murren, JR; Nadkarni, R; Parisot, N; Pizzorno, G; Psyrri, D; Rose, M; Rosenfield, AT; Zelterman, D | 1 |
| Dobrolecki, L; Estes, D; Hanna, N; Hickey, R; Kurup, A; Lin, C-; Mariano, L; Murry, DJ; Sidor, C; Yiannoutsos, CT | 1 |
| Argyriou, AA; Chroni, E; Iconomou, G; Kalofonos, HP; Koutras, A; Polychronopoulos, P | 1 |
| Allouache, D; Bozec, L; Gawande, SR; Genot, JY; Mefti, F; Piperno-Neumann, S; Tubiana-Hulin, M; Tubiana-Mathieu, N | 1 |
| Bodkin, D; Neubauer, MA; Oldham, F; Richards, DA; Richards, P | 1 |
| Baron, B; Bentzen, SM; Bertelsen, K; Cassidy, J; Eisenhauer, E; Nelstrop, A; Piccart, MJ; Rustin, GJ; Shreeves, G; Stuart, G; Timmers, P | 1 |
| Albers, P; Fechner, G; Kobalz, L; Reimann, M; Siener, R | 1 |
| Bonizzi, G; Curigliano, G; Goldhirsch, A; Munzone, E; Nolè, F; Renne, G; Rocca, A | 1 |
| Ahn, JB; Cho, BC; Choi, HJ; Kim, CB; Kim, JH; Lee, YC; Sohn, JH | 1 |
| Gréen, H; Horvath, G; Peterson, C; Rosenberg, P; Söderkvist, P | 1 |
| Perez, E; Wirk, B | 1 |
| Alberts, DS; Brady, M; Liu, PY; Markman, M; Monk, BJ; Rothenberg, ML | 1 |
| Amadori, D; Frassineti, GL; Gianni, L; Maltoni, R; Massa, I; Milandri, C; Nanni, O; Passardi, A; Zoli, W; Zumaglini, F | 1 |
| Reck, M | 1 |
| Ajani, JA; Bleyer, A; Chang, BB; Cherny, RC; Craig, C; Dakhil, S; Faust, J; Ho, L; Jiang, Y; Rousey, S; Yao, JC | 1 |
| de Korte, MA; de Vries, EG; Gietema, JA; Jager, PL; Jonkman, S; Kosterink, JG; Lub-De Hooge, MN; Perik, PJ; Sleijfer, DT; van der Graaf, WT; van Veldhuisen, DJ | 1 |
| Caprio, G; Di Seri, M; Frati, L; Romiti, A; Spinelli, GP; Terzoli, E; Tomao, F; Tomao, S | 1 |
| El-Naggar, AK; Jasser, SA; Kim, S; Myers, JN; Yazici, YD; Younes, MN | 1 |
| Bernath, AM; Carroll, TJ; Foster, N; Hillman, S; Jett, JR; Lair, BS; Mailliard, JA; Molina, JR; Nikcevich, D; Tazelaar, HD | 1 |
| Abadie-Lacourtoisie, S; Boisdron-Celle, M; Bourgeois, H; Chabrun, V; Chieze, S; Delozier, T; Ferru, A; Gamelin, E; Joly, F; Lortholary, A; Tourani, JM | 1 |
| Capomolla, E; Carpano, S; Cauchi, C; Conti, F; Foggi, P; Giacinti, L; Giannarelli, D; Leonetti, C; Lopez, M; Paoletti, G; Vici, P | 1 |
| Adjei, AA; Alberts, SR; Bruzek, L; Croghan, GA; Erlichman, C; Hanson, LJ; Jatoi, A; Ma, C; Mandrekar, SJ; Pitot, HC; Reid, JM; Tan, AD; Wright, JJ | 1 |
| Antoniou, D; Chaimala, D; Chondrou, E; Dariotaki, F; Karydis, I; Papageorgiou, C; Pavlakou, G; Stathopoulos, GP; Veslemes, M | 1 |
| Aisner, J; Guensch, L; Joyce, M; Lutzker, S; Schwartz, S; Sovak, MA; Wu, Y; Zheng, L | 1 |
| Argenta, PA; Carson, LF; Chen, MD; Downs, LS; Dusenbery, KE; Ghebre, R; Judson, PL | 1 |
| Chao, TY; Chao, Y; Chen, LT; Cheng, AL; Hsieh, RK; Kao, WY; Li, CP; Su, WC; Wu, MF; Yeh, KH | 1 |
| Ferrandina, G; Martinelli, E; Paglia, A; Ranelletti, FO; Scambia, G; Zannoni, GF | 1 |
| Fidler, IJ | 1 |
| Lee, VM; Trojanowski, JQ | 1 |
| Ambrosch, G; Eckersberger, F; Klepetko, W; Krajnik, G; Maier, A; Malayeri, R; Minar, W; Müller, RM; Pirker, R; Pohl, G; Pokrajac, B; Schäfer-Prokop, C; Schmeikal, S; Woltsche, M | 1 |
| Beijnen, JH; Binlich, F; Garrigue, JS; Huitema, AD; Lallemand, F; Lambert, G; Nol, A; Nuijen, B; Schellens, JH; Thijssen, B; Veltkamp, SA | 1 |
| Gazitt, Y; Rothenberg, ML; Shaughnessy, P | 1 |
| Ajani, J; Cox, JD; Komaki, R; Liao, Z; Liu, H; Swisher, S; Wang, SL | 1 |
| Bekele, BN; Chen, I; Daliani, DD; Dieringer, PY; Logothetis, CJ; Mathew, P; Pagliaro, LC; Zhou, X | 1 |
| Gu, YH; Huang, PW; Lu, KH; Shu, YQ | 1 |
| Grønlund, B | 1 |
| Karakuzu, A; Koc, M; Ozdemir, S | 1 |
| Aravantinos, G; Christodoulou, Ch; Malamos, NA; Rigatos, S; Skarlos, D; Stathopoulos, GP; Stathopoulos, J | 1 |
| Aihara, R; Asao, T; Haga, N; Kamiyama, Y; Kuwano, H; Mochiki, E; Nakabayashi, T; Nakamura, J; Ohno, T; Ohsawa, H; Ojima, H; Takeuchi, K | 1 |
| Johnson, DH; Langer, C; Li, S; Rapoport, BL; Schiller, J; Tester, W | 1 |
| Brames, MJ; Einhorn, LH; Juliar, B; Williams, SD | 1 |
| Bae, SH; Baek, JH; Cho, GJ; Chung, HY; Chung, JS; Do, YR; Hyun, MS; Jang, JS; Kim, JG; Kwon, KY; Lee, KH; Lee, WS; Park, KU; Ryoo, HM; Sohn, CH; Sohn, SK; Song, HS; Yu, W | 1 |
| Burstein, HJ; Come, SE; Gelman, R; Haldoupis, M; Lin, NU; Parker, LM; Ryabin, N; Shulman, LN; Winer, EP | 1 |
| Diestelhorst, A; Dunst, J; Fornara, P; Kühn, R; Kuhnt, T; Müller, AC; Scholz, HJ; Zietman, AL | 1 |
| Chen, YM; Perng, RP; Tsai, CM; Whang-Peng, J | 1 |
| Dakhil, S; Dy, GK; Geoffroy, FJ; Jett, JR; Krewer, KD; Krook, J; Kugler, J; Kutteh, L; Mailliard, J; Maurer, M; Rowland, K; Tazelaar, H; Wender, D | 1 |
| Eatock, MM; Eskens, FA; Evans, TR; Ferry, DR; Hawkins, RE; Jones, RJ; Wilke, H | 1 |
| Choomchuay, N; Leelahakorn, S; Manusirivithaya, S; Pataradool, K; Suekwatana, P; Tangjitgamol, S; Thawaramara, T | 1 |
| Alberola, V; Albert, A; Campos, JM; Caranyana, V; Juan, O; Muñoz, J | 1 |
| Bartolini, S; Cancellieri, A; Cappuzzo, F; Crino, L; Finocchiaro, G; Hirsch, FR; Ligorio, C; Magrini, E; Paioli, D; Rossi, E; Toschi, L; Trisolini, R; Varella-Garcia, M | 1 |
| Buch, AN; Chu, WW; Javaid, A; Kent, KM; Pichard, AD; Satler, LF; Smith, K; Torguson, R; Waksman, R; Xue, Z | 1 |
| Janus, SC; Ondrey, FG; Weurtz, B | 1 |
| Baron, AD; Burstein, HJ; Gelman, R; Hart, RD; Keshaviah, A; Lambert-Falls, R; Marcom, PK; Winer, EP | 1 |
| Bianco, A; Campbell, S; Caputo, F; D'Agostino, D; Gilli, M; Marsico, SA; Mazzarella, G; Piantedosi, FV; Pontillo, A | 1 |
| Cooney, KA; Dunn, RL; Fardig, JE; Mackler, NJ; Olson, KB; Pienta, KJ; Redman, BG; Smith, DC | 1 |
| Barnadas, A; Basterrechea, L; Capdevila, J; Ciria, JP; Farré, N; Gomez-Segura, G; Membrive, I; Pallarés, C; Paredes, A | 1 |
| Harish, CR; Satish, B; Tressa, K | 1 |
| Bria, E; Carpino, A; Cognetti, F; Cuppone, F; Fornier, M; Nisticò, C; Pace, A; Sperduti, I; Terzoli, E | 1 |
| Ando, T; Hirabayashi, N; Kawamura, S; Kobayashi, M; Kojima, H; Kondo, K; Konno, H; Matsuo, K; Miyashita, Y; Morita, S; Musha, N; Nagata, N; Ninomiya, M; Oba, K; Sakamoto, J; Usuki, H | 1 |
| Faerber, GJ; Weizer, AZ; Wolf, JS | 1 |
| Gluck, S; Lobo, C; Lopes, G; Silva, O | 1 |
| Beijnen, JH; Boddy, AV; Briasoulis, E; Calvert, H; Chatelut, E; Dittrich, C; Féty, R; Hempel, G; Hollema, H; Huitema, AD; Izquierdo, MA; Jodrell, DI; Joerger, M; Karlsson, M; Martoni, A; Pavlidis, N; Richel, DJ; Schellens, JH; Schrijvers, AH; Sleeboom, HP; Sorio, R; Strocchi, E; Tranchand, B; Twelves, C; Van der Vijgh, WJ; Vermorken, JB; Wilkins, J | 1 |
| Wang, HJ; Zheng, WX | 1 |
| Larbcharoensub, N; Lertkhachonsuk, AA; Rochanawutanon, M | 1 |
| Cella, D; Cobleigh, M; Davidson, NE; Dickler, M; Gralow, J; Miller, K; Perez, EA; Shenkier, T; Wang, M | 1 |
| Ferrell, B; Leong, L; Lowe, T | 1 |
| Chang, HM; Kang, HJ; Kang, YK; Kim, BS; Kim, TW; Lee, JS; Oh, ST; Ryu, MH; Sohn, HJ; Yook, JH | 1 |
| Blum, JL; Clawson, A; Edelman, G; Geister, BV; Kirby, RL; O'Shaughnessy, JA; Pippen, JE; Robert, NJ; Savin, MA | 1 |
| Capanu, M; Ilson, DH; Kelsen, DP; Ku, GY; O'Reilly, E; Schwartz, GK; Schwartz, LH; Shah, MA | 1 |
| Barrett, SV; Glasspool, RM; Hay, A; Kaye, SB; Paul, J; Vasey, PA | 1 |
| Albert, D; Axelrod, R; Botkin, D; Dowlati, A; Lilenbaum, R; Seigel, L; Thomas, S; Witt, K | 1 |
| Economopoulos, T; Fountzilas, G; Gaglia, A; Gouveris, P; Kassanos, D; Koumarianou, A; Panayiotidis, J; Papaxoinis, G; Pectasides, D; Pectasides, E; Psyrri, A; Sykiotis, C; Xiros, N | 1 |
| Barakat, HM; Ibrahim, SA; Mostafa, E; Nasar, MN; Rabie, AN; Rabie, NA | 1 |
| Capizzi, E; De Iaco, P; Fiorentino, M; Gabusi, E; Grigioni, AD; Rosati, M; Zamagni, C | 1 |
| Aikou, T; Aridome, K; Etoh, T; Hamanoue, M; Hokita, S; Ishigami, S; Iwashita, T; Komatsu, H; Maehara, Y; Maenohara, S; Miyazono, F; Morita, S; Nakajo, A; Nakano, S; Natsugoe, S; Sakamoto, J; Satoh, K; Takiuchi, H | 1 |
| Bayo, J; Bernabé, R; Jiménez, J; Lomas, M; Lopez-Ladrón, A; Moreno, A; Ruiz, M; Salvador, J; Valero, M; Vicente, D | 1 |
| Bui, V; Chevreau, C; Delord, JP; Fizazi, K; Flechon, A; Geoffrois, L; Kerbrat, P; Lotz, JP; Theodore, C; Yataqhene, Y | 1 |
| Haines, IE; Miklos, GL | 1 |
| Gridelli, C; Rossi, A; Torri, V | 1 |
| Bae, SB; Cho, DY; Cho, IS; Han, CS; Kim, S; Lee, HJ; Lee, KT; Park, JC; Park, SY; Yun, HJ | 1 |
| Armstrong, DK; Cella, D; Huang, HQ; Walker, JL; Wenzel, L | 1 |
| Ardavanis, A; Baziotis, N; Garoufali, A; Kountourakis, P; Kyriakou, F; Malliou, S; Mantzaris, I; Rigatos, G; Scorilas, A; Yiotis, I | 1 |
| Alberts, SR; Dakhil, SR; Flynn, PJ; Foster, NR; Hauge, MD; Jaslowski, AJ; Jatoi, A; Ma, C; Moore, DF; Rowland, KM; Stella, PJ; Thomas, SP | 1 |
| Bokar, JA; Brell, JM; Cooney, MM; Dowlati, A; Gibbons, J; Krishnamurthi, S; Ness, A; Nock, C; Remick, SC; Sanborn, SL | 1 |
| Blackwell, K; Lokshin, AE; Luong, TM; Marks, JR; Nolen, BM; Rand, A; Ta'san, S; Wang, Y | 1 |
| Beijnen, JH; Bierhorst, F; Heimans, JJ; Huizing, MT; Mandjes, IA; Pinedo, HM; Postma, TJ; ten Bokkel Huinink, WW; Vermorken, JB; Winograd, B | 1 |
| Chazard, M; Corette, L; Dieras, V; Garet, F; Marty, M; Mignot, L; Morvan, F; Onetto, N; Serin, D; Tubiana, N | 1 |
| DeVore, RF; Hande, KR; Johnson, DH; Paul, DM | 1 |
| Capri, G; Caraceni, A; Fulfaro, F; Gianni, L; Laffranchi, A; Martini, C; Munzone, E; Spreafico, C; Tarenzi, E; Villani, F | 1 |
| Dreps, A; Gatzemeier, U; Heckmayer, M; Neuhauss, R; Schlüter, I; von Pawel, J; Wagner, H | 1 |
| Alvarez-Vicent, J; Brandariz, A; Colomer, R; Cortés-Funes, H; Hitt, R; Hornedo, J; Mendiola, C; Sevilla, E | 1 |
| Bauknecht, T; Bochtler, H; Diergarten, K; du Bois, A; Köchli, O; Kreienberg, R; Kühnle, H; Lück, HJ; Meerpohl, HG; Möbus, V | 1 |
| Athanassiades, A; Bafaloukos, D; Dombros, N; Fountzilas, G; Giannakakis, T; Karakousis, K; Kosmidis, P; Skarlos, D | 1 |
| Allen, DG; Brand, AH; Grant, PT; Planner, RS; Sykes, PH; Toner, GC | 1 |
| Awada, A; Bruning, P; Gamucci, T; Klijn, J; Kusenda, Z; Paridaens, R; Piccart-Gebhart, MJ; Roy, JA; Van Vreckem, A | 1 |
| Boesgaard, M; Dombernowsky, P; Gehl, J; Jensen, BV; Paaske, T | 1 |
| Klaassen, U; Seeber, S; Wilke, H | 1 |
| Blom, R; Palm, N; Simonsen, E | 1 |
| Cowley, BD; Gattone, VH; Grantham, JJ; Kaneta, S; Martinez, JR; Nagao, S; Takahashi, H; Yamaguchi, T | 1 |
| Caleffi, M; Ferreira Filho, AF; Kalakun, L; Koya, R; Mans, DR; Menke, CH; Pohlman, P; Schunemann, H; Schwartsmann, G; Venegas, LF; Xavier, N | 1 |
| Beijnen, JH; Birkhofer, MJ; Helmerhorst, TJ; Huizing, MT; Lai, A; Rodenhuis, S; Rosing, H; Schaefers, MC; ten Bokkel Huinink, WW; van Warmerdam, LJ; Veenhof, CH | 1 |
| Gordon, AN; Matthews, CM; Nemunaitis, J; Stringer, CA; Willis, DL | 1 |
| Bolis, G; Broom, C; Carmichael, J; Coleman, R; Davidson, N; Fields, SC; Gordon, A; Gore, M; Heron, JF; Hudson, I; Malfetano, J; Malmström, H; Scarabelli, C; Spanczynski, M; ten Bokkel Huinink, W | 1 |
| Harper, P | 1 |
| Curé, H; Diéras, V; Guastalla, JP; Jacquin, JP; Leduc, B; Mignot, L; Mousseau, M; Orfeuvre, H; Paraïso, D; Pujade-Lauraine, E; Tubiana-Mathieu, N; Viens, P; Vincent, P; Weber, B | 1 |
| Alvarez, AM; Blajman, C; Breier, S; Cazap, E; Cóppola, FS; Ezcurdia, L; Fasce, H; Fein, L; Jovtis, SL; Lewi, D; Luchina, AM; Martínez, CA; Mickiewicz, E; Pasccón, G; Polera, J; Politi, PM; Rondinón, M; Rubio, G; Temperley, G; Triguboff, E; Uranga, G | 1 |
| Benito, D; Casado, A; Cervantes, A; del Campo, JM; Escobedo, A; Massuti, B; Mendiola, C; Moyano, A; Ojeda, B; Poveda, A | 1 |
| Aravantinos, G; Athanassiadis, A; Bafaloukos, D; Bamia, C; Fountzilas, G; Karphathios, S; Kosmidis, P; Papakostas, P; Pavlidis, N; Skarlos, DV; Stathopoulos, GP | 1 |
| Edelman, MJ; Houston, J; Lauder, I; Meyers, FJ | 1 |
| Pienta, KJ; Smith, DC | 1 |
| Edwards, RP; Hart, LA; Kelley, JL; Kunschner, AJ; Price, FV | 1 |
| Chan, S | 1 |
| Aapro, MS; Alaki, M; Bezwoda, WR; Deschênes, L; Douma, J; Drbal, J; Melnychuk, D; Murawsky, M; Nabholtz, JM; Rapoport, B; Riva, A; Rosso, R; Thuerlimann, B; Trillet-Lenoir, V; Vandenberg, TA | 1 |
| Bachelot, T; Biron, P; Blay, JY; Catimel, G; Chauvin, F; Droz, JP; Guastalla, JP; Merrouche, Y; Ray-Coquard, I | 1 |
| Barter, C; Berille, J; Bishop, J; Bougan, N; Friedlander, M; James, R; Loret, C; McKeage, M; Millward, M; Rischin, D; Toner, G; Zalcberg, J; Zimet, A | 1 |
| Diergarten, K; Eberhardt, W; Hanske, M; Harstrick, A; Klaassen, U; Korn, M; Müller, C; Seeber, S; Weyhofen, R; Wilke, H | 1 |
| Paridaens, R; Thomas, J; Van Oosterom, A; Van Vaerenbergh, W; Wildiers, J | 1 |
| Bradac, GB; Rudà, R; Schiffer, D; Soffietti, R | 1 |
| Andreotti, PE; Bruckner, HW; Cree, IA; Indefrei, D; Kurbacher, CM; Kurbacher, JA; Mallmann, P; Pöch, G; Wilhelm, L | 1 |
| de Boer, M; de Wit, R; Kerger, J; Kruit, WH; Stoter, G; Verweij, J | 1 |
| Brown, RE; Hutton, J | 1 |
| Bertelsen, K; Bjorkholm, E; Boman, K; Himmelmann, A; Hogberg, T; Horvath, G; Jacobsen, A; Kaern, J; Kuoppola, T; Lund, B; Onsrud, M; Puistola, U; Salmi, T; Sandvei, R; Scheistroen, M; Simonsen, E; Sorbe, B; Tholander, B; Tropé, C; Vartianen, J; Westberg, R | 1 |
| Blum, JL; Brown, CS; Burger, HU; Buzdar, AU; Griffin, T; Jones, SE; Kuter, I; LoRusso, PM; Osterwalder, B; Vogel, C | 1 |
| Gillenwater, H; Socinski, MA; Steagall, A | 1 |
| Aapro, M; Alakl, M; Bezwoda, WR; Deschênes, L; Douma, J; Drbal, J; Genot, JY; Hupperets, PS; Melnychuk, D; Molino, A; Murawsky, M; Nabholtz, JM; Nagykalnai, T; Nortier, JW; Pannuti, F; Rapoport, B; Richel, DJ; Rosso, R; Senn, HJ; Siedlecki, P; Skarlos, D; Tomiak, EM; Trillet-Lenoir, V; Vandenberg, TA; Wilking, N | 1 |
| Acito, L; Angiona, S; Bilancia, D; Costanzo, FD; Fioriti, L; Gasperoni, S; Giustini, L; Manzione, L; Sdrobolini, A; Valenti, L | 1 |
| Baile, WF; Beale, EA; Glober, GA; Kudelka, AP; Lenzi, R | 1 |
| Amato, S; Barbieri, M; Fasce, H; Grasso, S; Lacava, J; Langhi, M; Leone, B; Machiavelli, M; Ortiz, E; Pérez, J; Rodríguez, R; Romero Acuña, J; Romero Acuña, L; Romero, A; Vallejo, C | 1 |
| Dranitsaris, G; Leung, PP; Oza, AM; Puodziunas, A; Tannock, IF | 1 |
| Gerstner, JB; Grill, JP; Jett, JR; Kirschling, RJ; Krewer, KD; Kugler, JW; Kuross, SA; Marks, RS; Michalak, JC; Windschitl, HE | 1 |
| Hait, WN; Liao, J; Medina, DJ; Vassil, AD; Yang, GY; Yang, JM | 1 |
| Mattson, K | 1 |
| Gleave, ME; Goldie, J; Miayake, H; Nelson, C; Tolcher, A | 1 |
| Anderson, H; Bengtsson, NO; Bergh, J; Blomqvist, C; Mjaaland, I; Mouridsen, H; Ostenstad, B; Ottosson-Lönn, S; Palm-Sjövall, M; Pluzanska, A; Sjöström, J; Valvere, V; Wist, E | 1 |
| Fitch, TR; Hartmann, LC; Hatfield, AK; Hillman, DW; Ingle, JN; Kardinal, CG; Krook, JE; Mailliard, JA; Nair, S; Perez, EA; Stella, PJ | 1 |
| Goldberg, M; Langer, CJ; Millenson, MM; Movsas, B; Rogatko, A; Rogers, B; Schilder, RJ | 1 |
| Awada, A; Biganzoli, L; Bruning, P; Coleman, R; Gamucci, T; Houston, S; Klijn, JG; Paridaens, R; Piccart, M; Schachter, J; Sylvester, R; Van Vreckem, A; Wildiers, J | 1 |
| Alfonso, R; Casado, A; de Paz, L; Diaz-Rubio, E; Esteban, C; García-Conde, J; Garciía Carbonero, I; Insa, A; Lluch, A; Martín, M | 1 |
| Blume, KG; Chao, NJ; Feiner, RH; Hu, WW; Johnston, LJ; Long, GD; Negrin, RS; Shizuru, JA; Stockerl-Goldstein, K; Wong, RM | 1 |
| Aviles, V; Chalian, AA; Kligerman, MM; Machtay, M; Mirza, N; Rosenthal, DI; Treat, J; Weber, RS; Weinstein, GS | 1 |
| Blanco Sequeiros, G; Jekunen, AP; Kaleva-Kerola, J; Maiche, AG | 1 |
| Boukis, H; Janinis, J; Lefantzis, D; Panagos, G; Papadakou, M; Poulis, A; Xidakis, E | 1 |
| Capizzello, A; Foroglou, G; Fountzilas, G; Kalogera-Fountzila, A; Karavelis, A; Karkavelas, G; Selviaridis, P; Tourkantonis, A; Zamboglou, N | 1 |
| Andersen, JE; Atkinson, RJ; Bacon, M; Baron, B; Bertelsen, K; Birt, A; Blom, R; Cassidy, J; Grimshaw, R; James, K; Kaern, J; Kaye, S; Lhoas, F; Lindvall, B; Mangioni, C; Nardi, M; Paul, J; Pecorelli, S; Piccart, MJ; Roy, JA; Simonsen, E; Stuart, G; Swenerton, KD; Timmers, P; Trope, C; Tumolo, S; Vergote, I; Zee, B | 1 |
| Gleave, ME; Miyake, H; Nelson, C; Rennie, PS | 1 |
| Adelstein, DJ; Ciezki, J; DeCamp, M; Dumot, JA; Larto, MA; Rice, TW; Rybicki, LA; Saxton, J; Vargo, JJ; Zuccaro, G | 1 |
| Buesa, J; Coleman, R; di Paola, ED; Judson, IR; Lee, SM; Ruka, W; Seynaeve, C; Tonelli, D; van Glabbeke, M; van Hoessel, R; Verweij, J | 1 |
| Berille, J; Burkes, R; Coughlin, S; Dancey, J; Gralla, R; Gressot, L; Kim, Y; Levitan, N; Mattson, K; O'Rourke, M; Ramlau, R; Shepherd, FA; Vincent, M | 1 |
| Crawford, J; DeVore, R; Dunphy, F; Fossella, FV; Gamza, F; Gandara, D; Hammershaimb, L; Kalman, L; Karp, D; Kerr, RN; Kim, Y; Kris, M; Lee, JS; Miller, V; Moore, M; Natale, RR; Vokes, E | 1 |
| Choy, H; Devore, RF; Hande, KR; Johnson, DH; Porter, LL; Rosenblatt, P; Schlabach, L; Shyr, Y; Smith, C; Yunus, F | 1 |
| Anderson, H; Carmichael, J; Davidson, N; Falk, S; Gallant, G; Gustafson, N; Jeynes, A; Lopez, P; Nicolson, M; Ranson, M; Thatcher, N; Washington, T | 1 |
| Ceresoli, GL; Dell'Oro, S; Passoni, P; Villa, E | 1 |
| Adak, S; Amrein, PC; Barton, JJ; Colevas, AD; Costello, R; Posner, MR | 1 |
| Coleman, RE; Eggleton, SP; Howell, A; Maling, SJ; Miles, DW | 1 |
| Aravantinos, G; Bafaloukos, D; Dimopoulos, MA; Kiamouris, C; Kosmidis, P; Papadimitriou, C; Papakostas, P; Pavlidis, N; Sikiotis, K; Skarlos, DV | 1 |
| Agelaki, S; Androulakis, N; Georgoulias, V; Hatzidaki, D; Kakolyris, S; Kalbakis, K; Kourousis, C; Mavroudis, D; Sarmonis, G; Sarra, E; Souglakos, J; Vardakis, N | 1 |
| Dalbot, DC; Gordon, RJ; Griffin, T; Moiseenko, VM; O'Reilly, SM; Osterwalder, B; Van Belle, S | 1 |
| Dimopoulos, M; Fountzilas, G; Kalophonos, C; Kosmidis, P; Mylonakis, N; Nikolaidis, C; Papaconstantinou, C; Papadimitriou, C; Pavlidis, N; Samantas, E; Skarlos, D | 1 |
| Barbarisi, A; Benassai, G; Carbone, I; Ciccarelli, PD; Crovella, F; De Rosa, P; Frattolillo, A; Iaffaioli, RV; Libutti, M; Santangelo, M; Tortoriello, A; Turitto, G | 1 |
| Bauer, J; Borner, M; Crivellari, D; D'Incalci, M; Goldhirsch, A; Graffeo, R; Hess, D; Lombardi, D; Martinelli, G; Nolè, F; Pagani, O; Sessa, C; Thürlimann, B; Zucchetti, M | 1 |
| Blakey, D; Brettell, M; Briggs, P; Chapple, P; Eerhard, S; Gates, P; Januszewicz, EH; Juneja, S; Prince, HM; Quinn, M; Richardson, G; Rischin, D; Scarlett, J; Seymour, JF; Toner, GC; Wolf, M | 1 |
| Fossella, FV | 1 |
| Booser, D; Buzdar, AU; Dhingra, K; Fraschini, G; Frye, D; Holmes, FA; Hortobagyi, GN; Rivera, E; Theriault, RL; Valero, V; Walters, R | 1 |
| D'Agostino, G; Ferrandina, G; Greggi, S; Lorusso, D; Mancuso, S; Manzione, L; Salerno, MG; Scambia, G | 1 |
| Burton, A; Chan, KK; Earl, HM; Jenkins, AH; Jordan, SD; Luesley, D; Mould, JJ; Perren, T; Poole, CJ; Spooner, DA; Sturman, S | 1 |
| Bajamonde, A; Baselga, J; Eiermann, W; Fleming, T; Fuchs, H; Leyland-Jones, B; Norton, L; Paton, V; Pegram, M; Shak, S; Slamon, DJ; Wolter, J | 1 |
| Agelaki, S; Aravantinos, G; Georgoulias, V; Kakolyris, S; Karabekios, S; Kouroussis, C; Mavroudis, D; Rigatos, SK; Stathopoulos, GP; Tsavaris, N | 1 |
| Bengala, C; Conte, PF; Danesi, R; Del Tacca, M; Donati, S; Favre, C; Greco, F; Guarneri, V; Innocenti, F; Menconi, MC; Orlandini, C; Pazzagli, I | 1 |
| Blair, S; Carman, L; Colborn, D; George, C; Jones, J; Kuebler, JP; Laufman, LR; Moore, T; Patel, T; Roach, R; Rupert, R; Spiridonidis, CH; Zangmeister, J | 1 |
| Berzins, J; Gorbunova, V; Jassem, J; Jelic, S; Mrsic-Krmpotic, Z; Munier, S; Nagykalnai, T; Pieńkowski, T; Płuzańska, A; Renard, J; Weil, C; Wigler, N | 1 |
| Buhl, R; De Greve, JL; Fritz, MA; Gatzemeier, U; Gralla, R; Herrmann, R; Heussel, CP; Horowitz, JA; Huber, C; Kommoss, F; Kuball, J; Laufman, L; Perruchoud, AP; Rochlitz, C; Schuler, M; Shepherd, FA; Stewart, AK; Stewart, DJ | 1 |
| Piedbois, Y; Thirion, P | 1 |
| Bafaloukos, D; Briassoulis, E; Dimopoulos, AM; Fountzilas, G; Kalofonos, H; Kalogera-Fountzila, A; Keramopoulos, A; Kosmidis, P; Papadimitriou, C; Pavlidis, N; Razis, E; Samantas, E | 1 |
| Ansell, SM; Burch, PA; Kvols, LK; Mahoney, MR; Pitot, HC; Rubin, J | 1 |
| Abela, K; Aravantinos, G; Bafaloukos, D; Briassoulis, E; Dafni, U; Dimopoulos, MA; Fountzilas, G; Gogas, E; Kalofonos, HP; Kosmidis, P; Moulopoulos, LA; Papadimitriou, C; Papakostas, P; Pavlidis, N; Razis, E; Skarlos, D | 1 |
| Agelaki, S; Androulakis, N; Bania, E; Chainis, K; Georgoulias, V; Kakolyris, S; Kalofonos, C; Kouroussis, C; Papadakis, E; Rapti, A; Sarra, E; Toubis, M; Tsiafaki, X; Vardakis, N | 1 |
| Bauer, J; Borner, M; Crivellari, D; Goldhirsch, A; Graffeo, R; Hess, D; Lombardi, D; Martinelli, G; Nolè, F; Pagani, O; Sessa, C; Thürlimann, B; Veronesi, A | 1 |
| Ardizzoia, A; Conti, A; Fumagalli, E; Gardani, G; Lissoni, P; Maestroni, GJ; Tancini, G; Vaghi, M | 1 |
| Campbell, M; Cantrell, J; Cartmell, A; Ghalie, R; Harvey, J; Modiano, M; Newcomb, T; Rubin, A; Schuster, M; Urba, W | 1 |
| Pagani, O; Sessa, C | 1 |
| Athanasiadis, A; Constantinidis, TC; Delis, D; Fachantidou, E; Goutsikas, J; Hatziapostolou, P; Kontakiotis, T; Patakas, D; Zarogoulidis, K | 1 |
| Babb, J; Entmacher, M; Flinker, D; Garay, C; Gillon, T; Haas, N; Hudes, G; Minnitti, C; Rogatko, A; Roth, B; Weinstein, A; Yeslow, G | 1 |
| Kaern, J; Kisic, J; Kristensen, G; Tropé, C | 1 |
| Cairncross, JG; Fortin, D; Macdonald, DR; Stitt, L | 1 |
| Akashi-Tanaka, S; Fukutomi, T; Hasegawa, T; Katsumata, N; Miyakawa, K; Takahashi, T; Tsuda, H; Watanabe, T | 1 |
| Albain, KS; Clark, JI; Fisher, S; Hantel, A; Kancharla, K; Millbrandt, L; Panganiban, J; Qamar, R | 1 |
| Baselga, J | 1 |
| Carta, G; De Filippis, S; Rea, S; Recchia, F; Rosselli, M; Saggio, G | 1 |
| Beer, TM; Henner, WD; Lowe, BA; Pierce, WC | 1 |
| Amann, G; Attems, Y; Brodowicz, T; Fiebiger, WC; Hejna, M; Köstler, WJ; Krainer, M; Tomek, S; Wiltschke, CH; Zielinski, CC | 1 |
| Belani, CP; Harrington, D; Johnson, DH; Krook, J; Langer, C; Sandler, AB; Schiller, J; Sweeney, CJ; Zhu, J | 1 |
| Bastian, R; Choudhury, A; Clark, JI; Collins, S; Emami, B; Hofmeister, C; Matz, G; Melian, E; Petruzzelli, G | 1 |
| Chacón, JI; de Castro, J; Dorta, J; Espinosa, E; Feliu, J; González Barón, M; Lizón, J; Martin, G; Rodríguez, A; Sánchez Heras, B; Torrego, JC | 1 |
| Nishiwaki, Y; Saijo, N; Sakai, H; Tamura, T; Watanabe, K; Yokoyama, A; Yoneda, S | 1 |
| Broome, CM; Gutheil, JC; Hussain, M; Markowitz, AB; Vaughn, DJ | 1 |
| Blanchard, JM | 1 |
| Chen, YM; Lee, CS; Lee, YC; Perng, RP; Shih, JF; Tsai, CM; Whang-Peng, J | 1 |
| Eskens, FA; Polee, MB; Siersema, PD; Splinter, TA; Stoter, G; Tilanus, HW; van der Burg, ME; van der Gaast, A; Verweij, J | 1 |
| Bougnoux, Ph; Eymard, JC; Lotz, V; Mansouri, H; Namer, M; Spielmann, M; Tubiana-Hulin, M; Tubiana-Mathieu, N | 1 |
| Demetri, GD; Ette, E; Garg, V; Harding, MW; Overmoyer, B; Pollak, M; Russell, C; Seidman, AD; Tkaczuk, K; Toppmeyer, D; Verma, S | 1 |
| Forastiere, AA; Frenette, G; Glisson, BS; Khuri, FR; Murphy, BA | 1 |
| Sparano, JA | 1 |
| Dueñas, MR; Fernández, M; González, E; Jaén, A; Lozano, A; Martos, M; Medina, B; Mohedano, N; Porras, I; Sánchez-Rovira, P | 1 |
| Cohen, A; Hande, KR; Johnson, DH; Meshad, M; Nicholson, BP; Paul, DM; Shyr, Y | 1 |
| Boletis, J; Chiras, T; Kosmas, C; Kostakis, A; Tsavaris, NB; Vadiaka, M | 1 |
| Arun, B; Booser, D; Cristofanilli, M; Esmaeli, B; Esteva, FJ; Fritsche, HA; Guerra, LT; Hortobagyi, GN; Murray, JL; Pusztai, L; Smith, TL; Sneige, N; Valero, V | 1 |
| Kelly, WK; Kenneson, K; Morris, MJ; Osman, I; Reuter, VE; Scher, HI; Slovin, SF; Verbel, D | 1 |
| Carducci, MA; Eisenberger, MA; Laufer, M; Moore-Cooper, S; Sinibaldi, VJ; Zahurak, M | 1 |
| Choi, CW; Goo, BH; Kim, BS; Kim, JS; Kim, YH; Seo, JH; Shin, SW; Whang, YM | 1 |
| D'Agostino, G; Distefano, M; Ferrandina, G; Greggi, S; Mancuso, S; Poerio, A; Salerno, M; Scambia, G | 1 |
| Hamaguchi, Y; Ichikawa, Y; Ishikawa, T; Kawano, N; Maegawa, J; Nakatani, Y; Ogino, I; Ohnishi, H; Shimada, H; Shimura, M | 1 |
| Dierlamm, T; Dürk, H; Fiedler, W; Knuffmann, C; Kurt Hossfeld, D; Laack, E; Popp, J; Schmied, B; Verpoort, K; Wacker-Backerhaus, G; Zeller, W | 1 |
| Aebi, S; Betticher, DC; Calderoni, A; Solenthaler, M; von Briel, C | 1 |
| Aravantinos, G; Bafaloukos, D; Dimopoulos, MA; Efstathiou, E; Gika, D; Gourgoulis, GM; Kalofonos, C; Papadimitriou, CA; Sarris, K; Skarlos, D | 1 |
| George, CM; Mauer, AM; Otterson, GA; Prange, B; Rudin, CM; Szeto, L; Tomek, R; Villalona-Calero, MA; Vokes, EE | 1 |
| Bengtsson, NO; Blomqvist, C; Heikkilä, R; Malmström, P; Ostenstad, B; Paavonen, T; Saksela, E; Sjöström, J; Tynninen, O; Valvere, V; von Boguslawski, K; Wist, E | 1 |
| Arbea, L; Calvo, E; Cambeiro, M; Cortes, J; Diaz-Gonzalez, JA; Garcia-Foncillas, J; Garzon, C; Gil-Bazo, I; Gurpide, A; Martin-Algarra, S; Navarro, V; Nicolas, AI; Rodriguez, J | 1 |
46 review(s) available for paclitaxel and Disease Exacerbation
| Article | Year |
|---|---|
Atezolizumab for use in PD-L1-positive unresectable, locally advanced or metastatic triple-negative breast cancer.
Topics: Albumins; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; B7-H1 Antigen; Clinical Trials as Topic; Disease Progression; Dose-Response Relationship, Drug; Female; Humans; Maximum Tolerated Dose; Paclitaxel; Progression-Free Survival; Triple Negative Breast Neoplasms; Tumor Escape | 2020 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor Proteins, Signal Transducing; Adenine; Adenocarcinoma; Adipogenesis; Administration, Cutaneous; Administration, Ophthalmic; Adolescent; Adsorption; Adult; Aeromonas hydrophila; Aerosols; Aged; Aged, 80 and over; Aging; Agriculture; Air Pollutants; Air Pollution; Airway Remodeling; Alanine Transaminase; Albuminuria; Aldehyde Dehydrogenase 1 Family; Algorithms; AlkB Homolog 2, Alpha-Ketoglutarate-Dependent Dioxygenase; Alzheimer Disease; Amino Acid Sequence; Ammonia; Ammonium Compounds; Anaerobiosis; Anesthetics, Dissociative; Anesthetics, Inhalation; Animals; Anti-Bacterial Agents; Anti-HIV Agents; Anti-Infective Agents; Anti-Inflammatory Agents; Antibiotics, Antineoplastic; Antibodies, Antineutrophil Cytoplasmic; Antibodies, Monoclonal, Humanized; Antifungal Agents; Antigens, Bacterial; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Antioxidants; Antitubercular Agents; Antiviral Agents; Apolipoproteins E; Apoptosis; Arabidopsis; Arabidopsis Proteins; Arsenic; Arthritis, Rheumatoid; Asthma; Atherosclerosis; ATP-Dependent Proteases; Attitude of Health Personnel; Australia; Austria; Autophagy; Axitinib; Bacteria; Bacterial Outer Membrane Proteins; Bacterial Proteins; Bacterial Toxins; Bacterial Typing Techniques; Bariatric Surgery; Base Composition; Bayes Theorem; Benzoxazoles; Benzylamines; beta Catenin; Betacoronavirus; Betula; Binding Sites; Biological Availability; Biological Oxygen Demand Analysis; Biomarkers; Biomarkers, Tumor; Biopsy; Bioreactors; Biosensing Techniques; Birth Weight; Blindness; Blood Chemical Analysis; Blood Gas Analysis; Blood Glucose; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Blood-Brain Barrier; Blotting, Western; Body Mass Index; Body Weight; Bone and Bones; Bone Density; Bone Resorption; Borates; Brain; Brain Infarction; Brain Injuries, Traumatic; Brain Neoplasms; Breakfast; Breast Milk Expression; Breast Neoplasms; Bronchi; Bronchoalveolar Lavage Fluid; Buffaloes; Cadherins; Calcification, Physiologic; Calcium Compounds; Calcium, Dietary; Cannula; Caprolactam; Carbon; Carbon Dioxide; Carboplatin; Carcinogenesis; Carcinoma, Ductal; Carcinoma, Ehrlich Tumor; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Pancreatic Ductal; Carcinoma, Renal Cell; Cardiovascular Diseases; Carps; Carrageenan; Case-Control Studies; Catalysis; Catalytic Domain; Cattle; CD8-Positive T-Lymphocytes; Cell Adhesion; Cell Cycle Proteins; Cell Death; Cell Differentiation; Cell Line; Cell Line, Tumor; Cell Movement; Cell Nucleus; Cell Phone Use; Cell Proliferation; Cell Survival; Cell Transformation, Neoplastic; Cell Transformation, Viral; Cells, Cultured; Cellulose; Chemical Phenomena; Chemoradiotherapy; Child; Child Development; Child, Preschool; China; Chitosan; Chlorocebus aethiops; Cholecalciferol; Chromatography, Liquid; Circadian Clocks; Circadian Rhythm; Circular Dichroism; Cisplatin; Citric Acid; Clinical Competence; Clinical Laboratory Techniques; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clostridioides difficile; Clostridium Infections; Coculture Techniques; Cohort Studies; Cold Temperature; Colitis; Collagen Type I; Collagen Type I, alpha 1 Chain; Collagen Type XI; Color; Connective Tissue Diseases; Copper; Coronary Angiography; Coronavirus 3C Proteases; Coronavirus Infections; Cost of Illness; Counselors; COVID-19; COVID-19 Testing; Creatine Kinase; Creatinine; Cross-Over Studies; Cross-Sectional Studies; Cryoelectron Microscopy; Cryosurgery; Crystallography, X-Ray; Cues; Cultural Competency; Cultural Diversity; Curriculum; Cyclic AMP Response Element-Binding Protein; Cyclin-Dependent Kinase Inhibitor p21; Cycloparaffins; Cysteine Endopeptidases; Cytokines; Cytoplasm; Cytoprotection; Databases, Factual; Denitrification; Deoxycytidine; Diabetes Complications; Diabetes Mellitus; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diagnosis, Differential; Diatoms; Diet; Diet, High-Fat; Dietary Exposure; Diffusion Magnetic Resonance Imaging; Diketopiperazines; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Disease Models, Animal; Disease Progression; Disease-Free Survival; DNA; DNA Damage; DNA Glycosylases; DNA Repair; DNA-Binding Proteins; DNA, Bacterial; DNA, Viral; Docetaxel; Dose Fractionation, Radiation; Dose-Response Relationship, Drug; Down-Regulation; Doxorubicin; Drosophila; Drosophila melanogaster; Drug Carriers; Drug Delivery Systems; Drug Liberation; Drug Repositioning; Drug Resistance, Bacterial; Drug Resistance, Multiple, Bacterial; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Drug Synergism; Drug Therapy, Combination; Edema; Edible Grain; Education, Graduate; Education, Medical, Graduate; Education, Pharmacy; Ehlers-Danlos Syndrome; Electron Transport Complex III; Electron Transport Complex IV; Electronic Nicotine Delivery Systems; Emergency Service, Hospital; Empathy; Emulsions; Endothelial Cells; Endurance Training; Energy Intake; Enterovirus A, Human; Environment; Environmental Monitoring; Enzyme Assays; Enzyme Inhibitors; Epithelial Cells; Epithelial-Mesenchymal Transition; Epoxide Hydrolases; Epoxy Compounds; Erythrocyte Count; Erythrocytes; Escherichia coli; Escherichia coli Infections; Escherichia coli Proteins; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Esophagectomy; Estrogens; Etanercept; Ethiopia; Ethnicity; Ethylenes; Exanthema; Exercise; Exercise Test; Exercise Tolerance; Extracellular Matrix; Extracorporeal Membrane Oxygenation; Eye Infections, Fungal; False Negative Reactions; Fatty Acids; Fecal Microbiota Transplantation; Feces; Female; Femur Neck; Fermentation; Ferritins; Fetal Development; Fibroblast Growth Factor-23; Fibroblast Growth Factors; Fibroblasts; Fibroins; Fish Proteins; Flavanones; Flavonoids; Focus Groups; Follow-Up Studies; Food Handling; Food Supply; Food, Formulated; Forced Expiratory Volume; Forests; Fractures, Bone; Fruit and Vegetable Juices; Fusobacteria; G1 Phase Cell Cycle Checkpoints; G2 Phase Cell Cycle Checkpoints; Gamma Rays; Gastrectomy; Gastrointestinal Microbiome; Gastrointestinal Stromal Tumors; Gefitinib; Gels; Gemcitabine; Gene Amplification; Gene Expression; Gene Expression Regulation; Gene Expression Regulation, Bacterial; Gene Expression Regulation, Neoplastic; Gene Expression Regulation, Plant; Gene Knockdown Techniques; Gene-Environment Interaction; Genotype; Germany; Glioma; Glomerular Filtration Rate; Glucagon; Glucocorticoids; Glycemic Control; Glycerol; Glycogen Synthase Kinase 3 beta; Glycolipids; Glycolysis; Goblet Cells; Gram-Negative Bacterial Infections; Granulocyte Colony-Stimulating Factor; Graphite; Greenhouse Effect; Guanidines; Haemophilus influenzae; HCT116 Cells; Health Knowledge, Attitudes, Practice; Health Personnel; Health Services Accessibility; Health Services Needs and Demand; Health Status Disparities; Healthy Volunteers; Heart Failure; Heart Rate; Heart Transplantation; Heart-Assist Devices; HEK293 Cells; Heme; Heme Oxygenase-1; Hemolysis; Hemorrhage; Hepatitis B; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Hepatocytes; Hexoses; High-Throughput Nucleotide Sequencing; Hippo Signaling Pathway; Histamine; Histamine Agonists; Histidine; Histone Deacetylase 2; HIV Infections; HIV Reverse Transcriptase; HIV-1; Homebound Persons; Homeodomain Proteins; Homosexuality, Male; Hospice and Palliative Care Nursing; HSP70 Heat-Shock Proteins; Humans; Hyaluronan Receptors; Hydrogen; Hydrogen Peroxide; Hydrogen-Ion Concentration; Hydrolysis; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemia; Hypoglycemic Agents; Hypoxia; Idiopathic Interstitial Pneumonias; Imaging, Three-Dimensional; Imatinib Mesylate; Immunotherapy; Implementation Science; Incidence; INDEL Mutation; Induced Pluripotent Stem Cells; Industrial Waste; Infant; Infant, Newborn; Inflammation; Inflammation Mediators; Infliximab; Infusions, Intravenous; Inhibitory Concentration 50; Injections; Insecticides; Insulin-Like Growth Factor Binding Protein 5; Insulin-Secreting Cells; Interleukin-1; Interleukin-17; Interleukin-8; Internship and Residency; Intestines; Intracellular Signaling Peptides and Proteins; Ion Transport; Iridaceae; Iridoid Glucosides; Islets of Langerhans Transplantation; Isodon; Isoflurane; Isotopes; Italy; Joint Instability; Ketamine; Kidney; Kidney Failure, Chronic; Kidney Function Tests; Kidney Neoplasms; Kinetics; Klebsiella pneumoniae; Knee Joint; Kruppel-Like Factor 4; Kruppel-Like Transcription Factors; Lactate Dehydrogenase 5; Laparoscopy; Laser Therapy; Lasers, Semiconductor; Lasers, Solid-State; Laurates; Lead; Leukocyte L1 Antigen Complex; Leukocytes, Mononuclear; Light; Lipid Peroxidation; Lipopolysaccharides; Liposomes; Liver; Liver Cirrhosis; Liver Neoplasms; Liver Transplantation; Locomotion; Longitudinal Studies; Lopinavir; Lower Urinary Tract Symptoms; Lubricants; Lung; Lung Diseases, Interstitial; Lung Neoplasms; Lymphocyte Activation; Lymphocytes, Tumor-Infiltrating; Lymphoma, Mantle-Cell; Lysosomes; Macrophages; Male; Manganese Compounds; MAP Kinase Kinase 4; Mass Screening; Maternal Health; Medicine, Chinese Traditional; Melanoma, Experimental; Memantine; Membrane Glycoproteins; Membrane Proteins; Mesenchymal Stem Cell Transplantation; Metal Nanoparticles; Metalloendopeptidases; Metalloporphyrins; Methadone; Methane; Methicillin-Resistant Staphylococcus aureus; Mexico; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Mice, Inbred ICR; Mice, Knockout; Mice, Nude; Mice, SCID; Mice, Transgenic; Microarray Analysis; Microbial Sensitivity Tests; Microbiota; Micronutrients; MicroRNAs; Microscopy, Confocal; Microsomes, Liver; Middle Aged; Milk; Milk, Human; Minority Groups; Mitochondria; Mitochondrial Membranes; Mitochondrial Proteins; Models, Animal; Models, Molecular; Molecular Conformation; Molecular Docking Simulation; Molecular Dynamics Simulation; Molecular Epidemiology; Molecular Structure; Molecular Weight; Multilocus Sequence Typing; Multimodal Imaging; Muscle Strength; Muscle, Skeletal; Muscular Diseases; Mutation; Mycobacterium tuberculosis; Myocardial Stunning; Myristates; NAD(P)H Dehydrogenase (Quinone); Nanocomposites; Nanogels; Nanoparticles; Nanotechnology; Naphthalenes; Nasal Cavity; National Health Programs; Necrosis; Needs Assessment; Neoadjuvant Therapy; Neonicotinoids; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasm Proteins; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasm Transplantation; Neoplasms; Neoplastic Stem Cells; Netherlands; Neuroblastoma; Neuroprotective Agents; Neutrophils; NF-kappa B; NFATC Transcription Factors; Nicotiana; Nicotine; Nitrates; Nitrification; Nitrites; Nitro Compounds; Nitrogen; Nitrogen Dioxide; North Carolina; Nuclear Magnetic Resonance, Biomolecular; Nuclear Proteins; Nucleic Acid Hybridization; Nucleosomes; Nutrients; Obesity; Obesity, Morbid; Oceans and Seas; Oncogene Protein v-akt; Oncogenes; Oocytes; Open Reading Frames; Osteoclasts; Osteogenesis; Osteoporosis; Osteoporosis, Postmenopausal; Outpatients; Ovarian Neoplasms; Ovariectomy; Overweight; Oxazines; Oxidants; Oxidation-Reduction; Oxidative Stress; Oxides; Oxidoreductases; Oxygen; Oxygen Inhalation Therapy; Oxygenators, Membrane; Ozone; Paclitaxel; Paenibacillus; Pain Measurement; Palliative Care; Pancreatic Neoplasms; Pandemics; Parasympathetic Nervous System; Particulate Matter; Pasteurization; Patient Preference; Patient Satisfaction; Pediatric Obesity; Permeability; Peroxiredoxins; Peroxynitrous Acid; Pharmaceutical Services; Pharmacists; Pharmacy; Phaseolus; Phenotype; Phoeniceae; Phosphates; Phosphatidylinositol 3-Kinases; Phospholipid Transfer Proteins; Phospholipids; Phosphorus; Phosphorylation; Photoperiod; Photosynthesis; Phylogeny; Physical Endurance; Physicians; Pilot Projects; Piperidines; Pituitary Adenylate Cyclase-Activating Polypeptide; Plant Extracts; Plant Leaves; Plant Proteins; Plant Roots; Plaque, Atherosclerotic; Pneumonia; Pneumonia, Viral; Point-of-Care Testing; Polyethylene Glycols; Polymers; Polysorbates; Pore Forming Cytotoxic Proteins; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Postprandial Period; Poverty; Pre-Exposure Prophylaxis; Prediabetic State; Predictive Value of Tests; Pregnancy; Pregnancy Trimester, First; Pregnancy, High-Risk; Prenatal Exposure Delayed Effects; Pressure; Prevalence; Primary Graft Dysfunction; Primary Health Care; Professional Role; Professionalism; Prognosis; Progression-Free Survival; Prolactin; Promoter Regions, Genetic; Proof of Concept Study; Proportional Hazards Models; Propylene Glycol; Prospective Studies; Prostate; Protein Binding; Protein Biosynthesis; Protein Isoforms; Protein Kinase Inhibitors; Protein Phosphatase 2; Protein Processing, Post-Translational; Protein Serine-Threonine Kinases; Protein Structure, Tertiary; Protein Transport; Proteoglycans; Proteome; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-myc; Proto-Oncogene Proteins c-ret; Proto-Oncogene Proteins p21(ras); Proton Pumps; Protons; Protoporphyrins; Pseudomonas aeruginosa; Pseudomonas fluorescens; Pulmonary Artery; Pulmonary Disease, Chronic Obstructive; Pulmonary Gas Exchange; Pulmonary Veins; Pyrazoles; Pyridines; Pyrimidines; Qualitative Research; Quinoxalines; Rabbits; Random Allocation; Rats; Rats, Sprague-Dawley; Rats, Wistar; Receptors, Histamine H3; Receptors, Immunologic; Receptors, Transferrin; Recombinant Proteins; Recurrence; Reference Values; Referral and Consultation; Regional Blood Flow; Registries; Regulon; Renal Insufficiency, Chronic; Reperfusion Injury; Repressor Proteins; Reproducibility of Results; Republic of Korea; Research Design; Resistance Training; Respiration, Artificial; Respiratory Distress Syndrome; Respiratory Insufficiency; Resuscitation; Retinal Dehydrogenase; Retreatment; Retrospective Studies; Reverse Transcriptase Inhibitors; Rhinitis, Allergic; Ribosomal Proteins; Ribosomes; Risk Assessment; Risk Factors; Ritonavir; Rivers; RNA Interference; RNA-Seq; RNA, Messenger; RNA, Ribosomal, 16S; RNA, Small Interfering; Rosuvastatin Calcium; Rural Population; Saccharomyces cerevisiae; Saccharomyces cerevisiae Proteins; Salivary Ducts; Salivary Gland Neoplasms; San Francisco; SARS-CoV-2; Satiation; Satiety Response; Schools; Schools, Pharmacy; Seasons; Seawater; Selection, Genetic; Sequence Analysis, DNA; Serine-Threonine Kinase 3; Sewage; Sheep; Sheep, Domestic; Shock, Hemorrhagic; Signal Transduction; Silver; Silymarin; Single Photon Emission Computed Tomography Computed Tomography; Sirolimus; Sirtuin 1; Skin; Skin Neoplasms; Skin Physiological Phenomena; Sleep Initiation and Maintenance Disorders; Social Class; Social Participation; Social Support; Soil; Soil Microbiology; Solutions; Somatomedins; Soot; Specimen Handling; Spectrophotometry, Ultraviolet; Spectroscopy, Fourier Transform Infrared; Spectrum Analysis; Spinal Fractures; Spirometry; Staphylococcus aureus; STAT1 Transcription Factor; STAT3 Transcription Factor; Streptomyces coelicolor; Stress, Psychological; Stroke; Stroke Volume; Structure-Activity Relationship; Students, Medical; Students, Pharmacy; Substance Abuse Treatment Centers; Sulfur Dioxide; Surface Properties; Surface-Active Agents; Surveys and Questionnaires; Survival Analysis; Survival Rate; Survivin; Sweden; Swine; Swine, Miniature; Sympathetic Nervous System; T-Lymphocytes, Regulatory; Talaromyces; Tandem Mass Spectrometry; tau Proteins; Telemedicine; Telomerase; Telomere; Telomere Homeostasis; Temperature; Terminally Ill; Th1 Cells; Thiamethoxam; Thiazoles; Thiophenes; Thioredoxin Reductase 1; Thrombosis; Thulium; Thyroid Cancer, Papillary; Thyroid Carcinoma, Anaplastic; Thyroid Neoplasms; Time Factors; Titanium; Tomography, Emission-Computed, Single-Photon; Tomography, X-Ray Computed; TOR Serine-Threonine Kinases; Transcription Factor AP-1; Transcription Factors; Transcription, Genetic; Transcriptional Activation; Transcriptome; Transforming Growth Factor beta1; Transistors, Electronic; Translational Research, Biomedical; Transplantation Tolerance; Transplantation, Homologous; Transportation; Treatment Outcome; Tretinoin; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary; Tubulin Modulators; Tumor Microenvironment; Tumor Necrosis Factor Inhibitors; Tumor Necrosis Factor-alpha; Twins; Ultrasonic Therapy; Ultrasonography; Ultraviolet Rays; United States; Up-Regulation; Uranium; Urethra; Urinary Bladder; Urodynamics; Uromodulin; Uveitis; Vasoconstrictor Agents; Ventricular Function, Left; Vero Cells; Vesicular Transport Proteins; Viral Nonstructural Proteins; Visual Acuity; Vital Capacity; Vitamin D; Vitamin D Deficiency; Vitamin K 2; Vitamins; Volatilization; Voriconazole; Waiting Lists; Waste Disposal, Fluid; Wastewater; Water Pollutants, Chemical; Whole Genome Sequencing; Wine; Wnt Signaling Pathway; Wound Healing; Wounds and Injuries; WW Domains; X-linked Nuclear Protein; X-Ray Diffraction; Xanthines; Xenograft Model Antitumor Assays; YAP-Signaling Proteins; Yogurt; Young Adult; Zebrafish; Zebrafish Proteins; Ziziphus | 2016 |
Therapeutic options following second-line platinum-based chemotherapy in patients with recurrent ovarian cancer: Comparison of active surveillance and maintenance treatment.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Disease Progression; Female; Humans; Maintenance Chemotherapy; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Poly(ADP-ribose) Polymerase Inhibitors; Randomized Controlled Trials as Topic; Watchful Waiting | 2020 |
Impact of Nab-Paclitaxel-based Second-line Chemotherapy in Metastatic Pancreatic Cancer.
Topics: Academic Medical Centers; Adult; Aged; Aged, 80 and over; Albumins; Antineoplastic Agents; Carcinoma, Pancreatic Ductal; Disease Progression; Disease-Free Survival; Female; Humans; Indiana; Kaplan-Meier Estimate; Male; Middle Aged; Multivariate Analysis; Neoplasm Metastasis; Paclitaxel; Pancreatic Neoplasms; Proportional Hazards Models; Retrospective Studies; Risk Factors; Time Factors; Treatment Outcome | 2017 |
Dose-dense weekly chemotherapy in advanced ovarian cancer: An updated meta-analysis of randomized controlled trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Disease Progression; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Ovarian Neoplasms; Paclitaxel; Randomized Controlled Trials as Topic | 2018 |
Anticancer drug treatment for advanced lung cancer with interstitial lung disease.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Disease Progression; Etoposide; Follow-Up Studies; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Paclitaxel; Platinum; Retrospective Studies; Risk Assessment; Risk Factors | 2018 |
Pembrolizumab monotherapy versus chemotherapy for treatment of advanced urothelial carcinoma with disease progression during or following platinum-containing chemotherapy. A Cochrane Rapid Review.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Disease Progression; Docetaxel; Humans; Paclitaxel; Quality of Life; Taxoids; Urinary Bladder Neoplasms; Vinblastine | 2018 |
Treatment of severe or progressive Kaposi's sarcoma in HIV-infected adults.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Antiretroviral Therapy, Highly Active; Bleomycin; Disease Progression; Doxorubicin; Drug Therapy, Combination; HIV Infections; Humans; Immune Reconstitution Inflammatory Syndrome; Observational Studies as Topic; Paclitaxel; Polyethylene Glycols; Randomized Controlled Trials as Topic; Sarcoma, Kaposi; Vincristine | 2014 |
De novo large cell neuroendocrine carcinoma of the prostate gland with pelvic lymph node metastasis: a case report with review of literature.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Biopsy; Carcinoma, Large Cell; Carcinoma, Neuroendocrine; Chemotherapy, Adjuvant; Cisplatin; Cystoscopy; Disease Progression; Etoposide; Fatal Outcome; Humans; Immunohistochemistry; Laparoscopy; Leuprolide; Lymph Node Excision; Lymphatic Metastasis; Male; Meningeal Neoplasms; Middle Aged; Neoadjuvant Therapy; Neoplasm Grading; Paclitaxel; Pelvis; Prostatic Neoplasms; Robotic Surgical Procedures; Time Factors; Tomography, X-Ray Computed; Transurethral Resection of Prostate; Treatment Outcome | 2014 |
Taxane-containing regimens for metastatic breast cancer.
Topics: Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Bridged-Ring Compounds; Disease Progression; Female; Humans; Paclitaxel; Randomized Controlled Trials as Topic; Tamoxifen; Taxoids | 2015 |
[Latest advances in pancreatic tumours].
Topics: Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Contrast Media; Deoxycytidine; Diagnosis, Differential; Disease Progression; Early Detection of Cancer; Elasticity Imaging Techniques; Endosonography; Gemcitabine; Humans; Paclitaxel; Pancreatectomy; Pancreatic Cyst; Pancreatic Neoplasms; Pancreatitis, Alcoholic; Prognosis; Risk | 2015 |
Systemic therapy beyond first-line in advanced gastric cancer: An overview of the main randomized clinical trials.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Disease Progression; Humans; Neoadjuvant Therapy; Paclitaxel; Quality of Life; Randomized Controlled Trials as Topic; Stomach Neoplasms; Survival Analysis; Treatment Outcome | 2016 |
Tailoring the dosing schedule of nab-paclitaxel in metastatic breast cancer according to patient and disease characteristics: Recommendations from a panel of experts.
Topics: Albumins; Breast Neoplasms; Disease Progression; Dose-Response Relationship, Drug; Drug Administration Schedule; Expert Testimony; Female; Humans; Neoplasm Metastasis; Paclitaxel; Practice Guidelines as Topic; Precision Medicine | 2016 |
Management of patients treated with pertuzumab in the Australian clinical practice setting.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Australia; Breast Neoplasms; Bridged-Ring Compounds; Disease Management; Disease Progression; Docetaxel; Female; Humans; Neoplasm Recurrence, Local; Paclitaxel; Receptor, ErbB-2; Taxoids; Trastuzumab | 2016 |
High-dose chemotherapy as salvage treatment in germ-cell cancer: when, in whom and how.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease Progression; Dose-Response Relationship, Drug; Etoposide; Humans; Ifosfamide; Male; Neoplasm Recurrence, Local; Neoplasms, Germ Cell and Embryonal; Paclitaxel; Patient Selection; Salvage Therapy; Testicular Neoplasms; Vinblastine | 2017 |
Drug Insight: intracellular inhibitors of HER2--clinical development of lapatinib in breast cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Deoxycytidine; Disease Progression; Female; Fluorouracil; Genes, erbB-2; Humans; Lapatinib; Paclitaxel; Protein Kinase Inhibitors; Quinazolines; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Tamoxifen; Time Factors; Trastuzumab | 2008 |
The role of hormonal therapy in the management of hormonal-receptor-positive breast cancer with co-expression of HER2.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Disease Progression; Docetaxel; Drug Resistance, Neoplasm; Female; Humans; Paclitaxel; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Receptors, Estrogen; Selective Estrogen Receptor Modulators; Survival Analysis; Taxoids; Trastuzumab; Treatment Outcome | 2008 |
Reasons for response differences seen in the V15-32, INTEREST and IPASS trials.
Topics: Adenocarcinoma; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Asia; Asian People; Carboplatin; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase III as Topic; Disease Progression; Disease-Free Survival; Docetaxel; ErbB Receptors; Europe; Female; Gefitinib; Humans; Lung Neoplasms; Male; Multicenter Studies as Topic; Neoplasm Metastasis; Neoplasm Staging; North America; Paclitaxel; Platinum Compounds; Protein Kinase Inhibitors; Quinazolines; Randomized Controlled Trials as Topic; Recurrence; South America; Survival Analysis; Taxoids; Tumor Burden | 2009 |
New options for integrating antiangiogenic therapy and platinum-based first-line chemotherapy for advanced non-small-cell lung cancer.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Non-Small-Cell Lung; Disease Progression; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Paclitaxel; Platinum Compounds; Protein Kinase Inhibitors; Quinazolines; Vascular Endothelial Growth Factor A | 2008 |
Advanced ovarian cancer: a clinical update on first-line treatment, recurrent disease, and new agents.
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Carboplatin; Cisplatin; Clinical Trials as Topic; Disease Progression; Drug Therapy, Combination; Female; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Treatment Failure | 2004 |
[Treatment possibilities in breast cancer progressing after anthracyclines and/or taxanes].
Topics: Anthracyclines; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease Progression; Doxorubicin; Epothilones; Female; Fluorouracil; Gemcitabine; Humans; Paclitaxel; Salvage Therapy; Taxoids; Vinblastine; Vinorelbine | 2010 |
Malignant mixed Mullerian tumor of the ovary with two cases and review of the literature.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Combined Modality Therapy; Disease Progression; Docetaxel; Female; Follow-Up Studies; Humans; Hysterectomy; Mixed Tumor, Mullerian; Neoplasm Staging; Omentum; Ovarian Neoplasms; Ovariectomy; Paclitaxel; Palliative Care; Salpingectomy; Taxoids; Tomography, X-Ray Computed | 2011 |
[Metastatic non-small cell lung cancer: Systemic treatment of patients aged 70 and over].
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Deoxycytidine; Disease Progression; Drug Administration Schedule; Gemcitabine; Humans; Long-Term Care; Lung Neoplasms; Neoplasm Staging; Paclitaxel; Palliative Care; Prognosis; Vinblastine; Vinorelbine | 2011 |
[First-line bevacizumab in ovarian cancer].
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Clinical Trials, Phase III as Topic; Disease Progression; Female; Humans; Ovarian Neoplasms; Paclitaxel; Patient Selection; Randomized Controlled Trials as Topic; Treatment Outcome | 2011 |
Molecular targeting agents in the context of primary chemoradiation strategies.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Carboplatin; Carcinoma, Squamous Cell; Cetuximab; Chemoradiotherapy; Disease Progression; ErbB Receptors; Fluorouracil; Head and Neck Neoplasms; Humans; Molecular Targeted Therapy; Oropharyngeal Neoplasms; Paclitaxel; Squamous Cell Carcinoma of Head and Neck; Treatment Outcome | 2013 |
A rational approach to the management of recurrent or persistent ovarian carcinoma.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Chemotherapy, Cancer, Regional Perfusion; Decision Making; Deoxycytidine; Disease Progression; Doxorubicin; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Ovary; Paclitaxel; Polyethylene Glycols; Quality of Life; Randomized Controlled Trials as Topic | 2012 |
The role of chemotherapy in advanced prostate cancer.
Topics: Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Docetaxel; Estramustine; Humans; Male; Paclitaxel; Prostatic Neoplasms; Taxoids | 2002 |
Treatment for anthracycline-pretreated metastatic breast cancer.
Topics: Administration, Oral; Adult; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Clinical Trials, Phase III as Topic; Deoxycytidine; Disease Progression; Docetaxel; Doxorubicin; Economics, Pharmaceutical; Epirubicin; Female; Fluorouracil; Humans; Neoplasm Metastasis; Paclitaxel; Taxoids; Treatment Outcome | 2002 |
First-line chemotherapy for NSCLC: an overview of relevant trials.
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials as Topic; Disease Progression; Docetaxel; Humans; Lung Neoplasms; Paclitaxel; Quality of Life; Survival; Taxoids; Treatment Outcome | 2002 |
Clinical research in pancreatic cancer: the Radiation Therapy Oncology Group trials.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Combined Modality Therapy; Deoxycytidine; Disease Progression; Enzyme Inhibitors; Gastrointestinal Neoplasms; Gemcitabine; Humans; Paclitaxel; Quinolones; Radiotherapy, Conformal; Treatment Outcome | 2003 |
Taxane containing regimens for metastatic breast cancer.
Topics: Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Bridged-Ring Compounds; Disease Progression; Female; Humans; Paclitaxel; Randomized Controlled Trials as Topic; Tamoxifen; Taxoids | 2003 |
The role of interval debulking surgery in ovarian cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease Progression; Disease-Free Survival; Female; Gynecologic Surgical Procedures; Humans; Ovarian Neoplasms; Paclitaxel; Prognosis; Women's Health | 2003 |
Recurrent ovarian cancer: how important is it to treat to disease progression?
Topics: Altretamine; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Deoxycytidine; Disease Progression; Docetaxel; Doxorubicin; Etoposide; Female; Gemcitabine; Humans; Ovarian Neoplasms; Paclitaxel; Recurrence; Risk; Taxoids; Time Factors; Topotecan | 2004 |
Taxane containing regimens for metastatic breast cancer.
Topics: Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Bridged-Ring Compounds; Disease Progression; Female; Humans; Paclitaxel; Randomized Controlled Trials as Topic; Tamoxifen; Taxoids | 2005 |
Role of Gemcitabine in Breast Cancer Management: An Update.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; Deoxycytidine; Disease Progression; Female; Gemcitabine; Humans; Paclitaxel; Receptor, ErbB-2 | 2006 |
Progress from Alzheimer's tangles to pathological tau points towards more effective therapies now.
Topics: Alzheimer Disease; Antineoplastic Agents, Phytogenic; Brain; Disease Progression; Humans; Nerve Degeneration; Neurofibrillary Tangles; Paclitaxel; tau Proteins | 2006 |
Progressive epithelial ovarian carcinoma. Prognostic factors and clinical management.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; CA-125 Antigen; Carboplatin; Combined Modality Therapy; Cystadenocarcinoma, Serous; Denmark; Diagnostic Imaging; Disease Progression; Female; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Prognosis; Randomized Controlled Trials as Topic; Survival Analysis; Topotecan; Treatment Outcome | 2006 |
[Precursor lesions of type II endometrial cancer: diagnostic criteria and pathogenesis].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma in Situ; Cystadenocarcinoma, Papillary; Cystadenocarcinoma, Serous; Disease Progression; Endometrial Hyperplasia; Endometrial Neoplasms; Female; Humans; Hysterectomy; Paclitaxel; Precancerous Conditions; Radiotherapy, Adjuvant; Uterine Neoplasms | 2007 |
Quality-of-life issues in the management of epithelial ovarian cancer.
Topics: Antineoplastic Agents; Carboplatin; Cisplatin; Disease Progression; Docetaxel; Female; Humans; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Quality of Life; Taxoids | 2007 |
Long-term results from a phase II study of single agent paclitaxel (Taxol) in previously platinum treated patients with advanced ovarian cancer: the Nordic experience.
Topics: Adult; Antineoplastic Agents, Phytogenic; Cisplatin; Disease Progression; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Humans; Norway; Ovarian Neoplasms; Paclitaxel; Remission Induction; Salvage Therapy; Survival Analysis; Survival Rate; Treatment Outcome | 1998 |
Discussing disease progression and end-of-life decisions.
Topics: Antineoplastic Combined Chemotherapy Protocols; Attitude to Death; Carcinoma in Situ; Cisplatin; Communication; Decision Making; Disease Progression; Euthanasia; Female; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel; Physician-Patient Relations; Truth Disclosure | 1999 |
Second-line chemotherapy for non-small-cell lung cancer.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Disease Progression; Docetaxel; Drug Resistance, Neoplasm; Health Status; Humans; Ifosfamide; Lung Neoplasms; Paclitaxel; Randomized Controlled Trials as Topic; Survival Analysis; Taxoids; Vinblastine; Vinorelbine | 2000 |
Docetaxel and epirubicin in advanced breast cancer.
Topics: Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease Progression; Docetaxel; Epirubicin; Female; Humans; Paclitaxel; Taxoids | 2001 |
Herceptin alone or in combination with chemotherapy in the treatment of HER2-positive metastatic breast cancer: pivotal trials.
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Cyclophosphamide; Disease Progression; Disease-Free Survival; Doxorubicin; Drug Administration Schedule; Epirubicin; Female; Humans; In Situ Hybridization, Fluorescence; Multicenter Studies as Topic; Neoplasm Metastasis; Neoplasm Proteins; Paclitaxel; Quality of Life; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Retrospective Studies; Safety; Single-Blind Method; Survival Analysis; Trastuzumab; Treatment Outcome | 2001 |
[Molecular mechanisms of oncogenic transformation: what's new?].
Topics: Animals; Antineoplastic Agents, Phytogenic; CDC2-CDC28 Kinases; Cell Cycle; Cell Division; Cell Transformation, Neoplastic; Cyclin D1; Cyclin E; Cyclin-Dependent Kinase 2; Cyclin-Dependent Kinase Inhibitor p16; Cyclin-Dependent Kinase Inhibitor p21; Cyclin-Dependent Kinases; Cyclins; Disease Progression; Drug Resistance; Fusion Proteins, bcr-abl; Humans; Mice; Mutation; Neoplasm Metastasis; Neoplasm Proteins; Neoplasms; Neovascularization, Pathologic; Neural Cell Adhesion Molecules; Paclitaxel; Protein Serine-Threonine Kinases; Radiation Tolerance; Rats; Thrombospondins; Transforming Growth Factor beta; Tuberous Sclerosis | 2002 |
Taxanes for breast cancer: an evidence-based review of randomized phase II and phase III trials.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Bridged-Ring Compounds; Chemotherapy, Adjuvant; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Disease Progression; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Evidence-Based Medicine; Female; Genes, erbB-2; Humans; Infusions, Intravenous; Neoadjuvant Therapy; Neoplasm Staging; Paclitaxel; Quality of Life; Randomized Controlled Trials as Topic; Survival Analysis; Taxoids; Treatment Outcome | 2000 |
362 trial(s) available for paclitaxel and Disease Exacerbation
| Article | Year |
|---|---|
Impact of Pembrolizumab Versus Chemotherapy as Second-Line Therapy for Advanced Esophageal Cancer on Health-Related Quality of Life in KEYNOTE-181.
Topics: Adenocarcinoma; Antibodies, Monoclonal, Humanized; Disease Progression; Docetaxel; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Functional Status; Humans; Immune Checkpoint Inhibitors; Irinotecan; Paclitaxel; Quality of Life; Surveys and Questionnaires; Time Factors; Treatment Outcome | 2022 |
A phase II evaluation of temsirolimus with carboplatin and paclitaxel followed by temsirolimus consolidation in clear cell ovarian cancer: An NRG oncology trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Disease Progression; Female; Humans; Ovarian Neoplasms; Paclitaxel; Thrombocytopenia | 2022 |
Nal-IRI/LV5-FU versus paclitaxel as second-line therapy in patients with metastatic esophageal squamous cell carcinoma (OESIRI)-PRODIGE 62: A multicentre, randomised, non-comparative phase II study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase II as Topic; Disease Progression; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Fluorouracil; France; Humans; Irinotecan; Multicenter Studies as Topic; Neoplasm Recurrence, Local; Paclitaxel; Quality of Life; Randomized Controlled Trials as Topic; Survival Rate | 2020 |
[Clinical implications of the PORTEC-3 trial for the treatment of high-risk endometrial cancer].
Topics: Area Under Curve; Brachytherapy; Chemoradiotherapy, Adjuvant; Chemotherapy, Adjuvant; Cisplatin; Combined Modality Therapy; Disease Progression; Endometrial Neoplasms; Female; Humans; Hysterectomy; Lymph Node Excision; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Risk Factors; Survival Rate | 2020 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor Proteins, Signal Transducing; Adenine; Adenocarcinoma; Adipogenesis; Administration, Cutaneous; Administration, Ophthalmic; Adolescent; Adsorption; Adult; Aeromonas hydrophila; Aerosols; Aged; Aged, 80 and over; Aging; Agriculture; Air Pollutants; Air Pollution; Airway Remodeling; Alanine Transaminase; Albuminuria; Aldehyde Dehydrogenase 1 Family; Algorithms; AlkB Homolog 2, Alpha-Ketoglutarate-Dependent Dioxygenase; Alzheimer Disease; Amino Acid Sequence; Ammonia; Ammonium Compounds; Anaerobiosis; Anesthetics, Dissociative; Anesthetics, Inhalation; Animals; Anti-Bacterial Agents; Anti-HIV Agents; Anti-Infective Agents; Anti-Inflammatory Agents; Antibiotics, Antineoplastic; Antibodies, Antineutrophil Cytoplasmic; Antibodies, Monoclonal, Humanized; Antifungal Agents; Antigens, Bacterial; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Antioxidants; Antitubercular Agents; Antiviral Agents; Apolipoproteins E; Apoptosis; Arabidopsis; Arabidopsis Proteins; Arsenic; Arthritis, Rheumatoid; Asthma; Atherosclerosis; ATP-Dependent Proteases; Attitude of Health Personnel; Australia; Austria; Autophagy; Axitinib; Bacteria; Bacterial Outer Membrane Proteins; Bacterial Proteins; Bacterial Toxins; Bacterial Typing Techniques; Bariatric Surgery; Base Composition; Bayes Theorem; Benzoxazoles; Benzylamines; beta Catenin; Betacoronavirus; Betula; Binding Sites; Biological Availability; Biological Oxygen Demand Analysis; Biomarkers; Biomarkers, Tumor; Biopsy; Bioreactors; Biosensing Techniques; Birth Weight; Blindness; Blood Chemical Analysis; Blood Gas Analysis; Blood Glucose; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Blood-Brain Barrier; Blotting, Western; Body Mass Index; Body Weight; Bone and Bones; Bone Density; Bone Resorption; Borates; Brain; Brain Infarction; Brain Injuries, Traumatic; Brain Neoplasms; Breakfast; Breast Milk Expression; Breast Neoplasms; Bronchi; Bronchoalveolar Lavage Fluid; Buffaloes; Cadherins; Calcification, Physiologic; Calcium Compounds; Calcium, Dietary; Cannula; Caprolactam; Carbon; Carbon Dioxide; Carboplatin; Carcinogenesis; Carcinoma, Ductal; Carcinoma, Ehrlich Tumor; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Pancreatic Ductal; Carcinoma, Renal Cell; Cardiovascular Diseases; Carps; Carrageenan; Case-Control Studies; Catalysis; Catalytic Domain; Cattle; CD8-Positive T-Lymphocytes; Cell Adhesion; Cell Cycle Proteins; Cell Death; Cell Differentiation; Cell Line; Cell Line, Tumor; Cell Movement; Cell Nucleus; Cell Phone Use; Cell Proliferation; Cell Survival; Cell Transformation, Neoplastic; Cell Transformation, Viral; Cells, Cultured; Cellulose; Chemical Phenomena; Chemoradiotherapy; Child; Child Development; Child, Preschool; China; Chitosan; Chlorocebus aethiops; Cholecalciferol; Chromatography, Liquid; Circadian Clocks; Circadian Rhythm; Circular Dichroism; Cisplatin; Citric Acid; Clinical Competence; Clinical Laboratory Techniques; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clostridioides difficile; Clostridium Infections; Coculture Techniques; Cohort Studies; Cold Temperature; Colitis; Collagen Type I; Collagen Type I, alpha 1 Chain; Collagen Type XI; Color; Connective Tissue Diseases; Copper; Coronary Angiography; Coronavirus 3C Proteases; Coronavirus Infections; Cost of Illness; Counselors; COVID-19; COVID-19 Testing; Creatine Kinase; Creatinine; Cross-Over Studies; Cross-Sectional Studies; Cryoelectron Microscopy; Cryosurgery; Crystallography, X-Ray; Cues; Cultural Competency; Cultural Diversity; Curriculum; Cyclic AMP Response Element-Binding Protein; Cyclin-Dependent Kinase Inhibitor p21; Cycloparaffins; Cysteine Endopeptidases; Cytokines; Cytoplasm; Cytoprotection; Databases, Factual; Denitrification; Deoxycytidine; Diabetes Complications; Diabetes Mellitus; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diagnosis, Differential; Diatoms; Diet; Diet, High-Fat; Dietary Exposure; Diffusion Magnetic Resonance Imaging; Diketopiperazines; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Disease Models, Animal; Disease Progression; Disease-Free Survival; DNA; DNA Damage; DNA Glycosylases; DNA Repair; DNA-Binding Proteins; DNA, Bacterial; DNA, Viral; Docetaxel; Dose Fractionation, Radiation; Dose-Response Relationship, Drug; Down-Regulation; Doxorubicin; Drosophila; Drosophila melanogaster; Drug Carriers; Drug Delivery Systems; Drug Liberation; Drug Repositioning; Drug Resistance, Bacterial; Drug Resistance, Multiple, Bacterial; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Drug Synergism; Drug Therapy, Combination; Edema; Edible Grain; Education, Graduate; Education, Medical, Graduate; Education, Pharmacy; Ehlers-Danlos Syndrome; Electron Transport Complex III; Electron Transport Complex IV; Electronic Nicotine Delivery Systems; Emergency Service, Hospital; Empathy; Emulsions; Endothelial Cells; Endurance Training; Energy Intake; Enterovirus A, Human; Environment; Environmental Monitoring; Enzyme Assays; Enzyme Inhibitors; Epithelial Cells; Epithelial-Mesenchymal Transition; Epoxide Hydrolases; Epoxy Compounds; Erythrocyte Count; Erythrocytes; Escherichia coli; Escherichia coli Infections; Escherichia coli Proteins; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Esophagectomy; Estrogens; Etanercept; Ethiopia; Ethnicity; Ethylenes; Exanthema; Exercise; Exercise Test; Exercise Tolerance; Extracellular Matrix; Extracorporeal Membrane Oxygenation; Eye Infections, Fungal; False Negative Reactions; Fatty Acids; Fecal Microbiota Transplantation; Feces; Female; Femur Neck; Fermentation; Ferritins; Fetal Development; Fibroblast Growth Factor-23; Fibroblast Growth Factors; Fibroblasts; Fibroins; Fish Proteins; Flavanones; Flavonoids; Focus Groups; Follow-Up Studies; Food Handling; Food Supply; Food, Formulated; Forced Expiratory Volume; Forests; Fractures, Bone; Fruit and Vegetable Juices; Fusobacteria; G1 Phase Cell Cycle Checkpoints; G2 Phase Cell Cycle Checkpoints; Gamma Rays; Gastrectomy; Gastrointestinal Microbiome; Gastrointestinal Stromal Tumors; Gefitinib; Gels; Gemcitabine; Gene Amplification; Gene Expression; Gene Expression Regulation; Gene Expression Regulation, Bacterial; Gene Expression Regulation, Neoplastic; Gene Expression Regulation, Plant; Gene Knockdown Techniques; Gene-Environment Interaction; Genotype; Germany; Glioma; Glomerular Filtration Rate; Glucagon; Glucocorticoids; Glycemic Control; Glycerol; Glycogen Synthase Kinase 3 beta; Glycolipids; Glycolysis; Goblet Cells; Gram-Negative Bacterial Infections; Granulocyte Colony-Stimulating Factor; Graphite; Greenhouse Effect; Guanidines; Haemophilus influenzae; HCT116 Cells; Health Knowledge, Attitudes, Practice; Health Personnel; Health Services Accessibility; Health Services Needs and Demand; Health Status Disparities; Healthy Volunteers; Heart Failure; Heart Rate; Heart Transplantation; Heart-Assist Devices; HEK293 Cells; Heme; Heme Oxygenase-1; Hemolysis; Hemorrhage; Hepatitis B; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Hepatocytes; Hexoses; High-Throughput Nucleotide Sequencing; Hippo Signaling Pathway; Histamine; Histamine Agonists; Histidine; Histone Deacetylase 2; HIV Infections; HIV Reverse Transcriptase; HIV-1; Homebound Persons; Homeodomain Proteins; Homosexuality, Male; Hospice and Palliative Care Nursing; HSP70 Heat-Shock Proteins; Humans; Hyaluronan Receptors; Hydrogen; Hydrogen Peroxide; Hydrogen-Ion Concentration; Hydrolysis; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemia; Hypoglycemic Agents; Hypoxia; Idiopathic Interstitial Pneumonias; Imaging, Three-Dimensional; Imatinib Mesylate; Immunotherapy; Implementation Science; Incidence; INDEL Mutation; Induced Pluripotent Stem Cells; Industrial Waste; Infant; Infant, Newborn; Inflammation; Inflammation Mediators; Infliximab; Infusions, Intravenous; Inhibitory Concentration 50; Injections; Insecticides; Insulin-Like Growth Factor Binding Protein 5; Insulin-Secreting Cells; Interleukin-1; Interleukin-17; Interleukin-8; Internship and Residency; Intestines; Intracellular Signaling Peptides and Proteins; Ion Transport; Iridaceae; Iridoid Glucosides; Islets of Langerhans Transplantation; Isodon; Isoflurane; Isotopes; Italy; Joint Instability; Ketamine; Kidney; Kidney Failure, Chronic; Kidney Function Tests; Kidney Neoplasms; Kinetics; Klebsiella pneumoniae; Knee Joint; Kruppel-Like Factor 4; Kruppel-Like Transcription Factors; Lactate Dehydrogenase 5; Laparoscopy; Laser Therapy; Lasers, Semiconductor; Lasers, Solid-State; Laurates; Lead; Leukocyte L1 Antigen Complex; Leukocytes, Mononuclear; Light; Lipid Peroxidation; Lipopolysaccharides; Liposomes; Liver; Liver Cirrhosis; Liver Neoplasms; Liver Transplantation; Locomotion; Longitudinal Studies; Lopinavir; Lower Urinary Tract Symptoms; Lubricants; Lung; Lung Diseases, Interstitial; Lung Neoplasms; Lymphocyte Activation; Lymphocytes, Tumor-Infiltrating; Lymphoma, Mantle-Cell; Lysosomes; Macrophages; Male; Manganese Compounds; MAP Kinase Kinase 4; Mass Screening; Maternal Health; Medicine, Chinese Traditional; Melanoma, Experimental; Memantine; Membrane Glycoproteins; Membrane Proteins; Mesenchymal Stem Cell Transplantation; Metal Nanoparticles; Metalloendopeptidases; Metalloporphyrins; Methadone; Methane; Methicillin-Resistant Staphylococcus aureus; Mexico; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Mice, Inbred ICR; Mice, Knockout; Mice, Nude; Mice, SCID; Mice, Transgenic; Microarray Analysis; Microbial Sensitivity Tests; Microbiota; Micronutrients; MicroRNAs; Microscopy, Confocal; Microsomes, Liver; Middle Aged; Milk; Milk, Human; Minority Groups; Mitochondria; Mitochondrial Membranes; Mitochondrial Proteins; Models, Animal; Models, Molecular; Molecular Conformation; Molecular Docking Simulation; Molecular Dynamics Simulation; Molecular Epidemiology; Molecular Structure; Molecular Weight; Multilocus Sequence Typing; Multimodal Imaging; Muscle Strength; Muscle, Skeletal; Muscular Diseases; Mutation; Mycobacterium tuberculosis; Myocardial Stunning; Myristates; NAD(P)H Dehydrogenase (Quinone); Nanocomposites; Nanogels; Nanoparticles; Nanotechnology; Naphthalenes; Nasal Cavity; National Health Programs; Necrosis; Needs Assessment; Neoadjuvant Therapy; Neonicotinoids; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasm Proteins; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasm Transplantation; Neoplasms; Neoplastic Stem Cells; Netherlands; Neuroblastoma; Neuroprotective Agents; Neutrophils; NF-kappa B; NFATC Transcription Factors; Nicotiana; Nicotine; Nitrates; Nitrification; Nitrites; Nitro Compounds; Nitrogen; Nitrogen Dioxide; North Carolina; Nuclear Magnetic Resonance, Biomolecular; Nuclear Proteins; Nucleic Acid Hybridization; Nucleosomes; Nutrients; Obesity; Obesity, Morbid; Oceans and Seas; Oncogene Protein v-akt; Oncogenes; Oocytes; Open Reading Frames; Osteoclasts; Osteogenesis; Osteoporosis; Osteoporosis, Postmenopausal; Outpatients; Ovarian Neoplasms; Ovariectomy; Overweight; Oxazines; Oxidants; Oxidation-Reduction; Oxidative Stress; Oxides; Oxidoreductases; Oxygen; Oxygen Inhalation Therapy; Oxygenators, Membrane; Ozone; Paclitaxel; Paenibacillus; Pain Measurement; Palliative Care; Pancreatic Neoplasms; Pandemics; Parasympathetic Nervous System; Particulate Matter; Pasteurization; Patient Preference; Patient Satisfaction; Pediatric Obesity; Permeability; Peroxiredoxins; Peroxynitrous Acid; Pharmaceutical Services; Pharmacists; Pharmacy; Phaseolus; Phenotype; Phoeniceae; Phosphates; Phosphatidylinositol 3-Kinases; Phospholipid Transfer Proteins; Phospholipids; Phosphorus; Phosphorylation; Photoperiod; Photosynthesis; Phylogeny; Physical Endurance; Physicians; Pilot Projects; Piperidines; Pituitary Adenylate Cyclase-Activating Polypeptide; Plant Extracts; Plant Leaves; Plant Proteins; Plant Roots; Plaque, Atherosclerotic; Pneumonia; Pneumonia, Viral; Point-of-Care Testing; Polyethylene Glycols; Polymers; Polysorbates; Pore Forming Cytotoxic Proteins; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Postprandial Period; Poverty; Pre-Exposure Prophylaxis; Prediabetic State; Predictive Value of Tests; Pregnancy; Pregnancy Trimester, First; Pregnancy, High-Risk; Prenatal Exposure Delayed Effects; Pressure; Prevalence; Primary Graft Dysfunction; Primary Health Care; Professional Role; Professionalism; Prognosis; Progression-Free Survival; Prolactin; Promoter Regions, Genetic; Proof of Concept Study; Proportional Hazards Models; Propylene Glycol; Prospective Studies; Prostate; Protein Binding; Protein Biosynthesis; Protein Isoforms; Protein Kinase Inhibitors; Protein Phosphatase 2; Protein Processing, Post-Translational; Protein Serine-Threonine Kinases; Protein Structure, Tertiary; Protein Transport; Proteoglycans; Proteome; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-myc; Proto-Oncogene Proteins c-ret; Proto-Oncogene Proteins p21(ras); Proton Pumps; Protons; Protoporphyrins; Pseudomonas aeruginosa; Pseudomonas fluorescens; Pulmonary Artery; Pulmonary Disease, Chronic Obstructive; Pulmonary Gas Exchange; Pulmonary Veins; Pyrazoles; Pyridines; Pyrimidines; Qualitative Research; Quinoxalines; Rabbits; Random Allocation; Rats; Rats, Sprague-Dawley; Rats, Wistar; Receptors, Histamine H3; Receptors, Immunologic; Receptors, Transferrin; Recombinant Proteins; Recurrence; Reference Values; Referral and Consultation; Regional Blood Flow; Registries; Regulon; Renal Insufficiency, Chronic; Reperfusion Injury; Repressor Proteins; Reproducibility of Results; Republic of Korea; Research Design; Resistance Training; Respiration, Artificial; Respiratory Distress Syndrome; Respiratory Insufficiency; Resuscitation; Retinal Dehydrogenase; Retreatment; Retrospective Studies; Reverse Transcriptase Inhibitors; Rhinitis, Allergic; Ribosomal Proteins; Ribosomes; Risk Assessment; Risk Factors; Ritonavir; Rivers; RNA Interference; RNA-Seq; RNA, Messenger; RNA, Ribosomal, 16S; RNA, Small Interfering; Rosuvastatin Calcium; Rural Population; Saccharomyces cerevisiae; Saccharomyces cerevisiae Proteins; Salivary Ducts; Salivary Gland Neoplasms; San Francisco; SARS-CoV-2; Satiation; Satiety Response; Schools; Schools, Pharmacy; Seasons; Seawater; Selection, Genetic; Sequence Analysis, DNA; Serine-Threonine Kinase 3; Sewage; Sheep; Sheep, Domestic; Shock, Hemorrhagic; Signal Transduction; Silver; Silymarin; Single Photon Emission Computed Tomography Computed Tomography; Sirolimus; Sirtuin 1; Skin; Skin Neoplasms; Skin Physiological Phenomena; Sleep Initiation and Maintenance Disorders; Social Class; Social Participation; Social Support; Soil; Soil Microbiology; Solutions; Somatomedins; Soot; Specimen Handling; Spectrophotometry, Ultraviolet; Spectroscopy, Fourier Transform Infrared; Spectrum Analysis; Spinal Fractures; Spirometry; Staphylococcus aureus; STAT1 Transcription Factor; STAT3 Transcription Factor; Streptomyces coelicolor; Stress, Psychological; Stroke; Stroke Volume; Structure-Activity Relationship; Students, Medical; Students, Pharmacy; Substance Abuse Treatment Centers; Sulfur Dioxide; Surface Properties; Surface-Active Agents; Surveys and Questionnaires; Survival Analysis; Survival Rate; Survivin; Sweden; Swine; Swine, Miniature; Sympathetic Nervous System; T-Lymphocytes, Regulatory; Talaromyces; Tandem Mass Spectrometry; tau Proteins; Telemedicine; Telomerase; Telomere; Telomere Homeostasis; Temperature; Terminally Ill; Th1 Cells; Thiamethoxam; Thiazoles; Thiophenes; Thioredoxin Reductase 1; Thrombosis; Thulium; Thyroid Cancer, Papillary; Thyroid Carcinoma, Anaplastic; Thyroid Neoplasms; Time Factors; Titanium; Tomography, Emission-Computed, Single-Photon; Tomography, X-Ray Computed; TOR Serine-Threonine Kinases; Transcription Factor AP-1; Transcription Factors; Transcription, Genetic; Transcriptional Activation; Transcriptome; Transforming Growth Factor beta1; Transistors, Electronic; Translational Research, Biomedical; Transplantation Tolerance; Transplantation, Homologous; Transportation; Treatment Outcome; Tretinoin; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary; Tubulin Modulators; Tumor Microenvironment; Tumor Necrosis Factor Inhibitors; Tumor Necrosis Factor-alpha; Twins; Ultrasonic Therapy; Ultrasonography; Ultraviolet Rays; United States; Up-Regulation; Uranium; Urethra; Urinary Bladder; Urodynamics; Uromodulin; Uveitis; Vasoconstrictor Agents; Ventricular Function, Left; Vero Cells; Vesicular Transport Proteins; Viral Nonstructural Proteins; Visual Acuity; Vital Capacity; Vitamin D; Vitamin D Deficiency; Vitamin K 2; Vitamins; Volatilization; Voriconazole; Waiting Lists; Waste Disposal, Fluid; Wastewater; Water Pollutants, Chemical; Whole Genome Sequencing; Wine; Wnt Signaling Pathway; Wound Healing; Wounds and Injuries; WW Domains; X-linked Nuclear Protein; X-Ray Diffraction; Xanthines; Xenograft Model Antitumor Assays; YAP-Signaling Proteins; Yogurt; Young Adult; Zebrafish; Zebrafish Proteins; Ziziphus | 2016 |
Phase III randomized, double-blind study of paclitaxel with and without everolimus in patients with advanced gastric or esophagogastric junction carcinoma who have progressed after therapy with a fluoropyrimidine/platinum-containing regimen (RADPAC).
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Double-Blind Method; Esophagogastric Junction; Everolimus; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Mucositis; Paclitaxel; Progression-Free Survival; Stomach Neoplasms | 2020 |
Gemcitabine plus nab-paclitaxel until progression or alternating with FOLFIRI.3, as first-line treatment for patients with metastatic pancreatic adenocarcinoma: The Federation Francophone de Cancérologie Digestive-PRODIGE 37 randomised phase II study (FIR
Topics: Adenocarcinoma; Adult; Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Deoxycytidine; Disease Progression; Drug Substitution; Female; Fluorouracil; France; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Metastasis; Paclitaxel; Pancreatic Neoplasms; Progression-Free Survival; Treatment Outcome | 2020 |
The post-progression survival of patients with recurrent or persistent ovarian clear cell carcinoma: results from a randomized phase III study in JGOG3017/GCIG.
Topics: Adenocarcinoma, Clear Cell; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Disease Progression; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel | 2020 |
Tolerability of Nab-Paclitaxel Plus Gemcitabine as Adjuvant Setting in Japanese Patients With Resected Pancreatic Cancer: Phase I Study.
Topics: Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Chemotherapy, Adjuvant; Deoxycytidine; Disease Progression; Disease-Free Survival; Female; Gemcitabine; Humans; Japan; Male; Middle Aged; Paclitaxel; Pancreatectomy; Pancreatic Neoplasms; Time Factors | 2021 |
Morbidity and Mortality of Patients Who Underwent Minimally Invasive Esophagectomy After Neoadjuvant Chemoradiotherapy vs Neoadjuvant Chemotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma: A Randomized Clinical Trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adjuvant; Chemotherapy, Adjuvant; Cisplatin; Disease Progression; Dose Fractionation, Radiation; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Esophagectomy; Female; Humans; Intention to Treat Analysis; Laparoscopy; Lymphatic Metastasis; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasm, Residual; Paclitaxel; Postoperative Complications; Prospective Studies; Quality of Life; Survival Rate; Thoracoscopy | 2021 |
Treatment Rationale and Design for J-SONIC: A Randomized Study of Carboplatin Plus Nab-paclitaxel With or Without Nintedanib for Advanced Non-Small-cell Lung Cancer With Idiopathic Pulmonary Fibrosis.
Topics: Adult; Aged; Aged, 80 and over; Albumins; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Disease Progression; Female; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Survival Analysis; Young Adult | 2018 |
Phase II study of paclitaxel associated with lipid core nanoparticles (LDE) as third-line treatment of patients with epithelial ovarian carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Carcinoma, Ovarian Epithelial; Chemotherapy, Adjuvant; Deoxycytidine; Disease Progression; Disease-Free Survival; Doxorubicin; Female; Gemcitabine; Humans; Lipids; Nanoparticles; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Polyethylene Glycols | 2017 |
Randomized Controlled Trial Testing the Efficacy of Platinum-Free Interval Prolongation in Advanced Ovarian Cancer: The MITO-8, MaNGO, BGOG-Ov1, AGO-Ovar2.16, ENGOT-Ov1, GCIG Study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Deoxycytidine; Dioxoles; Disease Progression; Disease-Free Survival; Doxorubicin; Drug Administration Schedule; Early Termination of Clinical Trials; Europe; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Polyethylene Glycols; Prospective Studies; Tetrahydroisoquinolines; Time Factors; Topotecan; Trabectedin; Treatment Outcome | 2017 |
Olaparib in combination with paclitaxel in patients with advanced gastric cancer who have progressed following first-line therapy (GOLD): a double-blind, randomised, placebo-controlled, phase 3 trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Asia; Disease Progression; Disease-Free Survival; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Humans; Kaplan-Meier Estimate; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Paclitaxel; Phthalazines; Piperazines; Proportional Hazards Models; Remission Induction; Stomach Neoplasms; Survival Analysis; Treatment Outcome | 2017 |
A phase II study of nab-paclitaxel in combination with ramucirumab in patients with previously treated advanced gastric cancer.
Topics: Adenocarcinoma; Administration, Intravenous; Adult; Aged; Aged, 80 and over; Albumins; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Japan; Kaplan-Meier Estimate; Male; Middle Aged; Paclitaxel; Quality of Life; Ramucirumab; Stomach Neoplasms; Time Factors; Treatment Outcome | 2018 |
Trastuzumab and paclitaxel in patients with EGFR mutated NSCLC that express HER2 after progression on EGFR TKI treatment.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Female; Gene Dosage; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Paclitaxel; Protein Kinase Inhibitors; Receptor, ErbB-2; Survival Analysis; Trastuzumab; Treatment Outcome | 2018 |
Does adjuvant chemotherapy dose modification have an impact on the outcome of patients diagnosed with advanced stage ovarian cancer? An NRG Oncology/Gynecologic Oncology Group study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Chemotherapy, Adjuvant; Cytoreduction Surgical Procedures; Disease Progression; Disease-Free Survival; Dose-Response Relationship, Drug; Doxorubicin; Female; Granulocyte Colony-Stimulating Factor; Humans; Kaplan-Meier Estimate; Middle Aged; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Ovary; Paclitaxel; Peritoneal Neoplasms; Treatment Outcome | 2018 |
Nab-Paclitaxel and Gemcitabine as First-line Treatment of Advanced or Metastatic Cholangiocarcinoma: A Phase 2 Clinical Trial.
Topics: Administration, Intravenous; Adult; Aged; Aged, 80 and over; Albumins; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cholangiocarcinoma; Deoxycytidine; Disease Progression; Female; Gemcitabine; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Metastasis; Paclitaxel; Treatment Outcome | 2018 |
Disease-Free and Overall Survival Among Patients With Operable HER2-Positive Breast Cancer Treated With Sequential vs Concurrent Chemotherapy: The ACOSOG Z1041 (Alliance) Randomized Clinical Trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Disease Progression; Drug Administration Schedule; Epirubicin; Female; Fluorouracil; Humans; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Progression-Free Survival; Puerto Rico; Receptor, ErbB-2; Risk Factors; Time Factors; Trastuzumab; United States | 2019 |
Dynamic Contrast-enhanced Magnetic Resonance Imaging for Patients with Breast Cancer Receiving First-line Bevacizumab and Paclitaxel.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Contrast Media; Disease Progression; Female; Humans; Japan; Magnetic Resonance Imaging; Meglumine; Middle Aged; Organometallic Compounds; Paclitaxel; Predictive Value of Tests; Prospective Studies; Remission Induction; Time Factors; Treatment Outcome; Young Adult | 2018 |
Alisertib in Combination With Weekly Paclitaxel in Patients With Advanced Breast Cancer or Recurrent Ovarian Cancer: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Azepines; Breast Neoplasms; Disease Progression; Europe; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Progression-Free Survival; Pyrimidines; Time Factors; United States | 2019 |
Atezolizumab Plus nab-Paclitaxel in the Treatment of Metastatic Triple-Negative Breast Cancer With 2-Year Survival Follow-up: A Phase 1b Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Albumins; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Female; Humans; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Progression-Free Survival; Time Factors; Triple Negative Breast Neoplasms; United States | 2019 |
A Phase II Study of Tri-weekly Low-dose Nab-paclitaxel Chemotherapy for Patients with Advanced Gastric Cancer.
Topics: Aged; Aged, 80 and over; Albumins; Disease Progression; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Paclitaxel; Stomach Neoplasms; Survival Analysis; Treatment Outcome | 2018 |
Neoadjuvant plus adjuvant or only adjuvant nab-paclitaxel plus gemcitabine for resectable pancreatic cancer - the NEONAX trial (AIO-PAK-0313), a prospective, randomized, controlled, phase II study of the AIO pancreatic cancer group.
Topics: Adult; Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Clinical Trials, Phase II as Topic; Deoxycytidine; Disease Progression; Disease-Free Survival; Drug Combinations; Fluorouracil; Gemcitabine; Germany; Humans; Irinotecan; Leucovorin; Middle Aged; Multicenter Studies as Topic; Neoadjuvant Therapy; Organometallic Compounds; Oxaliplatin; Paclitaxel; Pancreatectomy; Pancreatic Neoplasms; Prognosis; Prospective Studies; Quality of Life; Randomized Controlled Trials as Topic; Survival Analysis; Young Adult | 2018 |
Effect of Taxane Plus Platinum Regimens vs Doxorubicin Plus Cisplatin as Adjuvant Chemotherapy for Endometrial Cancer at a High Risk of Progression: A Randomized Clinical Trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Carboplatin; Chemotherapy, Adjuvant; Cisplatin; Disease Progression; Doxorubicin; Endometrial Neoplasms; Female; Humans; Middle Aged; Paclitaxel; Risk; Taxoids; Treatment Outcome | 2019 |
Paclitaxel Drug-Coated Balloon After Bare-Metal Stent Implantation, an Alternative Treatment to Drug-Eluting Stent in High Bleeding Risk Patients (The Panelux Trial).
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Coronary Artery Disease; Disease Progression; Drug-Eluting Stents; France; Hemorrhage; Humans; Male; Outcome Assessment, Health Care; Paclitaxel; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prosthesis Design; Risk Adjustment; Time | 2019 |
Survival outcomes of the NeoALTTO study (BIG 1-06): updated results of a randomised multicenter phase III neoadjuvant clinical trial in patients with HER2-positive primary breast cancer.
Topics: Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Disease Progression; Female; Humans; Lapatinib; Mastectomy; Neoadjuvant Therapy; Paclitaxel; Progression-Free Survival; Protein Kinase Inhibitors; Receptor, ErbB-2; Risk Assessment; Risk Factors; Time Factors; Trastuzumab | 2019 |
Assessing the effectiveness and safety of liposomal paclitaxel in combination with cisplatin as first-line chemotherapy for patients with advanced NSCLC with regional lymph-node metastasis: study protocol for a randomized controlled trial (PLC-GC trial).
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chemistry, Pharmaceutical; China; Cisplatin; Clinical Protocols; Deoxycytidine; Disease Progression; Disease-Free Survival; Gemcitabine; Humans; Kaplan-Meier Estimate; Liposomes; Lung Neoplasms; Lymphatic Metastasis; Neoplasm Staging; Paclitaxel; Prospective Studies; Research Design; Time Factors; Treatment Outcome | 2013 |
Tumor response and health-related quality of life in clinically selected patients from Asia with advanced non-small-cell lung cancer treated with first-line gefitinib: post hoc analyses from the IPASS study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Asia; Carboplatin; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free Survival; ErbB Receptors; Exanthema; Female; Gefitinib; Humans; Lung Neoplasms; Male; Paclitaxel; Quality of Life; Quinazolines | 2013 |
A phase II study of weekly neoadjuvant chemotherapy followed by radical chemoradiation for locally advanced cervical cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Chemoradiotherapy; Combined Modality Therapy; Disease Progression; Drug Administration Schedule; Female; Humans; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Survival Analysis; Uterine Cervical Neoplasms; Young Adult | 2013 |
Phase2 study of bevacizumab with carboplatin-paclitaxel for non-small cell lung cancer with malignant pleural effusion.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Non-Small-Cell Lung; Disease Progression; Female; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Pleural Effusion, Malignant; Survival Rate; Treatment Outcome; Vascular Endothelial Growth Factor A | 2013 |
Angiogenic factors in relation to clinical effect in a phase II trial of weekly paclitaxel.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease Progression; Disease-Free Survival; Female; Fibroblast Growth Factor 2; Humans; Middle Aged; Paclitaxel; Receptor, ErbB-2; Time Factors; Trastuzumab; Triple Negative Breast Neoplasms; Vascular Endothelial Growth Factor A | 2013 |
Everolimus in combination with paclitaxel and carboplatin in patients with metastatic melanoma: a phase II trial of the Sarah Cannon Research Institute Oncology Research Consortium.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carboplatin; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Everolimus; Female; Humans; Male; Melanoma; Melanoma, Cutaneous Malignant; Middle Aged; Paclitaxel; Sirolimus; Skin Neoplasms; Treatment Outcome | 2013 |
Safety and efficacy of neratinib in combination with weekly paclitaxel and trastuzumab in women with metastatic HER2‑positive breast cancer: an NSABP Foundation Research Program phase I study.
Topics: Adult; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease Progression; Dose-Response Relationship, Drug; Female; Humans; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Paclitaxel; Quinolines; Receptor, ErbB-2; Trastuzumab; Treatment Outcome | 2013 |
A phase 2 study of everolimus combined with trastuzumab and paclitaxel in patients with HER2-overexpressing advanced breast cancer that progressed during prior trastuzumab and taxane therapy.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease Progression; Disease-Free Survival; Everolimus; Female; Humans; Kaplan-Meier Estimate; Middle Aged; Neoplasm Staging; Paclitaxel; Receptor, ErbB-2; Sirolimus; Taxoids; Trastuzumab; Treatment Failure | 2013 |
A phase II study of paclitaxel and nedaplatin as front-line chemotherapy in Chinese patients with metastatic esophageal squamous cell carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; China; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Female; Humans; Intention to Treat Analysis; Kaplan-Meier Estimate; Male; Middle Aged; Organoplatinum Compounds; Paclitaxel; Time Factors; Treatment Outcome | 2013 |
Randomised, double-blind trial of carboplatin and paclitaxel with daily oral cediranib or placebo in patients with advanced non-small cell lung cancer: NCIC Clinical Trials Group study BR29.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Disease Progression; Double-Blind Method; Drug Administration Schedule; Female; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Placebos; Quinazolines; Survival Analysis; Young Adult | 2014 |
The multicenter, phase II prospective study of paclitaxel plus capecitabine as first-line chemotherapy in advanced gastric carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Disease Progression; Disease-Free Survival; Female; Fluorouracil; Humans; Male; Paclitaxel; Prospective Studies; Stomach Neoplasms; Survival Analysis | 2014 |
Carboplatin plus paclitaxel once a week versus every 3 weeks in patients with advanced ovarian cancer (MITO-7): a randomised, multicentre, open-label, phase 3 trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Female; France; Humans; Italy; Kaplan-Meier Estimate; Middle Aged; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Proportional Hazards Models; Quality of Life; Risk Factors; Time Factors; Treatment Outcome; Young Adult | 2014 |
Paclitaxel and bevacizumab with or without capecitabine as first-line treatment for HER2-negative locally recurrent or metastatic breast cancer: a multicentre, open-label, randomised phase 2 trial.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Deoxycytidine; Disease Progression; Female; Fluorouracil; Humans; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Treatment Outcome; Triple Negative Breast Neoplasms | 2014 |
A randomized Phase III trial of weekly or 3-weekly doses of nab-paclitaxel versus weekly doses of Cremophor-based paclitaxel in patients with previously treated advanced gastric cancer (ABSOLUTE Trial).
Topics: Administration, Oral; Albumins; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Polyethylene Glycols; Prospective Studies; Quality of Life; Stomach Neoplasms; Treatment Outcome | 2015 |
A phase 2 study of bevacizumab in combination with carboplatin and paclitaxel in patients with non-squamous non-small-cell lung cancer harboring mutations of epidermal growth factor receptor (EGFR) after failing first-line EGFR-tyrosine kinase inhibitors
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Non-Small-Cell Lung; Disease Progression; ErbB Receptors; Female; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Paclitaxel; Recurrence; Retreatment; Risk Factors; Treatment Failure; Treatment Outcome | 2015 |
Predictors and impact of target vessel revascularization after stent implantation for acute ST-segment elevation myocardial infarction: lessons from HORIZONS-AMI.
Topics: Angioplasty, Balloon, Coronary; Antineoplastic Agents, Phytogenic; Antithrombins; Coronary Angiography; Coronary Restenosis; Disease Progression; Drug-Eluting Stents; Electrocardiography; Female; Hemorrhage; Heparin; Hirudins; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Myocardial Infarction; Outcome Assessment, Health Care; Paclitaxel; Peptide Fragments; Platelet Glycoprotein GPIIb-IIIa Complex; Postoperative Complications; Prognosis; Recombinant Proteins; Reoperation | 2015 |
Efficacy of chemotherapy after first-line gefitinib therapy in EGFR mutation-positive advanced non-small cell lung cancer-data from a randomized Phase III study comparing gefitinib with carboplatin plus paclitaxel (NEJ002).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Disease Progression; Drug Administration Schedule; ErbB Receptors; Exons; Female; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Quinazolines; Sequence Deletion; Tomography, X-Ray Computed; Treatment Outcome | 2015 |
Adding Erlotinib to Chemoradiation Improves Overall Survival but Not Progression-Free Survival in Stage III Non-Small Cell Lung Cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Brain Neoplasms; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Chemoradiotherapy; Disease Progression; Disease-Free Survival; Dose Fractionation, Radiation; Drug Administration Schedule; ErbB Receptors; Erlotinib Hydrochloride; Feasibility Studies; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Paclitaxel; Prospective Studies; Protein Kinase Inhibitors; Quinazolines; Radiotherapy, Intensity-Modulated; Time Factors | 2015 |
The association between in-stent neoatherosclerosis and native coronary artery disease progression: a long-term angiographic and optical coherence tomography cohort study.
Topics: Aged; Coronary Angiography; Coronary Restenosis; Coronary Stenosis; Disease Progression; Drug-Eluting Stents; Female; Graft Occlusion, Vascular; Humans; Male; Middle Aged; Neointima; Paclitaxel; Prosthesis Failure; Sirolimus; Tomography, Optical Coherence; Tubulin Modulators | 2015 |
Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Australia; Bevacizumab; Canada; Carboplatin; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Europe; Female; Humans; Infusions, Intravenous; Intention to Treat Analysis; Neoplasm Grading; Neoplasm Staging; New Zealand; Ovarian Neoplasms; Paclitaxel; Survival Analysis; Time Factors; Treatment Outcome | 2015 |
Long-term safety and anti-tumour activity of olaparib monotherapy after combination with carboplatin and paclitaxel in patients with advanced breast, ovarian or fallopian tube cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Disease Progression; Fallopian Tube Neoplasms; Female; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel; Phthalazines; Piperazines; Salvage Therapy; Treatment Failure | 2015 |
A Phase 3 Trial of 2 Years of Androgen Suppression and Radiation Therapy With or Without Adjuvant Chemotherapy for High-Risk Prostate Cancer: Final Results of Radiation Therapy Oncology Group Phase 3 Randomized Trial NRG Oncology RTOG 9902.
Topics: Adult; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Combined Modality Therapy; Disease Progression; Early Termination of Clinical Trials; Estramustine; Etoposide; Humans; Male; Middle Aged; Neoplasm Grading; Paclitaxel; Prostate-Specific Antigen; Prostatic Neoplasms; Time Factors | 2015 |
Standard first-line chemotherapy with or without nintedanib for advanced ovarian cancer (AGO-OVAR 12): a randomised, double-blind, placebo-controlled phase 3 trial.
Topics: Adult; Aged; Aged, 80 and over; Anemia; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Cytoreduction Surgical Procedures; Diarrhea; Disease Progression; Disease-Free Survival; Double-Blind Method; Fallopian Tube Neoplasms; Female; Humans; Indoles; Intention to Treat Analysis; Middle Aged; Neoplasm Staging; Neutropenia; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Response Evaluation Criteria in Solid Tumors; Thrombocytopenia; Young Adult | 2016 |
Taxanes versus S-1 as the first-line chemotherapy for metastatic breast cancer (SELECT BC): an open-label, non-inferiority, randomised phase 3 trial.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Disease Progression; Disease-Free Survival; Docetaxel; Drug Combinations; Edema; Fatigue; Female; Follow-Up Studies; Health Status; Humans; Liver Neoplasms; Middle Aged; Neutropenia; Oxonic Acid; Paclitaxel; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Survival Rate; Taxoids; Tegafur | 2016 |
Afatinib beyond progression in patients with non-small-cell lung cancer following chemotherapy, erlotinib/gefitinib and afatinib: phase III randomized LUX-Lung 5 trial.
Topics: Afatinib; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Prospective Studies; Protein Kinase Inhibitors; Quinazolines | 2016 |
Phase II/III weekly nab-paclitaxel plus gemcitabine or carboplatin versus gemcitabine/carboplatin as first-line treatment of patients with metastatic triple-negative breast cancer (the tnAcity study): study protocol for a randomized controlled trial.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Clinical Protocols; Deoxycytidine; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Female; Gemcitabine; Humans; Neoplasm Metastasis; Paclitaxel; Research Design; Survival Analysis; Time Factors; Treatment Outcome; Triple Negative Breast Neoplasms | 2015 |
Durable Clinical Effectiveness With Paclitaxel-Eluting Stents in the Femoropopliteal Artery: 5-Year Results of the Zilver PTX Randomized Trial.
Topics: Adult; Aged; Angioplasty; Anticoagulants; Arterial Occlusive Diseases; Aspirin; Clopidogrel; Combined Modality Therapy; Disease Progression; Disease-Free Survival; Drug-Eluting Stents; Equipment Failure; Female; Femoral Artery; Follow-Up Studies; Humans; Intermittent Claudication; Ischemia; Male; Middle Aged; Paclitaxel; Popliteal Artery; Recurrence; Stents; Ticlopidine; Vascular Patency | 2016 |
Adjusting for treatment switching in the METRIC study shows further improved overall survival with trametinib compared with chemotherapy.
Topics: Antineoplastic Agents; Dacarbazine; Disease Progression; Drug Substitution; Humans; MAP Kinase Kinase 1; MAP Kinase Kinase 2; Melanoma; Middle Aged; Mutation; Paclitaxel; Proto-Oncogene Proteins B-raf; Pyridones; Pyrimidinones; Survival Analysis | 2016 |
Capecitabine plus paclitaxel induction treatment in gastric cancer patients with liver metastasis: a prospective, uncontrolled, open-label Phase II clinical study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Combined Modality Therapy; Disease Progression; Female; Humans; Induction Chemotherapy; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Retreatment; Stomach Neoplasms; Survival Analysis; Treatment Outcome | 2016 |
Efficacy and safety profile of nab-paclitaxel plus gemcitabine in patients with metastatic pancreatic cancer treated to disease progression: a subanalysis from a phase 3 trial (MPACT).
Topics: Aged; Aged, 80 and over; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease Progression; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Metastasis; Paclitaxel; Pancreatic Neoplasms; Proportional Hazards Models; Retreatment; Survival Analysis; Treatment Outcome | 2016 |
Effect of a Proposed Trastuzumab Biosimilar Compared With Trastuzumab on Overall Response Rate in Patients With ERBB2 (HER2)-Positive Metastatic Breast Cancer: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Biosimilar Pharmaceuticals; Breast Neoplasms; Disease Progression; Docetaxel; Double-Blind Method; Female; Humans; Intention to Treat Analysis; Middle Aged; Paclitaxel; Receptor, ErbB-2; Remission Induction; Survival Analysis; Taxoids; Therapeutic Equipoise; Time Factors; Trastuzumab | 2017 |
Real-world and trial-based cost-effectiveness analysis of bevacizumab in HER2-negative metastatic breast cancer patients: a study of the Southeast Netherlands Breast Cancer Consortium.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Bridged-Ring Compounds; Cost-Benefit Analysis; Disease Progression; Docetaxel; Female; Health Resources; Humans; Kaplan-Meier Estimate; Netherlands; Paclitaxel; Quality-Adjusted Life Years; Receptor, ErbB-2; Taxoids | 2017 |
Induction chemotherapy followed by concurrent chemoradiation for patients with non-operable stage III non-small-cell lung cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Disease Progression; Female; Humans; Lung Neoplasms; Male; Medical Oncology; Middle Aged; Paclitaxel; Retrospective Studies | 2009 |
[Randomized phase II study of carboplatin/paclitaxel followed by gemcitabine versus carboplatin/gemcitabine followed by docetaxel in patients with advanced nonsmall cell lung cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease Progression; Docetaxel; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Survival Rate; Taxoids | 2008 |
Relationship between ERCC1 polymorphisms, disease progression, and survival in the Gynecologic Oncology Group Phase III Trial of intraperitoneal versus intravenous cisplatin and paclitaxel for stage III epithelial ovarian cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease Progression; Disease-Free Survival; DNA-Binding Proteins; Drug Resistance, Neoplasm; Endonucleases; Female; Humans; Infusions, Intravenous; Infusions, Parenteral; Kaplan-Meier Estimate; Middle Aged; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Polymorphism, Single Nucleotide | 2008 |
Randomized phase II study of vandetanib alone or with paclitaxel and carboplatin as first-line treatment for advanced non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Disease Progression; Female; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Piperidines; Quinazolines; Vascular Endothelial Growth Factor A | 2008 |
A phase II trial of weekly chemotherapy with paclitaxel plus gemcitabine as a first-line treatment in advanced non-small-cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Deoxycytidine; Disease Progression; Female; Gemcitabine; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Neutropenia; Paclitaxel; Survival Rate; Thrombocytopenia; Treatment Outcome | 2009 |
Neoadjuvant chemoradiation followed by surgery versus surgery alone for patients with adenocarcinoma or squamous cell carcinoma of the esophagus (CROSS).
Topics: Adenocarcinoma; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Carboplatin; Carcinoma, Squamous Cell; Disease Progression; Esophageal Neoplasms; Humans; Neoadjuvant Therapy; Paclitaxel; Patient Selection; Quality of Life; Radiotherapy Dosage; Research Design | 2008 |
Randomised phase II study of ASA404 combined with carboplatin and paclitaxel in previously untreated advanced non-small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Disease Progression; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Survival Rate; Treatment Outcome; Xanthones | 2008 |
Multi-center phase II trial of weekly paclitaxel plus cisplatin combination chemotherapy in patients with advanced gastric and gastro-esophageal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease Progression; Drug Administration Schedule; Esophageal Neoplasms; Esophagogastric Junction; Female; Humans; Male; Middle Aged; Nausea; Neutropenia; Paclitaxel; Stomach Neoplasms; Survival Rate; Treatment Outcome | 2009 |
Late clinical events after drug-eluting stents: the interplay between stent-related and natural history-driven events.
Topics: Angioplasty, Balloon, Coronary; Cardiovascular Agents; Coronary Artery Disease; Coronary Restenosis; Disease Progression; Double-Blind Method; Drug-Eluting Stents; Humans; Metals; Myocardial Infarction; Paclitaxel; Platelet Aggregation Inhibitors; Proportional Hazards Models; Prosthesis Design; Risk Assessment; Risk Factors; Stents; Thrombosis; Time Factors; Treatment Outcome | 2009 |
Gemcitabine combined with either pemetrexed or paclitaxel in the treatment of advanced non-small cell lung cancer: a randomized phase II SICOG trial.
Topics: Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease Progression; Disease-Free Survival; Female; Follow-Up Studies; Gemcitabine; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Neutropenia; Paclitaxel; Pemetrexed; Peripheral Nervous System Diseases; Survival Analysis | 2010 |
Treatment rationale and study design for the pointbreak study: a randomized, open-label phase III study of pemetrexed/carboplatin/bevacizumab followed by maintenance pemetrexed/bevacizumab versus paclitaxel/carboplatin/bevacizumab followed by maintenance
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Glutamates; Guanine; Humans; Lung Neoplasms; Paclitaxel; Pemetrexed; Prognosis; Treatment Outcome | 2009 |
Chemotherapy with paclitaxel and gemcitabine in progressive medullary and thyroid carcinoma of the follicular epithelium.
Topics: Adenocarcinoma, Follicular; Adult; Aged; Carcinoma, Medullary; Deoxycytidine; Disease Progression; Drug Therapy, Combination; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Thyroid Neoplasms | 2010 |
The effect of LMWH (Nadroparin) on tumor progression.
Topics: Anticoagulants; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Colonic Neoplasms; Cyclophosphamide; Disease Progression; Epirubicin; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Leucovorin; Male; Nadroparin; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Pilot Projects; Retrospective Studies; Survival Analysis; Time Factors | 2009 |
Preoperative weekly cisplatin, epirubicin, and paclitaxel (PET) improves prognosis in locally advanced breast cancer patients: an update of the Southern Italy Cooperative Oncology Group (SICOG) randomised trial 9908.
Topics: Adult; Aged; Algorithms; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; Cisplatin; Combined Modality Therapy; Disease Progression; Drug Administration Schedule; Epirubicin; Etoposide; Female; Follow-Up Studies; Humans; Italy; Middle Aged; Paclitaxel; Preoperative Care; Taxoids | 2010 |
Randomized phase II trial of weekly paclitaxel combined with carboplatin versus standard paclitaxel combined with carboplatin for elderly patients with advanced non-small-cell lung cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Disease Progression; Dosage Forms; Drug Administration Schedule; Female; Humans; Lung Neoplasms; Male; Paclitaxel; Survival Analysis; Treatment Outcome | 2010 |
Leuven dose-dense paclitaxel/carboplatin regimen in patients with primary advanced or recurrent endometrial carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Disease Progression; Dosage Forms; Dose-Response Relationship, Drug; Drug Administration Schedule; Endometrial Neoplasms; Female; Humans; Middle Aged; Paclitaxel; Recurrence; Remission Induction; Survival Analysis | 2009 |
A phase I open-label dose-escalation study of oral BIBF 1120 combined with standard paclitaxel and carboplatin in patients with advanced gynecological malignancies.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Disease Progression; Dose-Response Relationship, Drug; Female; Genital Neoplasms, Female; Humans; Indoles; Maximum Tolerated Dose; Middle Aged; Neoplasms, Glandular and Epithelial; Paclitaxel; Treatment Outcome | 2010 |
Phase I dose-finding study of paclitaxel with panitumumab, carboplatin and intensity-modulated radiotherapy in patients with locally advanced squamous cell cancer of the head and neck.
Topics: Adult; Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Combined Modality Therapy; Disease Progression; Dose-Response Relationship, Drug; Female; Head and Neck Neoplasms; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms, Squamous Cell; Paclitaxel; Panitumumab; Patient Compliance; Radiotherapy, Intensity-Modulated; Treatment Outcome | 2010 |
Carboplatin and paclitaxel in combination with oral enzastaurin in advanced ovarian or primary peritoneal cancer: results from a safety lead-in study.
Topics: Administration, Oral; Adult; Aged; Algorithms; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Disease Progression; Drug Interactions; Female; Humans; Indoles; Middle Aged; Neoadjuvant Therapy; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms | 2009 |
Second-line weekly paclitaxel in resistant or relapsed non-small cell lung cancer treated with docetaxel and carboplatin: a multi-center phase II study.
Topics: Adult; Aged; Anemia; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Disease Progression; Docetaxel; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Leukopenia; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Survival Analysis; Taxoids | 2010 |
A phase II trial of less than 7 weeks of concomitant cisplatin-paclitaxel chemoradiation in locally advanced cervical cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Disease Progression; Drug Administration Schedule; Female; Humans; Middle Aged; Neoplasm Invasiveness; Paclitaxel; Patient Compliance; Time Factors; Treatment Outcome; Uterine Cervical Neoplasms | 2010 |
A retrospective analysis of outcomes across histological subgroups in a three-arm phase III trial of gemcitabine in combination with carboplatin or paclitaxel versus paclitaxel plus carboplatin for advanced non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease Progression; Disease-Free Survival; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Retrospective Studies; Survival Analysis | 2010 |
Chemotherapy: Current drugs still have potential in advanced ovarian cancer.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Area Under Curve; Carboplatin; Cisplatin; Confidence Intervals; Disease Progression; Doxorubicin; Female; Humans; Ovarian Neoplasms; Paclitaxel; Sweden | 2010 |
Liposomal cisplatin combined with paclitaxel versus cisplatin and paclitaxel in non-small-cell lung cancer: a randomized phase III multicenter trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Disease Progression; Female; Humans; Liposomes; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Survival Rate; Time Factors; Treatment Outcome | 2010 |
[Comparison of the therapeutic effects of paclitaxel liposome-5-Fu versus paclitaxel-5-Fu on 67 patients with advanced gastric cancer].
Topics: Adult; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Female; Fluorouracil; Follow-Up Studies; Humans; Liposomes; Male; Nausea; Paclitaxel; Remission Induction; Stomach Neoplasms; Survival Rate; Vomiting | 2010 |
Multicenter phase II trial of S-1, paclitaxel and cisplatin triplet combination chemotherapy in patients with advanced gastric cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease Progression; Drug Combinations; Female; Follow-Up Studies; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Oxonic Acid; Paclitaxel; Prospective Studies; Stomach Neoplasms; Survival; Tegafur; Treatment Outcome | 2011 |
Randomized study of taxane versus TS-1 in women with metastatic or recurrent breast cancer (SELECT BC).
Topics: Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Breast Neoplasms; Cost-Benefit Analysis; Disease Progression; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Drug Combinations; Female; Humans; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Oxonic Acid; Paclitaxel; Quality of Life; Survival Rate; Taxoids; Tegafur | 2010 |
A pilot phase II trial of all-trans retinoic acid (Vesanoid) and paclitaxel (Taxol) in patients with recurrent or metastatic breast cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Black or African American; Breast Neoplasms; Disease Progression; Female; Hispanic or Latino; Humans; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Paclitaxel; Pilot Projects; Survival Rate; Treatment Outcome; Tretinoin | 2011 |
Neointimal coverage and stent strut apposition six months after implantation of a paclitaxel eluting stent in acute coronary syndromes: an optical coherence tomography study.
Topics: Acute Coronary Syndrome; Antineoplastic Agents, Phytogenic; Coronary Angiography; Coronary Restenosis; Diagnosis, Differential; Disease Progression; Drug-Eluting Stents; Female; Follow-Up Studies; Humans; Male; Middle Aged; Neointima; Paclitaxel; Prognosis; Prospective Studies; Prosthesis Failure; Time Factors; Tomography, Optical Coherence; Tunica Intima | 2011 |
Targeted therapies: Biomarkers in NSCLC for selecting cetuximab therapy.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Biomarkers, Tumor; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cetuximab; Disease Progression; Docetaxel; Drug Therapy, Combination; ErbB Receptors; Humans; Lung Neoplasms; Paclitaxel; Retrospective Studies; Taxoids; United States | 2010 |
Randomized phase III trial of 2nd line gemcitabine and paclitaxel chemotherapy in patients with advanced bladder cancer: short-term versus prolonged treatment [German Association of Urological Oncology (AUO) trial AB 20/99].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Deoxycytidine; Disease Progression; Disease-Free Survival; Gemcitabine; Humans; Middle Aged; Paclitaxel; Prognosis; Urinary Bladder Neoplasms | 2011 |
A randomized, double-blind, placebo-controlled, dose ranging study to assess the efficacy and safety of eltrombopag in patients receiving carboplatin/paclitaxel for advanced solid tumors.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzoates; Carboplatin; Disease Progression; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Hydrazines; Male; Middle Aged; Neoplasms; Paclitaxel; Placebos; Platelet Count; Polypharmacy; Pyrazoles; Treatment Outcome; Young Adult | 2010 |
Multicenter phase II study of weekly paclitaxel plus S-1 combination chemotherapy in patients with advanced gastric cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Confidence Intervals; Disease Progression; Drug Combinations; Female; Humans; Japan; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Oxonic Acid; Paclitaxel; Stomach Neoplasms; Tegafur | 2010 |
Phase 3 study of docosahexaenoic acid-paclitaxel versus dacarbazine in patients with metastatic malignant melanoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Dacarbazine; Disease Progression; Disease-Free Survival; Female; Humans; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Paclitaxel | 2011 |
Long-term results of a phase II trial of induction paclitaxel-carboplatin followed by concurrent radiation therapy and weekly paclitaxel and consolidation paclitaxel-carboplatin in stage III non-small cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Combined Modality Therapy; Disease Progression; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Radiotherapy Dosage; Remission Induction; Survival Rate; Time Factors; Treatment Outcome | 2011 |
Weekly paclitaxel in patients with recurrent or metastatic head and neck cancer.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Carcinoma, Squamous Cell; Disease Progression; Endpoint Determination; Female; Follow-Up Studies; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Paclitaxel; Survival Analysis; Treatment Outcome | 2011 |
Weekly regimen of paclitaxel and carboplatin as first-line chemotherapy in elderly patients with stage IIIB-IV non small cell lung cancer (NSCLC): results of a phase II study.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Disease Progression; Drug Administration Schedule; Female; Humans; Lung Neoplasms; Male; Neoplasm Staging; Paclitaxel; Survival Rate; Treatment Outcome | 2010 |
Assessing clinical benefit response in the treatment of gastric malignant ascites with non-measurable lesions: a multicenter phase II trial of paclitaxel for malignant ascites secondary to advanced/recurrent gastric cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Ascites; Ascitic Fluid; Disease Progression; Female; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Stomach Neoplasms; Survival Rate; Treatment Failure; Treatment Outcome; Waist Circumference | 2011 |
A feasibility study of bevacizumab plus dose-dense doxorubicin-cyclophosphamide (AC) followed by nanoparticle albumin-bound paclitaxel in early-stage breast cancer.
Topics: Adult; Aged; Albumin-Bound Paclitaxel; Albumins; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Carcinoma; Cyclophosphamide; Disease Progression; Dose-Response Relationship, Drug; Doxorubicin; Drug Administration Schedule; Feasibility Studies; Female; Humans; Middle Aged; Nanoparticles; Paclitaxel; Ventricular Function, Left | 2011 |
[The clinical analysis of paclitaxel at two dose levels plus carboplatin as the first-line treatment in advanced non-small cell lung cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Disease Progression; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Survival Rate; Treatment Outcome | 2011 |
Safety and efficacy of first-line bevacizumab with chemotherapy in Asian patients with advanced nonsquamous NSCLC: results from the phase IV MO19390 (SAiL) study.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Asian People; Bevacizumab; Carboplatin; Carcinoma, Non-Small-Cell Lung; China; Clinical Trials, Phase IV as Topic; Disease Progression; Drug Therapy, Combination; Female; Follow-Up Studies; Hong Kong; Humans; Lung Neoplasms; Male; Middle Aged; Multicenter Studies as Topic; Paclitaxel; Survival Analysis; Taiwan; Time Factors; Treatment Outcome | 2011 |
Second-line paclitaxel/carboplatin versus vinorelbine/carboplatin in patients who have advanced non-small-cell lung cancer pretreated with non-platinum-based chemotherapy: a multicenter randomized phase II study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease Progression; Docetaxel; Drug Administration Schedule; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Survival Rate; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 2011 |
Sunitinib plus paclitaxel versus bevacizumab plus paclitaxel for first-line treatment of patients with advanced breast cancer: a phase III, randomized, open-label trial.
Topics: Adult; Aged; Aged, 80 and over; Algorithms; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Carcinoma; Disease Progression; Female; Humans; Indoles; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Pyrroles; Sunitinib; Survival Analysis | 2011 |
Randomized phase III trial of paclitaxel/carboplatin with or without PF-3512676 (Toll-like receptor 9 agonist) as first-line treatment for advanced non-small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Disease Progression; Female; Humans; Lung Neoplasms; Male; Middle Aged; Oligodeoxyribonucleotides; Paclitaxel; Toll-Like Receptor 9; Treatment Outcome | 2011 |
Phase II study of sunitinib as maintenance therapy in patients with locally advanced or metastatic non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Disease Progression; Female; Follow-Up Studies; Humans; Indoles; Lung Neoplasms; Maintenance Chemotherapy; Male; Middle Aged; Neoplasm Metastasis; Paclitaxel; Pyrroles; Sunitinib; Survival Analysis | 2011 |
First-line bevacizumab in combination with weekly paclitaxel for metastatic breast cancer: efficacy and safety results from a large, open-label, single-arm Japanese study.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Disease Progression; Disease-Free Survival; Female; Humans; Hypertension; Japan; Middle Aged; Paclitaxel; Receptor, ErbB-2 | 2011 |
Cationic liposomal paclitaxel plus gemcitabine or gemcitabine alone in patients with advanced pancreatic cancer: a randomized controlled phase II trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cations; Deoxycytidine; Disease Progression; Dosage Forms; Female; Gemcitabine; Humans; Liposomes; Male; Middle Aged; Models, Biological; Neoplasm Staging; Paclitaxel; Pancreatic Neoplasms; Survival Analysis | 2012 |
Randomized phase II study of palifermin for reducing dysphagia in patients receiving concurrent chemoradiotherapy for locally advanced unresectable non-small cell lung cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Deglutition Disorders; Disease Progression; Disease-Free Survival; Double-Blind Method; Female; Fibroblast Growth Factor 7; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Severity of Illness Index; Treatment Outcome | 2012 |
Phase II study of a cremophor-free, polymeric micelle formulation of paclitaxel for patients with advanced urothelial cancer previously treated with gemcitabine and platinum.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Chemistry, Pharmaceutical; Cisplatin; Deoxycytidine; Disease Progression; Drug Administration Schedule; Female; Gemcitabine; Humans; Male; Micelles; Middle Aged; Organoplatinum Compounds; Paclitaxel; Polyethylene Glycols; Polymers; Prognosis; Urologic Neoplasms | 2012 |
Exposure-response relationship of AMG 386 in combination with weekly paclitaxel in recurrent ovarian cancer and its implication for dose selection.
Topics: Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Computer Simulation; Confounding Factors, Epidemiologic; Disease Progression; Dose-Response Relationship, Drug; Female; Humans; Models, Biological; Monte Carlo Method; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Proportional Hazards Models; Prospective Studies; Recombinant Fusion Proteins; Regression Analysis; Treatment Outcome | 2012 |
Vinorelbine versus paclitaxel for patients with advanced non-small cell lung cancer (NSCLC) and a performance status of 2.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Brain Neoplasms; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Disease Progression; Female; Follow-Up Studies; Humans; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Small Cell Lung Carcinoma; Survival Rate; Treatment Outcome; Vinblastine; Vinorelbine | 2012 |
CA-125 can be part of the tumour evaluation criteria in ovarian cancer trials: experience of the GCIG CALYPSO trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; CA-125 Antigen; Carboplatin; Disease Progression; Disease-Free Survival; Doxorubicin; Female; Humans; Ovarian Neoplasms; Paclitaxel; Polyethylene Glycols; Recurrence; Tomography, X-Ray Computed | 2012 |
Phase I/II trial of carboplatin and paclitaxel chemotherapy in combination with intravenous oncolytic reovirus in patients with advanced malignancies.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Combined Modality Therapy; Diarrhea; Disease Progression; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Head and Neck Neoplasms; Humans; Male; Mammalian orthoreovirus 3; Middle Aged; Nausea; Neoplasms; Oncolytic Virotherapy; Oncolytic Viruses; Paclitaxel; Stomatitis; Treatment Outcome | 2012 |
[A multicenter, randomized, double-blind, placebo-controlled safety study to evaluate the clinical effects and quality of life of paclitaxel-carboplatin (PC) alone or combined with endostar for advanced non-small cell lung cancer (NSCLC)].
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free Survival; Double-Blind Method; Endostatins; Follow-Up Studies; Humans; Leukopenia; Lung Neoplasms; Nausea; Neoplasm Staging; Paclitaxel; Prospective Studies; Quality of Life; Recombinant Proteins; Remission Induction | 2011 |
[Efficacy of endostar combined with chemotherapy in multi-cycle treatment of patients with advanced non-small cell lung cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Disease Progression; Endostatins; Endothelial Cells; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Neutropenia; Paclitaxel; Quality of Life; Recombinant Proteins; Remission Induction; Vinblastine; Vinorelbine; Vomiting | 2011 |
Weekly paclitaxel plus trastuzumab in metastatic breast cancer pretreated with anthracyclines--a phase II multipractice study.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease Progression; Female; Humans; Middle Aged; Neoplasm Grading; Neoplasm Metastasis; Neoplasm Staging; Paclitaxel; Prognosis; Trastuzumab; Treatment Outcome | 2012 |
Promising outcomes of definitive chemoradiation and cetuximab for patients with esophageal squamous cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cetuximab; Chemoradiotherapy; Cisplatin; Disease Progression; Disease-Free Survival; ErbB Receptors; Esophageal Neoplasms; Female; Follow-Up Studies; Humans; Male; Middle Aged; Paclitaxel; Treatment Outcome | 2012 |
A pilot study of paclitaxel combined with gemcitabine followed by interleukin-2 and granulocyte macrophage colony-stimulating factor for patients with metastatic melanoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cytokines; Deoxycytidine; Disease Progression; Drug Administration Schedule; Female; Gemcitabine; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Interleukin-2; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Paclitaxel; Pilot Projects; Survival Rate; Treatment Outcome | 2012 |
A Phase I clinical trial of the combination of imatinib and paclitaxel in patients with advanced or metastatic solid tumors refractory to standard therapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Chemotherapy, Adjuvant; Cohort Studies; Disease Progression; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Imatinib Mesylate; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Neutropenia; Paclitaxel; Piperazines; Pyrimidines; Radiotherapy, Adjuvant; Severity of Illness Index; Treatment Outcome | 2012 |
A phase I trial of nab-paclitaxel, gemcitabine, and capecitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Aged; Albumin-Bound Paclitaxel; Albumins; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; CA-19-9 Antigen; Capecitabine; Deoxycytidine; Disease Progression; Drug Administration Schedule; Female; Fluorouracil; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Maximum Tolerated Dose; Middle Aged; Paclitaxel; Pancreatic Neoplasms; Treatment Outcome | 2012 |
Bevacizumab maintenance in patients with advanced non-small-cell lung cancer, clinical patterns, and outcomes in the Eastern Cooperative Oncology Group 4599 Study: results of an exploratory analysis.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Non-Small-Cell Lung; Disease Management; Disease Progression; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Neoplasm Staging; Paclitaxel; Prognosis; Remission Induction; Retrospective Studies; Survival Rate | 2012 |
Impact of the first tumor response at eight weeks on overall survival in metastatic breast cancer patients treated with first-line combination chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease Progression; Epirubicin; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Paclitaxel; Proportional Hazards Models; Treatment Outcome | 2013 |
Radiotherapy alone versus radiochemotherapy in patients with stage IIIA adenocarcinoma (ADC) of the lung.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Carboplatin; Chemoradiotherapy; Disease Progression; Disease-Free Survival; Dose Fractionation, Radiation; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Paclitaxel; Prospective Studies; Radiotherapy; Time Factors | 2013 |
Docetaxel/cisplatin as first-line chemotherapy in patients with head and neck carcinoma: a phase II trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease Progression; Docetaxel; Female; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Survival Rate; Taxoids; Treatment Outcome | 2002 |
Doxorubicin and paclitaxel versus doxorubicin and cyclophosphamide as first-line chemotherapy in metastatic breast cancer: The European Organization for Research and Treatment of Cancer 10961 Multicenter Phase III Trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Disease Progression; Disease-Free Survival; Doxorubicin; Drug Administration Schedule; Europe; Female; Humans; Middle Aged; Paclitaxel; Survival Analysis; Treatment Outcome | 2002 |
Phase II study of docetaxel and epirubicin in Chinese patients with metastatic breast cancer.
Topics: Adolescent; Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Disease Progression; Docetaxel; Drug Therapy, Combination; Epirubicin; Female; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Quality of Life; Survival Analysis; Taxoids; Treatment Outcome | 2002 |
A randomized phase II study of sequential docetaxel and doxorubicin/cyclophosphamide in patients with metastatic breast cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Case-Control Studies; Cyclophosphamide; Disease Progression; Docetaxel; Doxorubicin; ErbB Receptors; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Receptor, ErbB-2; Remission Induction; Survival Rate; Taxoids | 2002 |
Isolated leptomeningeal carcinomatosis (carcinomatous meningitis) after taxane-induced major remission in patients with advanced breast cancer.
Topics: Adult; Aged; Breast Neoplasms; Combined Modality Therapy; Disease Progression; Docetaxel; Female; Humans; Incidence; Meningeal Neoplasms; Meningitis; Methotrexate; Middle Aged; Neoplasm Staging; Paclitaxel; Prospective Studies; Recurrence; Remission Induction; Survival Rate; Taxoids | 2002 |
Second-line, low-dose, weekly paclitaxel in patients with stage IIIB/IV nonsmall cell lung carcinoma who fail first-line chemotherapy with carboplatin plus paclitaxel.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Disease Progression; Drug Administration Schedule; Female; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Peripheral Nervous System Diseases; Survival Rate; Treatment Outcome | 2002 |
Phase II trial of irinotecan, paclitaxel and carboplatin in patients with previously untreated Stage IIIB/IV nonsmall cell lung carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Diarrhea; Disease Progression; Female; Humans; Infusions, Intravenous; Irinotecan; Lung Neoplasms; Male; Middle Aged; Nausea; Neutropenia; Paclitaxel; Survival Analysis; Vomiting | 2002 |
A phase II study of weekly gemcitabine and paclitaxel in patients with previously untreated stage IIIb and IV non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Anemia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease Progression; Disease-Free Survival; Female; Gemcitabine; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Neutropenia; Paclitaxel; Pneumonia; Thrombocytopenia; Treatment Outcome | 2002 |
Gemcitabine and docetaxel every 2 weeks in advanced non-small cell lung cancer: a phase II study of the Gruppo Oncologico Italia Meridionale.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cost Control; Deoxycytidine; Disease Progression; Docetaxel; Drug Costs; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neutropenia; Paclitaxel; Survival; Taxoids; Treatment Outcome | 2002 |
Docetaxel, 5-fluorouracil, and leucovorin as treatment for advanced gastric cancer: results of a phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Neoplasms; Disease Progression; Docetaxel; Female; Fluorouracil; Humans; Incidence; Infusions, Intravenous; Leucovorin; Liver Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neutropenia; Paclitaxel; Severity of Illness Index; Stomach Neoplasms; Survival Analysis; Taxoids; Time Factors; Treatment Outcome | 2002 |
Epirubicin/docetaxel regimen in progressive breast cancer-a phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease Progression; Docetaxel; Epirubicin; Female; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Taxoids; Treatment Outcome | 2002 |
Phase III randomized trial comparing three platinum-based doublets in advanced non-small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Disease Progression; Female; Gemcitabine; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Neutropenia; Paclitaxel; Survival Analysis; Thrombocytopenia; Treatment Outcome; Vinblastine; Vinorelbine | 2002 |
CT tumor measurement for therapeutic response assessment: comparison of unidimensional, bidimensional, and volumetric techniques initial observations.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease Progression; Docetaxel; Female; Fluorouracil; Follow-Up Studies; Humans; Liver; Liver Neoplasms; Paclitaxel; Taxoids; Tomography, Spiral Computed; Treatment Outcome | 2002 |
Docetaxel vs 5-fluorouracil plus vinorelbine in metastatic breast cancer after anthracycline therapy failure.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease Progression; Disease-Free Survival; Docetaxel; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Infections; Infusions, Intravenous; Middle Aged; Neoplasm Metastasis; Neutropenia; Paclitaxel; Palliative Care; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 2002 |
Intensive sequential dose dense chemotherapy with stem cell support as first-line treatment in advanced ovarian carcinoma: a phase II study.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Combined Modality Therapy; Cyclophosphamide; Disease Progression; Disease-Free Survival; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Hematologic Diseases; Humans; Life Tables; Mesna; Middle Aged; Ovarian Neoplasms; Paclitaxel; Peripheral Blood Stem Cell Transplantation; Peripheral Nervous System Diseases; Pilot Projects; Prognosis; Recombinant Proteins; Remission Induction; Survival Analysis; Treatment Outcome | 2002 |
Docetaxel as neoadjuvant therapy for radically treatable stage III non-small-cell lung cancer: a multinational randomised phase III study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Case-Control Studies; Combined Modality Therapy; Disease Progression; Docetaxel; Female; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Paclitaxel; Postoperative Period; Safety; Survival Rate; Taxoids; Treatment Outcome | 2003 |
Doxorubicin-paclitaxel: a safe regimen in terms of cardiac toxicity in metastatic breast carcinoma patients. Results from a European Organization for Research and Treatment of Cancer multicenter trial.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Disease Progression; Disease-Free Survival; Doxorubicin; Female; Follow-Up Studies; Heart; Humans; Middle Aged; Paclitaxel; Risk Factors; Safety; Survival Rate; Treatment Outcome | 2003 |
Phase II study of concurrent administration of doxorubicin and docetaxel as first-line chemotherapy for metastatic breast cancer.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease Progression; Docetaxel; Doxorubicin; Drug Administration Schedule; Female; Humans; Injections, Intravenous; Middle Aged; Neoplasm Staging; Paclitaxel; Taxoids; Treatment Failure; Treatment Outcome | 2003 |
A phase II trial of weekly paclitaxel, 5-fluorouracil, and leucovorin as first-line treatment for metastatic breast cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease Progression; Drug Administration Schedule; Female; Fluorouracil; Humans; Leucovorin; Middle Aged; Neoplasm Metastasis; Paclitaxel; Remission Induction; Survival Analysis; Treatment Outcome | 2003 |
Docetaxel and doxorubicin compared with doxorubicin and cyclophosphamide as first-line chemotherapy for metastatic breast cancer: results of a randomized, multicenter, phase III trial.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Disease Progression; Disease-Free Survival; Docetaxel; Doxorubicin; Female; Health Status; Hematologic Diseases; Humans; Middle Aged; Neoplasm Staging; Paclitaxel; Quality of Life; Survival Analysis; Taxoids; Treatment Outcome; Ventricular Dysfunction, Left | 2003 |
European experience of docetaxel and cisplatin in advanced gastric cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease Progression; Disease-Free Survival; Docetaxel; Female; Fluorouracil; Humans; Male; Middle Aged; Paclitaxel; Stomach Neoplasms; Taxoids | 2002 |
Long-term results of paclitaxel in FIGO stage III ovarian carcinoma.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Disease Progression; Female; Humans; Infusions, Intravenous; Middle Aged; Neoplasm Staging; Ovarian Neoplasms; Ovary; Paclitaxel; Survival Analysis | 2003 |
Weekly docetaxel as second-line therapy for patients with advanced breast cancer resistant to previous anthracycline treatment.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Disease Progression; Docetaxel; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Middle Aged; Neoplasm Metastasis; Neutropenia; Paclitaxel; Pulmonary Fibrosis; Survival Analysis; Taxoids; Treatment Outcome | 2003 |
Phase III trial of paclitaxel at two dose levels, the higher dose accompanied by filgrastim at two dose levels in platinum-pretreated epithelial ovarian cancer: an intergroup study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Dose-Response Relationship, Drug; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Logistic Models; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Ovarian Neoplasms; Paclitaxel; Platinum Compounds; Proportional Hazards Models; Recombinant Proteins; Survival Analysis | 2003 |
Prognostic value of quality of life scores for time to progression (TTP) and overall survival time (OS) in advanced breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cross-Over Studies; Disease Progression; Docetaxel; Female; Fluorouracil; Humans; Methotrexate; Paclitaxel; Prognosis; Quality of Life; Statistics as Topic; Survival Analysis; Taxoids | 2003 |
Clinical data and pharmacokinetics of a docetaxel-vinorelbine combination in anthracycline resistant/ relapsed metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease Progression; Docetaxel; Drug Interactions; Drug Resistance, Neoplasm; Female; Humans; Infusions, Intravenous; Injections, Intravenous; Middle Aged; Neoplasm Metastasis; Neutropenia; Paclitaxel; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 2003 |
Phase II study of docetaxel-vinorelbine in platinum-resistant, paclitaxel-pretreated ovarian cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease Progression; Disease-Free Survival; Docetaxel; Drug Resistance, Neoplasm; Female; Granulocyte Colony-Stimulating Factor; Humans; Leukopenia; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Ovarian Neoplasms; Paclitaxel; Prospective Studies; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 2003 |
Phase II trial of paclitaxel, estramustine, etoposide, and carboplatin in the treatment of patients with hormone-refractory prostate carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Animals; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Disease Progression; Estramustine; Etoposide; Humans; Male; Middle Aged; Paclitaxel; Prostate-Specific Antigen; Prostatic Neoplasms; Rats; Survival Rate; Treatment Outcome | 2003 |
Double high-dose chemotherapy with adriamycin, paclitaxel, cyclophosphamide, and thiotepa followed by autologous peripheral blood stem cell transplantation in women with metastatic breast cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Combined Modality Therapy; Cyclophosphamide; Disease Progression; Disease-Free Survival; Doxorubicin; Female; Granulocyte Colony-Stimulating Factor; Humans; Infusions, Intravenous; Middle Aged; Neoplasm Metastasis; Paclitaxel; Thiotepa; Treatment Outcome | 2003 |
Randomized phase III trial of paclitaxel, etoposide, and carboplatin versus carboplatin, etoposide, and vincristine in patients with small-cell lung cancer.
Topics: Adult; Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Small Cell; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Etoposide; Female; Hematologic Diseases; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Patient Selection; Prognosis; Proportional Hazards Models; Risk Factors; Survival Analysis; Treatment Outcome; Vincristine | 2003 |
Cisplatin as second-line therapy in ovarian carcinoma treated initially with single-agent paclitaxel: a Gynecologic Oncology Group study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Cisplatin; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel | 2003 |
Randomized phase II study of weekly paclitaxel versus paclitaxel and carboplatin as second-line therapy in disseminated melanoma: a multicentre trial of the Dermatologic Co-operative Oncology Group (DeCOG).
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Disease Progression; Female; Humans; Male; Melanoma; Paclitaxel; Time Factors; Treatment Outcome | 2003 |
Vinorelbine and cisplatin for metastatic breast cancer: a salvage regimen in patients progressing after docetaxel and anthracycline treatment.
Topics: Adolescent; Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Disease Progression; Docetaxel; Drug Resistance, Neoplasm; Female; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasm Metastasis; Paclitaxel; Salvage Therapy; Survival Analysis; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 2003 |
Phase II trial of 96-hour paclitaxel in previously treated patients with advanced esophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents, Phytogenic; Carcinoma, Squamous Cell; Disease Progression; Esophageal Neoplasms; Female; Humans; Infusions, Intravenous; Male; Middle Aged; Paclitaxel; Treatment Outcome | 2003 |
Paclitaxel for anthracycline-resistant AIDS-related Kaposi's sarcoma: clinical and angiogenic correlations.
Topics: Acquired Immunodeficiency Syndrome; Adult; Anthracyclines; Antineoplastic Agents, Phytogenic; Antiretroviral Therapy, Highly Active; Biomarkers, Tumor; Disease Progression; Female; Fibroblast Growth Factor 2; Humans; Interleukin-6; Male; Middle Aged; Neovascularization, Pathologic; Paclitaxel; Sarcoma, Kaposi; Skin Neoplasms; Time Factors; Tumor Necrosis Factor-alpha; Vascular Endothelial Growth Factor A | 2003 |
Biweekly paclitaxel in patients with metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Arthralgia; Breast Neoplasms; Disease Progression; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Middle Aged; Neoplasm Metastasis; Neutropenia; Paclitaxel; Treatment Outcome | 2003 |
Long-term survival in a phase III, randomised study of topotecan versus paclitaxel in advanced epithelial ovarian carcinoma.
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Disease Progression; Drug Administration Schedule; Female; Humans; Incidence; Infusions, Intravenous; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Quality of Life; Sensitivity and Specificity; Survival Analysis; Topotecan | 2004 |
Phase II study of weekly paclitaxel and trastuzumab in anthracycline- and taxane-pretreated patients with HER2-overexpressing metastatic breast cancer.
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease Progression; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Genes, erbB-2; Heart; Humans; Infusions, Intravenous; Middle Aged; Neoplasm Metastasis; Paclitaxel; Receptor, ErbB-2; Taxoids; Trastuzumab; Treatment Outcome | 2004 |
Weekly paclitaxel as first-line chemotherapy for elderly patients with metastatic breast cancer. A multicentre phase II trial.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Disease Progression; Female; Follow-Up Studies; Humans; Infusions, Intravenous; Paclitaxel; Survival Analysis | 2004 |
Biweekly paclitaxel plus gemcitabine in advanced breast cancer: phase II trial and predictive value of HER2 extracellular domain.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Disease Progression; Disease-Free Survival; DNA, Neoplasm; Drug Administration Schedule; Enzyme-Linked Immunosorbent Assay; Female; Gemcitabine; Genes, erbB-2; Humans; Infusions, Intravenous; Middle Aged; Paclitaxel; Predictive Value of Tests; Prognosis; Treatment Outcome | 2004 |
A phase II study of sequential carboplatin, paclitaxel and topotecan in patients with previously untreated advanced ovarian cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Disease Progression; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Middle Aged; Ovarian Neoplasms; Paclitaxel; Prognosis; Survival Analysis; Topotecan; Treatment Outcome | 2004 |
Real-time pharmacokinetics guiding clinical decisions; phase I study of a weekly schedule of liposome encapsulated paclitaxel in patients with solid tumours.
Topics: Adult; Aged; Analysis of Variance; Antineoplastic Agents, Phytogenic; Cohort Studies; Decision Making; Disease Progression; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Half-Life; Humans; Infusions, Intravenous; Liposomes; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Paclitaxel; Treatment Outcome | 2004 |
Phase II evaluation of paclitaxel by short intravenous infusion in metastatic melanoma.
Topics: Adult; Aged; Angiogenesis Inhibitors; Choroid Neoplasms; Disease Progression; Female; Humans; Injections, Intravenous; Liver Neoplasms; Male; Maximum Tolerated Dose; Melanoma; Middle Aged; Paclitaxel; Remission Induction; Skin Neoplasms; Survival Rate; Treatment Outcome | 2004 |
Phase II trial of trastuzumab followed by weekly paclitaxel/carboplatin as first-line treatment for patients with metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Disease Progression; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Middle Aged; Neoplasm Metastasis; Paclitaxel; Receptor, ErbB-2; Survival Analysis; Trastuzumab; Treatment Outcome | 2004 |
The combination of carboplatin and weekly paclitaxel: a safe and active regimen in advanced non small-cell lung cancer patients. A phase I-II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cohort Studies; Disease Progression; Female; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Paclitaxel; Time Factors; Treatment Outcome | 2004 |
Randomised controlled trial comparing single agent paclitaxel vs epidoxorubicin plus paclitaxel in patients with advanced ovarian cancer in early progression after platinum-based chemotherapy: an Italian Collaborative Study from the Mario Negri Institute,
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Disease Progression; Epirubicin; Female; Humans; Infusions, Intravenous; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Survival Analysis; Treatment Outcome | 2004 |
Phase II study of capecitabine in combination with paclitaxel in patients with anthracycline-pretreated advanced/metastatic breast cancer.
Topics: Adolescent; Adult; Aged; Anthracyclines; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease Progression; Female; Fluorouracil; Humans; Maximum Tolerated Dose; Middle Aged; Paclitaxel; Survival Rate; Treatment Outcome | 2004 |
A phase II study of oxaliplatin and paclitaxel in patients with advanced non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease Progression; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Survival Analysis; Treatment Outcome | 2004 |
Capecitabine plus paclitaxel as front-line combination therapy for metastatic breast cancer: a multicenter phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease Progression; Female; Fluorouracil; Humans; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Survival Analysis; Time Factors; Treatment Outcome | 2004 |
Prognostic and predictive impact of the HER-2/ neu extracellular domain (ECD) in the serum of patients treated with chemotherapy for metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Cyclophosphamide; Disease Progression; Disease-Free Survival; Enzyme-Linked Immunosorbent Assay; Epirubicin; Female; Gene Expression Profiling; Humans; Immunohistochemistry; Middle Aged; Neoplasm Metastasis; Paclitaxel; Prognosis; Receptor, ErbB-2 | 2004 |
The acquisition of hMLH1 methylation in plasma DNA after chemotherapy predicts poor survival for ovarian cancer patients.
Topics: Adaptor Proteins, Signal Transducing; Alleles; Carboplatin; Carrier Proteins; CpG Islands; Disease Progression; DNA; DNA Methylation; Female; Gene Silencing; Humans; Microsatellite Repeats; MutL Protein Homolog 1; Neoplasm Proteins; Nuclear Proteins; Ovarian Neoplasms; Paclitaxel; Polymerase Chain Reaction; Proportional Hazards Models; Random Allocation; Recurrence; Time Factors; Treatment Outcome | 2004 |
Phase I study of concomitant chemoradiotherapy with paclitaxel, fluorouracil, gemcitabine, and twice-daily radiation in patients with poor-prognosis cancer of the head and neck.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Clinical Trials as Topic; Combined Modality Therapy; Deoxycytidine; Disease Progression; Disease-Free Survival; Female; Fluorouracil; Gemcitabine; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neoplasm Metastasis; Paclitaxel; Prognosis; Radiometry; Time Factors; Treatment Outcome | 2004 |
Phase I/II study of DHA-paclitaxel in combination with carboplatin in patients with advanced malignant solid tumours.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Cohort Studies; Disease Progression; Docosahexaenoic Acids; Female; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Neoplasms; Paclitaxel; Time Factors | 2004 |
Combination of pegylated liposomal doxorubicin (PLD) and paclitaxel in patients with advanced soft tissue sarcoma: a phase II study of the Hellenic Cooperative Oncology Group.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Doxorubicin; Female; Histiocytoma, Benign Fibrous; Humans; Leiomyosarcoma; Liposarcoma; Liposomes; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Safety; Sarcoma; Survival Rate; Time Factors; Treatment Outcome | 2004 |
Phase II study of CT-2103 in patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Disease Progression; Drug Resistance, Neoplasm; Fallopian Tube Neoplasms; Female; Humans; Infusions, Intravenous; Middle Aged; Neoplasm Recurrence, Local; Nervous System Diseases; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Polyglutamic Acid; Taxoids | 2004 |
Analysis of further disease progression in metastatic non-small cell lung cancer: implications for locoregional treatment.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease Progression; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Pleural Effusion; Prognosis; Treatment Outcome | 2004 |
Secondary surgical cytoreduction for advanced ovarian carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Disease Progression; Female; Follow-Up Studies; Humans; Middle Aged; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Postoperative Complications; Survival Analysis | 2004 |
Up-front tandem high-dose chemotherapy compared with standard chemotherapy with doxorubicin and paclitaxel in metastatic breast cancer: results of a randomized trial.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Disease Progression; Dose-Response Relationship, Drug; Doxorubicin; Etoposide; Female; Humans; Infusions, Intravenous; Middle Aged; Mitoxantrone; Paclitaxel; Peripheral Blood Stem Cell Transplantation; Quality of Life; Survival Analysis; Treatment Outcome | 2005 |
Weekly paclitaxel as first-line chemotherapy in elderly advanced breast cancer patients: a phase II study of the Gruppo Italiano di Oncologia Geriatrica (GIOGer).
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Disease Progression; Female; Heart Diseases; Humans; Infusions, Intravenous; Neutropenia; Paclitaxel; Survival Analysis | 2005 |
Pathological and clinical response of a primary chemotherapy regimen combining vinorelbine, epirubicin, and paclitaxel as neoadjuvant treatment in patients with operable breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease Progression; Disease-Free Survival; Epirubicin; Female; Humans; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Treatment Outcome; Vinblastine; Vinorelbine | 2005 |
Advanced bronchioloalveolar carcinoma: a phase II trial of paclitaxel by 96-hour infusion (SWOG 9714): a Southwest Oncology Group study.
Topics: Adenocarcinoma, Bronchiolo-Alveolar; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Disease Progression; Female; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Survival Analysis | 2005 |
Randomized phase III intergroup trial of etoposide and cisplatin with or without paclitaxel and granulocyte colony-stimulating factor in patients with extensive-stage small-cell lung cancer: Cancer and Leukemia Group B Trial 9732.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Disease Progression; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Prospective Studies; Recombinant Proteins; Survival Rate; Time Factors | 2005 |
Study of paclitaxel, etoposide, and cisplatin chemotherapy combined with twice-daily thoracic radiotherapy for patients with limited-stage small-cell lung cancer: a Radiation Therapy Oncology Group 9609 phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Combined Modality Therapy; Disease Progression; Etoposide; Female; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Survival Analysis | 2005 |
Phase II multicenter study of the epidermal growth factor receptor antibody cetuximab and cisplatin for recurrent and refractory squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cetuximab; Cisplatin; Disease Progression; Drug Administration Schedule; Female; Fluorouracil; Head and Neck Neoplasms; Humans; Logistic Models; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Survival Analysis; Treatment Outcome | 2005 |
A phase II study of paclitaxel in advanced bronchioloalveolar carcinoma (EORTC trial 08956).
Topics: Adenocarcinoma, Bronchiolo-Alveolar; Adult; Aged; Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Disease Progression; Female; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Survival Analysis; Treatment Outcome | 2005 |
TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Disease Progression; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Placebos; Protein Kinase Inhibitors; Quinazolines; Survival Analysis | 2005 |
Phase II study of weekly paclitaxel and 24-hour infusion of high-dose 5-fluorouracil and leucovorin in the treatment of recurrent or metastatic gastric cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Female; Fluorouracil; Humans; Infusions, Intravenous; Leucovorin; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Prospective Studies; Stomach Neoplasms; Survival Analysis; Treatment Outcome | 2005 |
Long term results of CHART and weekly Paclitaxel in locally advanced non-small cell lung cancer.
Topics: Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Combined Modality Therapy; Disease Progression; Dose Fractionation, Radiation; Humans; Lung Neoplasms; Paclitaxel; Radiotherapy; Time Factors; Treatment Outcome | 2005 |
Randomized phase III study of docetaxel compared with paclitaxel in metastatic breast cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Chi-Square Distribution; Disease Progression; Docetaxel; Female; Humans; Infusions, Intravenous; Logistic Models; Middle Aged; Paclitaxel; Proportional Hazards Models; Quality of Life; Taxoids; Treatment Outcome | 2005 |
Multicenter phase II trial of ABI-007, an albumin-bound paclitaxel, in women with metastatic breast cancer.
Topics: Adult; Aged; Albumin-Bound Paclitaxel; Albumins; Breast Neoplasms; Disease Progression; Drug Hypersensitivity; Female; Humans; Infusions, Intravenous; Middle Aged; Neoplasm Metastasis; Paclitaxel | 2005 |
Isolated central nervous system metastases in patients with HER2-overexpressing advanced breast cancer treated with first-line trastuzumab-based therapy.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Central Nervous System Neoplasms; Cyclophosphamide; Disease Progression; Doxorubicin; Female; Follow-Up Studies; Gene Amplification; Humans; In Situ Hybridization, Fluorescence; Paclitaxel; Prevalence; Receptor, ErbB-2; Survival Rate; Time Factors; Trastuzumab; Vinblastine; Vinorelbine | 2005 |
Concurrent hyperfractionated radiotherapy and low-dose daily carboplatin/paclitaxel in patients with early-stage (I/II) non-small-cell lung cancer: long-term results of a phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Disease Progression; Dose Fractionation, Radiation; Drug Administration Schedule; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Paclitaxel; Survival Analysis; Treatment Outcome | 2005 |
Phase II to III study comparing doxorubicin and docetaxel with fluorouracil, doxorubicin, and cyclophosphamide as first-line chemotherapy in patients with metastatic breast cancer: results of a Dutch Community Setting Trial for the Clinical Trial Group of
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Disease Progression; Doxorubicin; Female; Fluorouracil; Humans; Infusions, Intravenous; Injections, Intravenous; Middle Aged; Neoplasm Metastasis; Paclitaxel; Survival Analysis | 2005 |
Phase I study of 90Y-CC49 monoclonal antibody therapy in patients with advanced non-small cell lung cancer: effect of chelating agents and paclitaxel co-administration.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Neoplasm; Antigens, Neoplasm; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chelating Agents; Clinical Trials as Topic; Disease Progression; Edetic Acid; Female; Glycoproteins; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neutropenia; Paclitaxel; Pentetic Acid; Radioimmunotherapy; Radiometry; Thrombocytopenia; Treatment Outcome; Up-Regulation; Yttrium Radioisotopes | 2005 |
Evaluation of irinotecan plus paclitaxel in patients with advanced non-small cell lung cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Diarrhea; Disease Progression; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Irinotecan; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Neutropenia; Paclitaxel; Survival Analysis; Time Factors | 2005 |
Recombinant human angiostatin (rhAngiostatin) in combination with paclitaxel and carboplatin in patients with advanced non-small-cell lung cancer: a phase II study from Indiana University.
Topics: Aged; Angiostatins; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carboplatin; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free Survival; Feasibility Studies; Female; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Paclitaxel; Proteomics; Recombinant Proteins; Survival Rate; Time Factors | 2006 |
First-line therapy with gemcitabine and paclitaxel in locally, recurrent or metastatic breast cancer: a phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Disease Progression; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Prognosis; Recurrence; Remission Induction; Time Factors; Treatment Outcome | 2005 |
Efficacy and safety of paclitaxel poliglumex as first-line chemotherapy in patients at high risk with advanced-stage non-small-cell lung cancer: results of a phase II study.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Disease Progression; Female; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Survival Analysis | 2005 |
Comparison of CA-125 and standard definitions of progression of ovarian cancer in the intergroup trial of cisplatin and paclitaxel versus cisplatin and cyclophosphamide.
Topics: Antineoplastic Combined Chemotherapy Protocols; CA-125 Antigen; Cisplatin; Cyclophosphamide; Disease Progression; Female; Humans; Ovarian Neoplasms; Paclitaxel; Retrospective Studies | 2006 |
Randomised phase II trial of gemcitabine and paclitaxel second-line chemotherapy in patients with transitional cell carcinoma (AUO Trial AB 20/99).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Deoxycytidine; Disease Progression; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Survival Analysis; Treatment Outcome; Urinary Bladder Neoplasms | 2006 |
Reverting estrogen-receptor-negative phenotype in HER-2-overexpressing advanced breast cancer patients exposed to trastuzumab plus chemotherapy.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease Progression; Female; Humans; Immunohistochemistry; Infusions, Intravenous; Paclitaxel; Phenotype; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Trastuzumab; Treatment Outcome; Vinblastine; Vinorelbine | 2006 |
Paclitaxel and leucovorin-modulated infusional 5-fluorouracil combination chemotherapy for metastatic gastric cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Diarrhea; Disease Progression; Female; Fluorouracil; Humans; Infusions, Intravenous; Leucovorin; Liver Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Mucositis; Multivariate Analysis; Neutropenia; Paclitaxel; Prognosis; Stomach Neoplasms; Survival Analysis; Treatment Outcome | 2006 |
mdr-1 single nucleotide polymorphisms in ovarian cancer tissue: G2677T/A correlates with response to paclitaxel chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B, Member 1; Carboplatin; Disease Progression; DNA Mutational Analysis; Exons; Female; Genotype; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel; Polymorphism, Single Nucleotide; Predictive Value of Tests; Recurrence; Reverse Transcriptase Polymerase Chain Reaction; Treatment Outcome | 2006 |
Phase II study of gemcitabine, doxorubicin and paclitaxel (GAT) as first-line chemotherapy for metastatic breast cancer: a translational research experience.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Disease Progression; Doxorubicin; Female; Gemcitabine; Humans; Infusions, Intravenous; Middle Aged; Neoplasm Metastasis; Paclitaxel; Survival Analysis; Treatment Outcome | 2006 |
Beyond the TRIBUTE trial: integrating HER1/EGFR tyrosine kinase inhibitors with chemotherapy in advanced NSCLC.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Disease Progression; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Paclitaxel; Protein Kinase Inhibitors; Quinazolines; Smoking; Survival; Treatment Outcome; Up-Regulation | 2006 |
A multi-center phase II study of sequential paclitaxel and bryostatin-1 (NSC 339555) in patients with untreated, advanced gastric or gastroesophageal junction adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bryostatins; Disease Progression; Dose-Response Relationship, Drug; Esophageal Neoplasms; Esophagogastric Junction; Female; Humans; Macrolides; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Survival Analysis | 2006 |
A phase II trial of a biweekly combination of paclitaxel and gemcitabine in metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Disease Progression; Drug Administration Schedule; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Treatment Outcome | 2006 |
Phase II NCCTG trial of oral topotecan and paclitaxel with G-CSF (filgrastim) support in patients with previously untreated extensive-stage small cell lung cancer.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Disease Progression; Female; Granulocyte Colony-Stimulating Factor; Humans; Infusions, Intravenous; Injections, Subcutaneous; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Survival Analysis; Topotecan; Treatment Outcome | 2006 |
Phase I-II study of pegylated liposomal doxorubicin combined with weekly paclitaxel as first-line treatment in patients with metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease Progression; Doxorubicin; Drug Interactions; Female; Heart; History, Medieval; Humans; Infusions, Intravenous; Liposomes; Maximum Tolerated Dose; Middle Aged; Paclitaxel; Treatment Outcome | 2006 |
A phase I and pharmacologic study of sequences of the proteasome inhibitor, bortezomib (PS-341, Velcade), in combination with paclitaxel and carboplatin in patients with advanced malignancies.
Topics: Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Boronic Acids; Bortezomib; Carboplatin; Disease Progression; Female; Hematologic Diseases; Humans; Male; Middle Aged; Neoplasms; Paclitaxel; Peripheral Nervous System Diseases; Proteasome Inhibitors; Pyrazines; Severity of Illness Index; Treatment Outcome | 2007 |
Rational drug sequencing of paclitaxel, gemcitabine and carboplatin in patients with untreated stage IV and select stage IIIB non-small cell lung cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease Progression; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Pleural Effusion; Survival Analysis; Treatment Outcome | 2006 |
Radiation therapy with concomitant and adjuvant cisplatin and paclitaxel in high-risk cervical cancer: long-term follow-up.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Disease Progression; Disease-Free Survival; Dose Fractionation, Radiation; Female; Humans; Middle Aged; Paclitaxel; Radiation-Sensitizing Agents; Radiotherapy Dosage; Survival Rate; Uterine Cervical Neoplasms | 2006 |
An open, multi-centre, phase II clinical trial to evaluate the efficacy and safety of paclitaxel, UFT, and leucovorin in patients with advanced gastric cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Drug Combinations; Female; Humans; Leucovorin; Male; Middle Aged; Paclitaxel; Prospective Studies; Safety; Stomach Neoplasms; Survival Rate; Tegafur; Treatment Outcome; Uracil | 2006 |
Induction chemotherapy with the TIP regimen (paclitaxel/ifosfamide/cisplatin) in stage III non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Austria; Carcinoma, Non-Small-Cell Lung; Cisplatin; Disease Progression; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Ifosfamide; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Recombinant Proteins; Taxoids; Treatment Outcome | 2006 |
A novel self-microemulsifying formulation of paclitaxel for oral administration to patients with advanced cancer.
Topics: Administration, Oral; Adult; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Cyclosporine; Disease Progression; Drug Administration Schedule; Drug Delivery Systems; Emulsifying Agents; Female; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Paclitaxel; Safety; Solubility; Tissue Distribution; Treatment Outcome | 2006 |
A phase II trial with gemcitabine and paclitaxel for the treatment of refractory and relapsed multiple myeloma patients.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Deoxycytidine; Disease Progression; Female; Gemcitabine; Humans; Male; Middle Aged; Multiple Myeloma; Paclitaxel; Recurrence; Time Factors; Treatment Outcome | 2006 |
Thalidomide/estramustine/paclitaxel in metastatic androgen-independent prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Disease Progression; Estramustine; Humans; Male; Middle Aged; Neoplasms, Hormone-Dependent; Paclitaxel; Prostate-Specific Antigen; Prostatic Neoplasms; Survival Rate; Taxoids; Thalidomide; Time Factors; Treatment Outcome | 2006 |
Paclitacxel and carboplatin in advanced non-small-cell lung cancer.
Topics: Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Carcinoma, Non-Small-Cell Lung; Disease Progression; Female; Humans; Injections, Intravenous; Lung Neoplasms; Male; Middle Aged; Nausea; Neoplasm Staging; Neutropenia; Paclitaxel; Thrombocytopenia; Tomography, X-Ray Computed; Treatment Outcome; Vomiting | 2006 |
Weekly administration of topotecan-paclitaxel as second-line treatment in ovarian cancer.
Topics: Adult; Aged; Aged, 80 and over; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Neutropenia; Ovarian Neoplasms; Paclitaxel; Patient Compliance; Remission Induction; Thrombocytopenia; Topotecan; Treatment Outcome | 2007 |
Phase I/II study of S-1 combined with paclitaxel in patients with unresectable and/or recurrent advanced gastric cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Drug Combinations; Female; Humans; Intestinal Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Oxonic Acid; Paclitaxel; Stomach Neoplasms; Survival Rate; Tegafur; Treatment Outcome | 2006 |
Randomized phase II trial of paclitaxel plus carboplatin or gemcitabine plus cisplatin in Eastern Cooperative Oncology Group performance status 2 non-small-cell lung cancer patients: ECOG 1599.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Disease Progression; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Survival Analysis | 2007 |
Phase II study of paclitaxel plus gemcitabine salvage chemotherapy for germ cell tumors after progression following high-dose chemotherapy with tandem transplant.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Female; Follow-Up Studies; Gemcitabine; Humans; Indiana; Kaplan-Meier Estimate; Male; Neoplasms, Germ Cell and Embryonal; Ovarian Neoplasms; Paclitaxel; Retrospective Studies; Salvage Therapy; Testicular Neoplasms; Time Factors; Treatment Failure; Treatment Outcome | 2007 |
Multicenter phase II study of weekly paclitaxel plus cisplatin combination chemotherapy in patients with advanced gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease Progression; Female; Fever; Follow-Up Studies; Humans; Male; Middle Aged; Nausea; Neoplasm Metastasis; Neutropenia; Paclitaxel; Recurrence; Stomach Neoplasms; Survival Rate | 2007 |
Phase II study of CT-2103 as first- or second-line chemotherapy in patients with metastatic breast cancer: unexpected incidence of hypersensitivity reactions.
Topics: Adult; Aged; Antineoplastic Agents; Breast Neoplasms; Disease Progression; Drug Hypersensitivity; Female; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Polyglutamic Acid; Taxoids | 2007 |
Organ-sparing treatment of advanced bladder cancer: paclitaxel as a radiosensitizer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Combined Modality Therapy; Disease Progression; Female; Humans; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Paclitaxel; Radiation-Sensitizing Agents; Recurrence; Treatment Outcome; Urinary Bladder Neoplasms | 2007 |
A Phase II randomized study of paclitaxel plus carboplatin or cisplatin against chemo-naive inoperable non-small cell lung cancer in the elderly.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Contraindications; Disease Progression; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Neoplasm Staging; Paclitaxel; Pneumonectomy; Retrospective Studies; Risk Factors; Severity of Illness Index; Taiwan; Treatment Outcome | 2006 |
Topotecan and paclitaxel in previously treated patients with relapsed small cell lung cancer: phase II trial of the North Central Cancer Treatment Group.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carcinoma, Small Cell; Disease Progression; Female; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Paclitaxel; Survival Rate; Topotecan | 2006 |
A phase II open-label study of DHA-paclitaxel (Taxoprexin) by 2-h intravenous infusion in previously untreated patients with locally advanced or metastatic gastric or oesophageal adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Disease Progression; Dose-Response Relationship, Drug; Esophageal Neoplasms; Female; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasm Metastasis; Paclitaxel; Stomach Neoplasms; Survival Analysis; Tomography, X-Ray Computed | 2008 |
Measurement and impact of co-morbidity in elderly patients with advanced non-small cell lung cancer treated with chemotherapy. A phase II study of weekly paclitaxel.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Comorbidity; Disease Progression; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Heart Diseases; Humans; Lung Neoplasms; Male; Multivariate Analysis; Paclitaxel; Patient Compliance; Proportional Hazards Models; Pulmonary Disease, Chronic Obstructive; Renal Insufficiency; Severity of Illness Index; Survival Analysis; Treatment Outcome; Vascular Diseases | 2007 |
In focus: non-small cell lung cancer: E1505.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Disease Progression; Humans; Lung Neoplasms; Neoplasm Staging; Neovascularization, Pathologic; Paclitaxel; Vascular Endothelial Growth Factor A | 2007 |
Trastuzumab plus vinorelbine or taxane chemotherapy for HER2-overexpressing metastatic breast cancer: the trastuzumab and vinorelbine or taxane study.
Topics: Adult; Aged; Aged, 80 and over; Alopecia; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Constipation; Disease Progression; Drug Administration Schedule; Fatigue; Female; Humans; Kaplan-Meier Estimate; Middle Aged; Nausea; Neoplasm Metastasis; Paclitaxel; Prospective Studies; Receptor, ErbB-2; Trastuzumab; Treatment Outcome; Vinblastine; Vinorelbine | 2007 |
Gemcitabine, ifosfamide and paclitaxel in advanced/metastatic non-small cell lung cancer patients: a phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease Progression; Disease-Free Survival; Female; Gemcitabine; Humans; Ifosfamide; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Paclitaxel; Survival Rate; Treatment Outcome | 2008 |
Phase II evaluation of oral estramustine, oral etoposide, and intravenous paclitaxel in patients with hormone-sensitive prostate adenocarcinoma.
Topics: Adenocarcinoma; Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Disease Progression; Estramustine; Etoposide; Feasibility Studies; Humans; Injections, Intravenous; Male; Middle Aged; Neoplasms, Hormone-Dependent; Paclitaxel; Prostate-Specific Antigen; Prostatic Neoplasms; Survival Rate; Treatment Outcome | 2007 |
Induction chemotherapy with paclitaxel plus carboplatin followed by paclitaxel with concurrent radiotherapy in stage IIIB non-small-cell lung cancer (NSCLC) patients: a phase II trial.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Disease Progression; Drug-Related Side Effects and Adverse Reactions; Humans; Lung Neoplasms; Middle Aged; Neoplasm Staging; Paclitaxel; Patient Compliance; Survival Analysis; Treatment Failure | 2007 |
Weekly epirubicin and paclitaxel with granulocyte colony-stimulating factor support in previously untreated metastatic breast cancer patients: a phase II study.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Epirubicin; Female; Granulocyte Colony-Stimulating Factor; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Recombinant Proteins | 2007 |
Multicenter phase II trial of combination chemotherapy with weekly paclitaxel and 5-fluorouracil for the treatment of advanced or recurrent gastric carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Disease Progression; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Stomach Neoplasms; Survival Analysis; Treatment Outcome | 2007 |
Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Disease Progression; Female; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Proportional Hazards Models; Quality of Life; Receptor, ErbB-2; Survival Analysis | 2007 |
A phase II study of paclitaxel and capecitabine as a first-line combination chemotherapy for advanced gastric cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma; Deoxycytidine; Disease Progression; Dose-Response Relationship, Drug; Female; Fluorouracil; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Metastasis; Paclitaxel; Stomach Neoplasms; Survival Analysis; Treatment Outcome | 2008 |
Phase II study of weekly albumin-bound paclitaxel for patients with metastatic breast cancer heavily pretreated with taxanes.
Topics: Abdominal Neoplasms; Adult; Aged; Albumin-Bound Paclitaxel; Albumins; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Bone Neoplasms; Breast Neoplasms; Disease Progression; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Middle Aged; Neoadjuvant Therapy; Neoplasm Metastasis; Paclitaxel; Survival Analysis; Taxoids; Treatment Outcome | 2007 |
Phase II trial of sequential paclitaxel and 1 h infusion of bryostatin-1 in patients with advanced esophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bryostatins; Carcinoma, Squamous Cell; Disease Progression; Esophageal Neoplasms; Female; Humans; Male; Middle Aged; Paclitaxel | 2008 |
Does body mass index affect progression-free or overall survival in patients with ovarian cancer? Results from SCOTROC I trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Body Mass Index; Carboplatin; Carcinoma; Combined Modality Therapy; Disease Progression; Disease-Free Survival; Docetaxel; Dose-Response Relationship, Drug; Female; Glomerular Filtration Rate; Humans; Middle Aged; Obesity; Ovarian Neoplasms; Overweight; Paclitaxel; Survival Analysis; Taxoids; Thinness | 2008 |
Randomized phase II trial of erlotinib or standard chemotherapy in patients with advanced non-small-cell lung cancer and a performance status of 2.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carboplatin; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Erlotinib Hydrochloride; Female; Humans; Karnofsky Performance Status; Lung Neoplasms; Male; Paclitaxel; Protein Kinase Inhibitors; Quality of Life; Quinazolines; Surveys and Questionnaires | 2008 |
Induction chemotherapy with paclitaxel and cisplatin, followed by concomitant cisplatin and radiotherapy for the treatment of locally advanced nasopharyngeal carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Cisplatin; Combined Modality Therapy; Disease Progression; Female; Humans; Male; Middle Aged; Nasopharyngeal Neoplasms; Paclitaxel; Patient Compliance; Radiotherapy; Radiotherapy, Adjuvant; Survival Analysis; Treatment Outcome | 2006 |
Quantification of free plasma DNA before and after chemotherapy in patients with advanced epithelial ovarian cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; CA-125 Antigen; Carboplatin; Disease Progression; DNA, Neoplasm; Female; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Ovariectomy; Paclitaxel; Survival Analysis; Treatment Outcome | 2008 |
A multicenter phase II study of biweekly paclitaxel and S-1 combination chemotherapy for unresectable or recurrent gastric cancer.
Topics: Adenocarcinoma; Aged; Alopecia; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Disease-Free Survival; Drug Combinations; Female; Gastrointestinal Diseases; Humans; Hyponatremia; Kaplan-Meier Estimate; Male; Middle Aged; Neutropenia; Oxonic Acid; Paclitaxel; Stomach Neoplasms; Survival Analysis; Tegafur | 2008 |
Phase-II study of weekly schedule of trastuzumab, paclitaxel, and carboplatin followed by a week off every 28 days for HER2+ metastatic breast cancer.
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Disease Progression; Female; Gastrointestinal Diseases; Genes, erbB-2; Half-Life; Hematologic Diseases; Humans; Middle Aged; Paclitaxel; Peripheral Nervous System Diseases; Survival Analysis; Trastuzumab | 2008 |
A phase II multicenter study of oxaliplatin in combination with paclitaxel in poor prognosis patients who failed cisplatin-based chemotherapy for germ-cell tumors.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Female; Humans; Male; Middle Aged; Neoplasms, Germ Cell and Embryonal; Organoplatinum Compounds; Ovarian Neoplasms; Oxaliplatin; Paclitaxel; Recurrence; Testicular Neoplasms | 2008 |
Phase II trial of biweekly paclitaxel plus infusional 5-fluorouracil and leucovorin in patients with advanced or recurrent inoperable gastric cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Drug Administration Schedule; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Paclitaxel; Recurrence; Stomach Neoplasms; Survival Analysis | 2009 |
Trastuzumab plus paclitaxel or docetaxel in HER-2-negative/HER-2 ECD-positive anthracycline- and taxane-refractory advanced breast cancer.
Topics: Adult; Aged; Anthracyclines; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Carrier Proteins; Disease Progression; Docetaxel; Drug Resistance, Neoplasm; Female; Genes, erbB-2; Humans; Middle Aged; Paclitaxel; Survival Analysis; Taxoids; Trastuzumab; Treatment Failure; Treatment Outcome | 2008 |
Bortezomib, paclitaxel, and carboplatin as a first-line regimen for patients with metastatic esophageal, gastric, and gastroesophageal cancer: phase II results from the North Central Cancer Treatment Group (N044B).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Carboplatin; Cardia; Disease Progression; Esophageal Neoplasms; Esophagogastric Junction; Female; Humans; Male; Middle Aged; Paclitaxel; Pyrazines; Stomach Neoplasms; Survival Rate; Treatment Outcome | 2008 |
Phase I trial of docetaxel and thalidomide: a regimen based on metronomic therapeutic principles.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Neovascularization, Pathologic; Paclitaxel; Thalidomide | 2008 |
Serum biomarker profiles and response to neoadjuvant chemotherapy for locally advanced breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Biomarkers, Tumor; Breast Neoplasms; Chemotherapy, Adjuvant; Disease Progression; Doxorubicin; Humans; Hyperthermia, Induced; Multivariate Analysis; Neoadjuvant Therapy; Paclitaxel; Retrospective Studies; Treatment Outcome | 2008 |
High-dose paclitaxel with granulocyte colony-stimulating factor in patients with advanced breast cancer refractory to anthracycline therapy: a European Cancer Center trial.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Breast Neoplasms; Cohort Studies; Disease Progression; Drug Resistance; Female; Granulocyte Colony-Stimulating Factor; Humans; Infusions, Intravenous; Leukopenia; Liver Neoplasms; Middle Aged; Netherlands; Neutropenia; Paclitaxel; Peripheral Nervous System Diseases; Remission Induction; Safety; Thrombocytopenia | 1995 |
Phase II randomized study of paclitaxel versus mitomycin in advanced breast cancer.
Topics: Adult; Aged; Breast Neoplasms; Chemotherapy, Adjuvant; Combined Modality Therapy; Cross-Over Studies; Disease Progression; Female; Humans; Infusions, Intravenous; Middle Aged; Mitomycins; Neoplasm Metastasis; Neutropenia; Paclitaxel; Peripheral Nervous System Diseases; Quality of Life; Remission Induction | 1995 |
Paclitaxel plus carboplatin for advanced lung cancer: preliminary results of a Vanderbilt University phase II trial--LUN-46.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cohort Studies; Disease Progression; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Remission Induction; Survival Rate; Tennessee; Thrombocytopenia | 1995 |
Paclitaxel in metastatic breast cancer: a trial of two doses by a 3-hour infusion in patients with disease recurrence after prior therapy with anthracyclines.
Topics: Adult; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Disease Progression; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Middle Aged; Paclitaxel | 1995 |
Chemotherapy of advanced inoperable non-small cell lung cancer with paclitaxel: a phase II trial.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Disease Progression; Female; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Neutropenia; Paclitaxel; Peripheral Nervous System Diseases; Premedication; Remission Induction | 1995 |
A phase I/II study of paclitaxel plus cisplatin as first-line therapy for head and neck cancers: preliminary results.
Topics: Adult; Aged; Alopecia; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Arthralgia; Carcinoma; Cisplatin; Combined Modality Therapy; Disease Progression; Dose-Response Relationship, Drug; Granulocyte Colony-Stimulating Factor; Head and Neck Neoplasms; Humans; Infusions, Intravenous; Injections, Intravenous; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Paresthesia; Remission Induction; Treatment Outcome | 1995 |
Paclitaxel combined with carboplatin in the first-line treatment of advanced ovarian cancer.
Topics: Adult; Aged; Agranulocytosis; Ambulatory Care; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Disease Progression; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Leukopenia; Middle Aged; Ovarian Neoplasms; Paclitaxel; Peripheral Nervous System Diseases; Remission Induction; Safety; Thrombocytopenia | 1995 |
A phase II study of paclitaxel in advanced breast cancer resistant to anthracyclines.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Disease Progression; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Middle Aged; Paclitaxel; Survival Rate | 1996 |
An ongoing European organization for research and treatment of cancer crossover trial comparing single-agent paclitaxel and doxorubicin as first- and second-line treatment of advanced breast cancer.
Topics: Adenocarcinoma; Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Cross-Over Studies; Disease Progression; Doxorubicin; Europe; Female; Heart Failure; Humans; Infusions, Intravenous; Injections, Intravenous; Middle Aged; Neutropenia; Paclitaxel; Prospective Studies; Remission Induction | 1996 |
Paclitaxel combined with weekly high-dose 5-fluorouracil/folinic acid and cisplatin in the treatment of advanced breast cancer.
Topics: Adult; Aged; Ambulatory Care; Antibiotics, Antineoplastic; Antidotes; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cisplatin; Disease Progression; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Infusions, Intravenous; Leucovorin; Middle Aged; Neoplasm Metastasis; Paclitaxel; Remission Induction; Survival Rate | 1996 |
A phase II study of doxorubicin/paclitaxel plus G-CSF for metastatic breast cancer.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease Progression; Dose-Response Relationship, Drug; Doxorubicin; Female; Follow-Up Studies; Granulocyte Colony-Stimulating Factor; Humans; Liver Neoplasms; Lung Neoplasms; Middle Aged; Neutropenia; Paclitaxel; Survival | 1997 |
Phase I and pharmacologic study of the combination paclitaxel and carboplatin as first-line chemotherapy in stage III and IV ovarian cancer.
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cystadenocarcinoma, Serous; Disease Progression; Female; Humans; Middle Aged; Neoplasm Staging; Neutropenia; Ovarian Neoplasms; Paclitaxel; Peripheral Nervous System Diseases; Thrombocytopenia | 1997 |
Phase I dose escalation of paclitaxel in patients with advanced ovarian cancer receiving cisplatin: rapid development of neurotoxicity is dose-limiting.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; CA-125 Antigen; Carcinoma; Cisplatin; Disease Progression; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Middle Aged; Neutropenia; Ovarian Neoplasms; Paclitaxel; Peripheral Nervous System Diseases; Recombinant Proteins | 1997 |
Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Camptothecin; Disease Progression; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Survival Analysis; Topotecan | 1997 |
ICON 2 and ICON 3 data in previously untreated ovarian cancer: results to date.
Topics: Alopecia; Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Cisplatin; Cyclophosphamide; Disease Progression; Disease-Free Survival; Doxorubicin; Drug Administration Schedule; Female; Humans; Leukopenia; Mucous Membrane; Nausea; Ovarian Neoplasms; Paclitaxel; Survival Rate; Thrombocytopenia; Treatment Outcome; Vomiting | 1997 |
Efficacy and safety of the combination paclitaxel/carboplatin in patients with previously treated advanced ovarian carcinoma: a multicenter French Groupe des Investigateurs Nationaux pour l'Etude des Cancers Ovariens phase II study.
Topics: Adolescent; Adult; Aged; Alopecia; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Carcinoma; Cisplatin; Confidence Intervals; Disease Progression; Female; France; Granulocyte Colony-Stimulating Factor; Humans; Injections, Intravenous; Middle Aged; Nausea; Neoplasm Recurrence, Local; Neoplasm Staging; Neutropenia; Ovarian Neoplasms; Paclitaxel; Peripheral Nervous System Diseases; Remission Induction; Safety; Survival Rate; Thrombocytopenia; Treatment Outcome | 1997 |
Paclitaxel in platinum-resistant ovarian cancer patients. Argentine Multicenter Taxol Group.
Topics: Adult; Aged; Ambulatory Care; Anemia; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Argentina; Biomarkers, Tumor; CA-125 Antigen; Cisplatin; Disease Progression; Drug Resistance, Neoplasm; Female; Humans; Infusions, Intravenous; Microtubules; Middle Aged; Nausea; Neoplasm Recurrence, Local; Neoplasm Staging; Neutropenia; Ovarian Neoplasms; Paclitaxel; Peripheral Nervous System Diseases; Premedication; Remission Induction; Survival Rate; Thrombocytopenia; Vomiting | 1997 |
Dose-escalated paclitaxel in 1-hour infusion with a fixed dose of cisplatin in previously untreated advanced ovarian cancer: a phase II trial of the Spanish Group for Ovarian Cancer.
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Confidence Intervals; Disease Progression; Dose-Response Relationship, Drug; Drug Administration Schedule; Feasibility Studies; Female; Humans; Incidence; Infusions, Intravenous; Laparotomy; Middle Aged; Neoplasm Staging; Neoplasm, Residual; Neoplasms, Glandular and Epithelial; Neutropenia; Ovarian Neoplasms; Paclitaxel; Peripheral Nervous System Diseases; Remission Induction; Reoperation; Spain; Survival Rate; Thrombocytopenia; Treatment Outcome | 1997 |
Paclitaxel with carboplatin versus paclitaxel with carboplatin alternating with cisplatin as first-line chemotherapy in advanced epithelial ovarian cancer: preliminary results of a Hellenic Cooperative Oncology Group study.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Cause of Death; Cisplatin; Combined Modality Therapy; Disease Progression; Drug Administration Schedule; Female; Follow-Up Studies; Greece; Humans; Infusions, Intravenous; Middle Aged; Neoplasm Staging; Neoplasm, Residual; Neoplasms, Glandular and Epithelial; Neutropenia; Ovarian Neoplasms; Paclitaxel; Remission Induction; Survival Rate; Thrombocytopenia | 1997 |
Phase I trial of paclitaxel, carboplatin, and methotrexate with granulocyte colony-stimulating factor and leucovorin in advanced transitional cell carcinoma.
Topics: Administration, Oral; Adult; Aged; Antidotes; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Carcinoma, Transitional Cell; Confidence Intervals; Disease Progression; Drug Administration Schedule; Feasibility Studies; Female; Granulocyte Colony-Stimulating Factor; Humans; Infusions, Intravenous; Leucovorin; Male; Methotrexate; Middle Aged; Neoplasm Staging; Nervous System Diseases; Neutropenia; Paclitaxel; Remission Induction; Salvage Therapy; Sepsis; Urinary Bladder Neoplasms | 1997 |
Paclitaxel, estramustine, and etoposide in the treatment of hormone-refractory prostate cancer.
Topics: Adenocarcinoma; Administration, Oral; Alopecia; Animals; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; DNA Replication; DNA, Neoplasm; Drug Administration Schedule; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Estramustine; Etoposide; Follow-Up Studies; Humans; Infusions, Intravenous; Male; Microtubules; Nuclear Matrix; Paclitaxel; Prostate-Specific Antigen; Prostatic Neoplasms; Rats; Remission Induction; Tumor Cells, Cultured | 1997 |
A trial of outpatient paclitaxel and carboplatin for advanced, recurrent, and histologic high-risk endometrial carcinoma: preliminary report.
Topics: Adult; Aged; Ambulatory Care; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Carcinoma; Cause of Death; Chemotherapy, Adjuvant; Disease Progression; Drug Resistance, Neoplasm; Endometrial Neoplasms; Female; Follow-Up Studies; Humans; Infusions, Intravenous; Leukopenia; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Radiography; Remission Induction; Risk Factors; Salvage Therapy; Sensation Disorders; Survival Rate; Thrombocytopenia | 1997 |
Docetaxel vs doxorubicin in metastatic breast cancer resistant to alkylating chemotherapy.
Topics: Adolescent; Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Bacterial Infections; Breast Neoplasms; Cause of Death; Disease Progression; Disease-Free Survival; Docetaxel; Doxorubicin; Drug Resistance, Neoplasm; Female; Fever; Heart Diseases; Humans; Infusions, Intravenous; Middle Aged; Neoplasm Metastasis; Neutropenia; Paclitaxel; Quality of Life; Remission Induction; Safety; Survival Rate; Taxoids; Thrombocytopenia | 1997 |
Docetaxel vs mitomycin plus vinblastine in anthracycline-resistant metastatic breast cancer.
Topics: Adolescent; Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Constipation; Disease Progression; Disease-Free Survival; Docetaxel; Drug Resistance, Neoplasm; Female; Humans; Infusions, Intravenous; Middle Aged; Mitomycins; Neoplasm Metastasis; Paclitaxel; Quality of Life; Remission Induction; Safety; Survival Rate; Taxoids; Thrombocytopenia; Vinblastine | 1997 |
Phase II study of docetaxel and cisplatin in advanced non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Disease Progression; Docetaxel; Female; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Survival Rate; Taxoids | 1998 |
Phase II study with cisplatin and paclitaxel in combination with weekly high-dose 24 h infusional 5-fluorouracil/leucovorin for first-line treatment of metastatic breast cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Disease Progression; Drug Administration Schedule; Female; Fluorouracil; Follow-Up Studies; Humans; Infusion Pumps; Infusions, Intravenous; Leucovorin; Middle Aged; Paclitaxel; Time Factors | 1998 |
PCV chemotherapy for recurrent oligodendrogliomas and oligoastrocytomas.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cisplatin; Combined Modality Therapy; Disease Progression; Female; Follow-Up Studies; Glioma; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasm Recurrence, Local; Oligodendroglioma; Paclitaxel; Radiotherapy, Adjuvant; Taxoids; Tomography, X-Ray Computed; Treatment Outcome; Vinblastine | 1998 |
Mitoxantrone combined with paclitaxel as salvage therapy for platinum-refractory ovarian cancer: laboratory study and clinical pilot trial.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Cisplatin; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Female; Follow-Up Studies; Humans; Middle Aged; Mitoxantrone; Ovarian Neoplasms; Paclitaxel; Pilot Projects; Remission Induction; Salvage Therapy; Treatment Outcome; Tumor Cells, Cultured | 1997 |
Docetaxel (Taxotere): an active agent in metastatic urothelial cancer; results of a phase II study in non-chemotherapy-pretreated patients.
Topics: Aged; Antineoplastic Agents, Phytogenic; Carcinoma, Transitional Cell; Disease Progression; Docetaxel; Drug Administration Schedule; Edema; Female; Humans; Infusions, Intravenous; Male; Middle Aged; Neutropenia; Paclitaxel; Taxoids; Treatment Outcome; Urologic Neoplasms | 1998 |
Long-term results from a phase II study of single agent paclitaxel (Taxol) in previously platinum treated patients with advanced ovarian cancer: the Nordic experience.
Topics: Adult; Antineoplastic Agents, Phytogenic; Cisplatin; Disease Progression; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Humans; Norway; Ovarian Neoplasms; Paclitaxel; Remission Induction; Salvage Therapy; Survival Analysis; Survival Rate; Treatment Outcome | 1998 |
Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease Progression; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Middle Aged; Paclitaxel; Survival Analysis | 1999 |
Second-line chemotherapy with 96-hour infusional paclitaxel in refractory non-small cell lung cancer: report of a phase II trial.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Disease Progression; Drug Administration Schedule; Female; Humans; Infusion Pumps; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Quality of Life; Retreatment; Survival Rate | 1999 |
Prospective randomized trial of docetaxel versus mitomycin plus vinblastine in patients with metastatic breast cancer progressing despite previous anthracycline-containing chemotherapy. 304 Study Group.
Topics: Adult; Aged; Analysis of Variance; Antineoplastic Agents; Breast Neoplasms; Disease Progression; Docetaxel; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Health Status; Humans; Middle Aged; Mitomycins; Neutropenia; Paclitaxel; Patient Compliance; Proportional Hazards Models; Prospective Studies; Survival Analysis; Taxoids; Thrombocytopenia; Vinblastine | 1999 |
Dose intensification of mitoxantrone in combination with paclitaxel in advanced breast cancer: a phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease Progression; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Humans; Infusions, Intravenous; Lymphatic Metastasis; Middle Aged; Mitoxantrone; Neoplasm Metastasis; Neoplasm Staging; Paclitaxel; Survival Analysis; Time Factors | 1999 |
Vinorelbine and paclitaxel as first-line chemotherapy in metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease Progression; Female; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Prospective Studies; Survival Rate; Vinblastine; Vinorelbine | 1999 |
Paclitaxel and G-CSF in previously untreated patients with extensive stage small-cell lung cancer: a phase II study of the North Central Cancer Treatment Group.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Carcinoma, Small Cell; Disease Progression; Female; Granulocyte Colony-Stimulating Factor; Humans; Lung Neoplasms; Male; Middle Aged; Neutropenia; Paclitaxel; Survival Rate; United States | 1999 |
Docetaxel (Taxotere) in the neo-adjuvant setting in non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Disease Progression; Docetaxel; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Taxoids; Treatment Outcome | 1999 |
Docetaxel compared with sequential methotrexate and 5-fluorouracil in patients with advanced breast cancer after anthracycline failure: a randomised phase III study with crossover on progression by the Scandinavian Breast Group.
Topics: Adult; Aged; Algorithms; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cross-Over Studies; Disease Progression; Docetaxel; Female; Fluorouracil; Humans; Methotrexate; Middle Aged; Paclitaxel; Patient Compliance; Taxoids; Treatment Failure | 1999 |
A phase II study of paclitaxel plus carboplatin as first-line chemotherapy for women with metastatic breast carcinoma.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Disease Progression; Drug Administration Schedule; Female; Humans; Middle Aged; Paclitaxel; Quality of Life; Survival Analysis; Treatment Outcome | 2000 |
Phase II trial of induction high-dose chemotherapy followed by surgical resection and radiation therapy for patients with marginally resectable non-small cell carcinoma of the lung.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Combined Modality Therapy; Disease Progression; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Thoracotomy; Treatment Outcome | 2000 |
Paclitaxel versus doxorubicin as first-line single-agent chemotherapy for metastatic breast cancer: a European Organization for Research and Treatment of Cancer Randomized Study with cross-over.
Topics: Adenocarcinoma; Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Chi-Square Distribution; Cross-Over Studies; Disease Progression; Doxorubicin; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Infusions, Intravenous; Injections, Intravenous; Logistic Models; Middle Aged; Paclitaxel; Proportional Hazards Models; Remission Induction; Survival Rate | 2000 |
Paclitaxel plus vinorelbine: an active regimen in metastatic breast cancer patients with prior anthracycline exposure.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Recurrence; Safety; Time Factors; Vinblastine; Vinorelbine | 2000 |
A phase I trial of 96-hour paclitaxel infusion plus accelerated radiotherapy of unrespectable head and neck cancer.
Topics: Aged; Antineoplastic Agents, Phytogenic; Carcinoma, Squamous Cell; Combined Modality Therapy; Disease Progression; Disease-Free Survival; Dose Fractionation, Radiation; Drug Administration Schedule; Drug Eruptions; Female; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neutropenia; Paclitaxel; Radiation-Sensitizing Agents; Stomatitis | 1999 |
High response rate with a lower dose of paclitaxel in combination with cisplatin in heavily pretreated patients with advanced breast carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Disease Progression; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Middle Aged; Paclitaxel; Treatment Outcome | 2000 |
Combination chemotherapy with docetaxel, cisplatin, and 5-fluorouracil in previously treated patients with advanced/recurrent head and neck cancer: a phase II feasibility study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease Progression; Disease-Free Survival; Docetaxel; Feasibility Studies; Female; Fluorouracil; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neutropenia; Paclitaxel; Recurrence; Taxoids | 2000 |
Radiation and concomitant weekly administration of paclitaxel in patients with glioblastoma multiforme. A phase II study.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Brain Neoplasms; Combined Modality Therapy; Disease Progression; Female; Glioblastoma; Humans; Male; Middle Aged; Paclitaxel; Radiotherapy; Survival Analysis; Time Factors | 1999 |
Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results.
Topics: Adult; Aged; Aged, 80 and over; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Cross-Over Studies; Cyclophosphamide; Disease Progression; Female; Follow-Up Studies; Humans; Middle Aged; Nausea; Neoplasm Staging; Neutropenia; Ovarian Neoplasms; Paclitaxel; Survival Analysis; Thrombocytopenia; Time Factors; Treatment Outcome; Vomiting | 2000 |
Does paclitaxel improve the chemoradiotherapy of locoregionally advanced esophageal cancer? A nonrandomized comparison with fluorouracil-based therapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chi-Square Distribution; Cisplatin; Combined Modality Therapy; Disease Progression; Dose Fractionation, Radiation; Esophageal Neoplasms; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Prognosis; Radiation-Sensitizing Agents; Retrospective Studies; Survival Analysis; Treatment Outcome | 2000 |
Randomized phase II study of docetaxel versus doxorubicin in first- and second-line chemotherapy for locally advanced or metastatic soft tissue sarcomas in adults: a study of the european organization for research and treatment of cancer soft tissue and b
Topics: Adult; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Cross-Over Studies; Disease Progression; Docetaxel; Doxorubicin; Female; Humans; Male; Paclitaxel; Sarcoma; Soft Tissue Neoplasms; Survival Analysis; Taxoids; Treatment Outcome | 2000 |
Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chi-Square Distribution; Cisplatin; Disease Progression; Docetaxel; Female; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Palliative Care; Proportional Hazards Models; Prospective Studies; Quality of Life; Survival Analysis; Taxoids; Treatment Outcome | 2000 |
Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group.
Topics: Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free Survival; Docetaxel; Drug Resistance, Neoplasm; Female; Humans; Ifosfamide; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Survival Analysis; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 2000 |
A phase II study of paclitaxel, carboplatin, and hyperfractionated radiation therapy for locally advanced inoperable non-small-cell lung cancer (a Vanderbilt Cancer Center Affiliate Network Study).
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Disease Progression; Dose Fractionation, Radiation; Drug Administration Schedule; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Prospective Studies; Radiation-Sensitizing Agents; Survival Rate | 2000 |
Randomized trial of paclitaxel plus supportive care versus supportive care for patients with advanced non-small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Disease Progression; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Proportional Hazards Models; Quality of Life; Survival Analysis; Treatment Outcome | 2000 |
Phase II study of paclitaxel and epirubicin as first-line treatment in patients with metastatic nonsmall cell lung carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free Survival; Epirubicin; Female; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Treatment Outcome; Ventricular Fibrillation | 2000 |
A phase II trial of palliative docetaxel plus 5-fluorouracil for squamous-cell cancer of the head and neck.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Disease Progression; Docetaxel; Female; Fluorouracil; Head and Neck Neoplasms; Humans; Male; Middle Aged; Paclitaxel; Palliative Care; Taxoids; Treatment Outcome | 2000 |
Phase II study of docetaxel in patients with liver metastases from breast cancer. UK study group.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Disease Progression; Docetaxel; Female; Humans; Liver Neoplasms; Middle Aged; Paclitaxel; Taxoids; Treatment Outcome | 2000 |
Ifosfamide plus oral etoposide salvage chemotherapy for platinum-resistant paclitaxel-pretreated ovarian cancer.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Drug Resistance, Neoplasm; Etoposide; Female; Humans; Ifosfamide; Infusions, Intravenous; Middle Aged; Ovarian Neoplasms; Paclitaxel; Prognosis; Salvage Therapy; Survival Analysis | 2000 |
Frontline treatment of advanced gastric cancer with docetaxel and granulocyte colony-stimulating factor (G-CSF): a phase II trial.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents, Phytogenic; Chemotherapy, Adjuvant; Confidence Intervals; Disease Progression; Docetaxel; Female; Fever; Follow-Up Studies; Gastrectomy; Granulocyte Colony-Stimulating Factor; Humans; Infusions, Intravenous; Male; Middle Aged; Neutropenia; Paclitaxel; Remission Induction; Stomach Neoplasms; Survival Rate; Taxoids; Treatment Outcome | 2000 |
[A comparative randomized phase-II study of Xeloda (capecitabine) and paclitaxel in patients with breast cancer progressing after anthracycline antibiotics].
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Australia; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease Progression; Europe; Female; Fluorouracil; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Treatment Failure; United States | 2000 |
Paclitaxel (175 mg/m2) plus carboplatin (6 AUC) versus paclitaxel (225 mg/m2) plus carboplatin (6 AUC) in advanced non-small-cell lung cancer (NSCLC): a multicenter randomized trial. Hellenic Cooperative Oncology Group (HeCOG).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Carcinoma, Non-Small-Cell Lung; Disease Progression; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Leukopenia; Lung Neoplasms; Male; Middle Aged; Nervous System Diseases; Paclitaxel; Prognosis; Survival Analysis; Treatment Outcome | 2000 |
Phase I dose escalation study of gemcitabine and paclitaxel plus colony-stimulating factors in previously treated patients with advanced breast and ovarian cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Disease Progression; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gemcitabine; Granulocyte Colony-Stimulating Factor; Humans; Middle Aged; Neutropenia; Ovarian Neoplasms; Paclitaxel; Thrombocytopenia | 2000 |
Epidoxorubicin and docetaxel as first-line chemotherapy in patients with advanced breast cancer: a multicentric phase I-II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease Progression; Disease-Free Survival; Docetaxel; Epirubicin; Female; Granulocyte Colony-Stimulating Factor; Humans; Middle Aged; Neutropenia; Paclitaxel; Taxoids; Treatment Outcome | 2000 |
Repetitive high-dose therapy with cyclophosphamide, thiotepa and docetaxel with peripheral blood progenitor cell and filgrastim support for metastatic and locally advanced breast cancer: results of a phase I study.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Diarrhea; Disease Progression; Docetaxel; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Lung Diseases, Interstitial; Middle Aged; Neoplasm Metastasis; Neutropenia; Paclitaxel; Recombinant Proteins; Remission Induction; Stomatitis; Survival Analysis; Taxoids; Thiotepa; Thrombocytopenia; Transplantation Conditioning | 2000 |
Phase II study of paclitaxel in patients with metastatic breast carcinoma refractory to standard chemotherapy.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Breast Neoplasms, Male; Disease Progression; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Male; Middle Aged; Neoplasm Metastasis; Paclitaxel | 2000 |
Topotecan and gemcitabine in platinum/paclitaxel-resistant ovarian cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Blood Cell Count; Cisplatin; Deoxycytidine; Disease Progression; Drug Administration Schedule; Drug Resistance, Neoplasm; Enzyme Inhibitors; Female; Gemcitabine; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel; Recurrence; Topotecan; Treatment Outcome | 2001 |
Phase II clinical trials of cisplatin-then-paclitaxel and paclitaxel-then-cisplatin in patients with previously untreated advanced epithelial ovarian cancer.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease Progression; Drug Administration Schedule; Female; Humans; Middle Aged; Nervous System Diseases; Ovarian Neoplasms; Paclitaxel | 2000 |
Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.
Topics: Adult; Aged; Anthracyclines; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Disease Progression; Doxorubicin; Epirubicin; Female; Heart Diseases; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Receptor, ErbB-2; Survival Analysis; Trastuzumab | 2001 |
Treatment of pancreatic cancer with a combination of docetaxel, gemcitabine and granulocyte colony-stimulating factor: a phase II study of the Greek Cooperative Group for Pancreatic Cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease Progression; Docetaxel; Female; Gemcitabine; Granulocyte Colony-Stimulating Factor; Humans; Infusions, Intravenous; Male; Middle Aged; Paclitaxel; Pancreatic Neoplasms; Taxoids; Treatment Outcome | 2001 |
High-dose thiotepa and melphalan with hemopoietic progenitor support following induction therapy with epirubicin-paclitaxel-containing regimens in metastatic breast cancer (MBC).
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Disease Progression; Epirubicin; Female; Gemcitabine; Hematopoietic Stem Cell Transplantation; Humans; Melphalan; Middle Aged; Paclitaxel; Survival Analysis; Thiotepa; Treatment Outcome | 2001 |
Second-line chemotherapy for non-small-cell lung cancer with monthly docetaxel and weekly gemcitabine: a phase II trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease Progression; Docetaxel; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Survival Analysis; Taxoids; Treatment Outcome | 2001 |
Doxorubicin and paclitaxel versus fluorouracil, doxorubicin, and cyclophosphamide as first-line therapy for women with metastatic breast cancer: final results of a randomized phase III multicenter trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Disease Progression; Doxorubicin; Female; Fluorouracil; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Survival Analysis; Treatment Outcome | 2001 |
Adenovirus-mediated wild-type p53 gene transfer in patients receiving chemotherapy for advanced non-small-cell lung cancer: results of a multicenter phase II study.
Topics: Adenoviridae; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Disease Progression; Female; Genes, p53; Genetic Therapy; Genetic Vectors; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Survival Analysis; Treatment Outcome | 2001 |
Dose-dense sequential chemotherapy with epirubicin and paclitaxel in advanced breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Confidence Intervals; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Epirubicin; Female; Greece; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Receptors, Estrogen; Receptors, Progesterone; Survival Analysis | 2001 |
A Phase II study of high-dose paclitaxel in patients with advanced neuroendocrine tumors.
Topics: Adenoma, Islet Cell; Adult; Aged; Antineoplastic Agents, Phytogenic; Carcinoid Tumor; Disease Progression; Disease-Free Survival; Female; Granulocyte Colony-Stimulating Factor; Humans; Infusions, Intravenous; Male; Middle Aged; Neutropenia; Paclitaxel; Pancreatic Neoplasms; Treatment Outcome | 2001 |
Dose-dense sequential chemotherapy with epirubicin and paclitaxel versus the combination, as first-line chemotherapy, in advanced breast cancer: a randomized study conducted by the Hellenic Cooperative Oncology Group.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease Progression; Dose-Response Relationship, Drug; Drug Administration Schedule; Epirubicin; Female; Granulocyte Colony-Stimulating Factor; Humans; Male; Middle Aged; Neutropenia; Paclitaxel; Survival Analysis; Treatment Outcome | 2001 |
Docetaxel in combination with gemcitabine plus rhG-CSF support as second-line treatment in non-small cell lung cancer. A multicenter phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Disease Progression; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Gemcitabine; Granulocyte Colony-Stimulating Factor; Hematologic Diseases; Humans; Life Tables; Lung Neoplasms; Male; Middle Aged; Neutropenia; Paclitaxel; Recombinant Proteins; Salvage Therapy; Survival Analysis; Survival Rate; Taxoids; Treatment Outcome | 2001 |
High incidence of central nervous system involvement in patients with metastatic or locally advanced breast cancer treated with epirubicin and docetaxel.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Breast Neoplasms; Disease Progression; Docetaxel; Epirubicin; Female; Humans; Incidence; Liver Neoplasms; Middle Aged; Paclitaxel; Receptor, ErbB-2; Receptors, Estrogen; Retrospective Studies; Taxoids | 2001 |
Efficacy of monochemotherapy with docetaxel (taxotere) in relation to prolactin secretion in heavily pretreated metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Bone Neoplasms; Breast Neoplasms; Disease Progression; Docetaxel; Female; Humans; Hyperprolactinemia; Injections, Intravenous; Liver Neoplasms; Lung Neoplasms; Middle Aged; Paclitaxel; Prolactin; Remission Induction; Taxoids | 2001 |
Mitoxantrone and paclitaxel combination chemotherapy in metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease Progression; Disease-Free Survival; Female; Humans; Infusions, Intravenous; Middle Aged; Mitoxantrone; Neoplasm Metastasis; Neutropenia; Paclitaxel; Prognosis; Treatment Outcome | 2001 |
A Phase II study of docetaxel and carboplatin in the treatment of non-small cell lung cancer.
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free Survival; Docetaxel; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Neutropenia; Paclitaxel; Taxoids; Treatment Outcome | 2001 |
Phase I trial of weekly paclitaxel plus oral estramustine phosphate in patients with hormone-refractory prostate cancer.
Topics: Adenocarcinoma; Administration, Oral; Aged; Aged, 80 and over; Anaphylaxis; Antineoplastic Combined Chemotherapy Protocols; Chemical and Drug Induced Liver Injury; Disease Progression; Disease-Free Survival; Drug Resistance, Neoplasm; Edema; Estramustine; Gonadotropin-Releasing Hormone; Humans; Infusions, Intravenous; Male; Middle Aged; Nausea; Paclitaxel; Prostatic Neoplasms; Thrombophlebitis; Treatment Outcome | 2001 |
Long-term results from a phase II study of paclitaxel combined with doxorubicin in recurrent platinum refractory ovarian cancer.
Topics: Adult; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease Progression; Disease-Free Survival; Doxorubicin; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Infusions, Intravenous; Middle Aged; Ovarian Neoplasms; Paclitaxel; Survival Analysis; Treatment Outcome | 2001 |
Pilot study of sequential vinorelbine and cisplatin followed by docetaxel for selected IIIB and stage IV non-small cell lung cancer.
Topics: Acute Kidney Injury; Aged; Aged, 80 and over; Agranulocytosis; Anemia; Antineoplastic Combined Chemotherapy Protocols; Back Pain; Carcinoma, Non-Small-Cell Lung; Cisplatin; Disease Progression; Docetaxel; Drug Administration Schedule; Female; Humans; Lung Neoplasms; Male; Middle Aged; Myocardial Infarction; Paclitaxel; Survival Analysis; Taxoids; Thrombocytopenia; Treatment Outcome; Vinblastine; Vinorelbine | 2001 |
Primary chemotherapy in stage IV ovarian cancer. A prospective phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cyclophosphamide; Cystadenocarcinoma; Disease Progression; Epirubicin; Female; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel; Prospective Studies; Survival Rate | 2001 |
Phase II study of weekly docetaxel in symptomatic androgen-independent prostate cancer.
Topics: Aged; Aged, 80 and over; Analgesics; Antineoplastic Agents, Phytogenic; Disease Progression; Docetaxel; Drug Administration Schedule; Humans; Infusions, Intravenous; Male; Middle Aged; Paclitaxel; Pain; Prostate-Specific Antigen; Prostatic Neoplasms; Taxoids | 2001 |
Docetaxel as rescue medication in anthracycline- and ifosfamide-resistant locally advanced or metastatic soft tissue sarcoma: results of a phase II trial.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Child; Child, Preschool; Disease Progression; Docetaxel; Drug Resistance, Neoplasm; Female; Humans; Ifosfamide; Male; Neoplasm Metastasis; Neoplasm Recurrence, Local; Paclitaxel; Prognosis; Sarcoma; Soft Tissue Neoplasms; Taxoids; Treatment Outcome | 2001 |
Outcome of patients with a performance status of 2 in Eastern Cooperative Oncology Group Study E1594: a Phase II trial in patients with metastatic nonsmall cell lung carcinoma .
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Disease Progression; Docetaxel; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Patient Selection; Prognosis; Risk Factors; Severity of Illness Index; Survival Analysis; Taxoids | 2001 |
Phase II evaluation of paclitaxel in combination with carboplatin in advanced head and neck carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Disease Progression; Female; Granulocyte Colony-Stimulating Factor; Head and Neck Neoplasms; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Paclitaxel; Survival Analysis; Thrombocytopenia; Treatment Outcome | 2001 |
Sequential therapy in advanced non-small-cell lung cancer with weekly paclitaxel followed by cisplatin-gemcitabine-vinorelbine. A phase II study.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Neutropenia; Paclitaxel; Peripheral Nervous System Diseases; Treatment Outcome; Vinblastine | 2001 |
A phase II study of paclitaxel plus cisplatin for advanced non-small-cell lung cancer in Japanese patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Disease Progression; Female; Humans; Hypotension; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Neutropenia; Paclitaxel; Peripheral Nervous System Diseases; Survival Analysis; Treatment Outcome | 2001 |
Phase II trial of weekly paclitaxel in patients with previously treated advanced urothelial cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Carcinoma; Disease Progression; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Male; Middle Aged; Paclitaxel; Survival Analysis; Treatment Outcome; Ureteral Neoplasms; Urinary Bladder Neoplasms | 2002 |
Paclitaxel plus carboplatin, compared with paclitaxel plus gemcitabine, shows similar efficacy while more cost-effective: a randomized phase II study of combination chemotherapy against inoperable non-small-cell lung cancer previously untreated.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cost-Benefit Analysis; Deoxycytidine; Disease Progression; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Survival Rate; Time Factors | 2002 |
Phase II study of bi-weekly administration of paclitaxel and cisplatin in patients with advanced oesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease Progression; Drug Administration Schedule; Esophageal Neoplasms; Esophagogastric Junction; Female; Humans; Infusions, Intravenous; Male; Middle Aged; Nervous System; Neutropenia; Paclitaxel; Survival Analysis; Treatment Outcome | 2002 |
Sequential or alternating administration of docetaxel (Taxotere) combined with FEC in metastatic breast cancer: a randomised phase II trial.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Disease Progression; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Epirubicin; Female; Fluorouracil; Humans; Middle Aged; Neoplasm Metastasis; Neutropenia; Paclitaxel; Taxoids; Treatment Outcome | 2002 |
Safety and efficacy of the multidrug resistance inhibitor Incel (biricodar; VX-710) in combination with paclitaxel for advanced breast cancer refractory to paclitaxel.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B, Member 1; Breast Neoplasms; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; Humans; Male; Middle Aged; Multidrug Resistance-Associated Proteins; Neoplasm Recurrence, Local; Paclitaxel; Piperidines; Pyridines; Safety; Time Factors; Tissue Distribution; Treatment Outcome | 2002 |
Phase II Trial of docetaxel and cisplatin combination chemotherapy in patients with squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease Progression; Docetaxel; Female; Head and Neck Neoplasms; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Paclitaxel; Survival Rate; Taxoids; Treatment Outcome | 2002 |
Phase II trial of gemcitabine/doxorubicin/paclitaxel administered every other week in patients with metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Disease Progression; Doxorubicin; Drug Administration Schedule; Drug Monitoring; Female; Follow-Up Studies; Gemcitabine; Heart; Humans; Middle Aged; Neutropenia; Paclitaxel; Survival Rate; Treatment Outcome | 2000 |
Paclitaxel, 5-fluorouracil, and leucovorin (TFL) in the treatment of metastatic breast cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Disease Progression; Drug Administration Schedule; Drug Monitoring; Female; Fluorouracil; Follow-Up Studies; Humans; Leucovorin; Middle Aged; Paclitaxel; Proportional Hazards Models; Soft Tissue Neoplasms; Survival Analysis; Time Factors; Treatment Outcome; Viscera | 2000 |
Phase II study of weekly docetaxel and trastuzumab for patients with HER-2-overexpressing metastatic breast cancer.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease Progression; Docetaxel; Drug Administration Schedule; Female; Gene Expression Regulation, Neoplastic; Humans; In Situ Hybridization, Fluorescence; Middle Aged; Paclitaxel; Receptor, ErbB-2; Taxoids; Time Factors; Trastuzumab; Treatment Outcome; Up-Regulation | 2002 |
HER-2 profiling and targeting in prostate carcinoma.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Disease Progression; Gene Expression Regulation, Neoplastic; Humans; Infusions, Intravenous; Male; Middle Aged; Paclitaxel; Prostate-Specific Antigen; Prostatic Neoplasms; Receptor, ErbB-2; Trastuzumab; Treatment Outcome | 2002 |
Phase II evaluation of docetaxel plus one-day oral estramustine phosphate in the treatment of patients with androgen independent prostate carcinoma.
Topics: Adenocarcinoma; Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Docetaxel; Estramustine; Humans; Infusions, Intravenous; Male; Middle Aged; Paclitaxel; Prostate-Specific Antigen; Prostatic Neoplasms; Taxoids; Treatment Outcome | 2002 |
A Phase II study of paclitaxel by 24-hour infusion and ifosfamide in anthracycline-resistant metastatic breast carcinoma.
Topics: Adult; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease Progression; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Ifosfamide; Infusions, Intravenous; Leukopenia; Male; Middle Aged; Neoplasm Metastasis; Paclitaxel; Survival Rate | 2002 |
Neoadjuvant treatment of locally advanced carcinoma of the uterine cervix with epirubicin, paclitaxel and cisplatin.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease Progression; Disease-Free Survival; Epirubicin; Female; Humans; Middle Aged; Neoplasm Staging; Paclitaxel; Treatment Outcome; Uterine Cervical Neoplasms | 2002 |
Docetaxel and carboplatin as second-line chemotherapy for metastatic non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free Survival; Docetaxel; Female; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Pilot Projects; Survival Rate; Taxoids; Treatment Outcome | 2002 |
Intensive chemotherapy with whole blood stem-cell support and concurrent chest radiotherapy in small cell lung cancer: a phase I/II trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Small Cell; Chi-Square Distribution; Combined Modality Therapy; Disease Progression; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Ifosfamide; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Prospective Studies; Radiotherapy Dosage; Survival Analysis; Treatment Outcome | 2002 |
Combination of ifosfamide, paclitaxel, and cisplatin for the treatment of metastatic and recurrent carcinoma of the uterine cervix: a phase II study of the Hellenic Cooperative Oncology Group.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease Progression; Drug Administration Schedule; Female; Humans; Ifosfamide; Infusions, Intravenous; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Outpatients; Paclitaxel; Prospective Studies; Survival Rate; Uterine Cervical Neoplasms | 2002 |
A pilot trial of G3139, a bcl-2 antisense oligonucleotide, and paclitaxel in patients with chemorefractory small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Disease Progression; Drug Resistance, Neoplasm; Female; Genes, bcl-2; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Oligonucleotides, Antisense; Paclitaxel; Thionucleotides; Treatment Outcome | 2002 |
Tumour microvessel density as predictor of chemotherapy response in breast cancer patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease Progression; Disease-Free Survival; Docetaxel; Female; Fluorouracil; Humans; Methotrexate; Neovascularization, Pathologic; Paclitaxel; Prognosis; Taxoids; Time Factors; Treatment Outcome | 2002 |
247 other study(ies) available for paclitaxel and Disease Exacerbation
| Article | Year |
|---|---|
Improved synthesis of 6-epi-dictyostatin and antitumor efficacy in mice bearing MDA-MB231 human breast cancer xenografts.
Topics: Animals; Body Weight; Breast Neoplasms; Cell Line, Tumor; Disease Progression; Female; Humans; Macrolides; Mice; Xenograft Model Antitumor Assays | 2008 |
CMBs carrying PTX and CRISPR/Cas9 targeting
Topics: Antineoplastic Agents, Phytogenic; Cell Line, Tumor; Cell Proliferation; CRISPR-Cas Systems; Cyclin-Dependent Kinase Inhibitor p21; Disease Progression; Drug Therapy; Endometrial Neoplasms; Female; Gene Editing; Gene Expression Regulation, Neoplastic; Gene Knockout Techniques; Humans; Microbubbles; Paclitaxel; Plasmids; Proliferating Cell Nuclear Antigen; Receptor, ErbB-2 | 2021 |
Multicenter Retrospective Study of Weekly Cetuximab Plus Paclitaxel for Recurrent or Metastatic Oral Squamous Cell Carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cetuximab; Disease Progression; Drug Administration Schedule; Female; Humans; Japan; Male; Middle Aged; Mouth Neoplasms; Neoplasm Recurrence, Local; Paclitaxel; Progression-Free Survival; Retrospective Studies; Squamous Cell Carcinoma of Head and Neck; Time Factors | 2021 |
Impact of previous nivolumab treatment on the response to taxanes in patients with recurrent/metastatic head and neck squamous cell carcinoma.
Topics: Aged; Bridged-Ring Compounds; Disease Progression; Docetaxel; Female; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Nivolumab; Paclitaxel; Retrospective Studies; Squamous Cell Carcinoma of Head and Neck; Taxoids; Treatment Outcome | 2021 |
The impact of SBF2 on taxane-induced peripheral neuropathy.
Topics: Black or African American; Cell Survival; Disease Progression; Female; Gene Knockdown Techniques; Humans; Induced Pluripotent Stem Cells; Paclitaxel; Peripheral Nervous System Diseases; Polymorphism, Single Nucleotide; Protein Tyrosine Phosphatases, Non-Receptor; Quality of Life; Sensory Receptor Cells; Sequence Analysis, RNA; Single-Cell Analysis; White People | 2022 |
Combination therapy with topotecan, paclitaxel, and bevacizumab improves progression-free survival in patients with recurrent high-grade neuroendocrine cervical cancer: a Neuroendocrine Cervical Tumor Registry (NeCTuR) study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Cervix Uteri; Cisplatin; Disease Progression; Female; Humans; Neoplasm Recurrence, Local; Paclitaxel; Progression-Free Survival; Registries; Retrospective Studies; Topotecan; Uterine Cervical Neoplasms | 2023 |
Multistate Pharmacometric Model to Define the Impact of Second-Line Immunotherapies on the Survival Outcome of the IMpower131 Study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Disease Progression; Humans; Immunotherapy; Lung Neoplasms; Paclitaxel | 2023 |
Synergistic cytotoxicity and co-autophagy inhibition in pancreatic tumor cells and cancer-associated fibroblasts by dual functional peptide-modified liposomes.
Topics: Animals; Antineoplastic Agents; Autophagy; Cancer-Associated Fibroblasts; Carcinoma, Pancreatic Ductal; Disease Progression; Female; Fibrosis; Humans; Hydroxychloroquine; Irinotecan; Liposomes; Mice; Mice, Nude; Nanomedicine; Neoplasm Metastasis; Neoplasm Transplantation; NIH 3T3 Cells; Paclitaxel; Pancreatic Neoplasms; Peptides; Wound Healing | 2019 |
SNHG22 overexpression indicates poor prognosis and induces chemotherapy resistance via the miR-2467/Gal-1 signaling pathway in epithelial ovarian carcinoma.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Ovarian Epithelial; Cisplatin; Disease Progression; Drug Resistance, Neoplasm; Female; Galectin 1; Gene Expression Regulation, Neoplastic; Humans; MicroRNAs; Middle Aged; Ovarian Neoplasms; Paclitaxel; Prognosis; RNA, Long Noncoding; Signal Transduction | 2019 |
Stromal-targeting radioimmunotherapy mitigates the progression of therapy-resistant tumors.
Topics: Adenocarcinoma; Animals; Disease Progression; Doxorubicin; Female; Lectins, C-Type; Macrophages; Mammary Neoplasms, Experimental; Mannose Receptor; Mannose-Binding Lectins; Mice; Mice, Inbred BALB C; Paclitaxel; Radioimmunotherapy; Receptors, Cell Surface; Single-Domain Antibodies; Stromal Cells | 2019 |
A novel strategy to block mitotic progression for targeted therapy.
Topics: Animals; Apoptosis; Breast Neoplasms; Cell Cycle Proteins; Cell Line, Tumor; Disease Progression; Drug Resistance, Neoplasm; Female; Humans; Mice, Inbred BALB C; Mitosis; Models, Biological; Models, Molecular; Molecular Targeted Therapy; Neoplasm Proteins; Paclitaxel; Prognosis; Proteasome Endopeptidase Complex; Proteolysis; Ubiquitin; Xenograft Model Antitumor Assays | 2019 |
Intraperitoneal Chemotherapy: The Lived Experiences of Taiwanese Patients With Ovarian Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease Progression; Female; Humans; Infusions, Parenteral; Middle Aged; Ovarian Neoplasms; Paclitaxel; Social Isolation; Social Support; Taiwan | 2019 |
Hyperprogressive Disease in Patients With Urothelial Carcinoma or Renal Cell Carcinoma Treated With PD-1/PD-L1 Inhibitors.
Topics: Aged; B7-H1 Antigen; Carcinoma, Renal Cell; Carcinoma, Transitional Cell; Creatinine; Disease Progression; Female; Follow-Up Studies; Humans; Immune Checkpoint Inhibitors; Incidence; Kidney Neoplasms; Male; Middle Aged; Paclitaxel; Programmed Cell Death 1 Receptor; Progression-Free Survival; Time Factors; Tumor Burden; Urinary Bladder Neoplasms | 2020 |
Hsa_circ_0002483 inhibited the progression and enhanced the Taxol sensitivity of non-small cell lung cancer by targeting miR-182-5p.
Topics: A549 Cells; Animals; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Cell Proliferation; Disease Progression; Drug Resistance, Neoplasm; Female; Forkhead Box Protein O1; Forkhead Box Protein O3; Gene Expression Regulation, Neoplastic; GRB2 Adaptor Protein; Heterografts; Humans; Male; Mice; MicroRNAs; Paclitaxel; RNA, Circular | 2019 |
Treatment and outcomes of a Danish ovarian cancer population.
Topics: Adult; Aged; Antineoplastic Agents; Carboplatin; Denmark; Disease Progression; Doxorubicin; Female; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Polyethylene Glycols; Retrospective Studies; Treatment Outcome | 2020 |
Cytotoxic chemotherapy in advanced non-small cell lung cancer with poor performance status: A retrospective analysis from routine clinical practice.
Topics: Adenocarcinoma of Lung; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Disease Progression; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Prognosis; Retrospective Studies; Survival Rate | 2020 |
Paclitaxel-loaded expansile nanoparticles improve survival following cytoreductive surgery in pleural mesothelioma xenografts.
Topics: Animals; Cell Line, Tumor; Combined Modality Therapy; Cytoreduction Surgical Procedures; Disease Models, Animal; Disease Progression; Humans; Lung Neoplasms; Mesothelioma; Mesothelioma, Malignant; Mice; Nanoparticles; Paclitaxel; Pleural Neoplasms; Pneumonectomy; Tumor Burden; Xenograft Model Antitumor Assays | 2020 |
Epigenetic Switch-Induced Viral Mimicry Evasion in Chemotherapy-Resistant Breast Cancer.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Chromatin Immunoprecipitation Sequencing; Disease Progression; DNA Methylation; DNA Transposable Elements; Drug Resistance, Neoplasm; Enhancer of Zeste Homolog 2 Protein; Epigenesis, Genetic; Female; Humans; Mice; Molecular Mimicry; Paclitaxel; RNA, Double-Stranded; Triple Negative Breast Neoplasms; Tumor Escape; Xenograft Model Antitumor Assays | 2020 |
CELF6 modulates triple-negative breast cancer progression by regulating the stability of FBP1 mRNA.
Topics: 3' Untranslated Regions; Antineoplastic Agents, Phytogenic; CELF Proteins; Cell Line, Tumor; Cell Movement; Disease Progression; Drug Resistance, Neoplasm; Female; Fructose-Bisphosphatase; Gene Knockdown Techniques; Genes, Reporter; Humans; Neoplasm Invasiveness; Neoplasm Proteins; Paclitaxel; RNA Stability; RNA, Messenger; RNA, Neoplasm; RNA, Small Interfering; Triple Negative Breast Neoplasms; Up-Regulation | 2020 |
Bevacizumab as maintenance treatment in BRCA mutated patients with advanced ovarian cancer: A large, retrospective, multicenter case-control study.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; BRCA1 Protein; BRCA2 Protein; Carboplatin; Case-Control Studies; Chemotherapy, Adjuvant; Cytoreduction Surgical Procedures; Disease Progression; Female; Humans; Maintenance Chemotherapy; Middle Aged; Mutation; Ovarian Neoplasms; Ovary; Paclitaxel; Progression-Free Survival; Retrospective Studies | 2020 |
Variants of
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Disease Progression; Female; Humans; Lung Neoplasms; Male; Middle Aged; Organic Cation Transport Proteins; Paclitaxel; Pemetrexed; Polymorphism, Single Nucleotide; Treatment Outcome | 2020 |
Silencing long non-coding RNA H19 combined with paclitaxel inhibits nasopharyngeal carcinoma progression.
Topics: Animals; Cell Line, Tumor; Cell Proliferation; Disease Progression; Gene Silencing; Humans; Mice; Mice, Nude; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Paclitaxel; RNA, Long Noncoding; Xenograft Model Antitumor Assays | 2020 |
Clinical outcomes of FOLFIRINOX and gemcitabine-nab paclitaxel for metastatic pancreatic cancer in the real world setting.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cause of Death; Deoxycytidine; Disease Progression; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Retrospective Studies; Survival Rate | 2021 |
Cost-effectiveness analysis of nab-paclitaxel plus gemcitabine versus folfirinox in the treatment of metastatic pancreatic cancer in china.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; China; Cost-Benefit Analysis; Deoxycytidine; Disease Progression; Fluorouracil; Gemcitabine; Health Care Costs; Hospitalization; Humans; Irinotecan; Leucovorin; Markov Chains; Neoplasm Metastasis; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Quality-Adjusted Life Years; Survival Rate | 2021 |
Clinical Utility of Pancreatic Cancer Circulating Tumor DNA in Predicting Disease Progression, Prognosis, and Response to Chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Albumins; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Circulating Tumor DNA; Deoxycytidine; Disease Progression; Female; Gemcitabine; High-Throughput Nucleotide Sequencing; Humans; Male; Middle Aged; Mutation; Paclitaxel; Pancreatic Neoplasms; Prognosis; Proto-Oncogene Proteins p21(ras); Survival Analysis | 2020 |
Complete response with combined BRAF and MEK inhibition in BRAF mutated advanced low-grade serous ovarian carcinoma.
Topics: Antineoplastic Agents; Benzimidazoles; Bevacizumab; CA-125 Antigen; Carbamates; Carboplatin; Cystadenocarcinoma, Serous; Disease Progression; Everolimus; Female; High-Throughput Nucleotide Sequencing; Humans; Imidazoles; MAP Kinase Kinase 1; Medroxyprogesterone; Mutation; Neoplasm Metastasis; Neoplasm Recurrence, Local; Ovarian Neoplasms; Oximes; Paclitaxel; Progression-Free Survival; Proto-Oncogene Proteins B-raf; Pyridones; Pyrimidinones; Recurrence; Sulfonamides; Tamoxifen; Treatment Outcome; Young Adult | 2020 |
LPCAT1 enhances castration resistant prostate cancer progression via increased mRNA synthesis and PAF production.
Topics: 1-Acylglycerophosphocholine O-Acyltransferase; Animals; Cell Line, Tumor; Cell Movement; Cell Proliferation; Disease Progression; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Humans; Imidazoles; Indoles; Male; Mice; Paclitaxel; PC-3 Cells; Platelet Activating Factor; Prostatic Neoplasms, Castration-Resistant; Up-Regulation | 2020 |
Overexpressed COL5A1 is correlated with tumor progression, paclitaxel resistance, and tumor-infiltrating immune cells in ovarian cancer.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Movement; Cell Proliferation; Collagen Type V; Databases, Genetic; Disease Progression; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Humans; Lymphocytes, Tumor-Infiltrating; Neoplasm Invasiveness; Ovarian Neoplasms; Paclitaxel; Tumor Microenvironment; Up-Regulation | 2021 |
Outcomes on anti-VEGFR-2/paclitaxel treatment after progression on immune checkpoint inhibition in patients with metastatic gastroesophageal adenocarcinoma.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Gastrointestinal Neoplasms; Humans; Immune Checkpoint Inhibitors; Male; Middle Aged; Neoplasm Metastasis; Paclitaxel; Pilot Projects; Prospective Studies; Ramucirumab; Survival Analysis; T-Lymphocytes, Regulatory; Treatment Outcome; Tumor Burden; Tumor Microenvironment | 2021 |
GDI2 is a target of paclitaxel that affects tumorigenesis of prostate cancer via the p75NTR signaling pathway.
Topics: Apoptosis; Carcinogenesis; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Disease Progression; Drug Evaluation, Preclinical; Gene Expression Regulation, Neoplastic; Guanine Nucleotide Dissociation Inhibitors; Humans; Male; Nerve Tissue Proteins; Paclitaxel; Prostatic Neoplasms; Receptors, Nerve Growth Factor; Signal Transduction; Up-Regulation | 2021 |
Cetuximab combined with paclitaxel or paclitaxel alone for patients with recurrent or metastatic head and neck squamous cell carcinoma progressing after EXTREME.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cetuximab; Confidence Intervals; Disease Progression; Female; Fluorouracil; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Platinum Compounds; Progression-Free Survival; Propensity Score; Retrospective Studies; Squamous Cell Carcinoma of Head and Neck | 2021 |
Impact of Maintenance Therapy for Patients with Non-small Cell Lung Cancer in a Real-world Setting.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Disease Progression; Female; Humans; Lung Neoplasms; Male; Middle Aged; Multivariate Analysis; Organoplatinum Compounds; Paclitaxel; Pemetrexed; Prospective Studies; Research Design; Treatment Outcome | 2017 |
Antitumor activity and safety profile of weekly carboplatin plus paclitaxel in metastatic breast cancer: a ten-year, monocentric, retrospective study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Carboplatin; Disease Progression; Drug Administration Schedule; Female; Humans; Kaplan-Meier Estimate; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Paclitaxel; Prognosis; Proportional Hazards Models; Retrospective Studies; Treatment Outcome | 2017 |
Therapeutic utility of natural estrogen receptor beta agonists on ovarian cancer.
Topics: Animals; Antineoplastic Agents, Hormonal; Apoptosis; Biological Products; Cell Line, Tumor; Cell Movement; Cell Survival; Cisplatin; Disease Models, Animal; Disease Progression; Drug Resistance, Neoplasm; Estrogen Receptor beta; Estrogens; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Mice; NF-kappa B; Ovarian Neoplasms; Paclitaxel; Signal Transduction; Xenograft Model Antitumor Assays | 2017 |
Does "OPTINAB" strategy ("stop-and-go") work in treatment of advanced pancreatic cancer (APC) with nab-paclitaxel-gemcitabine?
Topics: Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; CA-19-9 Antigen; Deoxycytidine; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Female; Gemcitabine; Humans; Male; Middle Aged; Paclitaxel; Pancreatic Neoplasms; Peripheral Nervous System Diseases; Retrospective Studies; Survival Rate | 2017 |
Kinase-driven metabolic signalling as a predictor of response to carboplatin-paclitaxel adjuvant treatment in advanced ovarian cancers.
Topics: Adult; Aged; Aged, 80 and over; AMP-Activated Protein Kinases; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Chemotherapy, Adjuvant; Disease Progression; Drug Resistance, Neoplasm; Epithelium; Female; Forkhead Box Protein O1; Forkhead Box Protein O3; Humans; Middle Aged; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Phosphorylation; Protein Array Analysis; Proto-Oncogene Proteins c-akt; Signal Transduction; TOR Serine-Threonine Kinases; Young Adult | 2017 |
Evaluation of Natriuretic Peptide in Non-small Cell Lung Cancer Patients Treated with Bevacizumab Together with Carboplatin-Paclitaxel: A Prospective Study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Carboplatin; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free Survival; Female; Humans; Lung Neoplasms; Male; Middle Aged; Natriuretic Peptides; Paclitaxel; Plasma; Prospective Studies | 2017 |
miR-34a attenuates glioma cells progression and chemoresistance via targeting PD-L1.
Topics: 3' Untranslated Regions; Apoptosis; B7-H1 Antigen; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Disease Progression; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Glioma; Humans; MicroRNAs; Paclitaxel | 2017 |
Tumor Progression of Non-Small Cell Lung Cancer Controlled by Albumin and Micellar Nanoparticles of Itraconazole, a Multitarget Angiogenesis Inhibitor.
Topics: Albumins; Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Disease Progression; Humans; Injections, Intravenous; Itraconazole; Lung; Lung Neoplasms; Male; Mice; Mice, Inbred NOD; Mice, SCID; Micelles; Nanoparticles; Paclitaxel; Polyethylene Glycols; Rats; Rats, Sprague-Dawley; Signal Transduction; Xenograft Model Antitumor Assays | 2017 |
[Clinical analysis of 36 cases of advanced non-small cell lung cancer (NSCLC) with performance status (PS) scores between 2 and 4].
Topics: Anti-Bacterial Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease Progression; Disease-Free Survival; Docetaxel; Female; Gemcitabine; Humans; Hypoxia; Lung Neoplasms; Male; Neoplasm Staging; Paclitaxel; Pemetrexed; Remission Induction; Response Evaluation Criteria in Solid Tumors; Severity of Illness Index; Taxoids | 2017 |
Efficacy and Tolerability of Second-line Nab-paclitaxel and Gemcitabine After Failure of First-line FOLFIRINOX for Advanced Pancreas Cancer: A Single-institution Experience.
Topics: Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease Progression; Drug Combinations; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Organometallic Compounds; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Progression-Free Survival; Retrospective Studies | 2018 |
First Report of Dramatic Tumor Responses with Ramucirumab and Paclitaxel After Progression on Pembrolizumab in Two Cases of Metastatic Gastroesophageal Adenocarcinoma.
Topics: Adenocarcinoma; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Esophageal Neoplasms; Female; Humans; Male; Middle Aged; Paclitaxel; Ramucirumab; Stomach Neoplasms | 2018 |
A serial three- and nine-year optical coherence tomography evaluation of neoatherosclerosis progression after sirolimus- and paclitaxel- -eluting stent implantation.
Topics: Aged; Atherosclerosis; Coronary Artery Disease; Coronary Restenosis; Disease Progression; Drug-Eluting Stents; Female; Humans; Longitudinal Studies; Male; Middle Aged; Paclitaxel; Percutaneous Coronary Intervention; Postoperative Period; Sirolimus; Tomography, Optical Coherence | 2018 |
Tumor progression and metastatic dissemination in ovarian cancer after dose-dense or conventional paclitaxel and cisplatin plus bevacizumab.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Bevacizumab; Cell Proliferation; Cisplatin; Cystadenocarcinoma, Serous; Disease Progression; Female; Humans; Mice; Mice, Nude; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2018 |
Paclitaxel inhibits the progression of cervical cancer by inhibiting autophagy via lncRNARP11-381N20.2.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Autophagy; Cell Line, Tumor; Cell Proliferation; Disease Progression; Female; Genome-Wide Association Study; Humans; Paclitaxel; RNA, Long Noncoding; Uterine Cervical Neoplasms | 2018 |
Economic Evaluation for the UK of Systemic Chemotherapies as First-Line Treatment of Metastatic Pancreatic Cancer.
Topics: Adult; Albumins; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Cost-Benefit Analysis; Deoxycytidine; Disease Progression; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Markov Chains; Neoplasm Metastasis; Network Meta-Analysis; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Progression-Free Survival; Quality-Adjusted Life Years; United Kingdom | 2018 |
[A Case Report of Surgery and Chemotherapy for a Patient with Rapidly Progressing Breast Cancer during Pregnancy].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Breast Neoplasms; Carcinoma, Ductal, Breast; Chemotherapy, Adjuvant; Disease Progression; Epirubicin; Female; Humans; Mastectomy, Radical; Paclitaxel; Pregnancy; Pregnancy Complications, Neoplastic | 2018 |
Inhibition of the Stromal p38MAPK/MK2 Pathway Limits Breast Cancer Metastases and Chemotherapy-Induced Bone Loss.
Topics: Administration, Oral; Animals; Antineoplastic Agents; Bone and Bones; Bone Neoplasms; Breast Neoplasms; Cell Line, Tumor; Disease Progression; Drug Therapy; Female; HEK293 Cells; Humans; Induction Chemotherapy; Intracellular Signaling Peptides and Proteins; Macrophages; MAP Kinase Signaling System; Mice; Neoplasm Metastasis; Osteoclasts; p38 Mitogen-Activated Protein Kinases; Paclitaxel; Prognosis; Protein Serine-Threonine Kinases; Quality of Life; Stromal Cells; Tumor Microenvironment | 2018 |
TRIM59 overexpression correlates with poor prognosis and contributes to breast cancer progression through AKT signaling pathway.
Topics: Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Disease Progression; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Humans; Intracellular Signaling Peptides and Proteins; MCF-7 Cells; Membrane Proteins; Metalloproteins; Neoplasm Staging; Paclitaxel; Prognosis; Proto-Oncogene Proteins c-akt; Signal Transduction; Survival Analysis; Tripartite Motif Proteins; Triple Negative Breast Neoplasms; Tumor Burden; Up-Regulation | 2018 |
MicroRNA-22 Suppresses Breast Cancer Cell Growth and Increases Paclitaxel Sensitivity by Targeting NRAS.
Topics: Biological Phenomena; Breast; Breast Neoplasms; Cell Line, Tumor; Cell Movement; Cell Proliferation; Disease Progression; Down-Regulation; Female; Gene Expression Regulation, Neoplastic; Genes, Tumor Suppressor; GTP Phosphohydrolases; HEK293 Cells; Humans; MCF-7 Cells; Membrane Proteins; MicroRNAs; Paclitaxel; Proto-Oncogene Mas | 2018 |
Second-line treatment efficacy and toxicity in older vs. non-older patients with advanced gastric cancer: A multicentre real-world study.
Topics: Adult; Age Factors; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma; Chemotherapy, Adjuvant; Cohort Studies; Disease Progression; Docetaxel; Female; Fluorouracil; Humans; Irinotecan; Italy; Kaplan-Meier Estimate; L-Lactate Dehydrogenase; Liver Neoplasms; Lymph Nodes; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Grading; Neoplasm Metastasis; Neoplasm Staging; Paclitaxel; Peritoneal Neoplasms; Platinum Compounds; Progression-Free Survival; Proportional Hazards Models; Receptor, ErbB-2; Retrospective Studies; Stomach Neoplasms; Treatment Failure | 2019 |
The clinical conundrum of managing relapsed small cell lung cancer.
Topics: Anthracyclines; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Benzodiazepinones; Carboplatin; Clinical Decision-Making; Disease Progression; Etoposide; Humans; Immunoconjugates; Irinotecan; Liver Neoplasms; Lung Neoplasms; Molecular Targeted Therapy; Neoplasm Recurrence, Local; Nivolumab; Paclitaxel; Piperazines; Pyrimidines; Salvage Therapy; Small Cell Lung Carcinoma; Temozolomide; Thiourea; Topotecan | 2019 |
PIWI-interacting RNA-36712 restrains breast cancer progression and chemoresistance by interaction with SEPW1 pseudogene SEPW1P RNA.
Topics: Animals; Breast; Breast Neoplasms; Cell Proliferation; Disease Progression; Down-Regulation; Doxorubicin; Drug Resistance, Neoplasm; Female; Humans; MicroRNAs; Paclitaxel; Prognosis; Pseudogenes; RNA, Messenger; RNA, Small Interfering; Selenoprotein W; Up-Regulation | 2019 |
Pediatric post-transplant hepatic kaposi sarcoma due to donor-derived human herpesvirus 8.
Topics: Biliary Atresia; Biopsy, Needle; Disease Progression; Female; Ganciclovir; Herpesvirus 8, Human; Humans; Immunosuppression Therapy; Infant; Liver; Liver Transplantation; Magnetic Resonance Imaging; Male; Paclitaxel; Postoperative Complications; Sarcoma, Kaposi; Tissue Donors | 2019 |
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carboplatin; Carcinoma, Ovarian Epithelial; Cell Line, Tumor; Chemotherapy, Adjuvant; Disease Progression; Drug Resistance, Neoplasm; Female; Humans; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Middle Aged; Ovarian Neoplasms; Paclitaxel; RNA, Messenger; Time Factors; Treatment Outcome | 2019 |
Chemoradiation induces epithelial-to-mesenchymal transition in esophageal adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cell Line, Tumor; Chemoradiotherapy; Disease Progression; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Esophageal Mucosa; Esophageal Neoplasms; Esophagectomy; Female; Fluorodeoxyglucose F18; Humans; Kaplan-Meier Estimate; Lymph Nodes; Male; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Positron-Emission Tomography; Primary Cell Culture; Progression-Free Survival; Signal Transduction; Transforming Growth Factor beta; Treatment Outcome; Xenograft Model Antitumor Assays | 2019 |
Computational modeling of pancreatic cancer patients receiving FOLFIRINOX and gemcitabine-based therapies identifies optimum intervention strategies.
Topics: Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Chemoradiotherapy; Clinical Decision-Making; Computer Simulation; Deoxycytidine; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Feasibility Studies; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Models, Biological; Neoadjuvant Therapy; Oxaliplatin; Paclitaxel; Pancreas; Pancreatectomy; Pancreatic Neoplasms; Remission Induction; Tumor Burden | 2019 |
Juxtaglomerular cell tumor: multicentric synchronous disease associated with paraneoplastic syndrome.
Topics: Antidiuretic Hormone Receptor Antagonists; Antineoplastic Combined Chemotherapy Protocols; Benzazepines; Dacarbazine; Deoxycytidine; Diagnosis, Differential; Disease Progression; Doxorubicin; Gemcitabine; Humans; Hyponatremia; Ifosfamide; Immunohistochemistry; Immunophenotyping; Inappropriate ADH Syndrome; Juxtaglomerular Apparatus; Kidney Neoplasms; Luminescent Measurements; Male; Middle Aged; Neoplasms, Multiple Primary; Paclitaxel; Paraneoplastic Syndromes; Renin; Tolvaptan; Vinblastine; Vinorelbine | 2013 |
Should bevacizumab be continued after progression on bevacizumab in recurrent ovarian cancer?
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Cisplatin; Cyclophosphamide; Disease Progression; Docetaxel; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Prognosis; Retrospective Studies; Survival Rate; Taxoids; Topotecan | 2013 |
Cost effectiveness of neoadjuvant chemotherapy in locally advanced operable head and neck cancer followed by surgery and postoperative radiotherapy: a Markov model-based decision analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemotherapy, Adjuvant; Cisplatin; Cost-Benefit Analysis; Decision Support Techniques; Disease Progression; Disease-Free Survival; Fluorouracil; Germany; Head and Neck Neoplasms; Humans; Induction Chemotherapy; Kaplan-Meier Estimate; Markov Chains; Monte Carlo Method; Neoadjuvant Therapy; Paclitaxel | 2013 |
Weekly paclitaxel--an effective treatment for advanced breast cancer.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Disease Progression; Drug Administration Schedule; Female; Humans; Liver Neoplasms; Lung Neoplasms; Middle Aged; Paclitaxel; Survival Rate; Treatment Outcome | 2013 |
The overexpression of P21-activated kinase 5 (PAK5) promotes paclitaxel-chemoresistance of epithelial ovarian cancer.
Topics: Apoptosis; Carcinoma, Ovarian Epithelial; Cell Line, Tumor; Cell Membrane; Cell Proliferation; Disease Progression; Drug Resistance, Neoplasm; Female; Humans; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; p21-Activated Kinases; Paclitaxel; RNA Interference | 2013 |
ABCB1 (MDR1) polymorphisms and ovarian cancer progression and survival: a comprehensive analysis from the Ovarian Cancer Association Consortium and The Cancer Genome Atlas.
Topics: Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Carboplatin; Carcinoma, Ovarian Epithelial; Disease Progression; Disease-Free Survival; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; Humans; Kaplan-Meier Estimate; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Pharmacogenetics; Polymorphism, Single Nucleotide; Proportional Hazards Models | 2013 |
Case of streptococcal toxic shock syndrome caused by rapidly progressive group A hemolytic streptococcal infection during postoperative chemotherapy for cervical cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Delayed Diagnosis; Disease Progression; Female; Humans; Hysterectomy; Immunocompromised Host; Omentum; Paclitaxel; Peritonitis; Postoperative Complications; Pregnancy; Pregnancy Complications, Neoplastic; Radiotherapy; Shock, Septic; Streptococcal Infections; Streptococcus pyogenes; Taxoids; Treatment Outcome; Uterine Cervical Neoplasms | 2014 |
Concurrent chemoradiotherapy with nedaplatin plus paclitaxel or fluorouracil for locoregionally advanced nasopharyngeal carcinoma: Survival and toxicity.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Disease Progression; Female; Fluorouracil; Humans; Male; Middle Aged; Multivariate Analysis; Nasopharyngeal Neoplasms; Organoplatinum Compounds; Paclitaxel; Radiotherapy Dosage; Radiotherapy, Intensity-Modulated | 2014 |
Microtubule-stabilizing agents delay the onset of EAE through inhibition of migration.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Autoantigens; Bridged Bicyclo Compounds, Heterocyclic; Cell Movement; Cell Proliferation; Cells, Cultured; Disease Models, Animal; Disease Progression; Docetaxel; Drug Synergism; Encephalomyelitis, Autoimmune, Experimental; Epothilones; Growth Inhibitors; Humans; Lactones; Mice; Mice, Inbred C57BL; Mice, Transgenic; Microtubules; Multiple Sclerosis; Paclitaxel; Taxoids | 2013 |
Novel isoprenoyl nanoassembled prodrug for paclitaxel delivery.
Topics: Animals; Antineoplastic Agents; Body Weight; Butadienes; Disease Models, Animal; Disease Progression; Drug Delivery Systems; Drug Screening Assays, Antitumor; Female; Hemiterpenes; Humans; Inhibitory Concentration 50; MCF-7 Cells; Mice; Mice, Inbred BALB C; Nanoparticles; Neoplasms, Experimental; Paclitaxel; Pentanes; Prodrugs; Tumor Cells, Cultured | 2013 |
High level of serum AMBP is associated with poor response to paclitaxel-capecitabine chemotherapy in advanced gastric cancer patients.
Topics: Adult; Aged; Alpha-Globulins; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Capecitabine; Deoxycytidine; Disease Progression; Female; Fluorouracil; Humans; Male; Middle Aged; Paclitaxel; Stomach Neoplasms | 2013 |
STX140, but not paclitaxel, inhibits mammary tumour initiation and progression in C3(1)/SV40 T/t-antigen transgenic mice.
Topics: Adenocarcinoma; Animals; Antigens, Polyomavirus Transforming; Antineoplastic Agents; Breast Neoplasms; Disease Progression; Drug Administration Schedule; Drug Dosage Calculations; Estrenes; Female; Humans; Hyperalgesia; Lung Neoplasms; Mammary Glands, Animal; Mammary Neoplasms, Experimental; Mice; Mice, Transgenic; Paclitaxel; Peripheral Nervous System Diseases; Rats; Survival Analysis; Transplantation, Heterologous | 2013 |
Knockdown of CABYR-a/b increases chemosensitivity of human non-small cell lung cancer cells through inactivation of Akt.
Topics: Animals; Antineoplastic Agents; Apoptosis; Calcium-Binding Proteins; Carcinoma, Non-Small-Cell Lung; Cell Growth Processes; Cell Line, Tumor; Cisplatin; Disease Progression; Drug Resistance, Neoplasm; Female; Gene Knockdown Techniques; Humans; Lung Neoplasms; Mice, Inbred BALB C; Mice, Nude; Paclitaxel; Phosphoproteins; Protein Isoforms; Proto-Oncogene Proteins c-akt; Signal Transduction; Transfection; Xenograft Model Antitumor Assays | 2014 |
[A case of rapidly fatal gastric cancer with disseminated carcinomatosis of the bone marrow].
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Neoplasms; Disease Progression; Disseminated Intravascular Coagulation; Fatal Outcome; Humans; Kidney Neoplasms; Male; Middle Aged; Paclitaxel; Stomach Neoplasms; Trastuzumab | 2013 |
Evaluation of progression prior to surgery after neoadjuvant chemoradiotherapy with computed tomography in esophageal cancer patients.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Carcinoma, Adenosquamous; Carcinoma, Squamous Cell; Chemoradiotherapy, Adjuvant; Disease Progression; Esophageal Neoplasms; Esophagectomy; Female; Follow-Up Studies; Humans; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Multidetector Computed Tomography; Neoadjuvant Therapy; Neoplasm Staging; Paclitaxel; Preoperative Care; Retrospective Studies; Sensitivity and Specificity; Treatment Outcome | 2014 |
In vitro chemosensitivity assay of ascites in epithelial ovarian cancer.
Topics: Antineoplastic Agents; Ascites; Carboplatin; Carcinoma, Ovarian Epithelial; Coloring Agents; Deoxycytidine; Disease Progression; Drug Screening Assays, Antitumor; Epirubicin; Etoposide; Female; Fluorouracil; Gemcitabine; Humans; Kaplan-Meier Estimate; Ki-67 Antigen; Middle Aged; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Predictive Value of Tests; Retrospective Studies; Survival Rate; Tetrazolium Salts; Thiazoles; Time Factors; Tumor Cells, Cultured; Tumor Suppressor Protein p53 | 2013 |
Different serial changes in the neointimal condition of sirolimus-eluting stents and paclitaxel-eluting stents: an optical coherence tomographic study.
Topics: Acute Coronary Syndrome; Aged; Antineoplastic Agents; Cohort Studies; Coronary Restenosis; Coronary Stenosis; Coronary Vessels; Disease Progression; Drug-Eluting Stents; Female; Humans; Male; Middle Aged; Neointima; Paclitaxel; Percutaneous Coronary Intervention; Retrospective Studies; Sirolimus; Tomography, Optical Coherence | 2014 |
Is there a role for second line therapy in advanced pancreatic cancer?
Topics: Albumins; Antineoplastic Agents; Deoxycytidine; Disease Progression; Drug Therapy; Drug Therapy, Combination; Gemcitabine; Humans; Paclitaxel; Pancreatic Neoplasms; Treatment Outcome | 2014 |
Stathmin1 regulates p27 expression, proliferation and drug resistance, resulting in poor clinical prognosis in cholangiocarcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Biomarkers, Tumor; Cell Line, Tumor; Cell Proliferation; Cholangiocarcinoma; Cyclin-Dependent Kinase Inhibitor p27; Disease Progression; Drug Resistance, Neoplasm; Female; Gene Expression; Gene Expression Regulation, Neoplastic; Humans; Immunohistochemistry; Male; Middle Aged; Paclitaxel; Protein Binding; RNA Interference; RNA, Small Interfering; Stathmin; Treatment Outcome | 2014 |
[Trastuzumab combined with chemotherapy in patients with HER2-positive chemo-refractory advanced gastric or gastro-esophageal junction adenocarcinoma].
Topics: Adenocarcinoma; Adult; Aged; Anorexia; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Disease Progression; Disease-Free Survival; Drug Resistance, Neoplasm; Esophagogastric Junction; Fatigue; Female; Follow-Up Studies; Humans; Irinotecan; Liver Neoplasms; Male; Middle Aged; Neutropenia; Paclitaxel; Pyrimidines; Receptor, ErbB-2; Remission Induction; Retrospective Studies; Stomach Neoplasms; Survival Rate; Trastuzumab | 2014 |
Astragaloside IV inhibits progression of lung cancer by mediating immune function of Tregs and CTLs by interfering with IDO.
Topics: Animals; Antineoplastic Agents; Carcinoma, Lewis Lung; Cell Line, Tumor; Coculture Techniques; Disease Progression; Drug Screening Assays, Antitumor; Female; Indoleamine-Pyrrole 2,3,-Dioxygenase; Mice, Inbred C57BL; Neoplasm Transplantation; Paclitaxel; Saponins; T-Lymphocytes, Cytotoxic; T-Lymphocytes, Regulatory; Triterpenes; Tryptophan; Tumor Burden; Tumor Escape | 2014 |
Long progression-free survival with first-line paclitaxel plus platinum is associated with improved response and progression-free survival with second-line docetaxel in advanced non-small-cell lung cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Disease Progression; Disease-Free Survival; Docetaxel; Drug Screening Assays, Antitumor; ErbB Receptors; Female; Humans; Lung Neoplasms; Male; Mexico; Middle Aged; Paclitaxel; Patient Selection; Taxoids; Treatment Outcome | 2014 |
The combination of Cl-IB-MECA with paclitaxel: a new anti-metastatic therapeutic strategy for melanoma.
Topics: Adenosine; Animals; Antineoplastic Agents; Cell Physiological Phenomena; Disease Progression; Drug Screening Assays, Antitumor; Humans; Inosine; Melanoma; Mice; Neoplasm Metastasis; Neoplasm Staging; Neovascularization, Pathologic; Paclitaxel; Receptor, Adenosine A3; Tumor Cells, Cultured | 2014 |
ARID3B increases ovarian tumor burden and is associated with a cancer stem cell gene signature.
Topics: AC133 Antigen; Animals; Antigens, CD; Antineoplastic Agents; Cell Adhesion; Cell Line, Tumor; Cell Movement; Cell Proliferation; Disease Progression; DNA-Binding Proteins; Drug Resistance, Neoplasm; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Glycoproteins; Humans; Mice, Nude; Neoplasm Invasiveness; Neoplastic Stem Cells; Ovarian Neoplasms; Paclitaxel; Peptides; Signal Transduction; Time Factors; Transfection; Tumor Burden; Xenograft Model Antitumor Assays | 2014 |
FOXM1 confers to epithelial-mesenchymal transition, stemness and chemoresistance in epithelial ovarian carcinoma cells.
Topics: Animals; Antineoplastic Agents; Biomarkers, Tumor; Blotting, Western; Carcinoma, Ovarian Epithelial; Cell Line, Tumor; Cell Proliferation; Cisplatin; Disease Progression; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Female; Forkhead Box Protein M1; Forkhead Transcription Factors; Humans; Immunohistochemistry; Mice, Inbred NOD; Mice, SCID; Neoplasms, Glandular and Epithelial; Neoplastic Stem Cells; Ovarian Neoplasms; Paclitaxel; RNA Interference; Survival Analysis; Thiostrepton; Tumor Burden; Xenograft Model Antitumor Assays | 2015 |
BRCA1-IRIS inactivation overcomes paclitaxel resistance in triple negative breast cancers.
Topics: Animals; Antineoplastic Agents, Phytogenic; Biomarkers, Tumor; BRCA1 Protein; Cell Line, Tumor; Cell Movement; Cell Survival; Cell Transformation, Neoplastic; Disease Models, Animal; Disease Progression; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; ErbB Receptors; Female; Forkhead Box Protein O3; Forkhead Transcription Factors; Gene Expression; Gene Silencing; Humans; Inhibitor of Apoptosis Proteins; Mice; Neoplastic Stem Cells; Paclitaxel; Peptide Fragments; Phenotype; Proteolysis; RNA Interference; RNA, Small Interfering; Signal Transduction; Survivin; Triple Negative Breast Neoplasms; Xenograft Model Antitumor Assays | 2015 |
[Prolonged remission achieved by using bevacizumab plus paclitaxel therapy combined with sequential radiotherapy for a rapidly growing chest wall recurrence of triple negative breast cancer - a case report].
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Chemoradiotherapy; Disease Progression; Female; Humans; Mastectomy, Modified Radical; Paclitaxel; Recurrence; Remission Induction; Thoracic Wall; Triple Negative Breast Neoplasms | 2015 |
Sequential versus "sandwich" sequencing of adjuvant chemoradiation for the treatment of stage III uterine endometrioid adenocarcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Endometrioid; Chemoradiotherapy, Adjuvant; Cisplatin; Disease Progression; Doxorubicin; Endometrial Neoplasms; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Retrospective Studies; Treatment Outcome | 2015 |
Efficacy and tolerability of paclitaxel, ifosfamide, and cisplatin as a neoadjuvant chemotherapy in locally advanced cervical carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease Progression; Feasibility Studies; Female; Humans; Ifosfamide; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Retrospective Studies; Treatment Outcome; Uterine Cervical Neoplasms; Young Adult | 2015 |
Paclitaxel combined with oxaliplatin as first-line chemotherapy for locally advanced or metastatic gastric cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Female; Follow-Up Studies; Humans; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Retrospective Studies; Stomach Neoplasms; Treatment Outcome | 2015 |
Combination therapy of liposomal paclitaxel and cisplatin as neoadjuvant chemotherapy in locally advanced cervical cancer.
Topics: Adenocarcinoma; Adult; Anemia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Adenosquamous; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Cisplatin; Disease Progression; Female; Humans; Liposomes; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Neutropenia; Paclitaxel; Peripheral Nervous System Diseases; Retrospective Studies; Treatment Outcome; Tumor Burden; Uterine Cervical Neoplasms | 2015 |
Nanoparticle albumin-bound paclitaxel (nab-paclitaxel) as second-line chemotherapy in HER2-negative, taxane-pretreated metastatic breast cancer patients: prospective evaluation of activity, safety, and quality of life.
Topics: Adult; Aged; Albumins; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Disease Progression; Disease-Free Survival; Endpoint Determination; Female; Humans; Middle Aged; Nanoparticles; Paclitaxel; Patient Compliance; Prospective Studies; Quality of Life; Receptor, ErbB-2; Taxoids | 2015 |
[Results of a drug use investigation of nanoparticle albumin-bound Paclitaxel for breast cancer].
Topics: Adolescent; Adult; Aged; Albumins; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease Progression; Drug Administration Schedule; Female; Humans; Middle Aged; Paclitaxel; Young Adult | 2015 |
miR-520h is crucial for DAPK2 regulation and breast cancer progression.
Topics: Apoptosis; Breast Neoplasms; Cell Line, Tumor; Death-Associated Protein Kinases; Disease Progression; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Humans; MicroRNAs; Paclitaxel; RNA, Messenger | 2016 |
Association of TERT Polymorphisms with Clinical Outcome of Non-Small Cell Lung Cancer Patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Disease Progression; Female; Gemcitabine; Gene Expression; Heterozygote; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Polymorphism, Single Nucleotide; Prognosis; Survival Analysis; Telomerase; Treatment Outcome; Vinblastine; Vinorelbine | 2015 |
MicroRNA-101 inhibits cell progression and increases paclitaxel sensitivity by suppressing MCL-1 expression in human triple-negative breast cancer.
Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Cell Line, Tumor; Cell Proliferation; Disease Progression; Female; Humans; MCF-7 Cells; Mice; Mice, Inbred BALB C; Mice, Nude; MicroRNAs; Middle Aged; Myeloid Cell Leukemia Sequence 1 Protein; Paclitaxel; Transfection; Triple Negative Breast Neoplasms | 2015 |
Neoadjuvant chemotherapy followed by large cone resection as fertility-sparing therapy in stage IB cervical cancer.
Topics: Abortion, Missed; Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Cervix Uteri; Chemotherapy, Adjuvant; Cisplatin; Conization; Disease Progression; Female; Fertility Preservation; Follow-Up Studies; Humans; Ifosfamide; Lymph Node Excision; Lymphatic Metastasis; Neoadjuvant Therapy; Neoplasm Staging; Paclitaxel; Pelvis; Pregnancy; Pregnancy Rate; Premature Birth; Retrospective Studies; Treatment Outcome; Tumor Burden; Uterine Cervical Neoplasms | 2015 |
Novel ZnO hollow-nanocarriers containing paclitaxel targeting folate-receptors in a malignant pH-microenvironment for effective monitoring and promoting breast tumor regression.
Topics: Animals; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Cell Line, Tumor; Cell Survival; Disease Progression; Drug Carriers; Female; Humans; Hydrogen-Ion Concentration; Metal Nanoparticles; Mice; Mice, Inbred BALB C; Mice, Nude; Microscopy, Fluorescence; Paclitaxel; Transplantation, Heterologous; Zinc Oxide | 2015 |
Retrospective analysis of second-line chemotherapy outcomes with paclitaxel or docetaxel in correlation with STMN1 polymorphism in advanced non-small cell lung cancer patients.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Disease Progression; Docetaxel; Female; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Polymorphism, Single Nucleotide; Retrospective Studies; Stathmin; Taxoids; Treatment Outcome | 2016 |
Effect of Hyperthermic Intraperitoneal Perfusion Chemotherapy in Combination with Intravenous Chemotherapy as Postoperative Adjuvant Therapy for Advanced Gastric Cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Female; Fluorouracil; Gastrectomy; Humans; Hyperthermia, Induced; Infusions, Intravenous; Infusions, Parenteral; Kaplan-Meier Estimate; Leucovorin; Lymph Node Excision; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Stomach Neoplasms; Time Factors; Treatment Outcome | 2014 |
Single-agent Taxane Versus Taxane-containing Combination Chemotherapy as Salvage Therapy for Advanced Urothelial Carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Clinical Trials, Phase II as Topic; Disease Progression; Disease-Free Survival; Docetaxel; Humans; Kaplan-Meier Estimate; Multivariate Analysis; Paclitaxel; Proportional Hazards Models; Retrospective Studies; Risk Factors; Salvage Therapy; Taxoids; Time Factors; Treatment Outcome; Urologic Neoplasms; Urothelium | 2016 |
Refractory Gestational Trophoblastic Neoplasia: A Novel Drug Combination With Paclitaxel and Carboplatin Produces Durable Complete Remission.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemical and Drug Induced Liver Injury; Chemotherapy-Induced Febrile Neutropenia; Chorionic Gonadotropin, beta Subunit, Human; Disease Progression; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Gestational Trophoblastic Disease; Humans; Mucositis; Paclitaxel; Pregnancy; Prospective Studies; Remission Induction; Retreatment; Salvage Therapy; Survival Rate; Thrombocytopenia | 2015 |
The inferior vena cava (IVC) syndrome as the initial manifestation of newly diagnosed gastric adenocarcinoma: a case report.
Topics: Adenocarcinoma; Anemia, Iron-Deficiency; Antineoplastic Combined Chemotherapy Protocols; Budd-Chiari Syndrome; Disease Progression; Edema; Endoscopy, Gastrointestinal; Fatigue; Female; Humans; Lower Extremity; Malaysia; Middle Aged; Neoplasm Staging; Paclitaxel; Stomach Neoplasms; Syndrome; Tomography, X-Ray Computed; Trastuzumab; Treatment Outcome; Vena Cava, Inferior | 2015 |
Vascular restoration: Is there a window of opportunity?
Topics: Angioplasty, Balloon, Coronary; Biocompatible Materials; Cell Proliferation; Coronary Angiography; Coronary Restenosis; Disease Progression; Drug-Eluting Stents; Humans; Metals; Muscle, Smooth, Vascular; Paclitaxel; Polymers; Thrombosis; Treatment Outcome | 2015 |
Survival outcome according to KRAS mutation status in newly diagnosed patients with stage IV non-small cell lung cancer treated with platinum doublet chemotherapy.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Disease Progression; Disease-Free Survival; DNA Mutational Analysis; Docetaxel; ErbB Receptors; Female; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Paclitaxel; Philadelphia; Proportional Hazards Models; Proto-Oncogene Proteins p21(ras); Retrospective Studies; Risk Factors; Taxoids; Time Factors; Treatment Outcome | 2015 |
[Examination of the Response Rate of Paclitaxel and Bevacizumab Therapy for Metastatic Advanced Breast Cancer According to the Lymphopenia Grade].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Disease Progression; Humans; Lymphopenia; Middle Aged; Neoplasm Metastasis; Paclitaxel | 2015 |
Cancer-testis antigen cyclin A1 is broadly expressed in ovarian cancer and is associated with prolonged time to tumor progression after platinum-based therapy.
Topics: Adult; Aged; Antineoplastic Agents; Biomarkers, Tumor; Carboplatin; Cyclin A1; Disease Progression; Female; Humans; Immunohistochemistry; Microarray Analysis; Middle Aged; Ovarian Neoplasms; Paclitaxel; Real-Time Polymerase Chain Reaction; RNA, Messenger; Survival Analysis | 2015 |
Weekly carboplatin in combination with weekly paclitaxel in the treatment of metastatic non-small cell lung cancer: a single center 10-year experience.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Palliative Care; Patient Care Planning; Retrospective Studies; Risk Factors; Treatment Outcome | 2016 |
Predicting therapeutic nanomedicine efficacy using a companion magnetic resonance imaging nanoparticle.
Topics: Animals; Antineoplastic Agents, Phytogenic; Cell Line, Tumor; Chemistry, Pharmaceutical; Disease Progression; DNA Damage; Female; Ferrosoferric Oxide; Fibrosarcoma; Humans; Macrophages; Magnetic Resonance Imaging; Magnetics; Mice, Inbred BALB C; Mice, Inbred C57BL; Mice, Nude; Mice, Transgenic; Nanomedicine; Nanoparticles; Ovarian Neoplasms; Paclitaxel; Particle Size; Polyethylene Glycols; Polyglactin 910; Predictive Value of Tests; Time Factors; Tissue Distribution; Tumor Microenvironment; Xenograft Model Antitumor Assays | 2015 |
Second-line treatment of recurrent HNSCC: tumor debulking in combination with high-dose-rate brachytherapy and a simultaneous cetuximab-paclitaxel protocol.
Topics: Aged; Brachytherapy; Carcinoma, Squamous Cell; Cetuximab; Cytoreduction Surgical Procedures; Disease Progression; Disease-Free Survival; Female; Head and Neck Neoplasms; Humans; Male; Middle Aged; Paclitaxel; Palliative Care; Prognosis; Retrospective Studies; Salvage Therapy; Treatment Outcome | 2016 |
Penile cancer metastasizing to the breast: a case report.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms, Male; Carcinoma, Squamous Cell; Deoxycytidine; Disease Progression; Fatal Outcome; Gemcitabine; Humans; Lung Neoplasms; Lymph Node Excision; Lymphatic Metastasis; Male; Middle Aged; Paclitaxel; Penile Neoplasms | 2016 |
[Efficacy and prognostic factors of 178 advanced non-small lung cancer patients undergoing different second-line chemotherapeutic regimens].
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chi-Square Distribution; Cisplatin; Disease Progression; Disease-Free Survival; Humans; Kaplan-Meier Estimate; Leukopenia; Lung Neoplasms; Paclitaxel; Prognosis; Regression Analysis; Retrospective Studies; Survival Rate; Taxoids | 2016 |
Inhibition of microtubule dynamics impedes repair of kidney ischemia/reperfusion injury and increases fibrosis.
Topics: Acetylation; Animals; Cell Cycle Checkpoints; Cell Proliferation; Checkpoint Kinase 2; Colchicine; Disease Progression; Epithelial Cells; Fibrosis; Kidney; Macrophages; Male; Mice; Microtubules; Monocytes; Paclitaxel; Phosphorylation; RAW 264.7 Cells; Reperfusion Injury; Tubulin; Wound Healing | 2016 |
Low doses of paclitaxel enhance liver metastasis of breast cancer cells in the mouse model.
Topics: Animals; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Cell Line, Tumor; Disease Models, Animal; Disease Progression; Epithelial-Mesenchymal Transition; Estrogens; Female; Gene Expression; Gene Expression Profiling; Humans; Inflammation Mediators; Liver; Liver Neoplasms; Mice; Neoplasm Invasiveness; NF-kappa B; Paclitaxel | 2016 |
Oxidative stress in the development, maintenance and resolution of paclitaxel-induced painful neuropathy.
Topics: Animals; Antineoplastic Agents, Phytogenic; Astrocytes; Cells, Cultured; Disease Models, Animal; Disease Progression; Ganglia, Spinal; Hyperalgesia; Lumbar Vertebrae; Male; Microglia; Neurons; Oxidative Stress; Paclitaxel; Pain; Peripheral Nervous System Diseases; Rats, Sprague-Dawley; Reactive Oxygen Species; Spinal Cord | 2016 |
Same Data; Different Interpretations.
Topics: Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Cetuximab; Data Interpretation, Statistical; Disease Progression; Disease-Free Survival; Drug Approval; Everolimus; Evidence-Based Medicine; Female; Humans; Lung Neoplasms; Medical Oncology; Ovarian Neoplasms; Paclitaxel; Protein Kinase Inhibitors; Reproducibility of Results; Time Factors; Treatment Outcome | 2016 |
NSAID-activated gene 1 mediates pro-inflammatory signaling activation and paclitaxel chemoresistance in type I human epithelial ovarian cancer stem-like cells.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents, Phytogenic; Biomarkers, Tumor; Carcinogenesis; Carcinoma, Ovarian Epithelial; Cell Line, Tumor; Chemokines; Disease Progression; Disease-Free Survival; Drug Resistance, Neoplasm; ErbB Receptors; Female; Fluorescent Antibody Technique; Growth Differentiation Factor 15; Humans; Immunohistochemistry; Inflammation; Kaplan-Meier Estimate; MAP Kinase Kinase Kinases; Microscopy, Confocal; Myeloid Differentiation Factor 88; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Neoplastic Stem Cells; NF-kappa B; Ovarian Neoplasms; Ovary; Paclitaxel; Prognosis; Signal Transduction; Smad4 Protein; Sulindac; Up-Regulation | 2016 |
Combination therapy with topotecan, paclitaxel, and bevacizumab improves progression-free survival in recurrent small cell neuroendocrine carcinoma of the cervix.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Carcinoma, Neuroendocrine; Disease Progression; Disease-Free Survival; Female; Humans; Neoplasm Recurrence, Local; Paclitaxel; Platinum; Retrospective Studies; Survival Rate; Topotecan; Uterine Cervical Neoplasms; Young Adult | 2017 |
A retrospective clinical study of comparing paclitaxel plus S-1 versus paclitaxel plus cisplatin as the first-line treatment for patients with advanced esophageal squamous cell carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; China; Cisplatin; Disease Progression; Disease-Free Survival; Drug Combinations; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Oxonic Acid; Paclitaxel; Retrospective Studies; Tegafur; Time Factors; Treatment Outcome | 2017 |
[A Study of Gemctabine plus Nab-Paclitaxel Therapy for Advanced Local Progressive Pancreatic Cancer].
Topics: Aged; Aged, 80 and over; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease Progression; Female; Gemcitabine; Humans; Male; Middle Aged; Paclitaxel; Pancreatic Neoplasms; Treatment Outcome | 2016 |
Perioperative chemotherapy versus neoadjuvant chemoradiotherapy for esophageal or GEJ adenocarcinoma: A propensity score-matched analysis comparing toxicity, pathologic outcome, and survival.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carboplatin; Chemoradiotherapy; Chemotherapy, Adjuvant; Cisplatin; Diarrhea; Disease Progression; Epirubicin; Esophageal Neoplasms; Esophagectomy; Esophagogastric Junction; Female; Follow-Up Studies; Humans; Leukopenia; Male; Middle Aged; Neoadjuvant Therapy; Netherlands; Paclitaxel; Propensity Score; Thromboembolism | 2017 |
Analysis of acute exacerbation of interstitial lung disease associated with chemotherapy in patients with lung cancer: A feasibility of S-1.
Topics: Acute-Phase Reaction; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Drug Combinations; Etoposide; Feasibility Studies; Female; Humans; Incidence; Lung Diseases, Interstitial; Lung Neoplasms; Male; Middle Aged; Oxonic Acid; Paclitaxel; Respiratory Insufficiency; Retrospective Studies; Tegafur | 2017 |
Prolonged response to gefitinib in bone metastasis.
Topics: Adenocarcinoma; Antineoplastic Agents, Phytogenic; Back Pain; Carboplatin; Disease Progression; Female; Gefitinib; Humans; Lung Neoplasms; Middle Aged; Paclitaxel; Protein Kinase Inhibitors; Quinazolines; Spinal Neoplasms; Time Factors | 2009 |
[Treatment of advanced penile cancer. Do we need new methods for chemotherapy?].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carboplatin; Cyclophosphamide; Disease Progression; Humans; Male; Methotrexate; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Palliative Care; Penile Neoplasms | 2008 |
Nine months to progression using fourth-line liposomally encapsulated paclitaxel against hepatocellular carcinoma.
Topics: alpha-Fetoproteins; Capsules; Carcinoma, Hepatocellular; Disease Progression; Drug-Related Side Effects and Adverse Reactions; Humans; Liposomes; Male; Paclitaxel; Time Factors | 2008 |
[Impact of neoadjuvant chemotherapy on the survival of patients with stage IIIc and IV epithelial ovarian cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cyclophosphamide; Cystadenocarcinoma, Papillary; Disease Progression; Disease-Free Survival; Female; Follow-Up Studies; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Retrospective Studies; Survival Rate; Taxoids | 2008 |
GLI2 knockdown using an antisense oligonucleotide induces apoptosis and chemosensitizes cells to paclitaxel in androgen-independent prostate cancer.
Topics: Androgens; Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Base Sequence; Cell Line, Tumor; Disease Progression; Dose-Response Relationship, Drug; Humans; Kruppel-Like Transcription Factors; Male; Membrane Proteins; Mice; Mice, Nude; Neoplasm Transplantation; Neoplasms, Hormone-Dependent; Nuclear Proteins; Oligonucleotides, Antisense; Paclitaxel; Prostatic Neoplasms; Saccharomyces cerevisiae Proteins; Zinc Finger Protein Gli2 | 2008 |
[Prediction of response to primary systemic chemotherapy involving weekly paclitaxel followed by FEC 100 for advanced breast cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Disease Progression; Epirubicin; Female; Fluorouracil; Humans; Middle Aged; Neoplasm Staging; Paclitaxel; Time Factors | 2008 |
Association of the ABCB1 gene polymorphisms 2677G>T/A and 3435C>T with clinical outcomes of paclitaxel monotherapy in metastatic breast cancer patients.
Topics: Adult; Aged; Alleles; Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter 1; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP-Binding Cassette Transporters; Breast Neoplasms; Disease Progression; DNA, Neoplasm; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Gene Frequency; Genotype; Haplotypes; Homozygote; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Polymorphism, Genetic; Regression Analysis; Survival Analysis; Treatment Outcome | 2009 |
Overexpression of indoleamine 2,3-dioxygenase in human endometrial carcinoma cells induces rapid tumor growth in a mouse xenograft model.
Topics: Animals; Antineoplastic Agents; Blotting, Western; Cell Line, Tumor; Cell Movement; Chromatography, High Pressure Liquid; Disease Progression; Endometrial Neoplasms; Enzyme Inhibitors; Female; Flow Cytometry; Fluorescent Antibody Technique; Humans; Indoleamine-Pyrrole 2,3,-Dioxygenase; Killer Cells, Natural; Mice; Mice, Nude; Paclitaxel; Reverse Transcriptase Polymerase Chain Reaction; Transfection; Xenograft Model Antitumor Assays | 2008 |
Efficacy assessment of sustained intraperitoneal paclitaxel therapy in a murine model of ovarian cancer using bioluminescent imaging.
Topics: Animals; Body Weight; Cell Line, Tumor; Cell Survival; Disease Models, Animal; Disease Progression; Female; Humans; Injections, Intraperitoneal; Luminescent Measurements; Mice; Mice, SCID; Ovarian Neoplasms; Paclitaxel; Survival Rate; Xenograft Model Antitumor Assays | 2008 |
TP53 codon 72 polymorphism associated with prognosis in patients with advanced gastric cancer treated with paclitaxel and cisplatin.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Codon; Disease Progression; Female; Humans; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Polymorphism, Single Nucleotide; Prognosis; Stomach Neoplasms; Survival Rate; Time Factors; Treatment Outcome; Tumor Suppressor Protein p53 | 2009 |
Stage II uterine papillary serous carcinoma: Carboplatin/paclitaxel chemotherapy improves recurrence and survival outcomes.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Carboplatin; Carcinoma, Papillary; Combined Modality Therapy; Cystadenocarcinoma, Serous; Disease Progression; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Retrospective Studies; Uterine Neoplasms | 2009 |
Local control and survival following concomitant chemoradiotherapy in inoperable stage I non-small-cell lung cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Combined Modality Therapy; Disease Progression; Docetaxel; Dose Fractionation, Radiation; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Radiotherapy, Conformal; Regression Analysis; Retrospective Studies; Survival Rate; Taxoids | 2009 |
Bone marrow CFU-GM and human tumor xenograft efficacy of three tubulin binding agents.
Topics: Animals; Antineoplastic Agents, Phytogenic; Body Weight; Bone Marrow Cells; Breast Neoplasms; Disease Progression; Female; Humans; Lymphoma; Male; Mice; Mice, Inbred BALB C; Multiple Myeloma; Oligopeptides; Paclitaxel; Prostatic Neoplasms; Tubulin; Tumor Stem Cell Assay; Vincristine; Xenograft Model Antitumor Assays | 2009 |
Prognostic factors in elderly patients with advanced non-small cell lung cancer treated with chemotherapy.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Deoxycytidine; Disease Progression; Etoposide; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Medical Records; Neoplasm Staging; Paclitaxel; Prognosis; Retrospective Studies; Survival Rate; Treatment Outcome; Vinblastine; Vinorelbine | 2009 |
Single-agent versus combination chemotherapy in patients with advanced non-small cell lung cancer and a performance status of 2: prognostic factors and treatment selection based on two large randomized clinical trials.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Biomarkers; Carboplatin; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase III as Topic; Deoxycytidine; Disease Progression; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Prognosis; Proportional Hazards Models; Randomized Controlled Trials as Topic; Regression Analysis; Survival Rate; Vinblastine; Vinorelbine | 2009 |
Role of the immunosuppressive enzyme indoleamine 2,3-dioxygenase in the progression of ovarian carcinoma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; CD8-Positive T-Lymphocytes; Cell Line, Tumor; Disease Progression; Drug Synergism; Female; Humans; Immunohistochemistry; Indoleamine-Pyrrole 2,3,-Dioxygenase; Lymphocytes, Tumor-Infiltrating; Mice; Mice, Inbred BALB C; Mice, Nude; Ovarian Neoplasms; Paclitaxel; Transfection; Tryptophan; Xenograft Model Antitumor Assays | 2009 |
The relationship between response to previous systemic treatment and the efficacy of subsequent pemetrexed therapy in advanced non-small cell lung cancer.
Topics: Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease Progression; Docetaxel; Drug Therapy, Combination; ErbB Receptors; Erlotinib Hydrochloride; Female; Gemcitabine; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Neoplasm Staging; Paclitaxel; Pemetrexed; Prognosis; Quinazolines; Retrospective Studies; Survival Analysis; Taxoids; Treatment Outcome | 2010 |
Role of cyclooxygenase-2 in tumor progression and survival of head and neck squamous cell carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Case-Control Studies; Clinical Trials, Phase II as Topic; Cohort Studies; Cyclooxygenase 2; Disease Progression; Female; Gene Expression Regulation, Neoplastic; Head and Neck Neoplasms; Humans; Hyperplasia; Ifosfamide; Immunoenzyme Techniques; Male; Neoplasm Invasiveness; Neoplasm Staging; Paclitaxel; Precancerous Conditions; Prognosis; Survival Rate | 2009 |
Weekly paclitaxel and trastuzumab as a first-line therapy in patients with HER2-overexpressing metastatic breast cancer: magnitude of HER2/neu amplification as a predictive factor for efficacy.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease Progression; Drug Administration Schedule; Female; Gene Amplification; Humans; In Situ Hybridization, Fluorescence; Middle Aged; Paclitaxel; Predictive Value of Tests; Receptor, ErbB-2; Survival Analysis; Trastuzumab | 2009 |
Value of serum CA125 levels in patients with high-risk, early stage epithelial ovarian cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; CA-125 Antigen; Carboplatin; Disease Progression; Disease-Free Survival; Epithelial Cells; Female; Humans; Middle Aged; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Proportional Hazards Models; ROC Curve; Young Adult | 2010 |
[Clinical investigation of weekly Carboplatin and Paclitaxel with concurrent radiation therapy for locally advanced non-small cell lung cancer].
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Disease Progression; Dose-Response Relationship, Drug; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Retrospective Studies; Survival Rate | 2009 |
Weekly paclitaxel for platin-resistant stage IV head and neck cancer patients.
Topics: Aged; Antineoplastic Agents, Phytogenic; Combined Modality Therapy; Disease Progression; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Organoplatinum Compounds; Otorhinolaryngologic Neoplasms; Paclitaxel; Palliative Care; Radiotherapy, Adjuvant; Survival Analysis | 2009 |
Successful treatment with paclitaxel/carboplatin chemotherapy in advanced adenocarcinoma of the urinary tract producing carcinoembryonic antigen, carbohydrate antigen 19-9 and carbohydrate antigen 125.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; CA-125 Antigen; CA-19-9 Antigen; Carboplatin; Carcinoembryonic Antigen; Disease Progression; Female; Humans; Paclitaxel; Tomography, X-Ray Computed; Treatment Outcome; Urinary Bladder Neoplasms | 2010 |
New treatment strategy enhances outcome for lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase II as Topic; Disease Progression; Disease-Free Survival; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Lung Neoplasms; Medical Oncology; Paclitaxel; Placebos; Randomized Controlled Trials as Topic; Time Factors; Treatment Outcome; Vorinostat | 2009 |
Combination chemotherapy with weekly paclitaxel or docetaxel, carboplatin, and estramustine for hormone-refractory prostate cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Disease Progression; Docetaxel; Drug Administration Schedule; Estramustine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasms, Hormone-Dependent; Paclitaxel; Prostate-Specific Antigen; Prostatic Neoplasms; Taxoids | 2010 |
Holding back the sea: the role for maintenance chemotherapy in metastatic breast cancer.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Cross-Over Studies; Disease Progression; Disease-Free Survival; Doxorubicin; Female; Follow-Up Studies; Humans; Liposomes; Multicenter Studies as Topic; Neoplasm Metastasis; Paclitaxel; Paresthesia; Polyethylene Glycols; Quality of Life; Randomized Controlled Trials as Topic; Research Design; Treatment Outcome | 2010 |
Neutropenia as a prognostic factor in advanced gastric cancer patients undergoing second-line chemotherapy with weekly paclitaxel.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Pharmacological; Carcinoma; Chemotherapy, Adjuvant; Disease Progression; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Neutropenia; Paclitaxel; Prognosis; Retrospective Studies; Stomach Neoplasms; Survival Analysis | 2010 |
Mucinous advanced epithelial ovarian carcinoma: clinical presentation and sensitivity to platinum-paclitaxel-based chemotherapy, the GINECO experience.
Topics: Adenocarcinoma, Mucinous; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Cystadenocarcinoma, Mucinous; Databases, Factual; Disease Progression; Female; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel; Platinum; Retrospective Studies; Young Adult | 2010 |
Tolerability of PLD/oxaliplatin regimen in recurrent ovarian cancer patients with previous fragility to carboplatin/paclitaxel treatment.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Disease Progression; Doxorubicin; Drug Administration Schedule; Female; Humans; Kaplan-Meier Estimate; Middle Aged; Neoplasm Staging; Neutropenia; Organoplatinum Compounds; Ovarian Neoplasms; Oxaliplatin; Paclitaxel; Polyethylene Glycols; Recurrence; Retrospective Studies; Treatment Outcome | 2011 |
Sarcoidosis development during induction chemotherapy for lung cancer mimicked progressive disease.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biopsy; Carboplatin; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Disease Progression; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Lymph Node Excision; Lymph Nodes; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Paclitaxel; Pneumonectomy; Positron-Emission Tomography; Radiopharmaceuticals; Sarcoidosis, Pulmonary; Tomography, X-Ray Computed | 2010 |
Cost-effectiveness analyses of docetaxel versus paclitaxel once weekly in patients with metastatic breast cancer in progression following anthracycline chemotherapy, in Spain.
Topics: Anthracyclines; Antineoplastic Agents; Breast Neoplasms; Clinical Trials, Phase III as Topic; Cost-Benefit Analysis; Disease Progression; Docetaxel; Female; Humans; Markov Chains; Paclitaxel; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; Salvage Therapy; Spain; Taxoids | 2010 |
Feasibility, toxicity, and efficacy of short induction chemotherapy of docetaxel plus cisplatin or carboplatin (TP) followed by concurrent chemoradio-therapy for organ preservation in advanced cancer of the hypopharynx, larynx, and base of tongue. Early r
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Disease Progression; Docetaxel; Feasibility Studies; Female; Follow-Up Studies; Humans; Hypopharyngeal Neoplasms; Image Processing, Computer-Assisted; Imaging, Three-Dimensional; Kaplan-Meier Estimate; Laryngeal Neoplasms; Leukopenia; Lymphatic Metastasis; Male; Neoadjuvant Therapy; Neoplasm Staging; Opportunistic Infections; Paclitaxel; Positron-Emission Tomography; Radiodermatitis; Radiotherapy Dosage; Radiotherapy Planning, Computer-Assisted; Salvage Therapy; Taxoids; Thrombocytopenia; Tomography, X-Ray Computed; Tongue Neoplasms; Treatment Outcome | 2011 |
Early, progressive, and sustained dysfunction of sensory axons underlies paclitaxel-induced neuropathy.
Topics: Adult; Axons; Breast Neoplasms; Disease Progression; Female; Humans; Membrane Potentials; Middle Aged; Paclitaxel; Polyneuropathies; Prospective Studies; Sensory Receptor Cells; Time Factors | 2011 |
The biphasic role of NF-kappaB in progression and chemoresistance of ovarian cancer.
Topics: Animals; Antineoplastic Agents; Apoptosis; Blotting, Western; Carboplatin; Cell Line, Tumor; Cell Nucleus; Disease Progression; Drug Resistance, Neoplasm; Epithelial Cells; Female; Humans; I-kappa B Proteins; Kaplan-Meier Estimate; Mice; Mice, Inbred BALB C; Mice, Nude; Mitogen-Activated Protein Kinases; NF-kappa B; NF-KappaB Inhibitor alpha; Ovarian Neoplasms; Paclitaxel; Phosphorylation; RNA Interference; Transcription Factor RelA; Xenograft Model Antitumor Assays | 2011 |
Synergy of nab-paclitaxel and bevacizumab in eradicating large orthotopic breast tumors and preexisting metastases.
Topics: Albumins; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Cell Line, Tumor; Disease Progression; Drug Synergism; Female; Humans; Mice; Mice, SCID; Neoplasm Metastasis; Neoplasm Staging; Neoplasm Transplantation; Paclitaxel; Transplantation, Heterotopic; Xenograft Model Antitumor Assays | 2011 |
Single nucleotide polypmorphisms in ERCC1 are associated with disease progression, and survival in patients with advanced stage ovarian and primary peritoneal carcinoma; a Gynecologic Oncology Group study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Deoxycytidine; Disease Progression; DNA-Binding Proteins; Doxorubicin; Endonucleases; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Polymorphism, Single Nucleotide; Topotecan | 2011 |
Serum levels of MMP-11 correlate with clinical outcome in Chinese patients with advanced gastric adenocarcinoma.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; China; Disease Progression; Disease-Free Survival; Docetaxel; Female; Follow-Up Studies; Humans; Male; Matrix Metalloproteinase 11; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Prognosis; Stomach Neoplasms; Taxoids; Treatment Outcome | 2011 |
AACR highlights: promise for treating pancreatic cancer.
Topics: Albumin-Bound Paclitaxel; Albumins; Anilides; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Autophagy; Chloroquine; Clinical Trials as Topic; Delayed Diagnosis; Deoxycytidine; Disease Progression; Gemcitabine; Genes, ras; Humans; Mice; Molecular Targeted Therapy; Mutation; Off-Label Use; Paclitaxel; Pancreatic Neoplasms; Pyridines; Signal Transduction; Transcription Factors; United States | 2011 |
Inflammatory breast cancer and secondary Pure Red Cell Aplasia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Blood Transfusion; Disease Progression; Female; Humans; Inflammatory Breast Neoplasms; Middle Aged; Paclitaxel; Red-Cell Aplasia, Pure | 2011 |
Angiosarcoma in an obese woman with worsening lymphedema after weight-loss and skin-reduction surgeries.
Topics: Dermatologic Surgical Procedures; Disease Progression; Fatal Outcome; Female; Gastric Bypass; Hemangiosarcoma; Humans; Lower Extremity; Lymphedema; Middle Aged; Obesity, Morbid; Paclitaxel; Plastic Surgery Procedures; Skin Neoplasms; Weight Loss | 2011 |
The role of paclitaxel in the development and treatment of multidrug resistant cancer cell lines.
Topics: ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cell Cycle; Cell Death; Cell Line, Tumor; Colonic Neoplasms; Disease Progression; Doxorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Glioblastoma; Glutathione; Humans; Inactivation, Metabolic; Paclitaxel; Rhodamine 123; RNA, Messenger; Vascular Endothelial Growth Factor A | 2011 |
Salvage chemotherapy with paclitaxel, ifosfamide, and cisplatin (TIP) in relapsed or cisplatin-refractory germ cell tumors.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease Progression; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Follow-Up Studies; Humans; Ifosfamide; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Neoplasms, Germ Cell and Embryonal; Paclitaxel; Retrospective Studies; Salvage Therapy; Seminoma; Testicular Neoplasms; Young Adult | 2011 |
Paclitaxel-loaded expansile nanoparticles in a multimodal treatment model of malignant mesothelioma.
Topics: Animals; Antineoplastic Agents, Phytogenic; Cell Line, Tumor; Combined Modality Therapy; Disease Models, Animal; Disease Progression; Female; Humans; Mesothelioma; Mice; Nanoparticles; Paclitaxel; Xenograft Model Antitumor Assays | 2011 |
Vascular responses to drug-eluting and bare metal stents in diabetic/hypercholesterolemic and nonatherosclerotic porcine coronary arteries.
Topics: Animals; Blood Vessel Prosthesis Implantation; Cell Movement; Coronary Artery Disease; Coronary Vessels; Diabetes Complications; Disease Progression; Drug-Eluting Stents; Humans; Hypercholesterolemia; Inflammation; Models, Animal; Neointima; Paclitaxel; Platelet Aggregation; Platelet Aggregation Inhibitors; Swine; T-Lymphocytes | 2011 |
A retrospective comparison of docetaxel and paclitaxel for patients with advanced or recurrent esophageal cancer who previously received platinum-based chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Disease-Free Survival; Docetaxel; Esophageal Neoplasms; Female; Follow-Up Studies; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Organoplatinum Compounds; Paclitaxel; Retrospective Studies; Taxoids | 2011 |
Single-agent paclitaxel in advanced anal cancer after failure of cisplatin and 5-fluorouracil chemotherapy.
Topics: Adult; Antineoplastic Agents; Anus Neoplasms; Carcinoma, Squamous Cell; Cisplatin; Disease Progression; Female; Fluorouracil; Humans; Male; Microtubules; Middle Aged; Neoplasm Metastasis; Paclitaxel; Treatment Outcome | 2011 |
Combined MEK and VEGFR inhibition in orthotopic human lung cancer models results in enhanced inhibition of tumor angiogenesis, growth, and metastasis.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Disease Progression; Humans; Lung Neoplasms; Male; Mice; Mice, Nude; Mitogen-Activated Protein Kinases; Molecular Targeted Therapy; Neovascularization, Pathologic; Paclitaxel; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; Receptors, Vascular Endothelial Growth Factor; Xenograft Model Antitumor Assays | 2012 |
GDF3 inhibits the growth of breast cancer cells and promotes the apoptosis induced by Taxol.
Topics: Antineoplastic Agents; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Disease Progression; Down-Regulation; Female; Gene Knockdown Techniques; Growth Differentiation Factor 3; Humans; Paclitaxel; Recombinant Fusion Proteins; Tumor Stem Cell Assay | 2012 |
Exploration of serum metabolomic profiles and outcomes in women with metastatic breast cancer: a pilot study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials, Phase III as Topic; Disease Progression; Female; Follow-Up Studies; Humans; Lapatinib; Metabolome; Metabolomics; Neoplasm Metastasis; Paclitaxel; Pilot Projects; Quinazolines; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Survival Analysis; Time Factors; Treatment Outcome | 2012 |
Cisplatin plus paclitaxel and maintenance of bevacizumab on tumour progression, dissemination, and survival of ovarian carcinoma xenograft models.
Topics: Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma; Carcinoma, Ovarian Epithelial; Cell Line, Tumor; Cisplatin; Disease Progression; Female; Humans; Mice; Mice, Nude; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Vascular Endothelial Growth Factor A | 2012 |
Aberrant expression of the neuronal-specific protein DCDC2 promotes malignant phenotypes and is associated with prostate cancer progression.
Topics: Binding Sites; Cell Movement; Disease Progression; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Humans; Male; Microtubule-Associated Proteins; Microtubules; Paclitaxel; Promoter Regions, Genetic; Prostatic Neoplasms; Reference Values; Transcription Factors; Tubulin Modulators | 2013 |
Notch3 overexpression as potential therapeutic target in advanced stage chemoresistant ovarian cancer.
Topics: Adenocarcinoma; Amyloid Precursor Protein Secretases; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Cisplatin; Disease Progression; Drug Resistance, Neoplasm; Enzyme Inhibitors; Female; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Humans; Japan; Kaplan-Meier Estimate; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Receptor, Notch3; Receptors, Notch; Retrospective Studies; RNA, Small Interfering; Survival Rate | 2012 |
Restoration of miR-200c to ovarian cancer reduces tumor burden and increases sensitivity to paclitaxel.
Topics: Animals; Anoikis; Cell Adhesion; Cell Line, Tumor; Disease Progression; Female; Humans; Immunohistochemistry; Mice; Mice, Inbred NOD; Mice, SCID; MicroRNAs; Ovarian Neoplasms; Paclitaxel; Transduction, Genetic; Transfection; Tubulin; Tumor Burden; Xenograft Model Antitumor Assays | 2012 |
Clinical and molecular features in patients with advanced non-small-cell lung carcinoma refractory to first-line platinum-based chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Anaplastic Lymphoma Kinase; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Disease Progression; Docetaxel; Drug Resistance, Neoplasm; ErbB Receptors; Exons; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Multivariate Analysis; Mutation; Paclitaxel; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins; Receptor Protein-Tyrosine Kinases; Retrospective Studies; Taxoids | 2013 |
Combined surgery, radiation, and PCV chemotherapy for astrocytomas compared to oligodendrogliomas and oligoastrocytomas WHO grade III.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Cisplatin; Cohort Studies; Combined Modality Therapy; Disease Progression; Female; Follow-Up Studies; Hematologic Diseases; Humans; Male; Middle Aged; Neoplasm Staging; Oligodendroglioma; Paclitaxel; Prospective Studies; Radiotherapy; Survival Rate; Taxoids; Treatment Outcome; Vinblastine; World Health Organization | 2002 |
Comment on "A pilot trial of G3139, a bcl-2 antisense oligonucleotide, and paclitaxel in patients with chemorefractory small-cell lung cancer", by C. M. Rudin et al. (Ann Oncol 2002; 13: 539-545).
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Disease Progression; Drug Resistance, Neoplasm; Genes, bcl-2; Humans; Lung Neoplasms; Oligonucleotides, Antisense; Paclitaxel; Thionucleotides; Treatment Outcome | 2003 |
Regulation of Bcl-2 during androgen-unresponsive progression of prostate cancer.
Topics: Androgens; Apoptosis; bcl-2-Associated X Protein; bcl-X Protein; Butyrates; Disease Progression; Humans; Male; Microscopy, Confocal; Oxidative Stress; Paclitaxel; Prostatic Neoplasms; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Tumor Cells, Cultured | 2002 |
A retrospective analysis of the outcome of patients who have received two prior chemotherapy regimens including platinum and docetaxel for recurrent non-small-cell lung cancer.
Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; Disease Progression; Docetaxel; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Platinum; Retrospective Studies; Survival Rate; Taxoids; Time Factors; Treatment Outcome | 2003 |
Weekly carboplatin and paclitaxel followed by concomitant paclitaxel, fluorouracil, and hydroxyurea chemoradiotherapy: curative and organ-preserving therapy for advanced head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Combined Modality Therapy; Disease Progression; Female; Fluorouracil; Head and Neck Neoplasms; Humans; Hydroxyurea; Lymph Nodes; Male; Middle Aged; Paclitaxel; Quality of Life; Radiotherapy Dosage; Remission Induction; Survival Rate; Treatment Outcome | 2003 |
Microtubule-associated parameters as predictive markers of docetaxel activity in advanced breast cancer patients: results of a pilot study.
Topics: Adult; Aged; Biomarkers, Tumor; Biopsy, Needle; Bone Neoplasms; Breast Neoplasms; Disease Progression; Docetaxel; Dose-Response Relationship, Drug; Female; Humans; Immunohistochemistry; Microtubules; Middle Aged; Neoplasm Invasiveness; Paclitaxel; Pilot Projects; Predictive Value of Tests; Prognosis; Sensitivity and Specificity; Soft Tissue Neoplasms; Survival Analysis; tau Proteins; Taxoids; Treatment Outcome; Tubulin | 2002 |
Weekly 1-h paclitaxel infusion in patients with recurrent endometrial cancer: a preliminary study.
Topics: Adult; Aged; Alopecia; Anemia; Antineoplastic Agents, Phytogenic; Disease Progression; Drug Evaluation; Endometrial Neoplasms; Female; Humans; Infusions, Intravenous; Leukopenia; Middle Aged; Neoplasm Recurrence, Local; Neurotoxicity Syndromes; Paclitaxel; Peripheral Nervous System Diseases; Pleurodynia, Epidemic; Severity of Illness Index; Survival Analysis; Time Factors; Treatment Outcome; Women's Health | 2003 |
High-dose consolidation chemotherapy with Idarubicin and alkylating agents following induction with gemcitabine-epirubicin-paclitaxel in metastatic breast cancer: a dose finding study.
Topics: Adult; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Daunorubicin; Deoxycytidine; Disease Progression; Disease-Free Survival; Dose-Response Relationship, Drug; Epirubicin; Female; Humans; Idarubicin; Melphalan; Middle Aged; Neoplasm Metastasis; Paclitaxel; Remission Induction; Taxoids; Thiotepa; Time Factors; Transplantation Conditioning; Treatment Outcome | 2003 |
Frequent disease progression and early recurrence in patients with familial ovarian cancer primarily treated with paclitaxel and cis- or carboplatin (preliminary report).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Carboplatin; Disease Progression; Female; Follow-Up Studies; Genes, BRCA1; Genetic Predisposition to Disease; Humans; Incidence; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Poland; Prospective Studies; Risk Factors; Sampling Studies; Survival Analysis; Treatment Failure | 2003 |
Weekly paclitaxel (Taxol) with or without trastuzumab (Herceptin) in advanced breast cancer: a community-based observation study.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Combined Modality Therapy; Disease Progression; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Infusions, Intravenous; Middle Aged; Neoplasm Staging; Paclitaxel; Retrospective Studies; Trastuzumab | 2003 |
[Experience in first-line chemotherapy with paclitaxel for the treatment of ovarian carcinomas].
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Blood Transfusion; Carboplatin; Carcinoma; Chemotherapy, Adjuvant; Cisplatin; Disease Progression; Drug Administration Schedule; Erythropoietin; Female; Humans; Hungary; Middle Aged; Neoplasm, Residual; Ovarian Neoplasms; Paclitaxel; Registries; Retrospective Studies; Survival Analysis; Treatment Outcome | 2003 |
Soluble factor from murine bladder tumor-2 cell elevates nitric oxide production in macrophages and enhances the taxol-mediated macrophage cytotoxicity on tumor cells.
Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Disease Progression; Female; Free Radical Scavengers; Macrophages; Male; Mice; Mice, Inbred C57BL; Mitosis; Nitric Oxide; Paclitaxel; Peritoneum; Tumor Cells, Cultured; Urinary Bladder Neoplasms | 2003 |
Analysis of factors associated with outcome in patients with malignant peritoneal mesothelioma undergoing surgical debulking and intraperitoneal chemotherapy.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Cancer, Regional Perfusion; Cisplatin; Combined Modality Therapy; Disease Progression; Female; Fluorouracil; Humans; Male; Mesothelioma; Middle Aged; Paclitaxel; Peritoneal Neoplasms; Proportional Hazards Models; Survival Analysis; Treatment Outcome | 2003 |
Induction chemotherapy followed by concomitant TFHX chemoradiotherapy with reduced dose radiation in advanced head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Cohort Studies; Combined Modality Therapy; Disease Progression; Disease-Free Survival; Female; Fluorouracil; Head and Neck Neoplasms; Humans; Hydroxyurea; Male; Middle Aged; Paclitaxel; Quality of Life; Radiotherapy Dosage; Remission Induction; Survival Rate | 2003 |
Improved Paclitaxel formulation hints at new chemotherapy approach.
Topics: Albumin-Bound Paclitaxel; Albumins; Antineoplastic Agents, Phytogenic; Clinical Trials, Phase III as Topic; Disease Progression; Drug Design; Humans; Nanotechnology; Paclitaxel; Polyethylene Glycols; Randomized Controlled Trials as Topic; Solubility; Taxoids | 2004 |
Ethical conflict in providing informed consent for clinical trials: a problematic example from the gynecologic cancer research community.
Topics: Antineoplastic Agents, Phytogenic; Clinical Trials, Phase III as Topic; Disease Progression; Female; Humans; Informed Consent; Moral Obligations; Ovarian Neoplasms; Paclitaxel; Patient Education as Topic; Patient Selection; Randomized Controlled Trials as Topic; Risk Assessment; Social Responsibility; Survival Analysis | 2004 |
Usefulness of collagen gel droplet embedded culture drug sensitivity testing in ovarian cancer.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Cell Culture Techniques; Cell Line, Tumor; Chemotherapy, Adjuvant; Cisplatin; Clinical Laboratory Techniques; Collagen; Disease Progression; Doxorubicin; Drug Resistance, Neoplasm; Etoposide; Female; Gels; Humans; Irinotecan; Middle Aged; Ovarian Neoplasms; Paclitaxel; Pharmaceutical Preparations; Recurrence; Remission Induction; Sensitivity and Specificity; Time Factors; Treatment Outcome | 2004 |
Induction of stem cell factor/c-Kit/slug signal transduction in multidrug-resistant malignant mesothelioma cells.
Topics: Apoptosis; Cell Line, Tumor; Cell Separation; Culture Media, Conditioned; Cytokines; Disease Progression; DNA, Complementary; Dose-Response Relationship, Drug; Down-Regulation; Doxorubicin; Drug Resistance, Multiple; Enzyme-Linked Immunosorbent Assay; Flow Cytometry; Gene Expression Regulation, Neoplastic; Humans; Immunoblotting; Immunoprecipitation; Lung Neoplasms; Mesothelioma; Paclitaxel; Phenotype; Plasmids; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-kit; Reverse Transcriptase Polymerase Chain Reaction; RNA, Small Interfering; Signal Transduction; Snail Family Transcription Factors; Stem Cell Factor; Transcription Factors; Transfection; Up-Regulation; Verapamil; Vincristine | 2004 |
Heat shock protein 27 increases after androgen ablation and plays a cytoprotective role in hormone-refractory prostate cancer.
Topics: Androgens; Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Cell Division; Disease Progression; Dose-Response Relationship, Drug; Heat-Shock Proteins; Humans; Male; Mice; Mice, Nude; Neoplasms, Hormone-Dependent; Oligonucleotides, Antisense; Paclitaxel; Prostatic Neoplasms; RNA, Small Interfering | 2004 |
Low-dose suramin enhanced paclitaxel activity in chemotherapy-naive and paclitaxel-pretreated human breast xenograft tumors.
Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Body Weight; Breast Neoplasms; Cell Line, Tumor; Cell Survival; Disease Progression; Drug Synergism; Female; Humans; Mice; Mice, Nude; Neoplasm Transplantation; Paclitaxel; Suramin; Time Factors; Treatment Outcome | 2004 |
Prognostic factors and long-term survivorship in patients with recurrent or metastatic carcinoma of the head and neck.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease Progression; Female; Fluorouracil; Head and Neck Neoplasms; Humans; Male; Middle Aged; Paclitaxel; Prognosis; Randomized Controlled Trials as Topic; Survival Analysis; Treatment Outcome | 2004 |
Fluoxetine inhibits multidrug resistance extrusion pumps and enhances responses to chemotherapy in syngeneic and in human xenograft mouse tumor models.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Carcinoma, Lewis Lung; Cell Line, Tumor; Disease Progression; Doxorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Drug Synergism; Female; Fluoxetine; Humans; Lung Neoplasms; Male; Mice; Mice, Inbred C57BL; Mice, Nude; Mitomycin; Neoplasms, Experimental; Paclitaxel; Tissue Distribution; Vinblastine; Xenograft Model Antitumor Assays | 2004 |
Can we do a better job preventing clinically-relevant peripheral neuropathy resulting from carboplatin/paclitaxel chemotherapy?
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Disease Progression; Female; Humans; Ovarian Neoplasms; Paclitaxel; Peripheral Nervous System Diseases; Quality of Life; Randomized Controlled Trials as Topic | 2004 |
[Role of taxanes in treatment of breast cancer].
Topics: Anthracyclines; Antibiotics, Antineoplastic; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Chemotherapy, Adjuvant; Clinical Trials, Phase III as Topic; Cyclophosphamide; Data Interpretation, Statistical; Disease Progression; Docetaxel; Doxorubicin; Epirubicin; Female; Humans; Neoadjuvant Therapy; Neoplasm Metastasis; Paclitaxel; Randomized Controlled Trials as Topic; Risk Assessment; Risk Factors; Taxoids; Time Factors; Trastuzumab | 2004 |
Paclitaxel/Platinum-based perioperative chemotherapy and surgery in stage IIIA non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Disease Progression; Drug Administration Schedule; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Perioperative Care; Platinum; Pneumonectomy; Survival Rate; Treatment Outcome | 2005 |
Efficacy of weekly paclitaxel in patients with docetaxel-resistant metastatic breast cancer.
Topics: Antineoplastic Agents, Phytogenic; Bone Neoplasms; Breast Neoplasms; Disease Progression; Docetaxel; Drug Resistance, Neoplasm; Female; Humans; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Middle Aged; Paclitaxel; Retrospective Studies; Salvage Therapy; Taxoids; Treatment Outcome | 2005 |
Opioid growth factor enhances tumor growth inhibition and increases the survival of paclitaxel-treated mice with squamous cell carcinoma of the head and neck.
Topics: Animals; Antineoplastic Agents, Phytogenic; Body Weight; Carcinoma, Squamous Cell; Cell Proliferation; Disease Progression; Enkephalin, Methionine; Head and Neck Neoplasms; Male; Mice; Mice, Nude; Paclitaxel; Survival Analysis | 2005 |
["Second line" polychemotherapy in metastatic urothelial cancer of the renal pelvis. Persisting partial remission by 18 treatment cycles of gemcitabine/paclitaxel after 24 treatment cycles gemcitabine/cisplatin "stable disease"].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Chemotherapy, Adjuvant; Cisplatin; Combined Modality Therapy; Deoxycytidine; Disease Progression; Drug Administration Schedule; Drug Resistance, Neoplasm; Gemcitabine; Humans; Kidney Neoplasms; Kidney Pelvis; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Remission Induction; Retroperitoneal Neoplasms; Tomography, X-Ray Computed | 2005 |
Front-line doublets in advanced non-small cell lung cancer: The golden age for second line chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Disease Progression; Docetaxel; Etoposide; Female; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Paclitaxel; Pemetrexed; Survival Rate; Taxoids | 2005 |
Delayed occurrence of restenosis in drug eluting stents: an evidence of delayed healing.
Topics: Adult; Angioplasty, Balloon, Coronary; Blood Vessel Prosthesis Implantation; Coronary Restenosis; Delayed-Action Preparations; Disease Progression; Drug Delivery Systems; Humans; Immunosuppressive Agents; Male; Middle Aged; Paclitaxel; Radiography; Risk Factors; Sirolimus; Stents; Time Factors | 2005 |
Endothelin B receptor agonist, IRL 1620, enhances the anti-tumor efficacy of paclitaxel in breast tumor rats.
Topics: Alkylating Agents; Animals; Antineoplastic Agents, Phytogenic; Disease Progression; Endothelin B Receptor Antagonists; Endothelins; Female; Mammary Neoplasms, Animal; Methylnitrosourea; Paclitaxel; Peptide Fragments; Rats; Rats, Sprague-Dawley; Receptor, Endothelin B; Tissue Distribution | 2005 |
Paclitaxel plus carboplatin-induced peripheral neuropathy. A prospective clinical and electrophysiological study in patients suffering from solid malignancies.
Topics: Aged; Antineoplastic Agents; Area Under Curve; Carboplatin; Disease Progression; Drug Therapy; Electrophysiology; Female; Follow-Up Studies; Humans; Male; Middle Aged; Neoplasms; Neural Conduction; Paclitaxel; Peripheral Nervous System Diseases; Prospective Studies; Time Factors | 2005 |
Pretreatment CA-125 and risk of relapse in advanced ovarian cancer.
Topics: Aged; Altretamine; Antineoplastic Combined Chemotherapy Protocols; CA-125 Antigen; Disease Progression; Female; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Predictive Value of Tests; Retrospective Studies; Survival Analysis | 2006 |
Indium-111-labeled trastuzumab scintigraphy in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Breast Neoplasms; Disease Progression; Female; Heart Diseases; Heart Neoplasms; Humans; Indium Radioisotopes; Middle Aged; Natriuretic Peptide, Brain; Neoplasm Metastasis; Paclitaxel; Pentetic Acid; Peptide Fragments; Predictive Value of Tests; Receptor, ErbB-2; Tomography, Emission-Computed, Single-Photon; Trastuzumab; Troponin I | 2006 |
Dual epidermal growth factor receptor and vascular endothelial growth factor receptor inhibition with NVP-AEE788 for the treatment of aggressive follicular thyroid cancer.
Topics: Adenocarcinoma, Follicular; Animals; Antineoplastic Combined Chemotherapy Protocols; Blotting, Western; Cell Line, Tumor; Cell Proliferation; Disease Models, Animal; Disease Progression; ErbB Receptors; Humans; Male; Mice; Mice, Nude; Paclitaxel; Phosphorylation; Predictive Value of Tests; Prognosis; Purines; Receptors, Vascular Endothelial Growth Factor; Structure-Activity Relationship; Thyroid Neoplasms; Xenograft Model Antitumor Assays | 2006 |
High activity of salvage treatment with biweekly paclitaxel-gemcitabine combination in heavily pretreated breast cancer patients.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Deoxycytidine; Disease Progression; Female; Gemcitabine; Granulocyte Colony-Stimulating Factor; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Salvage Therapy; Treatment Outcome | 2006 |
Predictive value of D-dimer plasma levels in response and progressive disease in patients with lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Bridged-Ring Compounds; Camptothecin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Deoxycytidine; Disease Progression; Docetaxel; Female; Fibrin Fibrinogen Degradation Products; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Patient Compliance; Predictive Value of Tests; Prospective Studies; Survival Analysis; Taxoids; Treatment Outcome; Vinblastine | 2006 |
Cyclo-oxygenase-2 (Cox-2) expression and resistance to platinum versus platinum/paclitaxel containing chemotherapy in advanced ovarian cancer.
Topics: Adult; Aged; Aged, 80 and over; Cyclooxygenase 2; Disease Progression; Drug Resistance, Neoplasm; Drug Therapy, Combination; Female; Humans; Middle Aged; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Platinum; Survival Rate | 2006 |
Antivascular therapy of cancer metastasis.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Bone Neoplasms; Disease Progression; Growth Substances; Humans; Imatinib Mesylate; Male; Mice; Mice, Nude; Neoplasm Metastasis; Neoplasms; Paclitaxel; Piperazines; Platelet-Derived Growth Factor; Prostatic Neoplasms; Pyrimidines; Receptors, Growth Factor; Receptors, Platelet-Derived Growth Factor | 2006 |
Intensity-modulated radiation therapy with concurrent chemotherapy for locally advanced cervical and upper thoracic esophageal cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Combined Modality Therapy; Disease Progression; Dose-Response Relationship, Radiation; Esophageal Neoplasms; Female; Fluorouracil; Humans; Middle Aged; Paclitaxel; Radiotherapy, Adjuvant; Radiotherapy, Intensity-Modulated; Retrospective Studies | 2006 |
Multiple cutaneous metastases from male breast carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms, Male; Carcinoma, Ductal, Breast; Combined Modality Therapy; Cyclophosphamide; Disease Progression; Doxorubicin; Epirubicin; Fatal Outcome; Fluorouracil; Humans; Lung Neoplasms; Lymph Node Excision; Lymphatic Metastasis; Male; Mastectomy, Radical; Megestrol Acetate; Middle Aged; Paclitaxel; Palliative Care; Skin Neoplasms | 2006 |
Paclitaxel and carboplatin for large cell neuroendocrine carcinoma of the uterine cervix.
Topics: Adult; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Brain Neoplasms; Carboplatin; Carcinoma, Large Cell; Carcinoma, Neuroendocrine; Chemotherapy, Adjuvant; Combined Modality Therapy; Disease Progression; Fatal Outcome; Female; Humans; Liver Neoplasms; Neoplasm Recurrence, Local; Ovariectomy; Paclitaxel; Uterine Cervical Neoplasms | 2007 |
EGFR and HER2 gene copy number and response to first-line chemotherapy in patients with advanced non-small cell lung cancer (NSCLC).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chi-Square Distribution; Cisplatin; Deoxycytidine; Disease Progression; Docetaxel; ErbB Receptors; Female; Gemcitabine; Humans; In Situ Hybridization, Fluorescence; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Proto-Oncogene Proteins c-akt; Receptor, ErbB-2; Survival Rate; Taxoids; Vinblastine; Vinorelbine | 2007 |
Long-term clinical outcomes and thrombosis rates of sirolimus-eluting versus paclitaxel-eluting stents in an unselected population with coronary artery disease (REWARDS registry).
Topics: Aged; Angioplasty, Balloon, Coronary; Coronary Angiography; Coronary Artery Disease; Coronary Restenosis; Coronary Thrombosis; Disease Progression; Female; Humans; Immunosuppressive Agents; Male; Middle Aged; Paclitaxel; Registries; Retrospective Studies; Sirolimus; Stents; Time Factors; Treatment Outcome | 2007 |
Inositol hexaphosphate and paclitaxel: symbiotic treatment of oral cavity squamous cell carcinoma.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Proliferation; Cell Survival; Disease Progression; Drug Synergism; Genes, Reporter; Humans; Mouth Neoplasms; NF-kappa B; Paclitaxel; Phytic Acid | 2007 |
Case report on clopidogrel rash after coronary placement of a paclitaxol-coated stent.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Stenosis; Disease Progression; Drug Hypersensitivity; Drug Therapy, Combination; Exanthema; Humans; Male; Middle Aged; Paclitaxel; Platelet Aggregation Inhibitors; Stents; Ticlopidine; Tubulin Modulators; Urticaria | 2007 |
Progression of disease despite good endoscopic local control of upper tract urothelial carcinoma.
Topics: Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Papillary; Carcinoma, Transitional Cell; Chemotherapy, Adjuvant; Combined Modality Therapy; Deoxycytidine; Disease Progression; Docetaxel; Electrocoagulation; Gemcitabine; Humans; Kidney Neoplasms; Kidney Pelvis; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Neoplasm Recurrence, Local; Nephrectomy; Paclitaxel; Taxoids; Ureteroscopy | 2007 |
Paclitaxel albumin-bound particles (abraxane) in combination with bevacizumab with or without gemcitabine: early experience at the University of Miami/Braman Family Breast Cancer Institute.
Topics: Albumin-Bound Paclitaxel; Albumins; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Deoxycytidine; Disease Progression; Female; Gemcitabine; Genes, erbB-2; Humans; Paclitaxel; Retrospective Studies | 2007 |
Population pharmacokinetics and pharmacodynamics of paclitaxel and carboplatin in ovarian cancer patients: a study by the European organization for research and treatment of cancer-pharmacology and molecular mechanisms group and new drug development group
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Disease Progression; Drug Design; Europe; Female; Humans; Kinetics; Neutropenia; Ovarian Neoplasms; Paclitaxel; Predictive Value of Tests; Thrombocytopenia; Treatment Outcome | 2007 |
Secondary vaginal involvement following radical surgical treatment for a stage I ovarian adenocarcinoma arising in mature cystic teratoma.
Topics: Adenocarcinoma; Adult; Carboplatin; Disease Progression; Female; Humans; Immunohistochemistry; Ovarian Neoplasms; Paclitaxel; Teratoma; Thailand; Vaginal Neoplasms | 2007 |
Carboplatin and paclitaxel in advanced or metastatic endometrial cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Disease Progression; Disease-Free Survival; Endometrial Neoplasms; Female; Humans; Kaplan-Meier Estimate; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Treatment Outcome | 2008 |
Paclitaxel plus bevacizumab for metastatic breast cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Disease Progression; Humans; Paclitaxel; Quality of Life; Survival Analysis | 2008 |
Paclitaxel plus bevacizumab for metastatic breast cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Bias; Breast Neoplasms; Disease Progression; Humans; Paclitaxel; Research Design | 2008 |
Validation of FACT/GOG-AD subscale for ovarian cancer-related abdominal discomfort: a Gynecologic Oncology Group study.
Topics: Abdominal Pain; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease Progression; Disease-Free Survival; Female; Humans; Injections, Intraperitoneal; Injections, Intravenous; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Pain Measurement; Surveys and Questionnaires | 2008 |
Paclitaxel (Taxol) as salvage therapy for relapsed ovarian cancer.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Disease Progression; Female; Humans; Infusions, Intra-Arterial; Middle Aged; Ovarian Neoplasms; Paclitaxel; Prognosis; Prospective Studies; Salvage Therapy; Survival Rate | 1996 |
Doxorubicin and paclitaxel, a highly active combination in the treatment of metastatic breast cancer.
Topics: Adult; Aged; Alopecia; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease Progression; Doxorubicin; Female; Heart; Heart Failure; Humans; Infusions, Intravenous; Middle Aged; Muscular Diseases; Nausea; Neoplasm Metastasis; Neutropenia; Paclitaxel; Pain; Paresthesia; Remission Induction; Stroke Volume; Ventricular Function, Left; Vomiting | 1996 |
Paclitaxel (Taxol) monotherapy in the treatment of progressive and recurrent ovarian carcinoma after platinum-based chemotherapy.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Disease-Free Survival; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Platinum Compounds; Retrospective Studies; Survival Analysis; Treatment Outcome | 1996 |
The effect of paclitaxel on the progression of polycystic kidney disease in rodents.
Topics: Animals; Disease Progression; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Female; Heterozygote; Homozygote; Kidney; Male; Mice; Mice, Inbred C57BL; Paclitaxel; Polycystic Kidney Diseases; Random Allocation; Rats; Rats, Inbred Strains; Renal Agents | 1997 |
Vinorelbine and cisplatin (CIVIC regimen) for the treatment of metastatic breast carcinoma after failure of anthracycline- and/or paclitaxel-containing regimens.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Breast Neoplasms; Carcinoma; Cisplatin; Confidence Intervals; Disease Progression; Female; Humans; Infusions, Intravenous; Injections, Intravenous; Middle Aged; Neutropenia; Paclitaxel; Peripheral Nervous System Diseases; Pilot Projects; Remission Induction; Risk Factors; Survival Rate; Thrombocytopenia; Treatment Failure; Vinblastine; Vinorelbine | 1998 |
Docetaxel is a potent cytotoxic drug in the treatment of advanced breast cancer.
Topics: Adult; Aged; Anthraquinones; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Cell Division; Disease Progression; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Infusions, Intravenous; Microtubules; Middle Aged; Mitosis; Neoplasm Staging; Neutropenia; Paclitaxel; Remission Induction; Survival Rate; Taxoids; Tubulin | 1998 |
Cost-utility model comparing docetaxel and paclitaxel in advanced breast cancer patients.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Costs and Cost Analysis; Disease Progression; Docetaxel; Female; Humans; Markov Chains; Models, Economic; Paclitaxel; Quality-Adjusted Life Years; Taxoids; Western World | 1998 |
Cost-utility analysis of chemotherapy using paclitaxel, docetaxel, or vinorelbine for patients with anthracycline-resistant breast cancer.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Cost-Benefit Analysis; Disease Progression; Docetaxel; Drug Resistance, Neoplasm; Female; Health Care Costs; Humans; Middle Aged; Paclitaxel; Quality-Adjusted Life Years; Survival Analysis; Taxoids; Vinblastine; Vinorelbine | 1999 |
Treatment of multidrug resistant (MDR1) murine leukemia with P-glycoprotein substrates accelerates the course of the disease.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cell Membrane; Cell Movement; Disease Progression; Drug Resistance, Neoplasm; Female; Flupenthixol; Humans; Hydrogen-Ion Concentration; Leukemia P388; Liver Neoplasms; Mechlorethamine; Mice; Neoplasm Invasiveness; Neoplasm Transplantation; Paclitaxel; Survival Rate; Tumor Cells, Cultured; Vincristine | 1999 |
Targeting bcl-2 gene to delay androgen-independent progression and enhance chemosensitivity in prostate cancer using antisense bcl-2 oligodeoxynucleotides.
Topics: Androgens; Animals; Antineoplastic Agents, Phytogenic; Blotting, Northern; Blotting, Western; Disease Progression; DNA Primers; DNA, Neoplasm; Docetaxel; Dose-Response Relationship, Drug; Drug Therapy, Combination; Gene Targeting; Genes, bcl-2; Male; Mice; Oligodeoxyribonucleotides, Antisense; Paclitaxel; Prostatic Neoplasms; Proto-Oncogene Proteins c-bcl-2; RNA, Messenger; Taxoids | 1999 |
Four-cycle high-dose therapy with hematopoietic support for metastatic breast cancer: no improvement in outcomes compared with single-course high-dose therapy.
Topics: Adjuvants, Pharmaceutic; Adult; Antineoplastic Combined Chemotherapy Protocols; Blood Transfusion; Breast Neoplasms; Carmustine; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Disease Progression; Dose-Response Relationship, Drug; Female; Hematopoietic Stem Cell Transplantation; Humans; Infections; Melphalan; Middle Aged; Mitoxantrone; Paclitaxel; Survival Rate; Thiotepa; Time Factors; Transplantation, Autologous | 2000 |
Acquisition of chemoresistant phenotype by overexpression of the antiapoptotic gene testosterone-repressed prostate message-2 in prostate cancer xenograft models.
Topics: Animals; Antineoplastic Agents, Phytogenic; Blotting, Northern; Blotting, Western; Clusterin; Disease Progression; DNA Fragmentation; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Glycoproteins; Humans; Male; Mice; Mice, Nude; Molecular Chaperones; Neoplasm Transplantation; Oligonucleotides, Antisense; Paclitaxel; Phenotype; Prostate-Specific Antigen; Prostatic Neoplasms; Time Factors; Tumor Cells, Cultured | 2000 |
Preoperative chemoradiotherapy using taxanes for locally advanced esophageal carcinoma.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemotherapy, Adjuvant; Clinical Trials as Topic; Combined Modality Therapy; Disease Progression; Esophageal Neoplasms; Humans; Neoadjuvant Therapy; Neoplasm Staging; Paclitaxel; Radiotherapy, Adjuvant; Reproducibility of Results; Treatment Outcome | 2001 |
PCV for oligodendroglial tumors: in search of prognostic factors for response and survival.
Topics: Adult; Age Factors; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Cisplatin; Cognition Disorders; Disease Progression; Female; Humans; Magnetic Resonance Imaging; Male; Multivariate Analysis; Oligodendroglioma; Paclitaxel; Prognosis; Survival Analysis; Taxoids; Vinblastine | 2001 |
Two special types of breast cancer presenting as progressive disease after neoadjuvant chemotherapy with docetaxel plus doxorubicin.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Squamous Cell; Disease Progression; Docetaxel; Doxorubicin; Female; Humans; Lymphatic Metastasis; Mammography; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Sternum; Taxoids | 2001 |
Addition of trastuzumab to chemotherapy produces 50% increase in survival in patients selected by FISH.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials, Phase III as Topic; Disease Progression; Disease-Free Survival; Female; Genes, erbB-2; Humans; Immunohistochemistry; In Situ Hybridization, Fluorescence; Neoplasm Metastasis; Paclitaxel; Patient Selection; Receptor, ErbB-2; Retrospective Studies; Trastuzumab | 2001 |
Clinical and pharmacokinetic data of a docetaxel-epirubicin combination in metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease Progression; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Epirubicin; Female; Humans; Liver Neoplasms; Middle Aged; Paclitaxel; Taxoids | 2001 |
Extragonadal seminoma after renal transplantation and immunosuppression; treatment in the presence of renal dysfunction: a case report and literature review.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carboplatin; Chromosome Aberrations; Chromosomes, Human, Pair 12; Diagnosis, Differential; Disease Progression; Etoposide; Fatal Outcome; Humans; Immunosuppressive Agents; Kidney Failure, Chronic; Kidney Transplantation; Male; Paclitaxel; Pelvic Neoplasms; Seminoma | 2001 |
Locally advanced mucinous carcinoma of the breast with sudden growth acceleration: a case report.
Topics: Adenocarcinoma, Mucinous; Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Combined Modality Therapy; Disease Progression; Doxorubicin; Female; Humans; Mastectomy, Radical; Paclitaxel; Radiotherapy Dosage | 2002 |
Comparison of unidimensional and bidimensional measurements in metastatic non-small cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Disease Progression; Female; Gemcitabine; Humans; Lung Neoplasms; Magnetic Resonance Imaging; Male; Middle Aged; Outcome Assessment, Health Care; Paclitaxel; Practice Guidelines as Topic; Retrospective Studies; Tomography, X-Ray Computed; Treatment Outcome; Vinblastine; Vinorelbine; World Health Organization | 2002 |